U.S. patent application number 16/388832 was filed with the patent office on 2019-11-28 for therapeutic combination of a pi3k inhibitor and a btk inhibitor.
The applicant listed for this patent is Acerta Pharma B.V.. Invention is credited to Tjeerd BARF, Todd COVEY, Ahmed HAMDY, Raquel IZUMI, Dave JOHNSON, Allard KAPTEIN, Brian LANNUTTI, Wayne ROTHBAUM, Roger ULRICH.
Application Number | 20190358235 16/388832 |
Document ID | / |
Family ID | 52697466 |
Filed Date | 2019-11-28 |
![](/patent/app/20190358235/US20190358235A1-20191128-C00001.png)
![](/patent/app/20190358235/US20190358235A1-20191128-C00002.png)
![](/patent/app/20190358235/US20190358235A1-20191128-C00003.png)
![](/patent/app/20190358235/US20190358235A1-20191128-C00004.png)
![](/patent/app/20190358235/US20190358235A1-20191128-C00005.png)
![](/patent/app/20190358235/US20190358235A1-20191128-C00006.png)
![](/patent/app/20190358235/US20190358235A1-20191128-C00007.png)
![](/patent/app/20190358235/US20190358235A1-20191128-C00008.png)
![](/patent/app/20190358235/US20190358235A1-20191128-C00009.png)
![](/patent/app/20190358235/US20190358235A1-20191128-C00010.png)
![](/patent/app/20190358235/US20190358235A1-20191128-C00011.png)
View All Diagrams
United States Patent
Application |
20190358235 |
Kind Code |
A1 |
HAMDY; Ahmed ; et
al. |
November 28, 2019 |
Therapeutic Combination of a PI3K Inhibitor and a BTK Inhibitor
Abstract
In some embodiments, the invention includes a therapeutic
combination of a phosphoinositide 3-kinase (PI3K) inhibitor,
including PI3K inhibitors selective for the .gamma.- and
.delta.-isoforms and selective for both .gamma.- and
.delta.-isoforms, and a Bruton's tyrosine kinase (BTK) inhibitor.
In some embodiments, the invention includes therapeutic methods of
using a BTK inhibitor and a PI3K-.delta. inhibitor to treat solid
tumor cancers by modulation of the tumor microenvironment,
including macrophages, monocytes, mast cells, helper T cells,
cytotoxic T cells, regulatory T cells, natural killer cells,
myeloid-derived suppressor cells, regulatory B cells, neutrophils,
dendritic cells, and fibroblasts.
Inventors: |
HAMDY; Ahmed; (Santa Cruz,
CA) ; ROTHBAUM; Wayne; (New York, NY) ; IZUMI;
Raquel; (San Carlos, CA) ; LANNUTTI; Brian;
(Solana Beach, CA) ; COVEY; Todd; (San Carlos,
CA) ; ULRICH; Roger; (Sammamish, WA) ;
JOHNSON; Dave; (Aptos, CA) ; BARF; Tjeerd;
(Ravenstein, NL) ; KAPTEIN; Allard; (Zaltbommel,
NL) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
Acerta Pharma B.V. |
Oss |
|
NL |
|
|
Family ID: |
52697466 |
Appl. No.: |
16/388832 |
Filed: |
April 18, 2019 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
15101864 |
Jun 3, 2016 |
10328080 |
|
|
PCT/IB2014/003121 |
Dec 5, 2014 |
|
|
|
16388832 |
|
|
|
|
61912515 |
Dec 5, 2013 |
|
|
|
61974665 |
Apr 3, 2014 |
|
|
|
62035777 |
Aug 11, 2014 |
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
A61K 31/517 20130101;
A61P 43/00 20180101; A61P 35/04 20180101; A61K 31/519 20130101;
A61K 31/4985 20130101; A61K 45/06 20130101; A61K 31/4985 20130101;
A61K 2300/00 20130101; A61K 2300/00 20130101; A61K 31/519 20130101;
A61K 2300/00 20130101; A61K 31/517 20130101; A61K 2300/00 20130101;
A61P 35/00 20180101; A61P 35/02 20180101; A61K 31/52 20130101; A61K
31/52 20130101; A61K 31/53 20130101 |
International
Class: |
A61K 31/52 20060101
A61K031/52; A61K 31/519 20060101 A61K031/519; A61K 45/06 20060101
A61K045/06; A61K 31/517 20060101 A61K031/517 |
Claims
1. A method of treating a hyperproliferative disorder in a subject,
comprising co-administering to a subject in need thereof a
therapeutically effective amount of a phosphoinositide 3-kinase
(PI3K) inhibitor, or of a pharmaceutically acceptable salt thereof,
in combination with a Bruton's tyrosine kinase (BTK) inhibitor, or
of a pharmaceutically acceptable salt thereof, wherein the BTK
inhibitor is: ##STR00037##
2. The method of claim 1, wherein the PI3K inhibitor is selected
from the group consisting of a PI3K-.gamma. inhibitor, a
PI3K-.delta. inhibitor, and a PI3K-.gamma.,.delta. inhibitor.
3. (canceled)
4. (canceled)
5. (canceled)
6. The method of claim 1, wherein the combination of the PI3K
inhibitor with the BTK inhibitor is administered by oral,
intravenous, intramuscular, intraperitoneal, subcutaneous or
transdermal means.
7. The method of claim 1, wherein the PI3K inhibitor and/or BTK
inhibitor is in the form of a pharmaceutically acceptable salt.
8. The method of claim 1, wherein the PI3K inhibitor is
administered to the subject before administration of the BTK
inhibitor.
9. The method of claim 1, wherein the PI3K inhibitor is
administered concurrently with the administration of the BTK
inhibitor.
10. The method of claim 1, wherein the PI3K inhibitor is
administered to the subject after administration of the BTK
inhibitor.
11. (canceled)
12. (canceled)
13. (canceled)
14. (canceled)
15. (canceled)
16. (canceled)
17. (canceled)
18. (canceled)
19. (canceled)
20. (canceled)
21. (canceled)
22. (canceled)
23. (canceled)
24. (canceled)
25. The method of claim 1 wherein the amount is effective to
inhibit signaling between the cells of the cancer and at least one
microenvironment selected from the group consisting of macrophages,
monocytes, mast cells, helper T cells, cytotoxic T cells,
regulatory T cells, natural killer cells, myeloid-derived
suppressor cells, regulatory B cells, neutrophils, dendritic cells,
and fibroblasts.
26. (canceled)
27. (canceled)
28. The method of claim 25, wherein the amount is further effective
to increase immune system recognition and rejection of the cancer
by the human.
29. (canceled)
30. (canceled)
31. (canceled)
32. A kit comprising a pharmaceutical composition comprising a PI3K
inhibitor and a pharmaceutical composition comprising a BTK
inhibitor, for co-administration of the PI3K inhibitor and the BTK
inhibitor, either simultaneously or separately.
33. (canceled)
34. (canceled)
35. (canceled)
36. (canceled)
37. (canceled)
38. (canceled)
39. The method of claim 1, wherein the hyperproliferative disorder
is mantle cell lymphoma.
40. The method of claim 1, wherein the hyperproliferative disorder
is acute myeloid leukemia.
41. The method of claim 1, wherein the hyperproliferative disorder
is indolent non-Hodgkin's Lymphomas.
42. The method of claim 1, wherein the hyperproliferative disorder
is activated B Cell-Diffuse Large B Cell Lymphoma.
43. The method of claim 1, wherein the hyperproliferative disorder
is germinal center B-cell like diffuse large B-cell lymphoma.
44. The method of claim 1, wherein the hyperproliferative disorder
is B cell acute lymphoblastic leukemia
Description
FIELD OF THE INVENTION
[0001] A therapeutic combination of a phosphoinositide 3-kinase
(PI3K) inhibitor and a Bruton's Tyrosine Kinase (BTK) inhibitor and
uses of the therapeutic combination are disclosed herein.
BACKGROUND OF THE INVENTION
[0002] PI3K kinases are members of a unique and conserved family of
intracellular lipid kinases that phosphorylate the 3'-OH group on
phosphatidylinositols or phosphoinositides. PI3K kinases are key
signaling enzymes that relay signals from cell surface receptors to
downstream effectors. The PI3K family comprises 15 kinases with
distinct substrate specificities, expression patterns, and modes of
regulation. The class I PI3K kinases (p110.alpha., p110.beta.,
p110.delta., and p110.gamma.) are typically activated by tyrosine
kinases or G-protein coupled receptors to generate PIP3, which
engages downstream effectors such as those in the Akt/PDK1 pathway,
mTOR, the Tec family kinases, and the Rho family GTPases.
[0003] The PI3K signaling pathway is known to be one of the most
highly mutated in human cancers. PI3K signaling is also a key
factor in disease states including hematologic malignancies,
non-Hodgkin lymphoma (such as diffuse large B-cell lymphoma),
allergic contact dermatitis, rheumatoid arthritis, osteoarthritis,
inflammatory bowel diseases, chronic obstructive pulmonary
disorder, psoriasis, multiple sclerosis, asthma, disorders related
to diabetic complications, and inflammatory complications of the
cardiovascular system such as acute coronary syndrome. The role of
PI3K in cancer has been discussed, for example, in J. A. Engleman,
Nat. Rev. Cancer 2009, 9, 550-562. The PI3K-.delta. and
PI3K-.gamma. isoforms are preferentially expressed in normal and
malignant leukocytes.
[0004] The delta (.delta.) isoform of class I PI3K (PI3K-.delta.)
is involved in mammalian immune system functions such as T-cell
function, B-cell activation, mast cell activation, dendritic cell
function, and neutrophil activity. Due to its role in immune system
function, PI3K-.delta. is also involved in a number of diseases
related to undesirable immune response such as allergic reactions,
inflammatory diseases, inflammation mediated angiogenesis,
rheumatoid arthritis, auto-immune diseases such as lupus, asthma,
emphysema and other respiratory diseases. The gamma (.gamma.)
isoform of class I PI3K (PI3K-.gamma.) is also involved in immune
system functions and plays a role in leukocyte signaling and has
been implicated in inflammation, rheumatoid arthritis, and
autoimmune diseases such as lupus.
[0005] Downstream mediators of the PI3K signal transduction pathway
include Akt and mammalian target of rapamycin (mTOR). One important
function of Akt is to augment the activity of mTOR, through
phosphorylation of TSC2 and other mechanisms. mTOR is a
serine-threonine kinase related to the lipid kinases of the PI3K
family and has been implicated in a wide range of biological
processes including cell growth, cell proliferation, cell motility
and survival. Disregulation of the mTOR pathway has been reported
in various types of cancer.
[0006] In view of the above, PI3K inhibitors are prime targets for
drug development, as described in J. E. Kurt and I. Ray-Coquard,
Anticancer Res. 2012, 32, 2463-70. Several PI3K inhibitors are
known, including those that are PI3K-.delta. inhibitors,
PI3K-.gamma. inhibitors, and PI3K-.delta.,.gamma. inhibitors.
[0007] Bruton's Tyrosine Kinase (BTK) is a Tec family non-receptor
protein kinase expressed in B cells and myeloid cells. The function
of BTK in signaling pathways activated by the engagement of the B
cell receptor (BCR) and FCER1 on mast cells is well established.
Functional mutations in BTK in humans result in a primary
immunodeficiency disease characterized by a defect in B cell
development with a block between pro- and pre-B cell stages. The
result is an almost complete absence of B lymphocytes, causing a
pronounced reduction of serum immunoglobulin of all classes. These
findings support a key role for BTK in the regulation of the
production of auto-antibodies in autoimmune diseases.
[0008] Other diseases with an important role for dysfunctional B
cells are B cell malignancies. The reported role for BTK in the
regulation of proliferation and apoptosis of B cells indicates the
potential for BTK inhibitors in the treatment of B cell lymphomas.
BTK inhibitors have thus been developed as potential therapies, as
described in O. Cruz et al., OncoTargets and Therapy 2013, 6,
161-176.
[0009] In many solid tumors, the supportive microenvironment (which
may make up the majority of the tumor mass) is a dynamic force that
enables tumor survival. The tumor microenvironment is generally
defined as a complex mixture of "cells, soluble factors, signaling
molecules, extracellular matrices, and mechanical cues that promote
neoplastic transformation, support tumor growth and invasion,
protect the tumor from host immunity, foster therapeutic
resistance, and provide niches for dominant metastases to thrive,"
as described in Swartz et al., Cancer Res., 2012, 72, 2473.
Although tumors express antigens that should be recognized by T
cells, tumor clearance by the immune system is rare because of
immune suppression by the microenvironment. Addressing the tumor
cells themselves with e.g. chemotherapy has also proven to be
insufficient to overcome the protective effects of the
microenvironment. New approaches are thus urgently needed for more
effective treatment of solid tumors that take into account the role
of the microenvironment.
[0010] The present invention provides the unexpected finding that
the combination of a PI3K inhibitor with a BTK inhibitor is
effective in the treatment of any of several types of cancers such
as leukemia, lymphoma and solid tumor cancers.
SUMMARY OF THE INVENTION
[0011] In an embodiment, the invention provides a composition
comprising a PI3K inhibitor and a BTK inhibitor in combination.
This composition is typically a pharmaceutical composition.
[0012] In an embodiment, the invention provides a composition
comprising a PI3K-.gamma. inhibitor and a BTK inhibitor in
combination. This composition is typically a pharmaceutical
composition.
[0013] In an embodiment, the invention provides a composition
comprising a PI3K-.delta. inhibitor and a BTK inhibitor in
combination. This composition is typically a pharmaceutical
composition.
[0014] In an embodiment, the invention provides a composition
comprising a PI3K-.gamma.,.delta. inhibitor and a BTK inhibitor in
combination. This composition is typically a pharmaceutical
composition.
[0015] In an embodiment, the invention provides a pharmaceutical
composition comprising a PI3K inhibitor and a BTK inhibitor in
combination for use in the treatment of leukemia, lymphoma or a
solid tumor cancer.
[0016] In an embodiment, the invention provides a pharmaceutical
composition comprising a PI3K-.gamma. inhibitor and a BTK inhibitor
in combination for use in the treatment of leukemia, lymphoma or a
solid tumor cancer.
[0017] In an embodiment, the invention provides a pharmaceutical
composition comprising a PI3K-.delta. inhibitor and a BTK inhibitor
in combination for use in the treatment of leukemia, lymphoma or a
solid tumor cancer.
[0018] In an embodiment, the invention provides a pharmaceutical
composition comprising a PI3K-.gamma.,.delta. inhibitor and a BTK
inhibitor in combination for use in the treatment of leukemia,
lymphoma or a solid tumor cancer.
[0019] In an embodiment, the invention provides a kit comprising a
composition comprising a PI3K inhibitor and a composition
comprising a BTK inhibitor. These compositions are typically both
pharmaceutical compositions. The kit is for co-administration of
the PI3K inhibitor and the BTK inhibitor, either simultaneously or
separately.
[0020] In an embodiment, the invention provides a kit comprising a
composition comprising a PI3K-.gamma. inhibitor and a composition
comprising a BTK inhibitor. These compositions are typically both
pharmaceutical compositions. The kit is for co-administration of
the PI3K-.gamma. inhibitor and the BTK inhibitor, either
simultaneously or separately.
[0021] In an embodiment, the invention provides a kit comprising a
composition comprising a PI3K-.delta. inhibitor and a composition
comprising a BTK inhibitor. These compositions are typically both
pharmaceutical compositions. The kit is for co-administration of
the PI3K-.delta. inhibitor and the BTK inhibitor, either
simultaneously or separately.
[0022] In an embodiment, the invention provides a kit comprising a
composition comprising a PI3K-.gamma.,.delta. inhibitor and a
composition comprising a BTK inhibitor. These compositions are
typically both pharmaceutical compositions. The kit is for
co-administration of the PI3K-.gamma.,.delta. inhibitor and the BTK
inhibitor, either simultaneously or separately.
[0023] In an embodiment, the invention provides a kit comprising a
composition comprising a PI3K inhibitor and a composition
comprising a BTK inhibitor for use in the treatment of leukemia,
lymphoma or a solid tumor cancer. The compositions are typically
both pharmaceutical compositions. The kit is for use in
co-administration of the PI3K inhibitor and the BTK inhibitor,
either simultaneously or separately, in the treatment of leukemia,
lymphoma or a solid tumor cancer.
[0024] In an embodiment, the invention provides a kit comprising a
composition comprising a PI3K-.gamma. inhibitor and a composition
comprising a BTK inhibitor for use in the treatment of leukemia,
lymphoma or a solid tumor cancer. The compositions are typically
both pharmaceutical compositions. The kit is for use in
co-administration of the PI3K-.gamma. inhibitor and the BTK
inhibitor, either simultaneously or separately, in the treatment of
leukemia, lymphoma or a solid tumor cancer.
[0025] In an embodiment, the invention provides a kit comprising a
composition comprising a PI3K-.delta. inhibitor and a composition
comprising a BTK inhibitor for use in the treatment of leukemia,
lymphoma or a solid tumor cancer. The compositions are typically
both pharmaceutical compositions. The kit is for use in
co-administration of the PI3K-.delta. inhibitor and the BTK
inhibitor, either simultaneously or separately, in the treatment of
leukemia, lymphoma or a solid tumor cancer.
[0026] In an embodiment, the invention provides a kit comprising a
composition comprising a PI3K-.gamma.,.delta. inhibitor and a
composition comprising a BTK inhibitor for use in the treatment of
leukemia, lymphoma or a solid tumor cancer. The compositions are
typically both pharmaceutical compositions. The kit is for use in
co-administration of the PI3K-.gamma.,.delta. inhibitor and the BTK
inhibitor, either simultaneously or separately, in the treatment of
leukemia, lymphoma or a solid tumor cancer.
[0027] In an embodiment, the invention provides a method of
treating leukemia, lymphoma or a solid tumor cancer in a subject,
comprising co-administering to a mammal in need thereof a
therapeutically effective amount of a PI3K inhibitor and a BTK
inhibitor.
[0028] In an embodiment, the invention provides a method of
treating leukemia, lymphoma or a solid tumor cancer in a subject,
comprising co-administering to a mammal in need thereof a
therapeutically effective amount of a PI3K-.gamma. inhibitor and a
BTK inhibitor.
[0029] In an embodiment, the invention provides a method of
treating leukemia, lymphoma or a solid tumor cancer in a subject,
comprising co-administering to a mammal in need thereof a
therapeutically effective amount of a PI3K-.delta. inhibitor and a
BTK inhibitor.
[0030] In an embodiment, the invention provides a method of
treating leukemia, lymphoma or a solid tumor cancer in a subject,
comprising co-administering to a mammal in need thereof a
therapeutically effective amount of a PI3K-.gamma.,.delta.
inhibitor and a BTK inhibitor.
[0031] The BTK inhibitor, in one specific embodiment, is a compound
of Formula (XVIII), or a pharmaceutically acceptable salt thereof.
The PI3K inhibitor, in one specific embodiment, is a PI3K-.delta.
inhibitor, in particular a compound of Formula IX, or a
pharmaceutically acceptable salt thereof. In one specific
embodiment, the BTK inhibitor is a compound of Formula (XVIII) or a
pharmaceutically acceptable salt thereof, and the PI3K inhibitor is
a PI3K-.delta. inhibitor, in particular a compound of Formula IX,
or a pharmaceutically acceptable salt thereof.
BRIEF DESCRIPTION OF THE DRAWINGS
[0032] The foregoing summary, as well as the following detailed
description of the invention, will be better understood when read
in conjunction with the appended drawings.
[0033] FIG. 1 illustrates the sensitivity of the TMD8 diffuse large
B cell lymphoma (DLBCL) cell line to individual treatment with the
BTK inhibitor of Formula XVIII ("Tested Btk Inhibitor") and the
PI3K inhibitor of Formula IX ("Tested PI3K Inhibitor") and combined
treatment with Formula XVIII and Formula IX ("Btki+PI3Ki") at
different concentrations. The concentration of the first agent in
the combination (the BTK inhibitor) and the concentration of the
individual agents is given on the x-axis, and the concentration of
the added PI3K inhibitor in combination with the BTK inhibitor is
given in the legend.
[0034] FIG. 2 illustrates the sensitivity of the MINO mantle cell
lymphoma cell to individual treatment with the BTK inhibitor of
Formula XVIII ("Tested Btk Inhibitor") and the PI3K inhibitor of
Formula IX ("Tested PI3K Inhibitor") and combined treatment with
Formula XVIII and Formula IX ("Btki+PI3Ki") at different
concentrations. The concentration of the first agent in the
combination (the BTK inhibitor) and the concentration of the
individual agents is given on the x-axis, and the concentration of
the added PI3K inhibitor in combination with the BTK inhibitor is
given in the legend.
[0035] FIG. 3 illustrates the proliferative activity in primary
mantle cell lymphoma cells of Formula XVIII ("Tested Btki") and
Formula IX ("Tested PI3Ki"). The percentage viability of cells ("%
viability", y-axis) is plotted versus the concentration of the
Formula XVIII ("[Tested Btk Inhibitor]", x-axis). The concentration
of the individual BTK and PI3K inhibitors (i.e. not in combination)
are also given on the x-axis.
[0036] FIG. 4 illustrates the interaction index of the combination
of the BTK inhibitor of Formula XVIII and the PI3K inhibitor of
Formula IX in primary mantle cell lymphoma cells.
[0037] FIG. 5 illustrates the synergy observed in certain cell
lines when the BTK inhibitor of Formula (XVIII) and the
PI3K-.delta. inhibitor of Formula (IX) are combined. The tested
cell lines include Maver-1 (B cell lymphoma, mantle), Jeko (B cell
lymphoma, mantle), CCRF (B lymphoblast, acute lymphoblastic
leukemia), and SUP-B15 (B lymphoblast, acute lymphoblastic
leukemia). The dose-effect curves for these cell lines are given in
FIG. 6, FIG. 7, FIG. 8, and FIG. 9. ED25, ED50, ED75, and ED90
refer to the effective doses causing 25%, 50%, 75%, and 90% of the
maximum biological effect (proliferation).
[0038] FIG. 6 illustrates the dose-effect curves obtained for the
tested Maver-1 cell line (B cell lymphoma, mantle) using combined
dosing of the BTK inhibitor of Formula (XVIII) ("Inh.1") and the
PI3K-.delta. inhibitor of Formula (IX) ("Inh.3"). The y-axis
("Effect") is given in units of Fa (fraction affected) and the
x-axis ("Dose") is given in linear units of .mu.M.
[0039] FIG. 7 illustrates the dose-effect curves obtained for the
tested Jeko cell line (B cell lymphoma, mantle) using combined
dosing of the BTK inhibitor of Formula (XVIII) ("Inh.1") and the
PI3K-.delta. inhibitor of Formula (IX) ("Inh.3"). The y-axis
("Effect") is given in units of Fa (fraction affected) and the
x-axis ("Dose") is given in linear units of .mu.M.
[0040] FIG. 8 illustrates the dose-effect curves obtained for the
tested CCRF cell line (B lymphoblast, acute lymphoblastic leukemia)
using combined dosing of the BTK inhibitor of Formula (XVIII)
("Inh.1") and the PI3K-.delta. inhibitor of Formula (IX) ("Inh.3").
The y-axis ("Effect") is given in units of Fa (fraction affected)
and the x-axis ("Dose") is given in linear units of .mu.M.
[0041] FIG. 9 illustrates the dose-effect curves obtained for the
tested SUP-B15 cell line (B lymphoblast, acute lymphoblastic
leukemia) using combined dosing of the BTK inhibitor of Formula
(XVIII) ("Inh.1") and the PI3K-.delta. inhibitor of Formula (IX)
("Inh.3"). The y-axis ("Effect") is given in units of Fa (fraction
affected) and the x-axis ("Dose") is given in linear units of
.mu.M.
[0042] FIG. 10 illustrates the synergy observed in certain cell
lines when the BTK inhibitor of Formula (XVIII) and the
PI3K-.delta. inhibitor of Formula (IX) are combined. The tested
cell lines include Jeko (B cell lymphoma, mantle cell lymphoma) and
SU-DHL-4 (activated B cell like (ABC) diffuse large B cell
lymphoma). The dose-effect curves for these cell lines are given in
FIG. 11 and FIG. 12.
[0043] FIG. 11 illustrates the dose-effect curves obtained for the
tested Jeko cell line (B cell lymphoma, mantle) using combined
dosing of the BTK inhibitor of Formula (XVIII) ("Inh.1") and the
PI3K-.delta. inhibitor of Formula (IX) ("Inh.3"). The y-axis
("Effect") is given in units of Fa (fraction affected) and the
x-axis ("Dose") is given in linear units of .mu.M.
[0044] FIG. 12 illustrates the dose-effect curves obtained for the
tested SU-DHL-4 cell line (diffuse large B cell lymphoma, ABC)
using combined dosing of the BTK inhibitor of Formula (XVIII)
("Inh.1") and the PI3K-.delta. inhibitor of Formula (IX) ("Inh.3").
The y-axis ("Effect") is given in units of Fa (fraction affected)
and the x-axis ("Dose") is given in linear units of .mu.M.
[0045] FIG. 13 illustrates the synergy observed in certain cell
lines when the BTK inhibitor of Formula (XVIII) and the
PI3K-.delta. inhibitor of Formula (IX) are combined. The tested
cell lines include CCRF (B lymphoblast, acute lymphoblastic
leukemia), SUP-B15 (B lymphoblast, acute lymphoblastic leukemia),
JVM-2 (prolymphocytic leukemia), Ramos (Burkitt's lymphoma), and
Mino (mantle cell lymphoma). The dose-effect curves for these cell
lines are given in FIG. 14, FIG. 15, FIG. 16, and FIG. 17. No
dose-effect curve is given for Ramos (Burkitt's lymphoma) because
of negative slope.
[0046] FIG. 14 illustrates the dose-effect curves obtained for the
tested CCRF cell line (B lymphoblast, acute lymphoblastic leukemia)
using combined dosing of the BTK inhibitor of Formula (XVIII)
("Inh.1") and the PI3K-.delta. inhibitor of Formula (IX) ("Inh.3").
The y-axis ("Effect") is given in units of Fa (fraction affected)
and the x-axis ("Dose") is given in linear units of .mu.M.
[0047] FIG. 15 illustrates the dose-effect curves obtained for the
tested SUP-B15 cell line (B lymphoblast, acute lymphoblastic
leukemia) using combined dosing of the BTK inhibitor of Formula
(XVIII) ("Inh.1") and the PI3K-.delta. inhibitor of Formula (IX)
("Inh.3"). The y-axis ("Effect") is given in units of Fa (fraction
affected) and the x-axis ("Dose") is given in linear units of
.mu.M.
[0048] FIG. 16 illustrates the dose-effect curves obtained for the
tested JVM-2 cell line (prolymphocytic leukemia) using combined
dosing of the BTK inhibitor of Formula (XVIII) ("Inh.1") and the
PI3K-.delta. inhibitor of Formula (IX) ("Inh.3"). The y-axis
("Effect") is given in units of Fa (fraction affected) and the
x-axis ("Dose") is given in linear units of .mu.M.
[0049] FIG. 17 illustrates the dose-effect curves obtained for the
tested Mino cell line (mantle cell lymphoma) using combined dosing
of the BTK inhibitor of Formula (XVIII) ("Inh.1") and the
PI3K-.delta. inhibitor of Formula (IX) ("Inh.3"). The y-axis
("Effect") is given in units of Fa (fraction affected) and the
x-axis ("Dose") is given in linear units of .mu.M.
[0050] FIG. 18 illustrates the synergy observed in certain cell
lines when the BTK inhibitor of Formula (XVIII) and the
PI3K-.delta. inhibitor of Formula (IX) are combined. The tested
cell lines include Raji (B lymphocyte, Burkitt's lymphoma),
SU-DHL-1 (DLBCL-ABC), and Pfeiffer (follicular lymphoma). The
dose-effect curves for these cell lines are given in FIG. 19, FIG.
20, and FIG. 21.
[0051] FIG. 19 illustrates the dose-effect curves obtained for the
tested Raji cell line (B lymphocyte, Burkitt's lymphoma) using
combined dosing of the BTK inhibitor of Formula (XVIII) ("Inh.1")
and the PI3K-.delta. inhibitor of Formula (IX) ("Inh.3"). The
y-axis ("Effect") is given in units of Fa (fraction affected) and
the x-axis ("Dose") is given in linear units of .mu.M.
[0052] FIG. 20 illustrates the dose-effect curves obtained for the
tested SU-DHL-1 cell line (DLBCL-ABC) using combined dosing of the
BTK inhibitor of Formula (XVIII) ("Inh.1") and the PI3K-.delta.
inhibitor of Formula (IX) ("Inh.3"). The y-axis ("Effect") is given
in units of Fa (fraction affected) and the x-axis ("Dose") is given
in linear units of .mu.M.
[0053] FIG. 21 illustrates the dose-effect curves obtained for the
tested Pfeiffer cell line (follicular lymphoma) using combined
dosing of the BTK inhibitor of Formula (XVIII) ("Inh.1") and the
PI3K-.delta. inhibitor of Formula (IX) ("Inh.3"). The y-axis
("Effect") is given in units of Fa (fraction affected) and the
x-axis ("Dose") is given in linear units of .mu.M.
[0054] FIG. 22 illustrates the synergy observed in certain cell
lines when the BTK inhibitor of Formula (XVIII) and the
PI3K-.delta. inhibitor of Formula (IX) are combined. The tested
cell lines include Ly1 (Germinal center B-cell like diffuse large
B-cell lymphoma, DLBCL-GCB), Ly7 (DLBCL-GCB), Ly19 (DLBCL-GCB),
SU-DHL-2 (Activated B-cell like diffuse large B-cell lymphoma,
DLBCL-ABC), and DOHH2 (follicular lymphoma, FL). The dose-effect
curves for these cell lines are given in FIG. 23, FIG. 24, FIG. 25,
and FIG. 26, except for the Ly19 cell line, which is not graphed
because of a negative slope.
[0055] FIG. 23 illustrates the dose-effect curves obtained for the
tested Ly1 cell line (DLBCL-GCB) using combined dosing of the BTK
inhibitor of Formula (XVIII) ("Inh.1") and the PI3K-.delta.
inhibitor of Formula (IX) ("Inh.3"). The y-axis ("Effect") is given
in units of Fa (fraction affected) and the x-axis ("Dose") is given
in linear units of .mu.M.
[0056] FIG. 24 illustrates the dose-effect curves obtained for the
tested Ly7 cell line (DLBCL-GCB) using combined dosing of the BTK
inhibitor of Formula (XVIII) ("Inh.1") and the PI3K-.delta.
inhibitor of Formula (IX) ("Inh.3"). The y-axis ("Effect") is given
in units of Fa (fraction affected) and the x-axis ("Dose") is given
in linear units of .mu.M.
[0057] FIG. 25 illustrates the dose-effect curves obtained for the
tested DOHH2 cell line (FL) using combined dosing of the BTK
inhibitor of Formula (XVIII) ("Inh.1") and the PI3K-.delta.
inhibitor of Formula (IX) ("Inh.3"). The y-axis ("Effect") is given
in units of Fa (fraction affected) and the x-axis ("Dose") is given
in linear units of .mu.M.
[0058] FIG. 26 illustrates the dose-effect curves obtained for the
tested SU-DHL-2 cell line (DLBCL-ABC) using combined dosing of the
BTK inhibitor of Formula (XVIII) ("Inh.1") and the PI3K-.delta.
inhibitor of Formula (IX) ("Inh.3"). The y-axis ("Effect") is given
in units of Fa (fraction affected) and the x-axis ("Dose") is given
in linear units of .mu.M.
[0059] FIG. 27 illustrates the synergy observed in certain cell
lines when Formula (XVIII) and Formula (IX) are combined. The
tested cell lines include U937 (histiocytic lymphoma and/or
myeloid), K562 (leukemia, myeloid, and/or chronic myelogenous
leukemia), Daudi (human Burkitt's lymphoma), and SU-DHL-6
(DLBCL-GCB and/or peripheral T-cell lymphoma, PTCL). The
dose-effect curves for these cell lines are given in FIG. 28, FIG.
29, FIG. 30, and FIG. 31.
[0060] FIG. 28 illustrates the dose-effect curves obtained for the
tested U937 cell line (histiocytic lymphoma and/or myeloid) using
combined dosing of the BTK inhibitor of Formula (XVIII) ("Inh.1")
and the PI3K-.delta. inhibitor of Formula (IX) ("Inh.3"). The
y-axis ("Effect") is given in units of Fa (fraction affected) and
the x-axis ("Dose") is given in linear units of .mu.M.
[0061] FIG. 29 illustrates the dose-effect curves obtained for the
tested K562 cell line (leukemia, myeloid, and/or chronic
myelogenous leukemia) using combined dosing of the BTK inhibitor of
Formula (XVIII) ("Inh.1") and the PI3K-.delta. inhibitor of Formula
(IX) ("Inh.3"). The y-axis ("Effect") is given in units of Fa
(fraction affected) and the x-axis ("Dose") is given in linear
units of .mu.M.
[0062] FIG. 30 illustrates the dose-effect curves obtained for the
tested Daudi cell line (human Burkitt's lymphoma) using combined
dosing of the BTK inhibitor of Formula (XVIII) ("Inh.1") and the
PI3K-.delta. inhibitor of Formula (IX) ("Inh.3"). The y-axis
("Effect") is given in units of Fa (fraction affected) and the
x-axis ("Dose") is given in linear units of .mu.M.
[0063] FIG. 31 illustrates the dose-effect curves obtained for the
tested SU-DHL-6 cell line (DLBCL-GCB and/or PTCL) using combined
dosing of the BTK inhibitor of Formula (XVIII) ("Inh.1") and the
PI3K-.delta. inhibitor of Formula (IX) ("Inh.3"). The y-axis
("Effect") is given in units of Fa (fraction affected) and the
x-axis ("Dose") is given in linear units of .mu.M.
[0064] FIG. 32 illustrates the synergy observed in certain cell
lines when the BTK inhibitor of Formula (XVIII) and the
PI3K-.delta. inhibitor of Formula (IX) are combined. The tested
cell lines include SU-DHL-6 (DLBCL-GCB or PTCL), TMD-8 (DLBCL-ABC),
HBL-1 (DLBCL-ABC), and Rec-1 (follicular lymphoma). The dose-effect
curves for these cell lines are given in FIG. 34, FIG. 35, FIG. 36,
and FIG. 37.
[0065] FIG. 33 illustrates the synergy observed in certain cell
lines when the BTK inhibitor of Formula (XVIII) and the
PI3K-.delta. inhibitor of Formula (IX) are combined. The tested
cell lines include SU-DHL-6 (DLBCL-GCB or PTCL), TMD-8 (DLBCL-ABC),
HBL-1 (DLBCL-ABC), and Rec-1 (follicular lymphoma). All
corresponding CIs are shown for each of the combinations tested as
listed on the x axis.
[0066] FIG. 34 illustrates the dose-effect curves obtained for the
tested SU-DHL-6 cell line (DLBCL-GCB or PTCL) cell line using
combined dosing of the BTK inhibitor of Formula (XVIII) ("Inh.1")
and the PI3K-.delta. inhibitor of Formula (IX) ("Inh.3"). The
y-axis ("Effect") is given in units of Fa (fraction affected) and
the x-axis ("Dose") is given in linear units of .mu.M.
[0067] FIG. 35 illustrates the dose-effect curves obtained for the
tested TMD-8 cell line (DLBCL-ABC) using combined dosing of the BTK
inhibitor of Formula (XVIII) ("Inh.1") and the PI3K-.delta.
inhibitor of Formula (IX) ("Inh.3"). The y-axis ("Effect") is given
in units of Fa (fraction affected) and the x-axis ("Dose") is given
in linear units of .mu.M.
[0068] FIG. 36 illustrates the dose-effect curves obtained for the
tested HBL-1 cell line (DLBCL-ABC) using combined dosing of the BTK
inhibitor of Formula (XVIII) ("Inh.1") and the PI3K-.delta.
inhibitor of Formula (IX) ("Inh.3"). The y-axis ("Effect") is given
in units of Fa (fraction affected) and the x-axis ("Dose") is given
in linear units of .mu.M.
[0069] FIG. 37 illustrates the dose-effect curves obtained for the
tested Rec-1 cell line (follicular lymphoma) using combined dosing
of the BTK inhibitor of Formula (XVIII) ("Inh.1") and the
PI3K-.delta. inhibitor of Formula (IX) ("Inh.3"). The y-axis
("Effect") is given in units of Fa (fraction affected) and the
x-axis ("Dose") is given in linear units of .mu.M.
[0070] FIG. 38 illustrates tumor growth suppression in an
orthotopic pancreatic cancer model. Mice were dosed orally with 15
mg/kg of the BTK inhibitor of Formula (XVIII), 15 mg/kg of the
PI3K-.delta. inhibitor of Formula (IX), or a combination of both
drugs. The statistical p-value (presumption against null
hypothesis) is shown for each tested single agent and for the
combination against the vehicle.
[0071] FIG. 39 illustrates the effects of oral dosing with 15 mg/kg
of the BTK inhibitor of Formula (XVIII), 15 mg/kg of the
PI3K-.delta. inhibitor of Formula (IX), or a combination of both
inhibitors on myeloid tumor-associated macrophages (TAMs) in
pancreatic tumor-bearing mice.
[0072] FIG. 40 illustrates the effects of oral dosing with 15 mg/kg
of the BTK inhibitor of Formula (XVIII), 15 mg/kg of the
PI3K-.delta. inhibitor of Formula (IX), or a combination of both
inhibitors on myeloid-derived suppressor cells (MDSCs) in
pancreatic tumor-bearing mice.
[0073] FIG. 41 illustrates the effects of oral dosing with 15 mg/kg
of the BTK inhibitor of Formula (XVIII), 15 mg/kg of the
PI3K-.delta. inhibitor of Formula (IX), or a combination of both
inhibitors on regulatory T cells (Tregs) in pancreatic
tumor-bearing mice.
[0074] FIG. 42 illustrates the effects of vehicle on flux at two
timepoints, as a control for comparison with FIG. 100, in the ID8
syngeneic orthotropic ovarian cancer model.
[0075] FIG. 43 illustrates the effects of the BTK inhibitor of
Formula (XVIII) on flux at two timepoints, for comparison with FIG.
99, in the ID8 syngeneic orthotropic ovarian cancer model.
[0076] FIG. 44 illustrates tumor response to treatment with the BTK
inhibitor of Formula (XVIII) correlates with a significant
reduction in immunosuppressive tumor associated lymphocytes in
tumor-bearing mice, in comparison to a control (vehicle).
[0077] FIG. 45 illustrates that treatment with the BTK inhibitor of
Formula (XVIII) impairs ID8 ovarian cancer growth in the syngeneic
murine model in comparison to a control (vehicle).
[0078] FIG. 46 illustrates that treatment with the BTK inhibitor of
Formula (XVIII) induces a tumor response that correlates with a
significant reduction in total B cells in tumor-bearing mice.
[0079] FIG. 47 illustrates that treatment with the BTK inhibitor of
Formula (XVIII) induces a tumor response that correlates with a
significant reduction in B regulatory cells (Bregs) in
tumor-bearing mice.
[0080] FIG. 48 illustrates that treatment with the BTK inhibitor of
Formula (XVIII) induces a tumor response that correlates with a
significant reduction in immunosuppressive tumor associated
Tregs.
[0081] FIG. 49 illustrates that treatment with the BTK inhibitor of
Formula (XVIII) induces a tumor response that correlates with an
increase in CD8.sup.+ T cells.
[0082] FIG. 50 illustrates the effects on tumor volume of vehicle
(measured in mm.sup.3) of the BTK inhibitor of Formula (XVIII), a
combination of the BTK inhibitor of Formula (XVIII) and gemcitabine
("Gem"), and gemcitabine alone.
[0083] FIG. 51 illustrates the effects on the amount of CD8.sup.+ T
cells, given as a percentage of cells expressing the T cell
receptor (CD3), of the BTK inhibitor of Formula (XVIII), a
combination of the BTK inhibitor of Formula (XVIII) and gemcitabine
("Gem"), and gemcitabine alone.
[0084] FIG. 52 illustrates the effects on the percentage of
CD4.sup.+, CD25.sup.+, and FoxP3.sup.+ T regulatory cells
("Tregs"), given as a percentage of cells expressing the T cell
receptor (CD3), of the BTK inhibitor of Formula (XVIII), a
combination of the BTK inhibitor of Formula (XVIII) and gemcitabine
("Gem"), and gemcitabine alone.
[0085] FIG. 53 illustrates the effects on the percentage of
CD11b.sup.+, LY6C.sup.low, F4/80.sup.+, and Csflr.sup.+
tumor-associated macrophages ("TAMs"), given as a percentage of
cells expressing the T cell receptor (CD3), of the BTK inhibitor of
Formula (XVIII), a combination of the BTK inhibitor of Formula
(XVIII) and gemcitabine ("Gem"), and gemcitabine alone.
[0086] FIG. 54 illustrates the effects on the percentage of
Gr1.sup.+ and LY6C.sup.hi, F4/80.sup.+, and Csflr.sup.+
myeloid-derived suppressor cells ("MDSCs"), given as a percentage
of cells expressing the T cell receptor (CD3), of the BTK inhibitor
of Formula (XVIII), a combination of the BTK inhibitor of Formula
(XVIII) and gemcitabine ("Gem"), and gemcitabine alone.
[0087] FIG. 55 illustrates representative photomicrographs and
comparison of maximal thrombus size in laser injured arterioles of
VWF HAI mutant mice infused with human platelets in the absence or
presence of various BTK inhibitors. Representative photomicrographs
are given as a comparison of maximal thrombus size in laser-injured
arterioles (1 .mu.M concentrations shown).
[0088] FIG. 56 illustrates a quantitative comparison obtained by in
vivo analysis of early thrombus dynamics in a humanized mouse laser
injury model using three BTK inhibitors at a concentration 1
.mu.M.
[0089] FIG. 57 illustrates the effect of the tested BTK inhibitors
on thrombus formation. The conditions used were N=4, 3 mice per
drug; anti-clotting agents <2000 .mu.M.sup.2. In studies with
ibrutinib, 48% MCL bleeding events were observed with 560 mg QD and
63% CLL bleeding events were observed with 420 mg QD, where
bleeding event is defined as subdural hematoma, ecchymoses, GI
bleeding, or hematuria.
[0090] FIG. 58 illustrates the effect of the concentration of the
tested BTK inhibitors on thrombus formation.
[0091] FIG. 59 illustrates the results of GPVI platelet aggregation
studies of Formula XVIII (IC50=1.15 .mu.M) and Formula XX-A
(ibrutinib, IC50=0.13 .mu.M).
[0092] FIG. 60 illustrates the results of GPVI platelet aggregation
studies of Formula XVIII and Formula XX-A (ibrutinib).
DETAILED DESCRIPTION OF THE INVENTION
[0093] Unless defined otherwise, all technical and scientific terms
used herein have the same meaning as is commonly understood by one
of skill in the art to which this invention belongs.
[0094] The terms "co-administration" and "administered in
combination with" as used herein, encompass administration of two
or more agents (such as at least one PI3K inhibitor and at least
one BTK inhibitor) to a subject (such as a human or a mammal), so
that both agents and/or their metabolites are present in the
subject at the same time. Agents are also referred to as active
ingredients, or active pharmaceutical ingredients, or drugs.
Co-administration includes simultaneous administration in separate
compositions (also referred to as concurrent administration),
administration at different times in separate compositions, or
administration in a composition in which both agents are present.
Simultaneous administration in separate compositions and
administration in a composition in which both agents are present
are preferred.
[0095] The term "effective amount" or "therapeutically effective
amount" refers to that amount of a compound or combination of
compounds as described herein that is sufficient to effect the
intended application including, but not limited to, disease
treatment. A therapeutically effective amount may vary depending
upon the intended application (in vitro or in vivo), or the subject
and disease condition being treated (e.g., the weight, age and
gender of the subject), the severity of the disease condition, the
manner of administration, etc. which can readily be determined by
one of ordinary skill in the art. The term also applies to a dose
that will induce a particular response in target cells, (e.g., the
reduction of platelet adhesion and/or cell migration). The specific
dose will vary depending on the particular compounds chosen, the
dosing regimen to be followed, whether the compound is administered
in combination with other compounds, timing of administration, the
tissue to which it is administered, and the physical delivery
system in which the compound is carried.
[0096] A "therapeutic effect" as that term is used herein,
encompasses a therapeutic benefit and/or a prophylactic benefit. A
prophylactic effect includes delaying or eliminating the appearance
of a disease or condition, delaying or eliminating the onset of
symptoms of a disease or condition, slowing, halting, or reversing
the progression of a disease or condition, or any combination
thereof.
[0097] The term "pharmaceutically acceptable salt" refers to salts
derived from a variety of organic and inorganic counter ions known
in the art. Pharmaceutically acceptable acid addition salts can be
formed with inorganic acids and organic acids. Inorganic acids from
which salts can be derived include, for example, hydrochloric acid,
hydrobromic acid, sulfuric acid, nitric acid and phosphoric acid.
Organic acids from which salts can be derived include, for example,
acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic
acid, maleic acid, malonic acid, succinic acid, fumaric acid,
tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic
acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic
acid and salicylic acid. Pharmaceutically acceptable base addition
salts can be formed with inorganic and organic bases. Inorganic
bases from which salts can be derived include, for example, sodium,
potassium, lithium, ammonium, calcium, magnesium, iron, zinc,
copper, manganese and aluminum. Organic bases from which salts can
be derived include, for example, primary, secondary, and tertiary
amines, substituted amines including naturally occurring
substituted amines, cyclic amines and basic ion exchange resins.
Specific examples include isopropylamine, trimethylamine,
diethylamine, triethylamine, tripropylamine, and ethanolamine. In
selected embodiments, the pharmaceutically acceptable base addition
salt is chosen from ammonium, potassium, sodium, calcium, and
magnesium salts.
[0098] "Pharmaceutically acceptable carrier" or "pharmaceutically
acceptable excipient" is intended to include any and all solvents,
dispersion media, coatings, antibacterial and antifungal agents,
isotonic and absorption delaying agents, and inert ingredients. The
use of such pharmaceutically acceptable carriers or
pharmaceutically acceptable excipients for active pharmaceutical
ingredients is well known in the art. Except insofar as any
conventional pharmaceutically acceptable carrier or
pharmaceutically acceptable excipient is incompatible with the
active pharmaceutical ingredient, its use in the therapeutic
compositions of the invention is contemplated. Supplementary active
pharmaceutical ingredients, such as other drugs, can also be
incorporated into the described compositions and methods.
[0099] "Prodrug" is intended to describe a compound that may be
converted under physiological conditions or by solvolysis to a
biologically active compound described herein. Thus, the term
"prodrug" refers to a precursor of a biologically active compound
that is pharmaceutically acceptable. A prodrug may be inactive when
administered to a subject, but is converted in vivo to an active
compound, for example, by hydrolysis. The prodrug compound often
offers the advantages of solubility, tissue compatibility or
delayed release in a mammalian organism (see, e.g., Bundgaard, H.,
Design of Prodrugs (1985) (Elsevier, Amsterdam). The term "prodrug"
is also intended to include any covalently bonded carriers, which
release the active compound in vivo when administered to a subject.
Prodrugs of an active compound, as described herein, may be
prepared by modifying functional groups present in the active
compound in such a way that the modifications are cleaved, either
in routine manipulation or in vivo, to yield the active parent
compound. Prodrugs include, for example, compounds wherein a
hydroxy, amino or mercapto group is bonded to any group that, when
the prodrug of the active compound is administered to a mammalian
subject, cleaves to form a free hydroxy, free amino or free
mercapto group, respectively. Examples of prodrugs include, but are
not limited to, acetates, formates and benzoate derivatives of an
alcohol, various ester derivatives of a carboxylic acid, or
acetamide, formamide and benzamide derivatives of an amine
functional group in the active compound.
[0100] The term "in vivo" refers to an event that takes place in a
subject's body.
[0101] The term "in vitro" refers to an event that takes places
outside of a subject's body. In vitro assays encompass cell-based
assays in which cells alive or dead are employed and may also
encompass a cell-free assay in which no intact cells are
employed.
[0102] Unless otherwise stated, the chemical structures depicted
herein are intended to include compounds which differ only in the
presence of one or more isotopically enriched atoms. For example,
compounds where one or more hydrogen atoms is replaced by deuterium
or tritium, or wherein one or more carbon atoms is replaced by
.sup.13C- or .sup.14C-enriched carbons, are within the scope of
this invention.
[0103] When ranges are used herein to describe, for example,
physical or chemical properties such as weight or chemical
formulae, all combinations and subcombinations of ranges and
specific embodiments therein are intended to be included. Use of
the term "about" when referring to a number or a numerical range
means that the number or numerical range referred to is an
approximation within experimental variability (or within
statistical experimental error), and thus the number or numerical
range may vary. The variation is typically from 0% to 10%,
preferably from 0% to 10%, more preferably from 0% to 5% of the
stated number or numerical range. The term "comprising" (and
related terms such as "comprise" or "comprises" or "having" or
"including") encompasses those embodiments such as, for example, an
embodiment of any composition of matter, method or process that
"consist of" or "consist essentially of" the described
features.
[0104] "Alkyl" refers to a straight or branched hydrocarbon chain
radical consisting solely of carbon and hydrogen atoms, containing
no unsaturation, having from one to ten carbon atoms (i.e.,
C.sub.1-C.sub.10alkyl and (C.sub.1-C.sub.10)alkyl). Whenever it
appears herein, a numerical range such as "1 to 10" refers to each
integer in the given range--e.g., "1 to 10 carbon atoms" means that
the alkyl group may consist of 1 carbon atom, 2 carbon atoms, 3
carbon atoms, etc., up to and including 10 carbon atoms, although
the definition is also intended to cover the occurrence of the term
"alkyl" where no numerical range is specifically designated.
Typical alkyl groups include, but are in no way limited to, methyl,
ethyl, propyl, isopropyl, n-butyl, iso-butyl, sec-butyl isobutyl,
tertiary butyl, pentyl, isopentyl, neopentyl, hexyl, heptyl, octyl,
nonyl and decyl. The alkyl moiety may be attached to the rest of
the molecule by a single bond, such as for example, methyl (Me),
ethyl (Et), n-propyl (Pr), 1-methylethyl (iso-propyl), n-butyl,
n-pentyl, 1,1-dimethylethyl (t-butyl) and 3-methylhexyl. Unless
stated otherwise specifically in the specification, an alkyl group
is optionally substituted by one or more of substituents which are
independently alkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl,
heterocycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl,
hydroxy, halo, cyano, trifluoromethyl, trifluoromethoxy, nitro,
trimethylsilanyl, --OR.sup.a, --SR.sup.a, --OC(O)--R.sup.a,
--N(R.sup.a).sub.2, --C(O)R.sup.a, --C(O)OR.sup.a,
--OC(O)N(R.sup.a).sub.2, --C(O)N(R.sup.a).sub.2,
--N(R.sup.a)C(O)OR.sup.a, --N(R.sup.a)C(O)R.sup.a,
--N(R.sup.a)C(O)N(R.sup.a).sub.2,
N(R.sup.a)C(NR.sup.a)N(R.sup.a).sub.2,
--N(R.sup.a)S(O).sub.tR.sup.a (where t is 1 or 2),
--S(O).sub.tOR.sup.a (where t is 1 or 2),
--S(O).sub.tN(R.sup.a).sub.2 (where t is 1 or 2), or
PO.sub.3(R.sup.a).sub.2 where each R.sup.a is independently
hydrogen, unsubstituted alkyl, fluoroalkyl, carbocyclyl,
carbocyclylalkyl, aryl, aralkyl, heterocycloalkyl,
heterocycloalkylalkyl, heteroaryl or heteroarylalkyl.
[0105] "Alkylaryl" refers to an -(alkyl)aryl radical where aryl and
alkyl are as disclosed herein and which are optionally substituted
by one or more of the substituents described as suitable
substituents for aryl and alkyl respectively.
[0106] "Alkylhetaryl" refers to an -(alkyl)hetaryl radical where
hetaryl and alkyl are as disclosed herein and which are optionally
substituted by one or more of the substituents described as
suitable substituents for aryl and alkyl respectively.
[0107] "Alkylheterocycloalkyl" refers to an -(alkyl) heterocycyl
radical where alkyl and heterocycloalkyl are as disclosed herein
and which are optionally substituted by one or more of the
substituents described as suitable substituents for
heterocycloalkyl and alkyl respectively.
[0108] An "alkene" moiety refers to a group consisting of at least
two carbon atoms and at least one carbon-carbon double bond, and an
"alkyne" moiety refers to a group consisting of at least two carbon
atoms and at least one carbon-carbon triple bond. The alkyl moiety,
whether saturated or unsaturated, may be branched, straight chain,
or cyclic.
[0109] "Alkenyl" refers to a straight or branched hydrocarbon chain
radical group consisting solely of carbon and hydrogen atoms,
containing at least one double bond, and having from two to ten
carbon atoms (i.e., C.sub.2-C.sub.10 alkenyl and
(C.sub.2-C.sub.10)alkenyl). Whenever it appears herein, a numerical
range such as "2 to 10" refers to each integer in the given
range--e.g., "2 to 10 carbon atoms" means that the alkenyl group
may consist of 2 carbon atoms, 3 carbon atoms, etc., up to and
including 10 carbon atoms. The alkenyl moiety may be attached to
the rest of the molecule by a single bond, such as for example,
ethenyl (i.e., vinyl), prop-1-enyl (i.e., allyl), but-1-enyl,
pent-1-enyl and penta-1,4-dienyl. Unless stated otherwise
specifically in the specification, an alkenyl group is optionally
substituted by one or more substituents which are independently
alkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl,
aryl, arylalkyl, heteroaryl, heteroarylalkyl, hydroxy, halo, cyano,
trifluoromethyl, trifluoromethoxy, nitro, trimethylsilanyl,
--OR.sup.a, --SR.sup.a, --OC(O)--R.sup.a, --N(R.sup.a).sub.2,
--C(O)R.sup.a, --C(O)OR.sup.a, --OC(O)N(R.sup.a).sub.2,
--C(O)N(R.sup.a).sub.2, --N(R.sup.a)C(O)OR.sup.a,
--N(R.sup.a)C(O)R.sup.a, --N(R.sup.a)C(O)N(R.sup.a).sub.2,
N(R.sup.a)C(NR.sup.a)N(R.sup.a).sub.2,
--N(R.sup.a)S(O).sub.tR.sup.a (where t is 1 or 2),
--S(O).sub.tOR.sup.a (where t is 1 or 2),
--S(O).sub.tN(R.sup.a).sub.2 (where t is 1 or 2), or
PO.sub.3(R.sup.a).sub.2, where each R.sup.a is independently
hydrogen, alkyl, fluoroalkyl, carbocyclyl, carbocyclylalkyl, aryl,
aralkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl or
heteroarylalkyl.
[0110] "Alkenyl-cycloalkyl" refers to an (alkenyl)cycloalkyl
radical where alkenyl and cycloalkyl are as disclosed herein and
which are optionally substituted by one or more of the substituents
described as suitable substituents for alkenyl and cycloalkyl
respectively.
[0111] "Alkynyl" refers to a straight or branched hydrocarbon chain
radical group consisting solely of carbon and hydrogen atoms,
containing at least one triple bond, having from two to ten carbon
atoms (i.e. C.sub.2-C.sub.10 alkynyl and
(C.sub.2-C.sub.10)alkynyl). Whenever it appears herein, a numerical
range such as "2 to 10" refers to each integer in the given
range--e.g., "2 to 10 carbon atoms" means that the alkynyl group
may consist of 2 carbon atoms, 3 carbon atoms, etc., up to and
including 10 carbon atoms. The alkynyl may be attached to the rest
of the molecule by a single bond, for example, ethynyl, propynyl,
butynyl, pentynyl and hexynyl. Unless stated otherwise specifically
in the specification, an alkynyl group is optionally substituted by
one or more substituents which independently are: alkyl,
heteroalkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl,
arylalkyl, heteroaryl, heteroarylalkyl, hydroxy, halo, cyano,
trifluoromethyl, trifluoromethoxy, nitro, trimethylsilanyl,
--OR.sup.a, --SR.sup.a, --OC(O)--R.sup.a, --N(R.sup.a).sub.2,
--C(O)R.sup.a, --C(O)OR.sup.a, --OC(O)N(R.sup.a).sub.2,
--C(O)N(R.sup.a).sub.2, --N(R.sup.a)C(O)OR.sup.a,
--N(R.sup.a)C(O)R.sup.a, --N(R.sup.a)C(O)N(R.sup.a).sub.2,
N(R.sup.a)C(NR.sup.a)N(R.sup.a).sub.2,
--N(R.sup.a)S(O).sub.tR.sup.a (where t is 1 or 2),
--S(O).sub.tOR.sup.a (where t is 1 or 2),
--S(O).sub.tN(R.sup.a).sub.2 (where t is 1 or 2), or
PO.sub.3(R.sup.a).sub.2, where each R.sup.a is independently
hydrogen, alkyl, fluoroalkyl, carbocyclyl, carbocyclylalkyl, aryl,
aralkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl or
heteroarylalkyl.
[0112] "Alkynyl-cycloalkyl" refers to an -(alkynyl)cycloalkyl
radical where alkynyl and cycloalkyl are as disclosed herein and
which are optionally substituted by one or more of the substituents
described as suitable substituents for alkynyl and cycloalkyl
respectively.
[0113] "Carboxaldehyde" refers to a --(C.dbd.O)H radical.
[0114] "Carboxyl" refers to a --(C.dbd.O)OH radical.
[0115] "Cyano" refers to a --CN radical.
[0116] "Cycloalkyl" refers to a monocyclic or polycyclic radical
that contains only carbon and hydrogen, and may be saturated, or
partially unsaturated. Cycloalkyl groups include groups having from
3 to 10 ring atoms (i.e. C.sub.2-C.sub.10 cycloalkyl and
(C.sub.2-C.sub.10)cycloalkyl). Whenever it appears herein, a
numerical range such as "3 to 10" refers to each integer in the
given range--e.g., "3 to 10 carbon atoms" means that the cycloalkyl
group may consist of 3 carbon atoms and greater, up to and
including 10 carbon atoms. Illustrative examples of cycloalkyl
groups include, but are not limited to the following moieties:
cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl,
cyclohexenyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl,
norbornyl, and the like. Unless stated otherwise specifically in
the specification, a cycloalkyl group is optionally substituted by
one or more substituents which independently are: alkyl,
heteroalkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl,
arylalkyl, heteroaryl, heteroarylalkyl, hydroxy, halo, cyano,
trifluoromethyl, trifluoromethoxy, nitro, trimethylsilanyl,
--OR.sup.a, --SR.sup.a, --OC(O)--R.sup.a, --N(R.sup.a).sub.2,
--C(O)R.sup.a, --C(O)OR.sup.a, --OC(O)N(R.sup.a).sub.2,
--C(O)N(R.sup.a).sub.2, --N(R.sup.a)C(O)OR.sup.a,
--N(R.sup.a)C(O)R.sup.a, --N(R.sup.a)C(O)N(R.sup.a).sub.2,
N(R.sup.a)C(NR.sup.a)N(R.sup.a).sub.2,
--N(R.sup.a)S(O).sub.tR.sup.a (where t is 1 or 2),
--S(O).sub.tOR.sup.a (where t is 1 or 2),
--S(O).sub.tN(R.sup.a).sub.2 (where t is 1 or 2), or
PO.sub.3(R.sup.a).sub.2, where each R.sup.a is independently
hydrogen, alkyl, fluoroalkyl, carbocyclyl, carbocyclylalkyl, aryl,
aralkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl or
heteroarylalkyl.
[0117] "Cycloalkyl-alkenyl" refers to a -(cycloalkyl)alkenyl
radical where cycloalkyl and alkenyl are as disclosed herein and
which are optionally substituted by one or more of the substituents
described as suitable substituents for cycloalkyl and alkenyl,
respectively.
[0118] "Cycloalkyl-heterocycloalkyl" refers to a
-(cycloalkyl)heterocycloalkyl radical where cycloalkyl and
heterocycloalkyl are as disclosed herein and which are optionally
substituted by one or more of the substituents described as
suitable substituents for cycloalkyl and heterocycloalkyl,
respectively.
[0119] "Cycloalkyl-heteroaryl" refers to a -(cycloalkyl)heteroaryl
radical where cycloalkyl and heteroaryl are as disclosed herein and
which are optionally substituted by one or more of the substituents
described as suitable substituents for cycloalkyl and heteroaryl,
respectively.
[0120] The term "alkoxy" refers to the group --O-alkyl, including
from 1 to 8 carbon atoms of a straight, branched, cyclic
configuration and combinations thereof attached to the parent
structure through an oxygen. Examples include, but are not limited
to, methoxy, ethoxy, propoxy, isopropoxy, cyclopropyloxy and
cyclohexyloxy. "Lower alkoxy" refers to alkoxy groups containing
one to six carbons.
[0121] The term "substituted alkoxy" refers to alkoxy wherein the
alkyl constituent is substituted (i.e., --O-(substituted alkyl)).
Unless stated otherwise specifically in the specification, the
alkyl moiety of an alkoxy group is optionally substituted by one or
more substituents which independently are: alkyl, heteroalkyl,
alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, arylalkyl,
heteroaryl, heteroarylalkyl, hydroxy, halo, cyano, trifluoromethyl,
trifluoromethoxy, nitro, trimethylsilanyl, --OR.sup.a, --SR.sup.a,
--OC(O)--R.sup.a, --N(R.sup.a).sub.2, --C(O)R.sup.a,
--C(O)OR.sup.a, --OC(O)N(R.sup.a).sub.2, --C(O)N(R.sup.a).sub.2,
--N(R.sup.a)C(O)OR.sup.a, --N(R.sup.a)C(O)R.sup.a,
--N(R.sup.a)C(O)N(R.sup.a).sub.2,
N(R.sup.a)C(NR.sup.a)N(R.sup.a).sub.2,
--N(R.sup.a)S(O).sub.tR.sup.a (where t is 1 or 2),
--S(O).sub.tOR.sup.a (where t is 1 or 2),
--S(O).sub.tN(R.sup.a).sub.2 (where t is 1 or 2), or
PO.sub.3(R.sup.a).sub.2, where each R.sup.a is independently
hydrogen, alkyl, fluoroalkyl, carbocyclyl, carbocyclylalkyl, aryl,
aralkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl or
heteroarylalkyl.
[0122] The term "alkoxycarbonyl" refers to a group of the formula
(alkoxy)(C.dbd.O)-- attached through the carbonyl carbon wherein
the alkoxy group has the indicated number of carbon atoms. Thus a
C.sub.1-C.sub.6 alkoxycarbonyl group is an alkoxy group having from
1 to 6 carbon atoms attached through its oxygen to a carbonyl
linker. "Lower alkoxycarbonyl" refers to an alkoxycarbonyl group
wherein the alkoxy group is a lower alkoxy group.
[0123] The term "substituted alkoxycarbonyl" refers to the group
(substituted alkyl)-O--C(O)-- wherein the group is attached to the
parent structure through the carbonyl functionality. Unless stated
otherwise specifically in the specification, the alkyl moiety of an
alkoxycarbonyl group is optionally substituted by one or more
substituents which independently are: alkyl, heteroalkyl, alkenyl,
alkynyl, cycloalkyl, heterocycloalkyl, aryl, arylalkyl, heteroaryl,
heteroarylalkyl, hydroxy, halo, cyano, trifluoromethyl,
trifluoromethoxy, nitro, trimethylsilanyl, --OR.sup.a, --SR.sup.a,
--OC(O)--R.sup.a, --N(R.sup.a).sub.2, --C(O)R.sup.a,
--C(O)OR.sup.a, --OC(O)N(R.sup.a).sub.2, --C(O)N(R.sup.a).sub.2,
--N(R.sup.a)C(O)OR.sup.a, --N(R.sup.a)C(O)R.sup.a,
--N(R.sup.a)C(O)N(R.sup.a).sub.2,
N(R.sup.a)C(NR.sup.a)N(R.sup.a).sub.2,
--N(R.sup.a)S(O).sub.tR.sup.a (where t is 1 or 2),
--S(O).sub.tOR.sup.a (where t is 1 or 2),
--S(O).sub.tN(R.sup.a).sub.2 (where t is 1 or 2), or
PO.sub.3(R.sup.a).sub.2, where each R.sup.a is independently
hydrogen, alkyl, fluoroalkyl, carbocyclyl, carbocyclylalkyl, aryl,
aralkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl or
heteroarylalkyl.
[0124] "Acyl" refers to the groups (alkyl)-C(O)--, (aryl)-C(O)--,
(heteroaryl)-C(O)--, (heteroalkyl)-C(O)-- and
(heterocycloalkyl)-C(O)--, wherein the group is attached to the
parent structure through the carbonyl functionality. If the R
radical is heteroaryl or heterocycloalkyl, the hetero ring or chain
atoms contribute to the total number of chain or ring atoms. Unless
stated otherwise specifically in the specification, the alkyl, aryl
or heteroaryl moiety of the acyl group is optionally substituted by
one or more substituents which are independently alkyl,
heteroalkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl,
arylalkyl, heteroaryl, heteroarylalkyl, hydroxy, halo, cyano,
trifluoromethyl, trifluoromethoxy, nitro, trimethylsilanyl,
--OR.sup.a, --SR.sup.a, --OC(O)--R.sup.a, --N(R.sup.a).sub.2,
--C(O)R.sup.a, --C(O)OR.sup.a, --OC(O)N(R.sup.a).sub.2,
--C(O)N(R.sup.a).sub.2, --N(R.sup.a)C(O)OR.sup.a,
--N(R.sup.a)C(O)R.sup.a, --N(R.sup.a)C(O)N(R.sup.a).sub.2,
N(R.sup.a)C(NR.sup.a)N(R.sup.a).sub.2,
--N(R.sup.a)S(O).sub.tR.sup.a (where t is 1 or 2),
--S(O).sub.tOR.sup.a (where t is 1 or 2),
--S(O).sub.tN(R.sup.a).sub.2 (where t is 1 or 2), or
PO.sub.3(R.sup.a).sub.2, where each R.sup.a is independently
hydrogen, alkyl, fluoroalkyl, carbocyclyl, carbocyclylalkyl, aryl,
aralkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl or
heteroarylalkyl.
[0125] "Acyloxy" refers to a R(C.dbd.O)O-- radical wherein "R" is
alkyl, aryl, heteroaryl, heteroalkyl or heterocycloalkyl, which are
as described herein. If the R radical is heteroaryl or
heterocycloalkyl, the hetero ring or chain atoms contribute to the
total number of chain or ring atoms. Unless stated otherwise
specifically in the specification, the "R" of an acyloxy group is
optionally substituted by one or more substituents which
independently are: alkyl, heteroalkyl, alkenyl, alkynyl,
cycloalkyl, heterocycloalkyl, aryl, arylalkyl, heteroaryl,
heteroarylalkyl, hydroxy, halo, cyano, trifluoromethyl,
trifluoromethoxy, nitro, trimethylsilanyl, --OR.sup.a, --SR.sup.a,
--OC(O)--R.sup.a, --N(R.sup.a).sub.2, --C(O)R.sup.a,
--C(O)OR.sup.a, --OC(O)N(R.sup.a).sub.2, --C(O)N(R.sup.a).sub.2,
--N(R.sup.a)C(O)OR.sup.a, --N(R.sup.a)C(O)R.sup.a,
--N(R.sup.a)C(O)N(R.sup.a).sub.2,
N(R.sup.a)C(NR.sup.a)N(R.sup.a).sub.2,
--N(R.sup.a)S(O).sub.tR.sup.a (where t is 1 or 2),
--S(O).sub.tOR.sup.a (where t is 1 or 2),
--S(O).sub.tN(R.sup.a).sub.2 (where t is 1 or 2), or
PO.sub.3(R.sup.a).sub.2, where each R.sup.a is independently
hydrogen, alkyl, fluoroalkyl, carbocyclyl, carbocyclylalkyl, aryl,
aralkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl or
heteroarylalkyl.
[0126] "Amino" or "amine" refers to a --N(R.sup.a).sub.2 radical
group, where each R.sup.a is independently hydrogen, alkyl,
fluoroalkyl, carbocyclyl, carbocyclylalkyl, aryl, aralkyl,
heterocycloalkyl, heterocycloalkylalkyl, heteroaryl or
heteroarylalkyl, unless stated otherwise specifically in the
specification. When a --N(R.sup.a).sub.2 group has two R.sup.a
substituents other than hydrogen, they can be combined with the
nitrogen atom to form a 4-, 5-, 6- or 7-membered ring. For example,
--N(R.sup.a).sub.2 is intended to include, but is not limited to,
1-pyrrolidinyl and 4-morpholinyl. Unless stated otherwise
specifically in the specification, an amino group is optionally
substituted by one or more substituents which independently are:
alkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl,
aryl, arylalkyl, heteroaryl, heteroarylalkyl, hydroxy, halo, cyano,
trifluoromethyl, trifluoromethoxy, nitro, trimethylsilanyl,
--OR.sup.a, --SR.sup.a, --OC(O)--R.sup.a, --N(R.sup.a).sub.2,
--C(O)R.sup.a, --C(O)OR.sup.a, --OC(O)N(R.sup.a).sub.2,
--C(O)N(R.sup.a).sub.2, --N(R.sup.a)C(O)OR.sup.a,
--N(R.sup.a)C(O)R.sup.a, --N(R.sup.a)C(O)N(R.sup.a).sub.2,
N(R.sup.a)C(NR.sup.a)N(R.sup.a).sub.2,
--N(R.sup.a)S(O).sub.tR.sup.a (where t is 1 or 2),
--S(O).sub.tOR.sup.a (where t is 1 or 2),
--S(O).sub.tN(R.sup.a).sub.2 (where t is 1 or 2), or
PO.sub.3(R.sup.a).sub.2, where each R.sup.a is independently
hydrogen, alkyl, fluoroalkyl, carbocyclyl, carbocyclylalkyl, aryl,
aralkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl or
heteroarylalkyl.
[0127] The term "substituted amino" also refers to N-oxides of the
groups --NHR.sup.d, and NR.sup.dR.sup.d each as described above.
N-oxides can be prepared by treatment of the corresponding amino
group with, for example, hydrogen peroxide or m-chloroperoxybenzoic
acid.
[0128] "Amide" or "amido" refers to a chemical moiety with formula
--C(O)N(R).sub.2 or --NHC(O)R, where R is selected from the group
consisting of hydrogen, alkyl, cycloalkyl, aryl, heteroaryl (bonded
through a ring carbon) and heteroalicyclic (bonded through a ring
carbon), each of which moiety may itself be optionally substituted.
The R.sub.2 of --N(R).sub.2 of the amide may optionally be taken
together with the nitrogen to which it is attached to form a 4-,
5-, 6- or 7-membered ring. Unless stated otherwise specifically in
the specification, an amido group is optionally substituted
independently by one or more of the substituents as described
herein for alkyl, cycloalkyl, aryl, heteroaryl, or
heterocycloalkyl. An amide may be an amino acid or a peptide
molecule attached to a compound of Formula (I), thereby forming a
prodrug. The procedures and specific groups to make such amides,
including the use of protecting groups, are known to those of skill
in the art and can readily be found in seminal sources such as
Greene and Wuts, Protective Groups in Organic Synthesis, 3.sup.rd
Ed., John Wiley & Sons, New York, N.Y., 1999.
[0129] "Aromatic" or "aryl" or "Ar" refers to an aromatic radical
with six to ten ring atoms (e.g., C.sub.6-C.sub.10 aromatic or
C.sub.6-C.sub.10 aryl) which has at least one ring having a
conjugated pi electron system which is carbocyclic (e.g., phenyl,
fluorenyl, and naphthyl). Bivalent radicals formed from substituted
benzene derivatives and having the free valences at ring atoms are
named as substituted phenylene radicals. Bivalent radicals derived
from univalent polycyclic hydrocarbon radicals whose names end in
"-yl" by removal of one hydrogen atom from the carbon atom with the
free valence are named by adding "-idene" to the name of the
corresponding univalent radical, e.g., a naphthyl group with two
points of attachment is termed naphthylidene. Whenever it appears
herein, a numerical range such as "6 to 10" refers to each integer
in the given range; e.g., "6 to 10 ring atoms" means that the aryl
group may consist of 6 ring atoms, 7 ring atoms, etc., up to and
including 10 ring atoms. The term includes monocyclic or fused-ring
polycyclic (i.e., rings which share adjacent pairs of ring atoms)
groups. Unless stated otherwise specifically in the specification,
an aryl moiety is optionally substituted by one or more
substituents which are independently alkyl, heteroalkyl, alkenyl,
alkynyl, cycloalkyl, heterocycloalkyl, aryl, arylalkyl, heteroaryl,
heteroarylalkyl, hydroxy, halo, cyano, trifluoromethyl,
trifluoromethoxy, nitro, trimethylsilanyl, --OR.sup.a, --SR.sup.a,
--OC(O)--R.sup.a, --N(R.sup.a).sub.2, --C(O)R.sup.a,
--C(O)OR.sup.a, --OC(O)N(R.sup.a).sub.2, --C(O)N(R.sup.a).sub.2,
--N(R.sup.a)C(O)OR.sup.a, --N(R.sup.a)C(O)R.sup.a,
--N(R.sup.a)C(O)N(R.sup.a).sub.2,
N(R.sup.a)C(NR.sup.a)N(R.sup.a).sub.2,
--N(R.sup.a)S(O).sub.tR.sup.a (where t is 1 or 2),
--S(O).sub.tOR.sup.a (where t is 1 or 2),
--S(O).sub.tN(R.sup.a).sub.2 (where t is 1 or 2), or
PO.sub.3(R.sup.a).sub.2, where each R.sup.a is independently
hydrogen, alkyl, fluoroalkyl, carbocyclyl, carbocyclylalkyl, aryl,
aralkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl or
heteroarylalkyl.
[0130] "Aralkyl" or "arylalkyl" refers to an (aryl)alkyl-radical
where aryl and alkyl are as disclosed herein and which are
optionally substituted by one or more of the substituents described
as suitable substituents for aryl and alkyl respectively.
[0131] "Ester" refers to a chemical radical of formula --COOR,
where R is selected from the group consisting of alkyl, cycloalkyl,
aryl, heteroaryl (bonded through a ring carbon) and heteroalicyclic
(bonded through a ring carbon). The procedures and specific groups
to make esters, including the use of protecting groups, are known
to those of skill in the art and can readily be found in seminal
sources such as Greene and Wuts, Protective Groups in Organic
Synthesis, 3.sup.rd Ed., John Wiley & Sons, New York, N.Y.,
1999. Unless stated otherwise specifically in the specification, an
ester group is optionally substituted by one or more substituents
which independently are: alkyl, heteroalkyl, alkenyl, alkynyl,
cycloalkyl, heterocycloalkyl, aryl, arylalkyl, heteroaryl,
heteroarylalkyl, hydroxy, halo, cyano, trifluoromethyl,
trifluoromethoxy, nitro, trimethylsilanyl, --OR.sup.a, --SR.sup.a,
--OC(O)--R.sup.a, --N(R.sup.a).sub.2, --C(O)R.sup.a,
--C(O)OR.sup.a, --OC(O)N(R.sup.a).sub.2, --C(O)N(R.sup.a).sub.2,
--N(R.sup.a)C(O)OR.sup.a, --N(R.sup.a)C(O)R.sup.a,
--N(R.sup.a)C(O)N(R.sup.a).sub.2,
N(R.sup.a)C(NR.sup.a)N(R.sup.a).sub.2,
--N(R.sup.a)S(O).sub.tR.sup.a (where t is 1 or 2),
--S(O).sub.tOR.sup.a (where t is 1 or 2),
--S(O).sub.tN(R.sup.a).sub.2 (where t is 1 or 2), or
PO.sub.3(R.sup.a).sub.2, where each R.sup.a is independently
hydrogen, alkyl, fluoroalkyl, carbocyclyl, carbocyclylalkyl, aryl,
aralkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl or
heteroarylalkyl.
[0132] "Fluoroalkyl" refers to an alkyl radical, as defined above,
that is substituted by one or more fluoro radicals, as defined
above, for example, trifluoromethyl, difluoromethyl,
2,2,2-trifluoroethyl, 1-fluoromethyl-2-fluoroethyl, and the like.
The alkyl part of the fluoroalkyl radical may be optionally
substituted as defined above for an alkyl group.
[0133] "Halo," "halide," or, alternatively, "halogen" is intended
to mean fluoro, chloro, bromo or iodo. The terms "haloalkyl,"
"haloalkenyl," "haloalkynyl," and "haloalkoxy" include alkyl,
alkenyl, alkynyl and alkoxy structures that are substituted with
one or more halo groups or with combinations thereof. For example,
the terms "fluoroalkyl" and "fluoroalkoxy" include haloalkyl and
haloalkoxy groups, respectively, in which the halo is fluorine.
[0134] "Heteroalkyl," "heteroalkenyl," and "heteroalkynyl" refer to
optionally substituted alkyl, alkenyl and alkynyl radicals and
which have one or more skeletal chain atoms selected from an atom
other than carbon, e.g., oxygen, nitrogen, sulfur, phosphorus or
combinations thereof. A numerical range may be given--e.g.,
C.sub.1-C.sub.4 heteroalkyl which refers to the chain length in
total, which in this example is 4 atoms long. A heteroalkyl group
may be substituted with one or more substituents which
independently are: alkyl, heteroalkyl, alkenyl, alkynyl,
cycloalkyl, heterocycloalkyl, aryl, arylalkyl, heteroaryl,
heteroarylalkyl, hydroxy, halo, cyano, nitro, oxo, thioxo,
trimethylsilanyl, --OR.sup.a, --SR.sup.a, --OC(O)--R.sup.a,
--N(R.sup.a).sub.2, --C(O)R.sup.a, --C(O)OR.sup.a,
--OC(O)N(R.sup.a).sub.2, --C(O)N(R.sup.a).sub.2,
--N(R.sup.a)C(O)OR.sup.a, --N(R.sup.a)C(O)R.sup.a,
--N(R.sup.a)C(O)N(R.sup.a).sub.2,
N(R.sup.a)C(NR.sup.a)N(R.sup.a).sub.2,
--N(R.sup.a)S(O).sub.tR.sup.a (where t is 1 or 2), --S(O)OR.sup.a
(where t is 1 or 2), --S(O).sub.tN(R.sup.a).sub.2 (where t is 1 or
2), or PO.sub.3(R.sup.a).sub.2, where each R.sup.a is independently
hydrogen, alkyl, fluoroalkyl, carbocyclyl, carbocyclylalkyl, aryl,
aralkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl or
heteroarylalkyl.
[0135] "Heteroalkylaryl" refers to an -(heteroalkyl)aryl radical
where heteroalkyl and aryl are as disclosed herein and which are
optionally substituted by one or more of the substituents described
as suitable substituents for heteroalkyl and aryl,
respectively.
[0136] "Heteroalkylheteroaryl" refers to an
-(heteroalkyl)heteroaryl radical where heteroalkyl and heteroaryl
are as disclosed herein and which are optionally substituted by one
or more of the substituents described as suitable substituents for
heteroalkyl and heteroaryl, respectively.
[0137] "Heteroalkylheterocycloalkyl" refers to an
-(heteroalkyl)heterocycloalkyl radical where heteroalkyl and
heterocycloalkyl are as disclosed herein and which are optionally
substituted by one or more of the substituents described as
suitable substituents for heteroalkyl and heterocycloalkyl,
respectively.
[0138] "Heteroalkylcycloalkyl" refers to an
-(heteroalkyl)cycloalkyl radical where heteroalkyl and cycloalkyl
are as disclosed herein and which are optionally substituted by one
or more of the substituents described as suitable substituents for
heteroalkyl and cycloalkyl, respectively.
[0139] "Heteroaryl" or "heteroaromatic" or "HetAr" refers to a 5-
to 18-membered aromatic radical (e.g., C.sub.5-C.sub.13 heteroaryl)
that includes one or more ring heteroatoms selected from nitrogen,
oxygen and sulfur, and which may be a monocyclic, bicyclic,
tricyclic or tetracyclic ring system. Whenever it appears herein, a
numerical range such as "5 to 18" refers to each integer in the
given range--e.g., "5 to 18 ring atoms" means that the heteroaryl
group may consist of 5 ring atoms, 6 ring atoms, etc., up to and
including 18 ring atoms. Bivalent radicals derived from univalent
heteroaryl radicals whose names end in "-yl" by removal of one
hydrogen atom from the atom with the free valence are named by
adding "-idene" to the name of the corresponding univalent
radical--e.g., a pyridyl group with two points of attachment is a
pyridylidene. A N-containing "heteroaromatic" or "heteroaryl"
moiety refers to an aromatic group in which at least one of the
skeletal atoms of the ring is a nitrogen atom. The polycyclic
heteroaryl group may be fused or non-fused. The heteroatom(s) in
the heteroaryl radical are optionally oxidized. One or more
nitrogen atoms, if present, are optionally quaternized. The
heteroaryl may be attached to the rest of the molecule through any
atom of the ring(s). Examples of heteroaryls include, but are not
limited to, azepinyl, acridinyl, benzimidazolyl, benzindolyl,
1,3-benzodioxolyl, benzofuranyl, benzooxazolyl, benzo[d]thiazolyl,
benzothiadiazolyl, benzo[b][1,4]dioxepinyl, benzo[b][1,4]oxazinyl,
1,4-benzodioxanyl, benzonaphthofuranyl, benzoxazolyl,
benzodioxolyl, benzodioxinyl, benzoxazolyl, benzopyranyl,
benzopyranonyl, benzofuranyl, benzofuranonyl, benzofurazanyl,
benzothiazolyl, benzothienyl(benzothiophenyl),
benzothieno[3,2-d]pyrimidinyl, benzotriazolyl,
benzo[4,6]imidazo[1,2-a]pyridinyl, carbazolyl, cinnolinyl,
cyclopenta[d]pyrimidinyl,
6,7-dihydro-5H-cyclopenta[4,5]thieno[2,3-d]pyrimidinyl,
5,6-dihydrobenzo[h]quinazolinyl, 5,6-dihydrobenzo[h]cinnolinyl,
6,7-dihydro-5H-benzo[6,7]cyclohepta[1,2-c]pyridazinyl,
dibenzofuranyl, dibenzothiophenyl, furanyl, furazanyl, furanonyl,
furo[3,2-c]pyridinyl,
5,6,7,8,9,10-hexahydrocycloocta[d]pyrimidinyl,
5,6,7,8,9,10-hexahydrocycloocta[d]pyridazinyl,
5,6,7,8,9,10-hexahydrocycloocta[d]pyridinyl, isothiazolyl,
imidazolyl, indazolyl, indolyl, indazolyl, isoindolyl, indolinyl,
isoindolinyl, isoquinolyl, indolizinyl, isoxazolyl,
5,8-methano-5,6,7,8-tetrahydroquinazolinyl, naphthyridinyl,
1,6-naphthyridinonyl, oxadiazolyl, 2-oxoazepinyl, oxazolyl,
oxiranyl, 5,6,6a,7,8,9,10,10a-octahydrobenzo[h]quinazolinyl,
1-phenyl-1H-pyrrolyl, phenazinyl, phenothiazinyl, phenoxazinyl,
phthalazinyl, pteridinyl, purinyl, pyranyl, pyrrolyl, pyrazolyl,
pyrazolo[3,4-d]pyrimidinyl, pyridinyl, pyrido[3,2-d]pyrimidinyl,
pyrido[3,4-d]pyrimidinyl, pyrazinyl, pyrimidinyl, pyridazinyl,
pyrrolyl, quinazolinyl, quinoxalinyl, quinolinyl, isoquinolinyl,
tetrahydroquinolinyl, 5,6,7,8-tetrahydroquinazolinyl,
5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidinyl,
6,7,8,9-tetrahydro-5H-cyclohepta[4,5]thieno[2,3-d]pyrimidinyl,
5,6,7,8-tetrahydropyrido[4,5-c]pyridazinyl, thiazolyl,
thiadiazolyl, thiapyranyl, triazolyl, tetrazolyl, triazinyl,
thieno[2,3-d]pyrimidinyl, thieno[3,2-d]pyrimidinyl,
thieno[2,3-c]pyridinyl, and thiophenyl (i.e. thienyl). Unless
stated otherwise specifically in the specification, a heteroaryl
moiety is optionally substituted by one or more substituents which
are independently: alkyl, heteroalkyl, alkenyl, alkynyl,
cycloalkyl, heterocycloalkyl, aryl, arylalkyl, heteroaryl,
heteroarylalkyl, hydroxy, halo, cyano, nitro, oxo, thioxo,
trimethylsilanyl, --OR.sup.a, --OC(O)--R.sup.a, --N(R.sup.a).sub.2,
--C(O)R.sup.a, --C(O)OR.sup.a, --OC(O)N(R.sup.a).sub.2,
--C(O)N(R.sup.a).sub.2, --N(R.sup.a)C(O)OR.sup.a,
--N(R.sup.a)C(O)R.sup.a, --N(R.sup.a)C(O)N(R.sup.a).sub.2,
N(R.sup.a)C(NR.sup.a)N(R.sup.a).sub.2,
--N(R.sup.a)S(O).sub.tR.sup.a (where t is 1 or 2),
--S(O).sub.tOR.sup.a (where t is 1 or 2),
--S(O).sub.tN(R.sup.a).sub.2 (where t is 1 or 2), or
PO.sub.3(R.sup.a).sub.2, where each R.sup.a is independently
hydrogen, alkyl, fluoroalkyl, carbocyclyl, carbocyclylalkyl, aryl,
aralkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl or
heteroarylalkyl.
[0140] Substituted heteroaryl also includes ring systems
substituted with one or more oxide (--O--) substituents, such as,
for example, pyridinyl N-oxides.
[0141] "Heteroarylalkyl" refers to a moiety having an aryl moiety,
as described herein, connected to an alkylene moiety, as described
herein, wherein the connection to the remainder of the molecule is
through the alkylene group.
[0142] "Heterocycloalkyl" refers to a stable 3- to 18-membered
non-aromatic ring radical that comprises two to twelve carbon atoms
and from one to six heteroatoms selected from nitrogen, oxygen and
sulfur. Whenever it appears herein, a numerical range such as "3 to
18" refers to each integer in the given range--e.g., "3 to 18 ring
atoms" means that the heterocycloalkyl group may consist of 3 ring
atoms, 4 ring atoms, etc., up to and including 18 ring atoms.
Unless stated otherwise specifically in the specification, the
heterocycloalkyl radical is a monocyclic, bicyclic, tricyclic or
tetracyclic ring system, which may include fused or bridged ring
systems. The heteroatoms in the heterocycloalkyl radical may be
optionally oxidized. One or more nitrogen atoms, if present, are
optionally quaternized. The heterocycloalkyl radical is partially
or fully saturated. The heterocycloalkyl may be attached to the
rest of the molecule through any atom of the ring(s). Examples of
such heterocycloalkyl radicals include, but are not limited to,
dioxolanyl, thienyl[1,3]dithianyl, decahydroisoquinolyl,
imidazolinyl, imidazolidinyl, isothiazolidinyl, isoxazolidinyl,
morpholinyl, octahydroindolyl, octahydroisoindolyl,
2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl,
oxazolidinyl, piperidinyl, piperazinyl, 4-piperidonyl,
pyrrolidinyl, pyrazolidinyl, quinuclidinyl, thiazolidinyl,
tetrahydrofuryl, trithianyl, tetrahydropyranyl, thiomorpholinyl,
thiamorpholinyl, 1-oxo-thiomorpholinyl, and
1,1-dioxo-thiomorpholinyl. Unless stated otherwise specifically in
the specification, a heterocycloalkyl moiety is optionally
substituted by one or more substituents which independently are:
alkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl,
aryl, arylalkyl, heteroaryl, heteroarylalkyl, hydroxy, halo, cyano,
nitro, oxo, thioxo, trimethylsilanyl, --OR.sup.a, --SR.sup.a,
--OC(O)--R.sup.a, --N(R.sup.a).sub.2, --C(O)R.sup.a,
--C(O)OR.sup.a, --OC(O)N(R.sup.a).sub.2, --C(O)N(R.sup.a).sub.2,
--N(R.sup.a)C(O)OR.sup.a, --N(R.sup.a)C(O)R.sup.a,
--N(R.sup.a)C(O)N(R.sup.a).sub.2,
N(R.sup.a)C(NR.sup.a)N(R.sup.a).sub.2,
--N(R.sup.a)S(O).sub.tR.sup.a (where t is 1 or 2),
--S(O).sub.tOR.sup.a (where t is 1 or 2),
--S(O).sub.tN(R.sup.a).sub.2 (where t is 1 or 2), or
PO.sub.3(R.sup.a).sub.2, where each R.sup.a is independently
hydrogen, alkyl, fluoroalkyl, carbocyclyl, carbocyclylalkyl, aryl,
aralkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl or
heteroarylalkyl.
[0143] "Heterocycloalkyl" also includes bicyclic ring systems
wherein one non-aromatic ring, usually with 3 to 7 ring atoms,
contains at least 2 carbon atoms in addition to 1-3 heteroatoms
independently selected from oxygen, sulfur, and nitrogen, as well
as combinations comprising at least one of the foregoing
heteroatoms; and the other ring, usually with 3 to 7 ring atoms,
optionally contains 1-3 heteroatoms independently selected from
oxygen, sulfur, and nitrogen and is not aromatic.
[0144] "Isomers" are different compounds that have the same
molecular formula. "Stereoisomers" are isomers that differ only in
the way the atoms are arranged in space--i.e., having a different
stereochemical configuration. "Enantiomers" are a pair of
stereoisomers that are non-superimposable mirror images of each
other. A 1:1 mixture of a pair of enantiomers is a "racemic"
mixture. The term "(.+-.)" is used to designate a racemic mixture
where appropriate. "Diastereoisomers" are stereoisomers that have
at least two asymmetric atoms, but which are not mirror-images of
each other. The absolute stereochemistry is specified according to
the Cahn-Ingold-Prelog R-S system. When a compound is a pure
enantiomer the stereochemistry at each chiral carbon can be
specified by either R or S. Resolved compounds whose absolute
configuration is unknown can be designated (+) or (-) depending on
the direction (dextro- or levorotatory) which they rotate plane
polarized light at the wavelength of the sodium D line. Certain of
the compounds described herein contain one or more asymmetric
centers and can thus give rise to enantiomers, diastereomers, and
other stereoisomeric forms that can be defined, in terms of
absolute stereochemistry, as (R)- or (S)-. The present chemical
entities, pharmaceutical compositions and methods are meant to
include all such possible isomers, including racemic mixtures,
optically pure forms and intermediate mixtures. Optically active
(R)- and (S)-isomers can be prepared using chiral synthons or
chiral reagents, or resolved using conventional techniques. When
the compounds described herein contain olefinic double bonds or
other centers of geometric asymmetry, and unless specified
otherwise, it is intended that the compounds include both E and Z
geometric isomers.
[0145] "Enantiomeric purity" as used herein refers to the relative
amounts, expressed as a percentage, of the presence of a specific
enantiomer relative to the other enantiomer. For example, if a
compound, which may potentially have an (R)- or an (S)-isomeric
configuration, is present as a racemic mixture, the enantiomeric
purity is about 50% with respect to either the (R)- or (S)-isomer.
If that compound has one isomeric form predominant over the other,
for example, 80% (S)- and 20% (R)-, the enantiomeric purity of the
compound with respect to the (S)-isomeric form is 80%. The
enantiomeric purity of a compound can be determined in a number of
ways known in the art, including but not limited to chromatography
using a chiral support, polarimetric measurement of the rotation of
polarized light, nuclear magnetic resonance spectroscopy using
chiral shift reagents which include but are not limited to
lanthanide containing chiral complexes or the Pirkle alcohol, or
derivatization of a compounds using a chiral compound such as
Mosher's acid followed by chromatography or nuclear magnetic
resonance spectroscopy.
[0146] "Moiety" refers to a specific segment or functional group of
a molecule. Chemical moieties are often recognized chemical
entities embedded in or appended to a molecule.
[0147] "Nitro" refers to the --NO.sub.2 radical.
[0148] "Oxa" refers to the --O-- radical.
[0149] "Oxo" refers to the .dbd.O radical.
[0150] "Tautomers" are structurally distinct isomers that
interconvert by tautomerization. "Tautomerization" is a form of
isomerization and includes prototropic or proton-shift
tautomerization, which is considered a subset of acid-base
chemistry. "Prototropic tautomerization" or "proton-shift
tautomerization" involves the migration of a proton accompanied by
changes in bond order, often the interchange of a single bond with
an adjacent double bond. Where tautomerization is possible (e.g. in
solution), a chemical equilibrium of tautomers can be reached. An
example of tautomerization is keto-enol tautomerization. A specific
example of keto-enol tautomerization is the interconversion of
pentane-2,4-dione and 4-hydroxypent-3-en-2-one tautomers. Another
example of tautomerization is phenol-keto tautomerization. A
specific example of phenol-keto tautomerization is the
interconversion of pyridin-4-ol and pyridin-4(1H)-one
tautomers.
[0151] The terms "enantiomerically enriched," "enantiomerically
pure" and "non-racemic," as used herein, refer to compositions in
which the percent by weight of one enantiomer is greater than the
amount of that one enantiomer in a control mixture of the racemic
composition (e.g., greater than 1:1 by weight). For example, an
enantiomerically enriched preparation of the (S)-enantiomer, means
a preparation of the compound having greater than 50% by weight of
the (S)-enantiomer relative to the (R)-enantiomer, such as at least
75% by weight, such as at least 80% by weight. In some embodiments,
the enrichment can be significantly greater than 80% by weight,
providing a "substantially enantiomerically enriched,"
"substantially enantiomerically pure" or a "substantially
non-racemic" preparation, which refers to preparations of
compositions which have at least 85% by weight of one enantiomer
relative to the other enantiomer, such as at least 90% by weight,
and such as at least 95% by weight. The terms "diastereomerically
enriched" and "diastereomerically pure," as used herein, refer to
compositions in which the percent by weight of one diastereomer is
greater than the amount of that one diastereomer in a control
mixture of diastereomers. In some embodiments, the enrichment can
be significantly greater than 80% by weight, providing a
"substantially diastereomerically enriched" or "substantially
diastereomerically pure" preparation, which refers to preparations
of compositions which have at least 85% by weight of one
diastereomer relative to other diastereomers, such as at least 90%
by weight, and such as at least 95% by weight.
[0152] In preferred embodiments, the enantiomerically enriched
composition has a higher potency with respect to therapeutic
utility per unit mass than does the racemic mixture of that
composition. Enantiomers can be isolated from mixtures by methods
known to those skilled in the art, including chiral high pressure
liquid chromatography (HPLC) and the formation and crystallization
of chiral salts; or preferred enantiomers can be prepared by
asymmetric syntheses. See, for example, Jacques, et al.,
Enantiomers, Racemates and Resolutions, Wiley Interscience, New
York, 1981; and Eliel, Stereochemistry of Carbon Compounds,
McGraw-Hill, N Y, 1962.
[0153] A "leaving group or atom" is any group or atom that will,
under selected reaction conditions, cleave from the starting
material, thus promoting reaction at a specified site. Examples of
such groups, unless otherwise specified, include halogen atoms and
mesyloxy, p-nitrobenzensulphonyloxy and tosyloxy groups.
[0154] "Protecting group" is intended to mean a group that
selectively blocks one or more reactive sites in a multifunctional
compound such that a chemical reaction can be carried out
selectively on another unprotected reactive site and the group can
then be readily removed after the selective reaction is complete. A
variety of protecting groups are disclosed, for example, in T. H.
Greene and P. G. M. Wuts, Protective Groups in Organic Synthesis,
Third Edition, John Wiley & Sons, New York, 1999.
[0155] "Solvate" refers to a compound in physical association with
one or more molecules of a pharmaceutically acceptable solvent.
[0156] "Substituted" means that the referenced group may have
attached one or more additional moieties individually and
independently selected from, for example, acyl, alkyl, alkylaryl,
cycloalkyl, aralkyl, aryl, carbohydrate, carbonate, heteroaryl,
heterocycloalkyl, hydroxy, alkoxy, aryloxy, mercapto, alkylthio,
arylthio, cyano, halo, carbonyl, ester, thiocarbonyl, isocyanato,
thiocyanato, isothiocyanato, nitro, oxo, perhaloalkyl,
perfluoroalkyl, phosphate, silyl, sulfinyl, sulfonyl, sulfonamidyl,
sulfoxyl, sulfonate, urea, and amino, including mono- and
di-substituted amino groups, and protected derivatives thereof. The
substituents themselves may be substituted, for example, a
cycloalkyl substituent may itself have a halide substituent at one
or more of its ring carbons. The term "substituted" also means that
one or more hydrogens on the designated atom/atoms is/are replaced
with a selection from the indicated group, provided that the
designated atom's normal valency under the existing circumstances
is not exceeded, and that the substitution results in a stable
compound. Combinations of substituents and/or variables are
permissible if such combinations result in stable compounds.
"Stable compound" or "stable structure" is defined as a compound or
structure that is sufficiently robust to survive isolation to a
useful degree of purity from a reaction mixture, and formulation
into an efficacious therapeutic agent. The terms "optionally
substituted" and "may optionally be substituted" means optional
substitution with the specified groups, radicals or moieties.
[0157] "Sulfanyl" refers to groups that include --S-(optionally
substituted alkyl), --S-(optionally substituted aryl),
--S-(optionally substituted heteroaryl) and --S-(optionally
substituted heterocycloalkyl).
[0158] "Sulfinyl" refers to groups that include --S(O)--H,
--S(O)-(optionally substituted alkyl), --S(O)-(optionally
substituted amino), --S(O)-(optionally substituted aryl),
--S(O)-(optionally substituted heteroaryl) and --S(O)-(optionally
substituted heterocycloalkyl).
[0159] "Sulfonyl" refers to groups that include --S(O.sub.2)--H,
--S(O.sub.2)-(optionally substituted alkyl),
--S(O.sub.2)-(optionally substituted amino),
--S(O.sub.2)-(optionally substituted aryl),
--S(O.sub.2)-(optionally substituted heteroaryl), and
--S(O.sub.2)-(optionally substituted heterocycloalkyl).
[0160] "Sulfonamidyl" or "sulfonamido" refers to a
--S(.dbd.O).sub.2--NRR radical, where each R is selected
independently from the group consisting of hydrogen, alkyl,
cycloalkyl, aryl, heteroaryl (bonded through a ring carbon) and
heteroalicyclic (bonded through a ring carbon). The R groups in
--NRR of the --S(.dbd.O).sub.2--NRR radical may be taken together
with the nitrogen to which it is attached to form a 4-, 5-, 6- or
7-membered ring. A sulfonamido group is optionally substituted by
one or more of the substituents described for alkyl, cycloalkyl,
aryl, heteroaryl, respectively.
[0161] "Sulfoxyl" refers to a --S(.dbd.O).sub.2OH radical.
[0162] "Sulfonate" refers to a --S(.dbd.O).sub.2--OR radical, where
R is selected from the group consisting of alkyl, cycloalkyl, aryl,
heteroaryl (bonded through a ring carbon) and heteroalicyclic
(bonded through a ring carbon). A sulfonate group is optionally
substituted on R by one or more of the substituents described for
alkyl, cycloalkyl, aryl, heteroaryl, respectively.
[0163] Compounds of the invention also include crystalline and
amorphous forms of those compounds, including, for example,
polymorphs, pseudopolymorphs, solvates, hydrates, unsolvated
polymorphs (including anhydrates), conformational polymorphs, and
amorphous forms of the compounds, as well as mixtures thereof.
"Crystalline form" and "polymorph" are intended to include all
crystalline and amorphous forms of the compound, including, for
example, polymorphs, pseudopolymorphs, solvates, hydrates,
unsolvated polymorphs (including anhydrates), conformational
polymorphs, and amorphous forms, as well as mixtures thereof,
unless a particular crystalline or amorphous form is referred
to.
Co-Administration of Compounds
[0164] An embodiment of the invention is a composition, such as a
pharmaceutical composition, comprising a combination of a PI3K
inhibitor and a BTK inhibitor. Another embodiment is a kit
containing both components formulated into separate pharmaceutical
compositions, which are formulated for co-administration.
[0165] Another embodiment of the invention is a method of treating
a disease or condition in a subject, in particular a
hyperproliferative disorder like leukemia, lymphoma or a solid
tumor cancer in a subject, comprising co-administering to the
subject in need thereof a therapeutically effective amount of a
combination of a PI3K inhibitor and a BTK inhibitor. The
pharmaceutical composition comprising the combination, and the kit,
are both for use in treating such disease or condition.
[0166] In an exemplary embodiment, the solid tumor cancer is
selected from the group consisting of breast, lung, colorectal,
thyroid, bone sarcoma and stomach cancers.
[0167] In an exemplary embodiment, the leukemia is selected from
the group consisting of acute myelogenous leukemia (AML), chronic
myelogenous leukemia (CML), and acute lymphoblastic leukemia
(ALL).
[0168] In a preferred embodiment, the PI3K inhibitor is a
PI3K-.gamma. inhibitor.
[0169] In another preferred embodiment, the PI3K inhibitor is a
PI3K-.delta. inhibitor.
[0170] In another preferred embodiment, the PI3K inhibitor is a
PI3K-.gamma.,.delta. inhibitor.
[0171] In a particularly preferred embodiment, the PI3K inhibitor
is a PI3K-.delta. inhibitor. This PI3K-.delta. inhibitor is more
preferably a compound of Formula VIII, even more preferably the
compound of Formula IX.
[0172] The BTK inhibitor is preferably a compound of Formula XVII,
even more preferably the compound of Formula XVIII.
[0173] In one specific embodiment, the PI3K inhibitor is a
PI3K-.delta. inhibitor and the BTK inhibitor is a compound of
Formula XVII, even more preferably the compound of Formula XVIII.
In a specifically preferred embodiment, the PI3K inhibitor is the
compound of Formula IX and the BTK inhibitor is the compound of
Formula XVIII. One or both of said inhibitors may also be in the
form of a pharmaceutically acceptable salt.
[0174] In an exemplary embodiment, the PI3K inhibitor is a PI3K
inhibitor selective for 6-PI3K, .gamma.-PI3K, or
.gamma.,.delta.-PI3K isoforms.
[0175] The combination may be administered by any route known in
the art. In an exemplary embodiment, the combination of the PI3K
inhibitor, which is preferably selected from the group consisting
of a PI3K-.gamma. inhibitor, a PI3K-.delta. inhibitor, and a
PI3K-.gamma.,.delta. inhibitor, with the BTK inhibitor is
administered by oral, intravenous, intramuscular, intraperitoneal,
subcutaneous or transdermal means. In one embodiment, the
administration is by injection.
[0176] In an exemplary embodiment, the PI3K inhibitor, which is
preferably selected from the group consisting of a PI3K-.gamma.
inhibitor, a PI3K-.delta. inhibitor, and a PI3K-.gamma.,.delta.
inhibitor, is in the form of a pharmaceutically acceptable
salt.
[0177] In an exemplary embodiment, the BTK inhibitor is in the form
of a pharmaceutically acceptable salt.
[0178] In an exemplary embodiment, the PI3K inhibitor, which is
preferably selected from the group consisting of a PI3K-.gamma.
inhibitor, a PI3K-.delta. inhibitor, and a PI3K-.gamma.,.delta.
inhibitor, is administered to the subject before administration of
the BTK inhibitor.
[0179] In an exemplary embodiment, the PI3K inhibitor, which is
preferably selected from the group consisting of a PI3K-.gamma.
inhibitor, a PI3K-.delta. inhibitor, and a PI3K-.gamma.,.delta.
inhibitor, is administered concurrently with the administration of
the BTK inhibitor.
[0180] In an exemplary embodiment, the PI3K inhibitor, which is
preferably selected from the group consisting of a PI3K-.gamma.
inhibitor, a PI3K-.delta. inhibitor, and a PI3K-.gamma.,.delta.
inhibitor, is administered to the subject after administration of
the BTK inhibitor.
[0181] In an exemplary embodiment, the subject is a mammal, such as
a human.
PI3K Inhibitors
[0182] In particular, it is one of the PI3K inhibitors described in
more detail in the following paragraphs. Preferably, it is a PI3K
inhibitor selected from the group consisting of PI3K-.gamma.
inhibitor, PI3K-.delta. inhibitor, and PI3K-.gamma.,.delta.
inhibitor. In one specific embodiment, it is a PI3K-.delta.
inhibitor. In a preferred embodiment, it is a compound of Formula
IX or a pharmaceutically acceptable salt thereof.
[0183] In an exemplary embodiment, the PI3K inhibitor, which may
preferably be selected from the group consisting of PI3K-.gamma.
inhibitor, PI3K-.delta. inhibitor, and PI3K-.gamma.,.delta.
inhibitor, is a compound selected from the structures disclosed in
U.S. Pat. Nos. 8,193,182 and 8,569,323, and U.S. Patent Application
Publication Nos. 2012/0184568 A1, 2013/0344061 A1, and 2013/0267521
A1. In an exemplary embodiment, the PI3K inhibitor is a compound of
Formula (I):
##STR00001##
or a pharmaceutically acceptable salt thereof, wherein: [0184] Cy
is aryl or heteroaryl substituted by 0 or 1 occurrences of R.sup.3
and 0, 1, 2, or 3 occurrences of R.sup.5; [0185] W.sub.b.sup.5 is
CR.sup.8, CHR.sup.8, or N; [0186] R.sup.8 is hydrogen, alkyl,
alkenyl, alkynyl, cycloalkyl, heteroalkyl, alkoxy, amido, amino,
acyl, acyloxy, sulfonamido, halo, cyano, hydroxyl or nitro; [0187]
B is hydrogen, alkyl, amino, heteroalkyl, cycloalkyl, heterocyclyl,
aryl, or heteroaryl, each of which is substituted with 0, 1, 2, 3,
or 4 occurrences of R.sup.2; [0188] each R.sup.2 is independently
alkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl,
aryl, arylalkyl, heteroaryl, heteroarylalkyl, alkoxy, amido, amino,
acyl, acyloxy, alkoxycarbonyl, sulfonamido, halo, cyano, hydroxyl,
nitro, phosphate, urea, or carbonate; [0189] X is
--(CH(R.sup.9)).sub.z--; [0190] Y is --N(R.sup.9)--C(.dbd.O)--,
--C(.dbd.O)--N(R.sup.9)--, --C(.dbd.O)--N(R.sup.9)--(CHR.sup.9)--,
--N(R.sup.9)--S(.dbd.O)--, --S(.dbd.O)--N(R.sup.9)--,
S(.dbd.O).sub.2--N(R.sup.9)--, --N(R.sup.9)--C(.dbd.O)--N(R.sup.9)
or --N(R.sup.9)S(.dbd.O).sub.2--; [0191] z is an integer of 1, 2,
3, or 4; [0192] R.sup.3 is alkyl, alkenyl, alkynyl, cycloalkyl,
heterocyclyl, fluoroalkyl, heteroalkyl, alkoxy, amido, amino, acyl,
acyloxy, sulfinyl, sulfonyl, sulfoxide, sulfone, sulfonamido, halo,
cyano, aryl, heteroaryl, hydroxyl, or nitro; [0193] each R.sup.5 is
independently alkyl, alkenyl, alkynyl, cycloalkyl, heteroalkyl,
alkoxy, amido, amino, acyl, acyloxy, sulfonamido, halo, cyano,
hydroxyl, or nitro; [0194] each R.sup.9 is independently hydrogen,
alkyl, cycloalkyl, heterocyclyl, or heteroalkyl; or two adjacent
occurrences of R.sup.9 together with the atoms to which they are
attached form a 4- to 7-membered ring; [0195] W.sub.d is
heterocyclyl, aryl, cycloalkyl, or heteroaryl, each of which is
substituted with one or more R.sup.10, R.sup.11, R.sup.12 or
R.sup.13, and [0196] R.sup.10, R.sup.11, R.sup.12 and R.sup.13 are
each independently hydrogen, alkyl, heteroalkyl, alkenyl, alkynyl,
cycloalkyl, heterocyclyl, aryl, arylalkyl, heteroaryl,
heteroarylalkyl, alkoxy, heterocyclyloxy, amido, amino, acyl,
acyloxy, alkoxycarbonyl, sulfonamido, halo, cyano, hydroxyl, nitro,
phosphate, urea, carbonate or NR'R'' wherein R' and R'' are taken
together with nitrogen to form a cyclic moiety.
[0197] In an exemplary embodiment, the PI3K inhibitor, PI3K-.gamma.
inhibitor, PI3K-.delta. inhibitor, or PI3K-.gamma.,.delta.
inhibitor is a compound of Formula (I-1):
##STR00002##
or a pharmaceutically acceptable salt thereof, wherein: [0198] B is
a moiety of Formula (II):
[0198] ##STR00003## [0199] W.sub.c is aryl, heteroaryl,
heterocycloalkyl, or cycloalkyl; [0200] q is an integer of 0, 1, 2,
3, or 4; [0201] X is a bond or --(CH(R.sup.9)).sub.z--, and z is an
integer of 1, 2, 3 or 4; [0202] Y is a bond, --N(R.sup.9)--, --O--,
--S--, --S(.dbd.O)--, --S(.dbd.O).sub.2, --C(.dbd.O)--,
--C(.dbd.O)(CHR.sup.9).sub.z--, --N(R.sup.9)--C(.dbd.O)--,
--N(R.sup.9)--C(.dbd.O)NH-- or --N(R.sup.9)C(R.sup.9).sub.2--;
[0203] z is an integer of 1, 2, 3, or 4; [0204] W.sub.d is:
[0204] ##STR00004## ##STR00005## [0205] X.sub.1, X.sub.2 and
X.sub.3 are each independently C, CR.sup.13 or N; and X.sub.4,
X.sub.5 and X.sub.6 are each independently N, NH, CR.sup.13, S or
O; [0206] R.sup.1 is hydrogen, alkyl, alkenyl, alkynyl, alkoxy,
amido, alkoxycarbonyl, sulfonamido, halo, cyano, or nitro; [0207]
R.sup.2 is alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl,
aryl, heteroaryl, heteroarylalkyl, alkoxy, amino, halo, cyano,
hydroxy or nitro; R.sup.3 is hydrogen, alkyl, alkenyl, alkynyl,
cycloalkyl, heterocycloalkyl, alkoxy, amido, amino, alkoxycarbonyl
sulfonamido, halo, cyano, hydroxy or nitro; and [0208] each
instance of R.sup.9 is independently hydrogen, alkyl, or
heterocycloalkyl.
[0209] In an exemplary embodiment, the PI3K inhibitor is a compound
of Formula (III), also known as
(S)-3-(1-((9H-purin-6-yl)amino)ethyl)-8-chloro-2-phenylisoquinolin-1(2H)--
one,
##STR00006##
or a pharmaceutically acceptable salt thereof.
[0210] In an exemplary embodiment, the PI3K inhibitor is a compound
of Formula (IV), also known as
(S)-3-amino-N-(1-(5-chloro-4-oxo-3-phenyl-3,4-dihydroquinazolin-2-yl)ethy-
l)pyrazine-2-carboxamide,
##STR00007##
or a pharmaceutically acceptable salt thereof.
[0211] In an exemplary embodiment, the PI3K inhibitor is a compound
selected from the structures disclosed in U.S. Pat. Nos. 8,193,199
and 8,586,739. In an exemplary embodiment, the PI3K inhibitor is a
compound of Formula (V):
##STR00008##
or a pharmaceutically-acceptable salt thereof, wherein: [0212]
X.sup.1 is C(R.sup.9) or N; [0213] X.sup.2 is C(R.sub.10) or N;
[0214] Y is N(R.sup.11), O or S; [0215] Z is CR.sup.8 or N; [0216]
n is 0, 1, 2 or 3; [0217] R.sup.1 is a direct-bonded or
oxygen-linked saturated, partially saturated or unsaturated 5-, 6-
or 7-membered monocyclic ring containing 0, 1, 2, 3 or 4 atoms
selected from N, O and S, but containing no more than one 0 or S,
wherein the available carbon atoms of the ring are substituted by
0, 1 or 2 oxo or thioxo groups, wherein the ring is substituted by
0 or 1 R.sup.2 substituents, and the ring is additionally
substituted by 0, 1, 2 or 3 substituents independently selected
from halo, nitro, cyano, C.sub.1-4alkyl, OC.sub.1-4alkyl,
OC.sub.1-4haloalkyl, NHC.sub.1-4, N(C.sub.1-4alkyl)C.sub.1-4 alkyl
and C.sub.1-4haloalkyl; [0218] R.sup.2 is selected from halo,
C.sub.1-4haloalkyl, cyano, nitro, --C(.dbd.O)R.sup.a,
--C(.dbd.O)OR.sup.a, --C(.dbd.O)NR.sup.aR.sup.a,
--C(.dbd.NR.sup.a)NR.sup.aR.sup.a, --OR.sup.a, --OC(.dbd.O)R.sup.a,
--OC(.dbd.O)NR.sup.aR.sup.a.
--OC(.dbd.O)N(R.sup.a)S(.dbd.O).sub.2R.sup.a,
--OC.sub.2-6alkylNR.sup.aR.sup.a, --OC.sub.2-6alkylOR.sup.a,
--SR.sup.a, OS(.dbd.O)R.sup.a, --S(.dbd.O).sub.2R.sup.a,
--S(.dbd.O).sub.2NR.sup.aR.sup.a,
--S(.dbd.O).sub.2N(R.sup.a)C(.dbd.O)R.sup.a,
--S(.dbd.O).sub.2N(R.sup.a)C(.dbd.O)OR.sup.a,
--S(.dbd.O).sub.2N(R.sup.a)C(.dbd.O)NR.sup.aR.sup.a,
--NR.sup.aR.sup.a, --N(R.sup.a)C(.dbd.O)R.sup.a,
--N(R.sup.a)C(.dbd.O)OR.sup.a,
--N(R.sup.a)C(.dbd.O)NR.sup.aR.sup.a,
--N(R.sup.a)C(.dbd.NR.sup.a)NR.sup.aR.sup.a,
--N(R.sup.a)S(.dbd.O).sub.2R.sup.a,
--N(R.sup.a)S(.dbd.O).sub.2NR.sup.aR.sup.a, --NR.sup.aC.sub.2-6
alkylNR.sup.aR.sup.a and --NR.sup.aC.sub.2-6 alkylOR.sup.a; or
R.sup.2 is selected from C.sub.1-6alkyl, phenyl, benzyl,
heteroaryl, heterocycle, --(C.sub.1-3 alkyl)heteroaryl,
--(C.sub.1-3 alkyl)heterocycle, --O(C.sub.1-3 alkyl)heteroaryl,
--O(C.sub.1-3 alkyl)heterocycle,
--NR.sup.a(C.sub.1-3alkyl)heteroaryl, --NR.sup.a(C.sub.1-3
alkyl)heterocycle, --(C.sub.1-3 alkyl)phenyl, --O(C.sub.1-3
alkyl)phenyl and --NR.sup.a(C.sub.1-3 alkyl)phenyl all of which are
substituted by 0, 1, 2 or 3 substituents selected from
C.sub.1-4haloalkyl, OC.sub.1-4alkyl, Br, Cl, F, I and
C.sub.1-4alkyl; [0219] R.sup.3 is selected from H, halo,
C.sub.1-4haloalkyl, cyano, nitro, --C(.dbd.O)R.sup.a,
--C(.dbd.O)R.sup.a, --C(.dbd.O)NR.sup.aR.sup.a,
--C(.dbd.NR.sup.a)NR.sup.aR.sup.a, --OR.sup.a, --OC(.dbd.O)R.sup.a,
--OC(.dbd.O)NR.sup.aR.sup.a,
--OC(.dbd.O)N(R.sup.a)S(.dbd.O).sub.2R.sup.2,
--OC.sub.2-6alkylNR.sup.aR.sup.a, --OC.sub.2-6alkylOR.sup.a,
--SR.sup.a, --S(.dbd.O)R.sup.a, --S(.dbd.O).sub.2R.sup.a,
--S(.dbd.O).sub.2NR.sup.aR.sup.a,
--S(.dbd.O).sub.2N(R.sup.a)C(.dbd.O)R.sup.a,
--S(.dbd.O).sub.2N(R.sup.a)C(.dbd.O)OR.sup.a,
--S(.dbd.O).sub.2N(R.sup.a)C(.dbd.O)NR.sup.aR.sup.a,
--NR.sup.aR.sup.a, --N(R.sup.a)C(.dbd.O)R.sup.a,
--N(R.sup.a)C(.dbd.O)OR.sup.a,
--N(R.sup.a)C(.dbd.O)NR.sup.aR.sup.a,
--N(R.sup.a)C(.dbd.NR.sup.a)NR.sup.aR.sup.a,
--N(R.sup.a)S(.dbd.O).sub.2R.sup.a,
--N(R.sup.a)S(.dbd.O).sub.2NR.sup.aNR.sup.aR.sup.a,
--NR.sup.aC.sub.2-6 alkylOR.sup.a, C.sub.1-6alkyl, phenyl, benzyl,
heteroaryl and heterocycle, wherein the C.sub.1-6alkyl, phenyl,
benzyl, heteroaryl and heterocycle are additionally substituted by
0, 1, 2 or 3 substituents selected from C.sub.1-6haloalkyl,
OC.sub.1-6alkyl, Br, Cl, F, I and C.sub.1-6alkyl; [0220] R.sup.4
is, independently, in each instance, halo, nitro, cyano,
C.sub.1-4alkyl, OC.sub.1-4alkyl, OC.sub.1-4haloalkyl,
NHC.sub.1-4alkyl, N(C.sub.1-4 alkyl)C.sub.1-4 alkyl or
C.sub.1-4haloalkyl; [0221] R.sup.5 is, independently, in each
instance, H, halo, C.sub.1-6alkyl, C.sub.1-4haloalkyl, or
C.sub.1-6alkyl substituted by 1, 2 or 3 substituents selected from
halo, cyano, OH, OC.sub.1-4alkyl, C.sub.1-4alkyl,
C.sub.1-3haloalkyl, OC.sub.1-4alkyl, NH.sub.2, NHC.sub.1-4alkyl,
N(C.sub.1-4 alkyl)C.sub.1-4 alkyl; or both R.sup.5 groups together
form a C.sub.3-6spiroalkyl substituted by 0, 1, 2 or 3 substituents
selected from halo, cyano, OH, OC.sub.1-4alkyl, C.sub.1-4alkyl,
C.sub.1-3haloalkyl, OC.sub.1-4alkyl, NH.sub.2, NHC.sub.1-4alkyl,
N(C.sub.1-4 alkyl)C.sub.1-4 alkyl; [0222] R.sup.6 is selected from
H, halo, C.sub.1-6alkyl, C.sub.1-4haloalkyl, cyano, nitro,
--C(.dbd.O)R.sup.a, --C(.dbd.O)OR.sup.a,
--C(.dbd.O)NR.sup.aR.sup.a, --C(.dbd.NR.sup.a)NR.sup.aR.sup.a,
--S(.dbd.O)R.sup.a, --S(.dbd.O).sub.2R.sup.a,
--S(.dbd.O).sub.2NR.sup.aR.sup.a,
--S(.dbd.O).sub.2N(R.sup.a)C(.dbd.O)R.sup.a,
--S(.dbd.O).sub.2N(R.sup.a)C(.dbd.O)OR.sup.a,
--S(.dbd.O).sub.2N(R.sup.a)C(.dbd.O)NR.sup.aR.sup.a; [0223] R.sup.7
is selected from H, halo, C.sub.1-6alkyl, C.sub.1-4haloalkyl,
cyano, nitro, --C(.dbd.O)R.sup.a, --C(.dbd.O)OR.sup.a,
--C(.dbd.O)NR.sup.aR.sup.a, --C(.dbd.NR.sup.a)NR.sup.aR.sup.a,
--S(.dbd.O)R.sup.a, --S(.dbd.O).sub.2R.sup.a,
--S(.dbd.O).sub.2NR.sup.aR.sup.a,
--S(.dbd.O).sub.2N(R.sup.a)C(.dbd.O)R.sup.a,
--S(.dbd.O).sub.2N(R.sup.a)C(.dbd.O)OR.sup.a,
--S(.dbd.O).sub.2N(R.sup.a)C(.dbd.O)NR.sup.aR.sup.a; [0224] R.sup.8
is selected from H, C.sub.1-6haloalkyl, Br, Cl, F, I, OR.sup.a,
NR.sup.aR.sup.a, C.sub.1-6alkyl, phenyl, benzyl, heteroaryl and
heterocycle, wherein the C.sub.1-6alkyl, phenyl, benzyl, heteroaryl
and heterocycle are additionally substituted by 0, 1, 2 or 3
substituents selected from C.sub.1-6haloalkyl, OC.sub.1-6alkyl, Br,
Cl, F, I and C.sub.1-6alkyl; [0225] R.sup.9 is selected from H,
halo, C.sub.1-4haloalkyl, cyano, nitro, --C(.dbd.O)R.sup.a,
--C(.dbd.O)OR.sup.a,
--C(.dbd.O)NR.sup.aR.sup.aC(.dbd.NR.sup.a)NR.sup.aR.sup.a,
--OR.sup.a, --OC(.dbd.O)R.sup.a, --OC(.dbd.O)NR.sup.aR.sup.a,
--OC(.dbd.O)N(R.sup.a)S(.dbd.O).sub.2R.sup.a,
--OC.sub.2-6alkylOR.sup.a, --SR.sup.a, --S(.dbd.O)R.sup.a,
--S(.dbd.O).sub.2R.sup.a, --S(.dbd.O).sub.2NR.sup.aR.sup.a,
--S(.dbd.O).sub.2N(R.sup.a)C(.dbd.O)R.sup.a,
--S(.dbd.O).sub.2N(R.sup.a)C(.dbd.O)OR.sup.a,
--S(.dbd.O).sub.2N(R.sup.a)C(.dbd.O)NR.sup.aR.sup.a,
NR.sup.aR.sup.a, --N(R.sup.a)C(.dbd.O)R.sup.a,
--N(R.sup.a)C(.dbd.O)OR.sup.a,
--N(R.sup.a)C(O)NR.sup.aR.sup.aN(R.sup.a)C(.dbd.NR.sup.a)NR.sup.aR.sup.a,
--N(R.sup.a)S(.dbd.O).sub.2R.sup.a,
--N(R.sup.a)S(.dbd.O).sub.2NR.sup.aR.sup.a,
--NR.sup.aC.sub.2-6alkylNR.sup.aR.sup.a, --NR.sup.aC.sub.1-6alkyl,
phenyl, benzyl, heteroaryl and heterocycle, wherein the C.sub.1-6
alkyl, phenyl, benzyl, heteroaryl and heterocycle are additionally
substituted by 0, 1, 2 or 3 substituents selected from halo,
C.sub.1-4haloalkyl, cyano, nitro, --C(.dbd.O)R.sup.a,
--C(.dbd.O)OR.sup.a, --C(.dbd.O)NR.sup.aR.sup.a,
--C(.dbd.NR.sup.a)NR.sup.aR.sup.a, --OR.sup.a, --OC(.dbd.O)R.sup.a,
OC(.dbd.O)NR.sup.aR.sup.a,
--OC(.dbd.O)N(R.sup.a)S(.dbd.O).sub.2R.sup.a,
--OC.sub.2-6alkylNR.sup.aR.sup.a, --OC.sub.2-6alkylOR.sup.a,
--SR.sup.a, --S(.dbd.O)R.sup.a, --S(.dbd.O).sub.2R.sup.a,
--S(.dbd.O).sub.2NR.sup.aR.sup.a,
--S(.dbd.O).sub.2N(R.sup.a)C(.dbd.O)R.sup.a,
--S(.dbd.O).sub.2N(R.sup.a)C(.dbd.O)OR.sup.a,
--S(.dbd.O).sub.2N(R.sup.a)C(.dbd.O)NR.sup.aR.sup.a,
NR.sup.aR.sup.a, --N(R.sup.a)C(.dbd.O)R.sup.a,
--N(R.sup.a)C(.dbd.O)OR.sup.a,
--N(R.sup.a)C(.dbd.O)NR.sup.aR.sup.a,
--N(R.sup.a)C(.dbd.NR.sup.a)NR.sup.aR.sup.a,
--N(R.sup.a)S(.dbd.O).sub.2R.sup.a,
--N(R.sup.a)S(.dbd.O).sub.2NR.sup.aR.sup.a, NR.sup.aC.sub.2-6
alkylOR.sup.a, --NR.sup.aC.sub.2-6 alkylOR.sup.a; or R.sup.9 is a
saturated, partially-saturated or unsaturated 5-, 6- or 7-membered
monocyclic ring containing 0, 1, 2, 3 or 4 atoms selected from N, O
and S, but containing no more than one O or S, wherein the
available carbon atoms of the ring are substituted by 0, 1 or 2 oxo
or thioxo groups, wherein the ring is substituted by 0, 1, 2, 3 or
4 substituents selected from halo, C.sub.1-4haloalkyl, cyano,
nitro, --C(.dbd.O)R.sup.a, --C(.dbd.O)OR.sup.a,
--C(.dbd.O)NR.sup.aR.sup.a, --C(.dbd.NR.sup.a)NR.sup.aR.sup.a,
--OR.sup.a, --OC(.dbd.O)R.sup.a, --OC(.dbd.O)NR.sup.aR.sup.a,
--OC(.dbd.O)N(R.sup.a)S(.dbd.O).sub.2R.sup.a,
--OC.sub.2-6alkylNR.sup.aR.sup.a, --OC.sub.2-6alkylOR.sup.a,
--SR.sup.a, --S(.dbd.O)R.sup.a, --S(.dbd.O).sub.2R.sup.a,
--S(.dbd.O).sub.2NR.sup.aR.sup.a,
--S(.dbd.O).sub.2N(R.sup.a)C(.dbd.O)R.sup.a,
--S(.dbd.O).sub.2N(R.sup.a)C(.dbd.O)OR.sup.a,
--S(.dbd.O).sub.2N(R.sup.a)C(.dbd.O)NR.sup.aR.sup.a,
--NR.sup.aR.sup.a, --N(R.sup.a)C(.dbd.O)R.sup.a,
--N(R.sup.a)C(.dbd.O)OR.sup.a,
--N(R.sup.a)C(.dbd.O)NR.sup.aR.sup.a,
--N(R.sup.a)C(.dbd.NR.sup.a)NR.sup.aR.sup.a,
--N(R.sup.a)S(.dbd.O).sub.2R.sup.a,
--N(R.sup.a)S(.dbd.O).sub.2NR.sup.aR.sup.a, --NR.sup.aC.sub.2-6
alkylNR.sup.aR.sup.a and --NR.sup.aC.sub.2-6 alkylOR.sup.a; [0226]
R.sup.10 is H, C.sub.1-3alkyl, C.sub.1-3haloalkyl, cyano, nitro,
CO.sub.2R.sup.a, C(.dbd.O)NR.sup.aR.sup.a,
--C(.dbd.NR.sup.a)NR.sup.aR.sup.a,
--S(.dbd.O).sub.2N(R.sup.a)C(.dbd.O)R.sup.a,
--S(.dbd.O).sub.2N(R.sup.a)C(.dbd.O)OR.sup.a,
--S(.dbd.O).sub.2N(R.sup.a)C(.dbd.O)NR.sup.aR.sup.a,
--S(.dbd.O)R.sup.b, S(.dbd.O).sub.2R.sup.b or
S(.dbd.O).sub.2NR.sup.aR.sup.a; [0227] R.sup.11 is H or
C.sub.1-4alkyl; [0228] R.sup.a is independently, at each instance,
H or R.sup.b; and [0229] R.sup.b is independently, at each
instance, phenyl, benzyl or C.sub.1-6alkyl, the phenyl, benzyl and
C.sub.1-6 alkyl being substituted by 0, 1, 2 or 3 substituents
selected from halo, C.sub.1-4alkyl, C.sub.1-3 haloalkyl,
--OC.sub.1-4alkyl, --NH.sub.2, --NHC.sub.1-4alkyl, --N(C.sub.1-4
alkyl)C.sub.1-4 alkyl.
[0230] In a preferred embodiment, X.sup.1 is C(R.sup.9). In a
further preferred embodiment, X.sup.1 is C(R.sup.9) and X.sup.2 is
N. In a further embodiment, X.sup.1 is C(R.sup.9) and X.sup.2 is
C(R.sup.10).
[0231] In a preferred embodiment, R.sup.1 is phenyl substituted by
0 or 1 R.sup.2 substituents, and the phenyl is additionally
substituted by 0, 1, 2 or 3 substituents independently selected
from halo, nitro, cyano, C.sub.1-4alkyl, OC.sub.1-4alkyl,
OC.sub.1-4haloalkyl, NHC.sub.1-4alkyl, N(C.sub.1-4 alkyl)C.sub.1-4
alkyl and C.sub.1-4haloalkyl. In one specific embodiment, R.sup.1
is unsubstituted phenyl. In a further specific embodiment, R.sup.1
is phenyl substituted by 1, 2 or 3 substituents independently
selected from halo, nitro, cyano, C.sub.1-4alkyl, OC.sub.1-4alkyl,
OC.sub.1-4haloalkyl, NHC.sub.1-4alkyl, N(C.sub.1-4 alkyl)C.sub.1-4
alkyl and C.sub.1-4haloalkyl.
[0232] In one specific embodiment, R.sup.1 is selected from
2-methylphenyl, 2-chlorophenyl, 2-trifluoromethylphenyl,
2-fluorophenyl and 2-methoxyphenyl.
[0233] In a further preferred embodiment, R.sup.1 is phenoxy.
[0234] In a further preferred embodiment, R.sup.1 is a
direct-bonded or oxygen-linked saturated, partially-saturated or
unsaturated 5-, 6- or 7-membered monocyclic ring containing 1, 2, 3
or 4 atoms selected from N, O and S, but containing no more than
one O or S, wherein the available carbon atoms of the ring are
substituted by 0, 1 or 2 oxo or thioxo groups, wherein the ring is
substituted by 0 or 1 R.sup.2 substituents, and the ring is
additionally substituted by 0, 1, 2 or 3 substituents independently
selected from halo, nitro, cyano, C.sub.1-4alkyl, OC.sub.1-4alkyl,
OC.sub.1-4haloalkyl, NHC.sub.1-4alkyl, N(C.sub.1-4 alkyl)C.sub.1-4
alkyl and C.sub.1-4haloalkyl.
[0235] In one specific embodiment, R.sup.1 is an unsaturated 5- or
6-membered monocyclic ring containing 1, 2, 3 or 4 atoms selected
from N, O and S, but containing no more than one O or S, wherein
the ring is substituted by 0 or 1 R.sup.2 substituents, and the
ring is additionally substituted by 0, 1, 2 or 3 substituents
independently selected from halo, nitro, cyano, C.sub.1-4alkyl,
OC.sub.1-4alkyl, 0C.sub.1-4haloalkyl, NHC.sub.1-4alkyl, N(C.sub.1-4
alkyl)C.sub.1-4 alkyl and C.sub.1-4haloalkyl.
[0236] In a further specific embodiment, R.sup.1 is an unsaturated
5- or 6-membered monocyclic ring containing 1, 2, 3 or 4 atoms
selected from N, O and S, but containing no more than one O or S,
wherein the ring is substituted by 1, 2 or 3 substituents
independently selected from halo, nitro, cyano, C.sub.1-4alkyl,
OC.sub.1-4alkyl, OC.sub.1-4haloalkyl, NHC.sub.1-4alkyl, N(C.sub.1-4
alkyl)C.sub.1-4 alkyl and C.sub.1-4haloalkyl.
[0237] In one specific embodiment, R.sup.1 is an unsubstituted
unsaturated 5- or 6-membered monocyclic ring containing 1, 2, 3 or
4 atoms selected from N, O and S.
[0238] In a further specific embodiment, R.sup.1 is selected from
pyridyl and pyrimidinyl.
[0239] In one embodiment, R.sup.3 is selected from halo,
C.sub.1-4haloalkyl, cyano, nitro, --C(O)R.sup.a,
--C(.dbd.O)OR.sup.a, --C(.dbd.O)NR.sup.aR.sup.a,
--C(NR.sup.a)NR.sup.aR.sup.a, --OR.sup.a, --OC(.dbd.O)R.sup.a,
--OC(.dbd.O)NR.sup.aR.sup.a,
--OC(.dbd.O)N(R.sup.a)S(.dbd.O).sub.2R.sup.a,
--OC.sub.2-6alkylNR.sup.aR.sup.a, --OC.sub.2-6alkylOR.sup.a,
--SR.sup.a, --S(.dbd.O)R.sup.a, --S(.dbd.O).sub.2R.sup.a,
--S(.dbd.O)NR.sup.aR.sup.a,
--S(.dbd.O).sub.2N(R.sup.a)C(.dbd.O)R.sup.a,
--S(.dbd.O).sub.2N(R.sup.a)C(O)OR.sup.a,
--S(.dbd.O).sub.2N(R.sup.a)C(.dbd.O)NR.sup.aR.sup.a,
--NR.sup.aR.sup.a, --N(R.sup.a)C(.dbd.O)R.sup.a,
--N(R.sup.a)C(.dbd.O)OR.sup.a,
--N(R.sup.a)C(.dbd.O)NR.sup.aR.sup.a,
--N(R.sup.a)C(.dbd.NR.sup.a)NR.sup.aR.sup.a,
--N(R.sup.a)S(.dbd.O).sub.2R.sup.a,
--N(R.sup.a)S(.dbd.O).sub.2NR.sup.aR.sup.a, --NR.sup.aC.sub.2-6
alkylNR.sup.aR.sup.a, --NR.sup.a, C.sub.1-6alkyl, phenyl, benzyl,
heteroaryl and heterocycle, wherein the C.sub.1-6alkyl, phenyl,
benzyl, heteroaryl and heterocycle are additionally substituted by
0, 1, 2 or 3 substituents selected from C.sub.1-6haloalkyl,
OC.sub.1-6alkyl, Br, Cl, F, I and C.sub.1-6alkyl.
[0240] In one preferred embodiment, R.sup.3 is H.
[0241] In another preferred embodiment, R.sup.3 is selected from F,
Cl, C.sub.1-6alkyl, phenyl, benzyl, heteroaryl and heterocycle,
wherein the C.sub.1-6alkyl, phenyl, benzyl, heteroaryl and
heterocycle are additionally substituted by 0, 1, 2 or 3
substituents selected from C.sub.1-6haloalkyl, OC.sub.1-6alkyl, Br,
Cl, F, I and C.sub.1-6alkyl.
[0242] In one embodiment, R.sup.5 is, independently, in each
instance, H, halo, C.sub.1-6alkyl, C.sub.1-4haloalkyl, or
C.sub.1-6alkyl substituted by 1, 2 or 3 substituents selected from
halo, cyano, OH, OC.sub.1-4alkyl, C.sub.1-4alkyl,
C.sub.1-3haloalkyl, OC.sub.1-4alkyl, NH.sub.2, NHC.sub.1-4alkyl,
N(C.sub.1-4 alkyl)C.sub.1-4 alkyl; or both R.sup.5 groups together
form a C.sub.3-6spiroalkyl substituted by 0, 1, 2 or 3 substituents
selected from halo, cyano, OH, OC.sub.1-4alkyl, C.sub.1-4alkyl,
C.sub.1-3haloalkyl, OC.sub.1-4alkyl, NH.sub.2, NHC.sub.1-4alkyl,
N(C.sub.1-4 alkyl)C.sub.1-4alkyl.
[0243] In one preferred embodiment, R.sup.5 is H.
[0244] In another preferred embodiment, one R.sup.5 is S-methyl,
the other is H.
[0245] In another preferred embodiment, at least one R.sup.5 is
halo, C.sub.1-6alkyl, C.sub.1-4haloalkyl, or C.sub.1-6alkyl
substituted by 1, 2 or 3 substituents selected from halo, cyano,
OH, OC.sub.1-4alkyl, C.sub.1-4alkyl, C.sub.1-3haloalkyl,
OC.sub.1-4alkyl, NH.sub.2, NHC.sub.1-4alkyl, N(C.sub.1-4
alkyl)C.sub.1-4 alkyl.
[0246] In a preferred embodiment, R.sup.6 is H.
[0247] In another preferred embodiment, R.sup.6 is F, Cl, cyano or
nitro.
[0248] In a preferred embodiment, R.sup.7 is H.
[0249] In another preferred embodiment, R.sup.7 is F, Cl, cyano or
nitro.
[0250] In a preferred embodiment, R.sup.8 is selected from H,
CF.sub.3, C.sub.1-3alkyl, Br, Cl and F.
[0251] In one specific embodiment, R.sup.8 is H.
[0252] In another specific embodiment, R.sup.8 is selected from
CF.sub.3, C.sub.1-3alkyl, Br, Cl and F.
[0253] In a preferred embodiment, R.sup.9 is H.
[0254] In another embodiment, R.sup.9 is selected from halo,
C.sub.1-4haloalkyl, cyano, nitro, C(.dbd.O)R.sup.a,
--C(.dbd.O)OR.sup.a, --C(.dbd.O)NR.sup.aR.sup.a,
--C(.dbd.NR.sup.a)NR.sup.aR.sup.a, --OR.sup.a, --OC(.dbd.O)R.sup.a,
--OC(.dbd.O)NR.sup.aR.sup.a,
--OC(.dbd.O)N(R.sup.a)S(.dbd.O).sub.2R.sup.a,
--OC.sub.2-6alkylNR.sup.aR.sup.a, --OC.sub.2-6alkylOR.sup.a,
--SR.sup.a, --S(.dbd.O)R.sup.a, --S(.dbd.O).sub.2R.sup.a,
--S(.dbd.O).sub.2NR.sup.aR.sup.a,
S(.dbd.O).sub.2N(R.sup.a)C(.dbd.O)R.sup.a,
--S(.dbd.O).sub.2N(R.sup.a)C(.dbd.O)OR.sup.a,
--S(.dbd.O).sub.2N(R.sup.a)C(.dbd.O)NR.sup.aR.sup.a,
--NR.sup.aR.sup.a, --N(R.sup.a)C(.dbd.O)R.sup.a,
--N(R.sup.a)C(.dbd.O)OR.sup.a,
--N(R.sup.a)C(.dbd.O)NR.sup.aR.sup.a,
--N(R.sup.a)C(.dbd.NR.sup.a)NR.sup.aR.sup.a,
--N(R.sup.a)S(.dbd.O).sub.2R.sup.a,
--N(R.sup.a)S(.dbd.O).sub.2NR.sup.aR.sup.a,
--NR.sup.aC.sub.2-6alkylNR.sup.aR.sup.a,
--NR.sup.aC.sub.2-6alkylOR.sup.a, C.sub.1-6alkyl, phenyl, benzyl,
heteroaryl and heterocycle, wherein the C.sub.1-6alkyl, phenyl,
benzyl, heteroaryl and heterocycle are additionally substituted by
0, 1, 2 or 3 substituents selected from halo, C.sub.1-4haloalkyl,
cyano, nitro, --C(.dbd.O)R.sup.a, --C(.dbd.O)OR.sup.a,
--C(.dbd.O)NR.sup.aR.sup.a, --C(.dbd.NR.sup.a)NR.sup.aR.sup.a,
--OR.sup.a, --OC(.dbd.O)R.sup.a, --OC(.dbd.O)NR.sup.aR.sup.a,
--OC(.dbd.O)N(R.sup.a)S(.dbd.O).sub.2R.sup.a,
--OC.sub.2-6alkylOR.sup.a, --SR.sup.a, --S(.dbd.O)R.sup.a,
--S(.dbd.O).sub.2R.sup.a, --S(.dbd.O).sub.2NR.sup.aR.sup.a,
--S(.dbd.O).sub.2N(R.sup.a)C(.dbd.O)R.sup.a,
--S(.dbd.O).sub.2N(R.sup.a)C(.dbd.O)OR.sup.a,
--S(.dbd.O).sub.2N(R.sup.a)C(.dbd.O)NR.sup.aR.sup.a,
--NR.sup.aR.sup.a, --N(R.sup.a)C(.dbd.O)R.sup.a,
--N(R.sup.a)C(.dbd.O)OR.sup.a,
--N(R.sup.a)C(.dbd.O)NR.sup.aR.sup.a,
--N(R.sup.a)C(.dbd.NR.sup.a)NR.sup.aR.sup.a,
--N(R.sup.a)S(.dbd.O).sub.2R.sup.a,
--N(R.sup.a)S(.dbd.O).sub.2NR.sup.aR.sup.a, --NR.sup.aC.sub.2-6
alkylNR.sup.aR.sup.a, --NR.sup.aC.sub.2-6 alkyl OR.sup.a.
[0255] In one embodiment, R.sup.9 is a saturated,
partially-saturated or unsaturated 5-, 6- or 7-membered monocyclic
ring containing 0, 1, 2, 3 or 4 atoms selected from N, O and S, but
containing no more than one O or S, wherein the available carbon
atoms of the ring are substituted by 0, 1 or 2 oxo or thioxo
groups, wherein the ring is substituted by 0, 1, 2, 3 or 4
substituents selected from halo, C.sub.1-4haloalkyl, cyano, nitro,
--C(.dbd.O)R.sup.a, --C(.dbd.O)OR.sup.a,
--C(.dbd.O)NR.sup.aR.sup.a, --C(.dbd.NR.sup.a)NR.sup.aR.sup.a,
--OR.sup.a, --OC(.dbd.O)R.sup.a, --OC(.dbd.O)NR.sup.aR.sup.a,
--OC(.dbd.O)N(R.sup.a)S(.dbd.O).sub.2R.sup.a,
--OC.sub.2-6alkylNR.sup.aR.sup.a, --OC.sub.2-6alkylOR.sup.a,
--SR.sup.a, --S(.dbd.O)R.sup.a, --S(.dbd.O).sub.2R.sup.a,
--S(.dbd.O).sub.2NR.sup.aR.sup.a,
--S(.dbd.O).sub.2N(R.sup.a)C(.dbd.O)R.sup.a,
--S(.dbd.O).sub.2N(R.sup.a)C(.dbd.O)OR.sup.a,
--S(.dbd.O).sub.2N(R.sup.a)C(.dbd.O)NR.sup.aR.sup.a,
--NR.sup.aR.sup.a, --N(R.sup.a)C(.dbd.O)R.sup.a,
--N(R.sup.a)C(.dbd.O)OR.sup.a,
--N(R.sup.a)C(.dbd.O)NR.sup.aR.sup.a,
--N(R.sup.a)C(.dbd.NR.sup.a)NR.sup.aR.sup.a,
--N(R.sup.a)S(.dbd.O).sub.2R.sup.a,
--N(R.sup.a)S(.dbd.O).sub.2NR.sup.aR.sup.a,
--NR.sup.aC.sub.2-6alkylNR.sup.aR.sup.a and
--NR.sup.aC.sub.2-6alkylOR.sup.a.
[0256] In one preferred embodiment, R.sup.10 is H.
[0257] In another preferred embodiment, R.sup.m is cyano, nitro,
CO.sub.2R.sup.a, C(.dbd.O)NR.sup.aR.sup.a,
--C(.dbd.NR.sup.a)NR.sup.aR.sup.a,
--S(.dbd.O).sub.2N(R.sup.a)C(.dbd.O)R.sup.a,
--S(.dbd.O).sub.2N(R.sup.a)C(.dbd.O)OR.sup.a,
--S(.dbd.O).sub.2N(R.sup.a)C(.dbd.O)NR.sup.aR.sup.a,
S(.dbd.O)R.sup.b, S(.dbd.O).sub.2R.sup.b or
S(.dbd.O).sub.2NR.sup.aR.sup.a.
[0258] In one preferred embodiment, R.sup.11 is H.
[0259] In another exemplary embodiment, the PI3K inhibitor is a
compound of Formula (VI):
##STR00009##
or a pharmaceutically-acceptable salt thereof, wherein: [0260]
X.sup.1 is C(R.sup.9) or N; [0261] X.sup.2 is C(R.sup.10) or N;
[0262] Y is N(R.sup.11), O or S; [0263] Z is CR.sup.8 or N; [0264]
R.sup.1 is a direct-bonded or oxygen-linked saturated,
partially-saturated or unsaturated 5-, 6- or 7-membered monocyclic
ring containing 0, 1, 2, 3 or 4 atoms selected from N, O and S, but
containing no more than one O or S, wherein the available carbon
atoms of the ring are substituted by 0, 1 or 2 oxo or thioxo
groups, wherein the ring is substituted by 0 or 1 R.sup.2
substituents, and the ring is additionally substituted by 0, 1, 2
or 3 substituents independently selected from halo, nitro, cyano,
C.sub.1-4alkyl, OC.sub.1-4alkyl, OC.sub.1-4haloalkyl,
NHC.sub.1-4alkyl, N(C.sub.1-4 alkyl)C.sub.1-4 alkyl and
C.sub.1-4haloalkyl; [0265] R.sup.2 is selected from halo,
C.sub.1-4haloalkyl, cyano, nitro, --C(.dbd.O)R.sup.a,
--C(.dbd.O)OR.sup.a, --C(.dbd.O)NR.sup.aR.sup.a,
--C(.dbd.NR.sup.a)NR.sup.aR.sup.a, --OR.sup.a, --OC(.dbd.O)R.sup.a,
--OC(.dbd.O)NR.sup.aR.sup.a,
--OC(.dbd.O)N(R.sup.a)S(.dbd.O).sub.2R.sup.a,
--OC.sub.2-6alkylNR.sup.aR.sup.a, --OC.sub.2-6alkylOR.sup.a,
--S(.dbd.O)R.sup.a, --S(.dbd.O).sub.2R.sup.a,
--S(.dbd.O).sub.2NR.sup.aR.sup.a,
--S(.dbd.O).sub.2N(R.sup.a)C(.dbd.O)R.sup.a,
--S(.dbd.O).sub.2N(R.sup.a)C(.dbd.O)OR.sup.a,
--S(.dbd.O).sub.2N(R.sup.a)C(.dbd.O)NR.sup.aR.sup.a,
--NR.sup.aR.sup.a, --N(R.sup.a)C(.dbd.O)R.sup.a,
--N(R.sup.a)C(.dbd.O)OR.sup.a,
--N(R.sup.a)C(.dbd.O)NR.sup.aR.sup.a,
--N(R.sup.a)C(.dbd.NR.sup.a)NR.sup.aR.sup.a,
N(R.sup.a)S(.dbd.O).sub.2R.sup.a,
--N(R.sup.a)S(.dbd.O).sub.2NR.sup.aR.sup.a, --NR.sup.aC.sub.2-6
alkylNR.sup.aR.sup.a and --NR.sup.aC.sub.2-6 alkylOR.sup.a; or
R.sup.2 is selected from C.sub.1-6alkyl, phenyl, benzyl,
heteroaryl, heterocycle, --(C.sub.1-3alkyl)heteroaryl,
--(C.sub.1-3alkyl)heterocycle, --O(C.sub.1-3alkyl)heteroaryl,
--O(C.sub.1-3alkyl)heterocycle,
--NR.sup.a(C.sub.1-3alkyl)heteroaryl,
--NR.sup.a(C.sub.1-3alkyl)heterocycle, --(C.sub.1-3alkyl)phenyl,
--O(C.sub.1-3 alkyl)phenyl and --NR.sup.a(C.sub.1-3 alkyl)phenyl
all of which are substituted by 0, 1, 2 or 3 substituents selected
from C.sub.1-4haloalkyl, OC.sub.1-4alkyl, Br, Cl, F, I and
C.sub.1-4alkyl; [0266] R.sup.3 is selected from H, halo,
C.sub.1-4haloalkyl, cyano, nitro, --C(.dbd.O)R.sup.a,
--C(.dbd.O)OR.sup.a,
C(.dbd.O)NR.sup.aR.sup.aC(.dbd.NR.sup.a)NR.sup.aR.sup.a,
--OR.sup.a, --OC(.dbd.O)R.sup.a, --OC(.dbd.O)NR.sup.aR.sup.a,
--OC(.dbd.O)N(R.sup.a)S(.dbd.O).sub.2R.sup.a,
--OC.sub.2-6alkylNR.sup.aR.sup.a, --OC.sub.2-6alkylOR.sup.a,
--SR.sup.a, --S(.dbd.O)R.sup.a, --S(.dbd.O).sub.2R.sup.a,
--S(.dbd.O).sub.2NR.sup.aR.sup.a,
--S(.dbd.O).sub.2N(R.sup.a)C(.dbd.O)R.sup.a,
--S(.dbd.O).sub.2N(R.sup.a)C(.dbd.O)OR.sup.a,
--S(.dbd.O).sub.2N(R.sup.a)C(.dbd.O)NR.sup.aR.sup.a,
NR.sup.aR.sup.a, --N(R.sup.a)C(.dbd.O)R.sup.a,
--N(R.sup.a)C(.dbd.O)OR.sup.a,
--N(R.sup.a)C(.dbd.O)NR.sup.aR.sup.a,
--N(R.sup.a)C(.dbd.NR.sup.a)NR.sup.aR.sup.a,
--N(R.sup.a)S(.dbd.O).sub.2R.sup.a,
--N(R.sup.a)S(.dbd.O).sub.2NR.sup.aR.sup.a, --NR.sup.aC.sub.2-6
alkylOR.sup.a, C.sub.1-6alkyl, phenyl, benzyl, heteroaryl and
heterocycle, wherein the C.sub.1-6alkyl, phenyl, benzyl, heteroaryl
and heterocycle are additionally substituted by 0, 1, 2 or 3
substituents selected from C.sub.1-6haloalkyl, OC.sub.1-6alkyl, Br,
Cl, F, I and C.sub.1-6alkyl; [0267] R.sup.5 is, independently, in
each instance, H, halo, C.sub.1-6alkyl, C.sub.1-4haloalkyl, or
C.sub.1-6alkyl substituted by 1, 2 or 3 substituents selected from
halo, cyano, OH, OC.sub.1-4alkyl, C.sub.1-4alkyl,
C.sub.1-3haloalkyl, OC.sub.1-4alkyl, NH.sub.2, NHC.sub.1-4alkyl,
N(C.sub.1-4 alkyl)C.sub.1-4 alkyl; or both R.sup.5 groups together
form a C.sub.3-6-spiroalkyl substituted by 0, 1, 2 or 3
substituents selected from halo, cyano, OH, OC.sub.1-4alkyl,
C.sub.1-4alkyl, C.sub.1-3haloalkyl, OC.sub.1-4alkyl, NH.sub.2,
NHC.sub.1-4alkyl, N(C.sub.1-4 alkyl)C.sub.1-4 alkyl; [0268] R.sup.6
is selected from H, halo, C.sub.1-6alkyl, C.sub.1-4haloalkyl,
cyano, nitro, --C(.dbd.O)R.sup.a, --C(.dbd.O)OR.sup.a,
--C(.dbd.O)NR.sup.aR.sup.a, --C(.dbd.NR.sup.a)NR.sup.aR.sup.a,
--S(.dbd.O)R.sup.a, --S(.dbd.O).sub.2R.sup.a,
--S(.dbd.O).sub.2NR.sup.aR.sup.a,
--S(.dbd.O).sub.2N(R.sup.a)C(.dbd.O)R.sup.a,
--S(.dbd.O).sub.2N(R.sup.a)C(.dbd.O)OR.sup.a,
--S(.dbd.O).sub.2N(R.sup.a)C(.dbd.O)NR.sup.aR.sup.a; [0269] R.sup.7
is selected from H, halo, C.sub.1-6alkyl, C.sub.1-4haloalkyl,
cyano, nitro, --C(.dbd.O)R.sup.a, --C(.dbd.O)OR.sup.a,
--C(.dbd.O)NR.sup.aR.sup.a, --C(.dbd.NR.sup.a)NR.sup.aR.sup.a,
--S(.dbd.O)R.sup.aS(.dbd.O).sub.2R.sup.a,
--S(.dbd.O).sub.2NR.sup.aR.sup.a,
--S(.dbd.O).sub.2N(R.sup.a)C(.dbd.O)R.sup.a,
--S(.dbd.O).sub.2N(R.sup.a)C(.dbd.O)OR.sup.a,
--S(.dbd.O).sub.2N(R.sup.a)C(.dbd.O)NR.sup.aR.sup.a; [0270] R.sup.8
is selected from H, C.sub.1-6haloalkyl, Br, Cl, F, I, OR.sup.a,
NR.sup.aR.sup.a, C.sub.1-6alkyl, phenyl, benzyl, heteroaryl and
heterocycle, wherein the C.sub.1-6alkyl, phenyl, benzyl, heteroaryl
and heterocycle are additionally substituted by 0, 1, 2 or 3
substituents selected from C.sub.1-6haloalkyl, OC.sub.1-6 alkyl,
Br, Cl, F, I and C.sub.1-6alkyl; [0271] R.sup.9 is selected from H,
halo, C.sub.1-4haloalkyl, cyano, nitro, --C(.dbd.O)R.sup.a,
--C(.dbd.O)OR.sup.a, --C(.dbd.O)NR.sup.aR.sup.a,
--C(.dbd.NR.sup.a)NR.sup.aR.sup.a, --OR.sup.a, --OC(.dbd.O)R.sup.a,
OC(.dbd.O)NR.sup.aR.sup.a,
--OC(.dbd.O)N(R.sup.a)S(.dbd.O).sub.2R.sup.a,
--OC.sub.2-6alkylNR.sup.aR.sup.a, --OC.sub.2-6alkylOR.sup.a,
--SR.sup.a, --S(.dbd.O)R.sup.a, --S(.dbd.O).sub.2R.sup.a,
--S(.dbd.O).sub.2NR.sup.aR.sup.a,
--S(.dbd.O).sub.2N(R.sup.a)C(.dbd.O)R.sup.a,
--S(.dbd.O).sub.2N(R.sup.a)C(.dbd.O)OR.sup.a,
--S(.dbd.O).sub.2N(R.sup.a)C(.dbd.O)NR.sup.aR.sup.a,
--NR.sup.aR.sup.a, --N(R.sup.a)C(.dbd.O)R.sup.a,
--N(R.sup.a)C(.dbd.O)OR.sup.a,
--N(R.sup.a)C(.dbd.O)NR.sup.aR.sup.a,
--N(R.sup.a)C(.dbd.NR.sup.a)NR.sup.aR.sup.a,
--N(R.sup.a)S(.dbd.O).sub.2R.sup.a,
--N(R.sup.a)S(.dbd.O).sub.2NR.sup.aR.sup.a, --NR.sup.aC.sub.2-6
alkylNR.sup.aR.sup.a, --NR.sup.aC.sub.2-6 alkylOR.sup.a,
C.sub.1-6alkyl, phenyl, benzyl, heteroaryl and heterocycle, wherein
the C.sub.1-6alkyl, phenyl, benzyl, heteroaryl and heterocycle are
additionally substituted by 0, 1, 2 or 3 substituents selected from
halo, C.sub.1-4haloalkyl, cyano, nitro, --C(.dbd.O)R.sup.a,
--C(.dbd.O)OR.sup.a, --C(.dbd.O)NR.sup.aR.sup.a,
--C(.dbd.NR.sup.a)NR.sup.aR.sup.a, --OR.sup.a, --OC(.dbd.O)R.sup.a,
--OC(.dbd.O)NR.sup.aR.sup.a,
--OC(.dbd.O)N(R.sup.a)S(.dbd.O).sub.2R.sup.a,
--OC.sub.2-6alkylOR.sup.a, --SR.sup.a, --S(.dbd.O)R.sup.a,
--S(.dbd.O).sub.2R.sup.a, --S(.dbd.O).sub.2NR.sup.aR.sup.a,
--S(.dbd.O).sub.2N(R.sup.a)C(.dbd.O)R.sup.a,
--S(.dbd.O).sub.2N(R.sup.a)C(.dbd.O)OR.sup.a,
--S(.dbd.O).sub.2N(R.sup.a)C(.dbd.O)NR.sup.aR.sup.a,
NR.sup.aR.sup.a, --N(R.sup.a)C(.dbd.O)R.sup.a,
--N(R.sup.a)C(.dbd.O)OR.sup.a,
--N(R.sup.a)C(.dbd.O)NR.sup.aR.sup.a,
--N(R.sup.a)C(.dbd.NR.sup.a)NR.sup.aR.sup.a,
--N(R.sup.a)S(.dbd.O).sub.2R.sup.a,
--N(R.sup.a)S(.dbd.O).sub.2NR.sup.aR.sup.a, --NR.sup.aC.sub.2-6
alkylNR.sup.a, --NR.sup.aC.sub.2-6 alkylOR.sup.a; or R.sup.9 is a
saturated, partially-saturated or unsaturated 5-, 6- or 7-membered
monocyclic ring containing 0, 1, 2, 3 or 4 atoms selected from N, O
and S, but containing no more than one O or S, wherein the
available carbon atoms of the ring are substituted by 0, 1 or 2 oxo
or thioxo groups, wherein the ring is substituted by 0, 1, 2, 3 or
4 substituents selected from halo, C.sub.1-4haloalkyl, cyano,
nitro, --C(.dbd.O)R.sup.a, --C(.dbd.O)OR.sup.a,
--C(.dbd.O)NR.sup.aR.sup.a, --C(.dbd.NR.sup.a)NR.sup.aR.sup.a,
--OR.sup.a, --OC(.dbd.O)R.sup.a, --OC(.dbd.O)NR.sup.aR.sup.a,
--OC(.dbd.O)N(R.sup.a)S(.dbd.O).sub.2R.sup.a,
--OC.sub.2-6alkylOR.sup.a, --SR.sup.a, --S(.dbd.O)R.sup.a,
--S(.dbd.O).sub.2R.sup.a, --S(.dbd.O).sub.2NR.sup.aR.sup.a,
--S(.dbd.O).sub.2N(R.sup.a)C(.dbd.O)R.sup.a,
--S(.dbd.O).sub.2N(R.sup.a)C(.dbd.O)OR.sup.a,
--S(.dbd.O).sub.2N(R.sup.a)C(.dbd.O)NR.sup.aR.sup.a,
--NR.sup.aR.sup.a, --N(R.sup.a)C(.dbd.O)R.sup.a,
--N(R.sup.a)C(.dbd.O)OR.sup.a,
--N(R.sup.a)C(.dbd.O)NR.sup.aR.sup.a,
--N(R.sup.a)C(.dbd.NR.sup.a)NR.sup.aR.sup.a,
--N(R.sup.a)S(.dbd.O).sub.2R.sup.a,
--N(R.sup.a)S(.dbd.O).sub.2NR.sup.aR.sup.a, --NR.sup.aC.sub.2-6
alkylNR.sup.aR.sup.a and --NR.sup.aC.sub.2-6 alkylOR.sup.a; [0272]
R.sup.10 is H, C.sub.1-3alkyl, C.sub.1-3haloalkyl, cyano, nitro,
CO.sub.2R.sup.a, C(.dbd.O)NR.sup.aR.sup.a,
--C(.dbd.NR.sup.a)NR.sup.aR.sup.a,
--S(.dbd.O).sub.2N(R.sup.a)C(.dbd.O)R.sup.a,
--S(.dbd.O).sub.2N(R.sup.a)C(.dbd.O)OR.sup.a,
--S(.dbd.O).sub.2N(R.sup.a)C(.dbd.O)NR.sup.aR.sup.a,
--S(.dbd.O)R.sup.b, S(.dbd.O).sub.2R.sup.b or
S(.dbd.O).sub.2NR.sup.aR.sup.a; --R.sup.11 is H or C.sub.1-4alkyl;
[0273] R.sup.a is independently, at each instance, H or R.sup.b;
and [0274] R.sup.b is independently, at each instance, phenyl,
benzyl or C.sub.1-6alkyl, the phenyl, benzyl and C.sub.1-6 alkyl
being substituted by 0, 1, 2 or 3 substituents selected from halo,
C.sub.1-4alkyl, C.sub.1-3 haloalkyl, --OC.sub.1-4alkyl, --NH.sub.2,
--NHC.sub.1-4alkyl, --N(C.sub.1-4 alkyl)C.sub.1-4 alkyl.
[0275] In a preferred embodiment, X.sup.1 is C(R.sup.9). In a
further preferred embodiment, X.sup.1 is C(R.sup.9) and X.sup.2 is
N. In a further embodiment, X.sup.1 is C(R.sup.9) and X.sup.2 is
C(R.sup.10).
[0276] In a preferred embodiment, R.sup.1 is phenyl substituted by
0 or 1 R.sup.2 substituents, and the phenyl is additionally
substituted by 0, 1, 2 or 3 substituents independently selected
from halo, nitro, cyano, C.sub.1-4alkyl, OC.sub.1-4alkyl,
OC.sub.1-4haloalkyl, NHC.sub.1-4alkyl, N(C.sub.1-4 alkyl)C.sub.1-4
alkyl and C.sub.1-4haloalkyl. In one specific embodiment, R.sup.1
is unsubstituted phenyl. In a further specific embodiment, R.sup.1
is phenyl substituted by 1, 2 or 3 substituents independently
selected from halo, nitro, cyano, C.sub.1-4alkyl, OC.sub.1-4alkyl,
OC.sub.1-4haloalkyl, NHC.sub.1-4alkyl, N(C.sub.1-4 alkyl)C.sub.1-4
alkyl and C.sub.1-4haloalkyl.
[0277] In one specific embodiment, R.sup.1 is selected from
2-methylphenyl, 2-chlorophenyl, 2-trifluoromethylphenyl,
2-fluorophenyl and 2-methoxyphenyl.
[0278] In a further preferred embodiment, R.sup.1 is phenoxy.
[0279] In a further preferred embodiment, R.sup.1 is a
direct-bonded or oxygen-linked saturated, partially-saturated or
unsaturated 5-, 6- or 7-membered monocyclic ring containing 1, 2, 3
or 4 atoms selected from N, O and S, but containing no more than
one O or S, wherein the available carbon atoms of the ring are
substituted by 0, 1 or 2 oxo or thioxo groups, wherein the ring is
substituted by 0 or 1 R.sup.2 substituents, and the ring is
additionally substituted by 0, 1, 2 or 3 substituents independently
selected from halo, nitro, cyano, C.sub.1-4alkyl, OC.sub.1-4alkyl,
OC.sub.1-4haloalkyl, NHC.sub.1-4alkyl, N(C.sub.1-4 alkyl)C.sub.1-4
alkyl and C.sub.1-4haloalkyl.
[0280] In one specific embodiment, R.sup.1 is an unsaturated 5- or
6-membered monocyclic ring containing 1, 2, 3 or 4 atoms selected
from N, O and S, but containing no more than one O or S, wherein
the ring is substituted by 0 or 1 R.sup.2 substituents, and the
ring is additionally substituted by 0, 1, 2 or 3 substituents
independently selected from halo, nitro, cyano, C.sub.1-4alkyl,
OC.sub.1-4alkyl, 0C.sub.1-4haloalkyl, NHC.sub.1-4alkyl, N(C.sub.1-4
alkyl)C.sub.1-4 alkyl and C.sub.1-4haloalkyl.
[0281] In a further specific embodiment, R.sup.1 is an unsaturated
5- or 6-membered monocyclic ring containing 1, 2, 3 or 4 atoms
selected from N, O and S, but containing no more than one O or S,
wherein the ring is substituted by 1, 2 or 3 substituents
independently selected from halo, nitro, cyano, C.sub.1-4alkyl,
OC.sub.1-4alkyl, OC.sub.1-4haloalkyl, NHC.sub.1-4alkyl, N(C.sub.1-4
alkyl)C.sub.1-4 alkyl and C.sub.1-4haloalkyl.
[0282] In one specific embodiment, R.sup.1 is an unsubstituted
unsaturated 5- or 6-membered monocyclic ring containing 1, 2, 3 or
4 atoms selected from N, O and S.
[0283] In a further specific embodiment, R.sup.1 is selected from
pyridyl and pyrimidinyl.
[0284] In one embodiment, R.sup.3 is selected from halo,
C.sub.1-4haloalkyl, cyano, nitro, --C(O)R.sup.a,
--C(.dbd.O)OR.sup.a, --C(.dbd.O)NR.sup.aR.sup.a,
--C(NR.sup.a)NR.sup.aR.sup.a, --OR.sup.a, --OC(.dbd.O)R.sup.a,
--OC(.dbd.O)NR.sup.aR.sup.a,
--OC(.dbd.O)N(R.sup.a)S(.dbd.O).sub.2R.sup.a,
--OC.sub.2-6alkylNR.sup.aR.sup.a, --OC.sub.2-6alkylOR.sup.a,
--SR.sup.a, --S(.dbd.O)R.sup.a, --S(.dbd.O).sub.2R.sup.a,
--S(.dbd.O)NR.sup.aR.sup.a,
--S(.dbd.O).sub.2N(R.sup.a)C(.dbd.O)R.sup.a,
--S(.dbd.O).sub.2N(R.sup.a)C(O)OR.sup.a,
--S(.dbd.O).sub.2N(R.sup.a)C(.dbd.O)NR.sup.aR.sup.a,
--NR.sup.aR.sup.a, --N(R.sup.a)C(.dbd.O).sub.2R.sup.a,
--N(R.sup.a)C(.dbd.O)OR.sup.a,
--N(R.sup.a)C(.dbd.O)NR.sup.aR.sup.a,
--N(R.sup.a)C(.dbd.NR.sup.a)NR.sup.aR.sup.a,
--N(R.sup.a)S(.dbd.O).sub.2R.sup.a,
--N(R.sup.a)S(.dbd.O).sub.2NR.sup.aR.sup.a,
--NR.sup.aC.sub.2-6alkylNR.sup.aR.sup.a, --NR.sup.a,
C.sub.1-6alkyl, phenyl, benzyl, heteroaryl and heterocycle, wherein
the C.sub.1-6alkyl, phenyl, benzyl, heteroaryl and heterocycle are
additionally substituted by 0, 1, 2 or 3 substituents selected from
C.sub.1-6haloalkyl, OC.sub.1-6alkyl, Br, Cl, F, I and
C.sub.1-6alkyl.
[0285] In one preferred embodiment, R.sup.3 is H.
[0286] In another preferred embodiment, R.sup.3 is selected from F,
Cl, C.sub.1-6alkyl, phenyl, benzyl, heteroaryl and heterocycle,
wherein the C.sub.1-6alkyl, phenyl, benzyl, heteroaryl and
heterocycle are additionally substituted by 0, 1, 2 or 3
substituents selected from C.sub.1-6haloalkyl, OC.sub.1-6alkyl, Br,
Cl, F, I and C.sub.1-6alkyl.
[0287] In one embodiment, R.sup.5 is, independently, in each
instance, H, halo, C.sub.1-6alkyl, C.sub.1-4 haloalkyl, or
C.sub.1-6alkyl substituted by 1, 2 or 3 substituents selected from
halo, cyano, OH, OC.sub.1-4 alkyl, C.sub.1-4alkyl,
C.sub.1-3haloalkyl, OC.sub.1-4alkyl, NH.sub.2, NHC.sub.1-4alkyl,
N(C.sub.1-4 alkyl)C.sub.1-4 alkyl; or both R.sup.5 groups together
form a C.sub.3-6spiroalkyl substituted by 0, 1, 2 or 3 substituents
selected from halo, cyano, OH, OC.sub.1-4alkyl, C.sub.1-4alkyl,
C.sub.1-3haloalkyl, OC.sub.1-4alkyl, NH.sub.2, NHC.sub.1-4alkyl,
N(C.sub.1-4 alkyl)C.sub.1-4alkyl.
[0288] In one preferred embodiment, R.sup.5 is H.
[0289] In another preferred embodiment, one R.sup.5 is S-methyl,
the other is H.
[0290] In another preferred embodiment, at least one R.sup.5 is
halo, C.sub.1-6alkyl, C.sub.1-4haloalkyl, or C.sub.1-6alkyl
substituted by 1, 2 or 3 substituents selected from halo, cyano,
OH, OC.sub.1-4alkyl, C.sub.1-4alkyl, C.sub.1-3haloalkyl,
OC.sub.1-4alkyl, NH.sub.2, NHC.sub.1-4alkyl, N(C.sub.1-4
alkyl)C.sub.1-4 alkyl.
[0291] In a preferred embodiment, R.sup.6 is H.
[0292] In another preferred embodiment, R.sup.6 is F, Cl, cyano or
nitro.
[0293] In a preferred embodiment, R.sup.7 is H.
[0294] In another preferred embodiment, R.sup.7 is F, Cl, cyano or
nitro.
[0295] In a preferred embodiment, R.sup.8 is selected from H,
CF.sub.3, C.sub.1-3alkyl, Br, Cl and F.
[0296] In one specific embodiment, R.sup.8 is H.
[0297] In another specific embodiment, R.sup.8 is selected from
CF.sub.3, C.sub.1-3alkyl, Br, Cl and F.
[0298] In a preferred embodiment, R.sup.9 is H.
[0299] In another embodiment, R.sup.9 is selected from halo,
C.sub.1-4haloalkyl, cyano, nitro, --C(.dbd.O)R.sup.a,
--C(.dbd.O)OR.sup.a, --C(.dbd.O)NR.sup.aR.sup.a,
--C(.dbd.NR.sup.a)NR.sup.aR.sup.a, --OR.sup.a, --OC(.dbd.O)R.sup.a,
--OC(.dbd.O)NR.sup.aR.sup.a,
--OC(.dbd.O)N(R.sup.a)S(.dbd.O).sub.2R.sup.a,
--OC.sub.2-6alkylNR.sup.aR.sup.a, --OC.sub.2-6alkylOR.sup.a,
--SR.sup.a, --S(.dbd.O)R.sup.a, --S(.dbd.O).sub.2R.sup.a,
--S(.dbd.O).sub.2NR.sup.aR.sup.a,
--S(.dbd.O).sub.2N(R.sup.a)C(.dbd.O)R.sup.a,
--S(.dbd.O).sub.2N(R.sup.a)C(.dbd.O)OR.sup.a,
--S(.dbd.O).sub.2N(R.sup.a)C(.dbd.O)NR.sup.aR.sup.a,
--NR.sup.aR.sup.a, --N(R.sup.a)C(.dbd.O)R.sup.a,
--N(R.sup.a)C(.dbd.O)OR.sup.a,
--N(R.sup.a)C(.dbd.O)NR.sup.aR.sup.a,
--N(R.sup.a)C(.dbd.NR.sup.a)NR.sup.aR.sup.a,
--N(R.sup.a)S(.dbd.O).sub.2R.sup.a,
--N(R.sup.a)S(.dbd.O).sub.2NR.sup.aR.sup.a, --NR.sup.aC.sub.2-6
alkylNR.sup.aR.sup.a, --NR.sup.aC.sub.2-6 alkylOR.sup.a,
C.sub.1-6alkyl, phenyl, benzyl, heteroaryl and heterocycle, wherein
the C.sub.1-6alkyl, phenyl, benzyl, heteroaryl and heterocycle are
additionally substituted by 0, 1, 2 or 3 substituents selected from
halo, C.sub.1-4haloalkyl, cyano, nitro, --C(.dbd.O)R.sup.a,
--C(.dbd.O)OR.sup.a, --C(.dbd.O)NR.sup.aR.sup.a,
--C(.dbd.NR.sup.a)NR.sup.aR.sup.a, --OR.sup.a, --OC(.dbd.O)R.sup.a,
--OC(.dbd.O)NR.sup.aR.sup.a,
--OC(.dbd.O)N(R.sup.a)S(.dbd.O).sub.2R.sup.a,
--OC.sub.2-6alkylOR.sup.a, --SR.sup.a, --S(.dbd.O)R.sup.a,
--S(.dbd.O).sub.2R.sup.a, --S(.dbd.O).sub.2NR.sup.aR.sup.a,
--S(.dbd.O).sub.2N(R.sup.a)C(.dbd.O)R.sup.a,
--S(.dbd.O).sub.2N(R.sup.a)C(.dbd.O)OR.sup.a,
--S(.dbd.O).sub.2N(R.sup.a)C(.dbd.O)NR.sup.aR.sup.a,
--NR.sup.aR.sup.a, --N(R.sup.a)C(.dbd.O)R.sup.a,
--N(R.sup.a)C(.dbd.O)OR.sup.a,
--N(R.sup.a)C(.dbd.O)NR.sup.aR.sup.a,
--N(R.sup.a)C(.dbd.NR.sup.a)NR.sup.aR.sup.a,
--N(R.sup.a)S(.dbd.O).sub.2R.sup.a,
--N(R.sup.a)S(.dbd.O).sub.2NR.sup.aR.sup.a, --NR.sup.aC.sub.2-6
alkylNR.sup.aR.sup.a, --NR.sup.aC.sub.2-6 alkylOR.sup.a.
[0300] In one embodiment, R.sup.9 is a saturated,
partially-saturated or unsaturated 5-, 6- or 7-membered monocyclic
ring containing 0, 1, 2, 3 or 4 atoms selected from N, O and S, but
containing no more than one O or S, wherein the available carbon
atoms of the ring are substituted by 0, 1 or 2 oxo or thioxo
groups, wherein the ring is substituted by 0, 1, 2, 3 or 4
substituents selected from halo, C.sub.1-4haloalkyl, cyano, nitro,
--C(.dbd.O)R.sup.a, --C(.dbd.O)OR.sup.a,
--C(.dbd.O)NR.sup.aR.sup.a, --C(.dbd.NR.sup.a)NR.sup.aR.sup.a,
--OR.sup.a, --OC(.dbd.O)R.sup.a, --OC(.dbd.O)NR.sup.aR.sup.a,
--OC(.dbd.O)N(R.sup.a)S(.dbd.O).sub.2R.sup.a,
--OC.sub.2-6alkylNR.sup.aR.sup.a, --OC.sub.2-6alkylOR.sup.a,
--SR.sup.a, --S(.dbd.O)R.sup.a, --S(.dbd.O).sub.2R.sup.a,
--S(.dbd.O).sub.2NR.sup.aR.sup.a,
--S(.dbd.O).sub.2N(R.sup.a)C(.dbd.O)R.sup.a,
--S(.dbd.O).sub.2N(R.sup.a)C(.dbd.O)OR.sup.a,
--S(.dbd.O).sub.2N(R.sup.a)C(.dbd.O)NR.sup.aR.sup.a,
--NR.sup.aR.sup.a, --N(R.sup.a)C(.dbd.O)R.sup.a,
--N(R.sup.a)C(.dbd.O)OR.sup.a,
--N(R.sup.a)C(.dbd.O)NR.sup.aR.sup.a,
--N(R.sup.a)C(.dbd.NR.sup.a)NR.sup.aR.sup.a,
--N(R.sup.a)S(.dbd.O).sub.2R.sup.a,
--N(R.sup.a)S(.dbd.O).sub.2NR.sup.aR.sup.a,
--NR.sup.aC.sub.2-6alkylNR.sup.aR.sup.a and
--NR.sup.aC.sub.2-6alkylOR.sup.a.
[0301] In one preferred embodiment, R.sup.10 is H.
[0302] In another preferred embodiment, R.sup.10 is cyano, nitro,
CO.sub.2R.sup.a, C(.dbd.O)NR.sup.aR.sup.a,
--C(.dbd.NR.sup.a)NR.sup.aR.sup.a,
--S(.dbd.O).sub.2N(R.sup.a)C(.dbd.O)R.sup.a,
--S(.dbd.O).sub.2N(R.sup.a)C(.dbd.O)OR.sup.a,
--S(.dbd.O).sub.2N(R.sup.a)C(.dbd.O)NR.sup.aR.sup.a,
S(.dbd.O)R.sup.b, S(.dbd.O).sub.2R.sup.b or
S(.dbd.O).sub.2NR.sup.aR.sup.a.
[0303] In one preferred embodiment, R.sup.11 is H.
[0304] In another exemplary embodiment, the PI3K inhibitor is a
compound of Formula (VII):
##STR00010##
or a pharmaceutically-acceptable salt thereof, wherein: [0305]
X.sup.1 is C(R.sup.9) or N; [0306] X.sup.2 is C(R.sup.10) or N;
[0307] Y is N(R.sup.11), O or S; [0308] Z is CR.sup.8 or N; R.sup.1
is a direct-bonded or oxygen-linked saturated, partially-saturated
or unsaturated 5-, 6- or 7-membered monocyclic ring containing 0,
1, 2, 3 or 4 atoms selected from N, O and S, but containing no more
than one O or S, wherein the available carbon atoms of the ring are
substituted by 0, 1 or 2 oxo or thioxo groups, wherein the ring is
substituted by 0 or 1 R.sup.2 substituents, and the ring is
additionally substituted by 0, 1, 2 or 3 substituents independently
selected from halo, nitro, cyano, C.sub.1-4alkyl, OC.sub.1-4alkyl,
OC.sub.1-4haloalkyl, NHC.sub.1-4alkyl, N(C.sub.1-4 alkyl)C.sub.1-4
alkyl and C.sub.1-4haloalkyl; [0309] R.sup.2 is selected from halo,
C.sub.1-4haloalkyl, cyano, nitro, --C(.dbd.O)R.sup.a,
--C(.dbd.O)OR.sup.a, --C(.dbd.O)NR.sup.aR.sup.a,
--C(.dbd.NR.sup.a)NR.sup.aR.sup.a, --OR.sup.a, --OC(.dbd.O)R.sup.a,
--OC(.dbd.O)NR.sup.aR.sup.a,
--OC(.dbd.O)N(R.sup.a)S(.dbd.O).sub.2R.sup.a,
--OC.sub.2-6alkylNR.sup.aR.sup.a, --OC.sub.2-6alkylOR.sup.a,
--SR.sup.a, --S(.dbd.O)R.sup.a, --S(.dbd.O).sub.2R.sup.a,
--S(.dbd.O).sub.2NR.sup.aR.sup.a,
--S(.dbd.O).sub.2N(R.sup.a)C(.dbd.O)R.sup.a,
--S(.dbd.O).sub.2N(R.sup.a)C(.dbd.O)OR.sup.a,
--S(.dbd.O).sub.2N(R.sup.a)C(.dbd.O)NR.sup.aR.sup.a,
NR.sup.aR.sup.a, --N(R.sup.a)C(.dbd.O)R.sup.a,
--N(R.sup.a)C(.dbd.O)OR.sup.a,
--N(R.sup.a)C(.dbd.O)NR.sup.aR.sup.a,
--N(R.sup.a)C(.dbd.NR.sup.a)NR.sup.aR.sup.a,
--N(R.sup.a)S(.dbd.O).sub.2R.sup.a,
--N(R.sup.a)S(.dbd.O).sub.2NR.sup.aR.sup.a, --NR.sup.aC.sub.2-6
alkylNR.sup.aR.sup.a and --NR.sup.aC.sub.2-6 alkylOR.sup.a; or
R.sup.2 is selected from C.sub.1-6alkyl, phenyl, benzyl,
heteroaryl, heterocycle, --(C.sub.1-3alkyl)heteroaryl,
--(C.sub.1-3alkyl)heterocycle, --O(C.sub.1-3alkyl)heteroaryl,
--O(C.sub.1-3alkyl)heterocycle,
--NR.sup.a(C.sub.1-3alkyl)heteroaryl,
--NR.sup.a(C.sub.1-3alkyl)heterocycle, --(C.sub.1-3alkyl)phenyl,
--O(C.sub.1-3 alkyl)phenyl and --NR.sup.a(C.sub.1-3 alkyl)phenyl
all of which are substituted by 0, 1, 2 or 3 substituents selected
from C.sub.1-4haloalkyl, OC.sub.1-4alkyl, Br, Cl, F, I and
C.sub.1-4alkyl; [0310] R.sup.3 is selected from H, halo,
C.sub.1-4haloalkyl, cyano, nitro, --C(.dbd.O)R.sup.a,
--C(.dbd.O)OR.sup.a, --C(.dbd.O)NR.sup.aR.sup.a,
--C(.dbd.NR.sup.a)NR.sup.aR.sup.a, --OR.sup.a, --OC(.dbd.O)R.sup.a,
--OC(.dbd.O)NR.sup.aR.sup.a,
--OC(.dbd.O)N(R.sup.a)S(.dbd.O).sub.2R.sup.a,
--OC.sub.2-6alkylNR.sup.aR.sup.a, --OC.sub.2-6alkylOR.sup.1,
--SR.sup.a, --S(.dbd.O)R.sup.a, --S(.dbd.O).sub.2R.sup.a,
--S(.dbd.O).sub.2NR.sup.aR.sup.a,
--S(.dbd.O).sub.2N(R.sup.a)C(.dbd.O)R.sup.a,
--S(.dbd.O).sub.2N(R.sup.a)C(.dbd.O) OR.sup.a,
--S(.dbd.O).sub.2N(R.sup.a)C(.dbd.O)NR.sup.aR.sup.a,
--NR.sup.aR.sup.a, --N(R.sup.a)C(.dbd.O)R.sup.a,
--N(R.sup.a)C(.dbd.O)OR.sup.a,
--N(R.sup.a)C(.dbd.O)NR.sup.aR.sup.a,
--N(R.sup.a)C(.dbd.NR.sup.a)NR.sup.aR.sup.a,
--N(R.sup.a)S(.dbd.O).sub.2R.sup.a,
--N(R.sup.a)S(.dbd.O).sub.2NR.sup.aR.sup.a, --NR.sup.aC.sub.2-6
alkylNR.sup.aR.sup.a, --NR.sup.aC.sub.2-6 alkylOR.sup.a,
C.sub.1-6alkyl, phenyl, benzyl, heteroaryl and heterocycle, wherein
the C.sub.1-6alkyl, phenyl, benzyl, heteroaryl and heterocycle are
additionally substituted by 0, 1, 2 or 3 substituents selected from
C.sub.1-6haloalkyl, OC.sub.1-6alkyl, Br, Cl, F, I and
C.sub.1-6alkyl; [0311] R.sup.5 is, independently, in each instance,
H, halo, C.sub.1-6alkyl, C.sub.1-4haloalkyl, or C.sub.1-6alkyl
substituted by 1, 2 or 3 substituents selected from halo, cyano,
OH, OC.sub.1-4alkyl, C.sub.1-4alkyl, C.sub.1-3haloalkyl,
OC.sub.1-4alkyl, NH.sub.2, NHC.sub.1-4alkyl, N(C.sub.1-4
alkyl)C.sub.1-4 alkyl; or both R.sup.5 groups together form a
C.sub.3-6-spiroalkyl substituted by 0, 1, 2 or 3 substituents
selected from halo, cyano, OH, OC.sub.1-4alkyl, C.sub.1-3haloalkyl,
OC.sub.1-4alkyl, NH.sub.2, NHC.sub.1-4alkyl, N(C.sub.1-4
alkyl)C.sub.1-4 alkyl; [0312] R.sup.6 is selected from H, halo,
C.sub.1-6alkyl, C.sub.1-4haloalkyl, cyano, nitro,
--C(.dbd.O)R.sup.a, --C(.dbd.O)OR.sup.a,
--C(.dbd.O)NR.sup.aR.sup.a, --C(.dbd.NR.sup.a)NR.sup.aR.sup.a,
--S(.dbd.O)R.sup.aS(.dbd.O).sub.2R.sup.a,
--S(.dbd.O).sub.2NR.sup.aR.sup.a,
--S(.dbd.O).sub.2N(R.sup.a)C(.dbd.O)R.sup.a,
--S(.dbd.O).sub.2N(R.sup.a)C(.dbd.O)OR.sup.a,
--S(.dbd.O).sub.2N(R.sup.a)C(.dbd.O)NR.sup.aR.sup.a; [0313] R.sup.7
is selected from H, halo, C.sub.1-6alkyl, C.sub.1-4haloalkyl,
cyano, nitro, --C(.dbd.O)R.sup.a, --C(.dbd.O)OR.sup.a,
--C(.dbd.O)NR.sup.aR.sup.a, --C(.dbd.NR.sup.a)NR.sup.aR.sup.a,
--S(.dbd.O)R.sup.aS(.dbd.O).sub.2R.sup.a,
--S(.dbd.O).sub.2NR.sup.aR.sup.a,
--S(.dbd.O).sub.2N(R.sup.a)C(.dbd.O)R.sup.a,
--S(.dbd.O).sub.2N(R.sup.a)C(.dbd.O)OR.sup.a,
--S(.dbd.O).sub.2N(R.sup.a)C(.dbd.O)NR.sup.aR.sup.a; [0314] R.sup.8
is selected from H, C.sub.1-6haloalkyl, Br, Cl, F, I, OR.sup.a,
NR.sup.aR.sup.a, C.sub.1-6alkyl, phenyl, benzyl, heteroaryl and
heterocycle, wherein the C.sub.1-6alkyl, phenyl, benzyl, heteroaryl
and heterocycle are additionally substituted by 0, 1, 2 or 3
substituents selected from C.sub.1-6haloalkyl, OC.sub.1-6alkyl, Br,
Cl, F, I and C.sub.1-6alkyl; [0315] R.sup.9 is selected from H,
halo, C.sub.1-4haloalkyl, cyano, nitro, --C(.dbd.O)R.sup.a,
--C(.dbd.O)OR.sup.a, --C(.dbd.O)NR.sup.aR.sup.a,
--C(.dbd.NR.sup.a)NR.sup.aR.sup.a, --OR.sup.a, --OC(.dbd.O)R.sup.a,
--OC(.dbd.O)NR.sup.aR.sup.a,
--OC(.dbd.O)N(R.sup.a)S(.dbd.O).sub.2R.sup.a,
--OC.sub.2-6alkylNR.sup.aR.sup.a, --OC.sub.2-6alkylOR.sup.a,
--SR.sup.a, --S(.dbd.O)R.sup.a, --S(.dbd.O).sub.2R.sup.a,
--S(.dbd.O).sub.2NR.sup.aR.sup.a,
--S(.dbd.O).sub.2N(R.sup.a)C(.dbd.O)R.sup.a,
--S(.dbd.O).sub.2N(R.sup.a)C(.dbd.O)OR.sup.a,
--S(.dbd.O).sub.2N(R.sup.a)C(.dbd.O)NR.sup.aR.sup.a,
--NR.sup.aR.sup.a, --N(R.sup.a)C(.dbd.O)R.sup.a,
--N(R.sup.a)C(.dbd.O)OR.sup.a,
--N(R.sup.a)C(.dbd.O)NR.sup.aR.sup.a,
--N(R.sup.a)C(.dbd.NR.sup.a)NR.sup.aR.sup.a,
--N(R.sup.a)S(.dbd.O).sub.2R.sup.a,
--N(R.sup.a)S(.dbd.O).sub.2NR.sup.aR.sup.a, --NR.sup.aC.sub.2-6
alkylOR.sup.a, C.sub.1-6alkyl, phenyl, benzyl, heteroaryl and
heterocycle, wherein the C.sub.1-6alkyl, phenyl, benzyl, heteroaryl
and heterocycle are additionally substituted by 0, 1, 2 or 3
substituents selected from halo, C.sub.1-4haloalkyl, cyano, nitro,
--C(.dbd.O)R.sup.a, --C(.dbd.O)OR.sup.a,
--C(.dbd.O)NR.sup.aR.sup.a, --C(.dbd.NR.sup.a)NR.sup.aR.sup.a,
--OR.sup.8, --OC(.dbd.O)R.sup.8, --OC(.dbd.O)NR.sup.2R.sup.8,
--OC(.dbd.O)N(R.sup.a)S(.dbd.O).sub.2R.sup.a,
--OC.sub.2-6alkylNR.sup.aR.sup.a, --OC.sub.2-6alkylOR.sup.a,
--SR.sup.a, --S(.dbd.O)R.sup.a, --S(.dbd.O).sub.2R.sup.8,
--S(.dbd.O).sub.2NR.sup.aR.sup.a,
--S(.dbd.O).sub.2N(R.sup.a)C(.dbd.O)R.sup.a,
--S(.dbd.O).sub.2N(R.sup.a)C(.dbd.O)OR.sup.a,
--S(.dbd.O).sub.2N(R.sup.a)C(.dbd.O)NR.sup.aR.sup.a,
--NR.sup.aR.sup.a, --N(R.sup.a)C(.dbd.O)R.sup.a,
--N(R.sup.a)C(.dbd.O)OR.sup.a,
--N(R.sup.a)C(.dbd.O)NR.sup.aR.sup.a,
--N(R.sup.a)C(.dbd.NR.sup.a)NR.sup.aR.sup.a,
--N(R.sup.a)S(.dbd.O).sub.2R.sup.a,
--N(R.sup.a)S(.dbd.O).sub.2NR.sup.aR.sup.a, --NR.sup.aC.sub.2-6
alkylNR.sup.aR.sup.a, --NR.sup.aC.sub.2-6 alkylOR.sup.a; or R.sup.9
is a saturated, partially-saturated or unsaturated 5-, 6- or
7-membered monocyclic ring containing 0, 1, 2, 3 or 4 atoms
selected from N, O and S, but containing no more than one O or S,
wherein the available carbon atoms of the ring are substituted by
0, 1 or 2 oxo or thioxo groups, wherein the ring is substituted by
0, 1, 2, 3 or 4 substituents selected from halo,
C.sub.1-4haloalkyl, cyano, nitro, --C(.dbd.O)R.sup.a,
--C(.dbd.O)OR.sup.a, --C(.dbd.O)NR.sup.aR.sup.a,
--C(.dbd.NR.sup.a)NR.sup.aR.sup.a, --OR.sup.a, --OC(.dbd.O)R.sup.a,
--OC(.dbd.O)NR.sup.aR.sup.a,
--OC(.dbd.O)N(R.sup.a)S(.dbd.O).sub.2R.sup.a,
--OC.sub.2-6alkylNR.sup.aR.sup.a, --OC.sub.2-6alkylOR.sup.a,
--SR.sup.a, --S(.dbd.O)R.sup.a, --S(.dbd.O).sub.2R.sup.a,
--S(.dbd.O).sub.2NR.sup.aR.sup.a,
--S(.dbd.O).sub.2N(R.sup.a)C(.dbd.O)R.sup.a,
--S(.dbd.O).sub.2N(R.sup.a)C(.dbd.O)OR.sup.a,
--S(.dbd.O).sub.2N(R.sup.a)C(.dbd.O)NR.sup.aR.sup.a,
--NR.sup.aR.sup.a, --N(R.sup.a)C(.dbd.O)R.sup.a,
--N(R.sup.a)C(.dbd.O)OR.sup.a,
--N(R.sup.a)C(.dbd.O)NR.sup.aR.sup.a,
--N(R.sup.a)C(.dbd.NR.sup.a)NR.sup.aR.sup.a,
--N(R.sup.a)S(.dbd.O).sub.2R.sup.a,
--N(R.sup.a)S(.dbd.O).sub.2NR.sup.aR.sup.a, --NR.sup.aC.sub.2-6
alkylNR.sup.aR.sup.a and --NR.sup.aC.sub.2-6 alkylOR.sup.a; [0316]
R.sup.10 is H, C.sub.1-3alkyl, C.sub.1-3haloalkyl, cyano, nitro,
CO.sub.2R.sup.a, C(.dbd.O)NR.sup.aR.sup.a,
--C(.dbd.NR.sup.a)NR.sup.aR.sup.a,
--S(.dbd.O).sub.2N(R.sup.a)C(.dbd.O)R.sup.a,
--S(.dbd.O).sub.2N(R.sup.a)C(.dbd.O)OR.sup.a,
--S(.dbd.O).sub.2N(R.sup.a)C(.dbd.O)NR.sup.aR.sup.a,
--S(.dbd.O)R.sup.b, S(.dbd.O).sub.2R.sup.b or
S(.dbd.O).sub.2NR.sup.aR.sup.a; [0317] R.sup.11 is H or
C.sub.1-4alkyl; [0318] R.sup.a is independently, at each instance,
H or R.sup.b; and [0319] R.sup.b is independently, at each
instance, phenyl, benzyl or C.sub.1-6alkyl, the phenyl, benzyl and
C.sub.1-6alkyl being substituted by 0, 1, 2 or 3 substituents
selected from halo, C.sub.1-4alkyl, C.sub.1-3haloalkyl,
--OC.sub.1-4alkyl, --NH.sub.2, --NHC.sub.1-4alkyl, --N(C.sub.1-4
alkyl)C.sub.1-4 alkyl.
[0320] In a preferred embodiment, X.sup.1 is C(R.sup.9). In a
further preferred embodiment, X.sup.1 is C(R.sup.9) and X.sup.2 is
N. In a further embodiment, X.sup.1 is C(R.sup.9) and X.sup.2 is
C(R.sup.10).
[0321] In a preferred embodiment, R.sup.1 is phenyl substituted by
0 or 1 R.sup.2 substituents, and the phenyl is additionally
substituted by 0, 1, 2 or 3 substituents independently selected
from halo, nitro, cyano, C.sub.1-4alkyl, OC.sub.1-4alkyl,
OC.sub.1-4haloalkyl, NHC.sub.1-4alkyl, N(C.sub.1-4 alkyl)C.sub.1-4
alkyl and C.sub.1-4haloalkyl. In one specific embodiment, R.sup.1
is unsubstituted phenyl. In a further specific embodiment, R.sup.1
is phenyl substituted by 1, 2 or 3 substituents independently
selected from halo, nitro, cyano, C.sub.1-4alkyl, OC.sub.1-4alkyl,
OC.sub.1-4haloalkyl, NHC.sub.1-4alkyl, N(C.sub.1-4 alkyl)C.sub.1-4
alkyl and C.sub.1-4haloalkyl.
[0322] In one specific embodiment, R.sup.1 is selected from
2-methylphenyl, 2-chlorophenyl, 2-trifluoromethylphenyl,
2-fluorophenyl and 2-methoxyphenyl.
[0323] In a further preferred embodiment, R.sup.1 is phenoxy.
[0324] In a further preferred embodiment, R.sup.1 is a
direct-bonded or oxygen-linked saturated, partially-saturated or
unsaturated 5-, 6- or 7-membered monocyclic ring containing 1, 2, 3
or 4 atoms selected from N, O and S, but containing no more than
one O or S, wherein the available carbon atoms of the ring are
substituted by 0, 1 or 2 oxo or thioxo groups, wherein the ring is
substituted by 0 or 1 R.sup.2 substituents, and the ring is
additionally substituted by 0, 1, 2 or 3 substituents independently
selected from halo, nitro, cyano, C.sub.1-4alkyl, OC.sub.1-4alkyl,
OC.sub.1-4haloalkyl, NHC.sub.1-4alkyl, N(C.sub.1-4 alkyl)C.sub.1-4
alkyl and C.sub.1-4haloalkyl.
[0325] In one specific embodiment, R.sup.1 is an unsaturated 5- or
6-membered monocyclic ring containing 1, 2, 3 or 4 atoms selected
from N, O and S, but containing no more than one O or S, wherein
the ring is substituted by 0 or 1 R.sup.2 substituents, and the
ring is additionally substituted by 0, 1, 2 or 3 substituents
independently selected from halo, nitro, cyano, C.sub.1-4alkyl,
OC.sub.1-4alkyl, OC.sub.1-4haloalkyl, NHC.sub.1-4alkyl, N(C.sub.1-4
alkyl)C.sub.1-4 alkyl and C.sub.1-4haloalkyl.
[0326] In a further specific embodiment, R.sup.1 is an unsaturated
5- or 6-membered monocyclic ring containing 1, 2, 3 or 4 atoms
selected from N, O and S, but containing no more than one O or S,
wherein the ring is substituted by 1, 2 or 3 substituents
independently selected from halo, nitro, cyano, C.sub.1-4alkyl,
OC.sub.1-4alkyl, OC.sub.1-4haloalkyl, NHC.sub.1-4alkyl, N(C.sub.1-4
alkyl)C.sub.1-4 alkyl and C.sub.1-4haloalkyl.
[0327] In one specific embodiment, R.sup.1 is an unsubstituted
unsaturated 5- or 6-membered monocyclic ring containing 1, 2, 3 or
4 atoms selected from N, O and S.
[0328] In a further specific embodiment, R.sup.1 is selected from
pyridyl and pyrimidinyl.
[0329] In one embodiment, R.sup.3 is selected from halo,
C.sub.1-4haloalkyl, cyano, nitro, --C(O)R.sup.a,
--C(.dbd.O)OR.sup.a, --C(.dbd.O)NR.sup.aR.sup.a,
--C(NR.sup.a)NR.sup.aR.sup.a, --OR.sup.a, --OC(.dbd.O)R.sup.a,
--OC(.dbd.O)NR.sup.aR.sup.a,
--OC(.dbd.O)N(R.sup.a)S(.dbd.O).sub.2R.sup.a,
--OC.sub.2-6alkylNR.sup.aR.sup.a, --OC.sub.2-6alkylOR.sup.a,
--SR.sup.a, --S(.dbd.O)R.sup.a, --S(.dbd.O).sub.2R.sup.a,
--S(.dbd.O)NR.sup.aR.sup.a,
--S(.dbd.O).sub.2N(R.sup.a)C(.dbd.O)R.sup.a,
--S(.dbd.O).sub.2N(R.sup.a)C(O)OR.sup.a,
--S(.dbd.O).sub.2N(R.sup.a)C(.dbd.O)NR.sup.aR.sup.a,
--NR.sup.aR.sup.a, --N(R.sup.a)C(.dbd.O)R.sup.a,
--N(R.sup.a)C(.dbd.O)OR.sup.a,
--N(R.sup.a)C(.dbd.O)NR.sup.aR.sup.a,
--N(R.sup.a)C(.dbd.NR.sup.a)NR.sup.aR.sup.a,
--N(R.sup.a)S(.dbd.O).sub.2R.sup.a,
--N(R.sup.a)S(.dbd.O).sub.2NR.sup.aR.sup.a, --NR.sup.aC.sub.2-6
alkylNR.sup.aR.sup.a, --NR.sup.a, C.sub.1-6alkyl, phenyl, benzyl,
heteroaryl and heterocycle, wherein the C.sub.1-6alkyl, phenyl,
benzyl, heteroaryl and heterocycle are additionally substituted by
0, 1, 2 or 3 substituents selected from C.sub.1-6haloalkyl,
OC.sub.1-6alkyl, Br, Cl, F, I and C.sub.1-6alkyl.
[0330] In one preferred embodiment, R.sup.3 is H.
[0331] In another preferred embodiment, R.sup.3 is selected from F,
Cl, C.sub.1-6alkyl, phenyl, benzyl, heteroaryl and heterocycle,
wherein the C.sub.1-6alkyl, phenyl, benzyl, heteroaryl and
heterocycle are additionally substituted by 0, 1, 2 or 3
substituents selected from C.sub.1-6haloalkyl, OC.sub.1-6alkyl, Br,
Cl, F, I and C.sub.1-6alkyl.
[0332] In one embodiment, R.sup.5 is, independently, in each
instance, H, halo, C.sub.1-6alkyl, C.sub.1-4haloalkyl, or
C.sub.1-6alkyl substituted by 1, 2 or 3 substituents selected from
halo, cyano, OH, OC.sub.1-4alkyl, C.sub.1-4alkyl,
C.sub.1-3haloalkyl, OC.sub.1-4alkyl, NH.sub.2, NHC.sub.1-4alkyl,
N(C.sub.1-4 alkyl)C.sub.1-4 alkyl; or both R.sup.5 groups together
form a C.sub.3-6spiroalkyl substituted by 0, 1, 2 or 3 substituents
selected from halo, cyano, OH, OC.sub.1-4alkyl, C.sub.1-4alkyl,
C.sub.1-3haloalkyl, OC.sub.1-4alkyl, NH.sub.2, NHC.sub.1-4alkyl,
N(C.sub.1-4 alkyl)C.sub.1-4alkyl.
[0333] In one preferred embodiment, R.sup.5 is H.
[0334] In another preferred embodiment, one R.sup.5 is S-methyl,
the other is H.
[0335] In another preferred embodiment, at least one R.sup.5 is
halo, C.sub.1-6alkyl, C.sub.1-4haloalkyl, or C.sub.1-6alkyl
substituted by 1, 2 or 3 substituents selected from halo, cyano,
OH, OC.sub.1-4alkyl, C.sub.1-4alkyl, C.sub.1-3haloalkyl,
OC.sub.1-4alkyl, NH.sub.2, NHC.sub.1-4alkyl, N(C.sub.1-4
alkyl)C.sub.1-4 alkyl.
[0336] In a preferred embodiment, R.sup.6 is H.
[0337] In another preferred embodiment, R.sup.6 is F, Cl, cyano or
nitro.
[0338] In a preferred embodiment, R.sup.7 is H.
[0339] In another preferred embodiment, R.sup.7 is F, Cl, cyano or
nitro.
[0340] In a preferred embodiment, R.sup.8 is selected from H,
CF.sub.3, C.sub.1-3alkyl, Br, Cl and F.
[0341] In one specific embodiment, R.sup.8 is H.
[0342] In another specific embodiment, R.sup.8 is selected from
CF.sub.3, C.sub.1-3alkyl, Br, Cl and F.
[0343] In a preferred embodiment, R.sup.9 is H.
[0344] In another embodiment, R.sup.9 is selected from halo,
C.sub.1-4haloalkyl, cyano, nitro, --C(.dbd.O)R.sup.a,
--C(.dbd.O)OR.sup.a, --C(.dbd.O)NR.sup.aR.sup.a,
--C(.dbd.NR.sup.a)NR.sup.aR.sup.a, --OR.sup.a, --OC(.dbd.O)R.sup.a,
--OC(.dbd.O)NR.sup.aR.sup.a,
--OC(.dbd.O)N(R.sup.a)S(.dbd.O).sub.2R.sup.a,
--OC.sub.2-6alkylNR.sup.aR.sup.a, --OC.sub.2-6alkylOR.sup.a,
--SR.sup.a, --S(.dbd.O)R.sup.a, --S(.dbd.O).sub.2R.sup.a,
--S(.dbd.O).sub.2NR.sup.aR.sup.a,
--S(.dbd.O).sub.2N(R.sup.a)C(.dbd.O)R.sup.a,
--S(.dbd.O).sub.2N(R.sup.a)C(.dbd.O)OR.sup.a,
--S(.dbd.O).sub.2N(R.sup.a)C(.dbd.O)NR.sup.aR.sup.a,
--NR.sup.aR.sup.a, --N(R.sup.a)C(.dbd.O)R.sup.a,
--N(R.sup.a)C(.dbd.O)OR.sup.a,
--N(R.sup.a)C(.dbd.O)NR.sup.aR.sup.a,
--N(R.sup.a)C(.dbd.NR.sup.a)NR.sup.aR.sup.a,
--N(R.sup.a)S(.dbd.O).sub.2R.sup.a,
--N(R.sup.a)S(.dbd.O).sub.2NR.sup.aR.sup.a, --NR.sup.aC.sub.2-6
alkylNR.sup.aR.sup.a, --NR.sup.aC.sub.2-6alkylOR.sup.a,
C.sub.1-6alkyl phenyl, benzyl, heteroaryl and heterocycle, wherein
the C.sub.1-6alkyl, phenyl, benzyl, heteroaryl and heterocycle are
additionally substituted by 0, 1, 2 or 3 substituents selected from
halo, C.sub.1-4haloalkyl, cyano, nitro, --C(.dbd.O)R.sup.a,
--C(.dbd.O)OR.sup.a, --C(.dbd.O)NR.sup.aR.sup.a,
--C(.dbd.NR.sup.a)NR.sup.aR.sup.a, --OR.sup.a, --OC(.dbd.O)R.sup.a,
--OC(.dbd.O)NR.sup.aR.sup.a,
--OC(.dbd.O)N(R.sup.a)S(.dbd.O).sub.2R.sup.a,
--OC.sub.2-6alkylOR.sup.a, --SR.sup.a, --S(.dbd.O)R.sup.a,
--S(.dbd.O).sub.2R.sup.a, --S(.dbd.O).sub.2NR.sup.aR.sup.a,
--S(.dbd.O).sub.2N(R.sup.a)C(.dbd.O)R.sup.a,
--S(.dbd.O).sub.2N(R.sup.a)C(.dbd.O) OR.sup.a,
--S(.dbd.O).sub.2N(R.sup.a)C(.dbd.O)NR.sup.aR.sup.a,
--NR.sup.aR.sup.a, --N(R.sup.a)C(.dbd.O)R.sup.a,
--N(R.sup.a)C(.dbd.O)OR.sup.a,
--N(R.sup.a)C(.dbd.O)NR.sup.aR.sup.a,
--N(R.sup.a)C(.dbd.NR.sup.a)NR.sup.aR.sup.a,
--N(R.sup.a)S(.dbd.O).sub.2R.sup.a,
--N(R)S(.dbd.O).sub.2NR.sup.aR.sup.a,
--NR.sup.aC.sub.2-6alkylNR.sup.aR.sup.a,
--NR.sup.aC.sub.2-6alkylOR.sup.a.
[0345] In one embodiment, R.sup.9 is a saturated,
partially-saturated or unsaturated 5-, 6- or 7-membered monocyclic
ring containing 0, 1, 2, 3 or 4 atoms selected from N, O and S, but
containing no more than one O or S, wherein the available carbon
atoms of the ring are substituted by 0, 1 or 2 oxo or thioxo
groups, wherein the ring is substituted by 0, 1, 2, 3 or 4
substituents selected from halo, C.sub.1-4haloalkyl, cyano, nitro,
--C(.dbd.O)R.sup.a, --C(.dbd.O)OR.sup.a,
--C(.dbd.O)NR.sup.aR.sup.a, --C(.dbd.NR.sup.a)NR.sup.aR.sup.a,
--OR.sup.a, --OC(.dbd.O)R.sup.a, --OC(.dbd.O)NR.sup.aR.sup.a,
--OC(.dbd.O)N(R.sup.a)S(.dbd.O).sub.2R.sup.a,
--OC.sub.2-6alkylNR.sup.aR.sup.a, --OC.sub.2-6alkylOR.sup.a,
--SR.sup.a, --S(.dbd.O)R.sup.a, --S(.dbd.O).sub.2R.sup.a,
--S(.dbd.O).sub.2NR.sup.aR.sup.a,
--S(.dbd.O).sub.2N(R.sup.a)C(.dbd.O)R.sup.a,
--S(.dbd.O).sub.2N(R.sup.a)C(.dbd.O)OR.sup.a,
--S(.dbd.O).sub.2N(R.sup.a)C(.dbd.O)NR.sup.aR.sup.a,
--NR.sup.aR.sup.a, --N(R.sup.a)C(.dbd.O)R.sup.a,
--N(R.sup.aC(.dbd.O)OR.sup.a, --N(R.sup.a)C(.dbd.O)NR.sup.aR.sup.a,
--N(R.sup.a)C(.dbd.NR.sup.a)NR.sup.aR.sup.a,
--N(R.sup.a)S(.dbd.O).sub.2R.sup.a,
--N(R.sup.a)S(.dbd.O).sub.2NR.sup.aR.sup.a, --NR.sup.aC.sub.2-6
alkylNR.sup.aR.sup.a and --NR.sup.aC.sub.2-6alkylOR.sup.a.
[0346] In one preferred embodiment, R.sup.10 is H.
[0347] In another preferred embodiment, R.sup.10 is cyano, nitro,
CO.sub.2R.sup.a, C(.dbd.O)NR.sup.aR.sup.a,
--C(.dbd.NR.sup.a)NR.sup.aR.sup.a,
--S(.dbd.O).sub.2N(R.sup.a)C(.dbd.O)R.sup.a,
--S(.dbd.O).sub.2N(R.sup.a)C(.dbd.O)OR.sup.a,
--S(.dbd.O).sub.2N(R.sup.a)C(.dbd.O)NR.sup.aR.sup.a,
S(.dbd.O)R.sup.b, S(.dbd.O).sub.2R.sup.b or
S(.dbd.O).sub.2NR.sup.aR.sup.a.
[0348] In one preferred embodiment, R.sup.11 is H.
[0349] In another exemplary embodiment, the PI3K inhibitor is a
compound of Formula (VIII):
##STR00011##
or a pharmaceutically-acceptable salt thereof, wherein: [0350]
X.sup.1 is C(R.sup.9) or N; [0351] X.sup.2 is C(R.sup.10) or N;
[0352] Y is N(R.sup.11), O or S; [0353] Z is CR.sup.8 or N; [0354]
R.sup.1 is a direct-bonded or oxygen-linked saturated,
partially-saturated or unsaturated 5-, 6- or 7-membered monocyclic
ring containing 0, 1, 2, 3 or 4 atoms selected from N, O and S, but
containing no more than one O or S, wherein the available carbon
atoms of the ring are substituted by 0, 1 or 2 oxo or thioxo
groups, wherein the ring is substituted by 0 or 1 R.sup.2
substituents, and the ring is additionally substituted by 0, 1, 2
or 3 substituents independently selected from halo, nitro, cyano,
C.sub.1-4alkyl, OC.sub.1-4alkyl, OC.sub.1-4haloalkyl,
NHC.sub.1-4alkyl, N(C.sub.1-4 alkyl)C.sub.1-4 alkyl and
C.sub.1-4haloalkyl; [0355] R.sup.2 is selected from halo,
C.sub.1-4haloalkyl, cyano, nitro, --C(.dbd.O)R.sup.a,
--C(.dbd.O)OR.sup.a,
--C(.dbd.O)NR.sup.aR.sup.a--C(.dbd.NR.sup.a)NR.sup.aR.sup.a,
--OR.sup.a, --OC(.dbd.O)R.sup.a, --OC(.dbd.O)NR.sup.aR.sup.a,
--OC(.dbd.O)N(R.sup.a)S(.dbd.O).sub.2R.sup.a,
--OC.sub.2-6alkylOR.sup.a, --SR.sup.a, --S(.dbd.O)R.sup.a,
--S(.dbd.O).sub.2R.sup.a, --S(.dbd.O).sub.2NR.sup.aR.sup.a,
--S(.dbd.O).sub.2N(R.sup.a)C(.dbd.O)R.sup.a,
--S(.dbd.O).sub.2N(R.sup.a)C(.dbd.O)OR.sup.a,
--S(.dbd.O).sub.2N(R.sup.a)C(.dbd.O)NR.sup.aR.sup.a,
--NR.sup.aR.sup.a, --N(R.sup.a)C(.dbd.O)R.sup.a,
--N(R.sup.a)C(.dbd.O)OR.sup.a,
--N(R.sup.a)C(.dbd.O)NR.sup.aR.sup.a,
--N(R.sup.a)C(.dbd.NR.sup.a)NR.sup.aR.sup.a,
--N(R.sup.a)S(.dbd.O).sub.2R.sup.a,
--N(R.sup.a)S(.dbd.O).sub.2NR.sup.aR.sup.a, --NR.sup.aC.sub.2-6
alkylNR.sup.aR.sup.a and --NR.sup.aC.sub.2-6 alkylOR.sup.a; or
R.sup.2 is selected from C.sub.1-6alkyl, phenyl, benzyl,
heteroaryl, heterocycle, --(C.sub.1-3alkyl)heteroaryl,
--(C.sub.1-3alkyl)heterocycle, --O(C.sub.1-3 alkyl)heteroaryl,
--O(C.sub.1-3alkyl)heterocycle,
--NR.sup.a(C.sub.1-3alkyl)heteroaryl, --NR.sup.a(C.sub.1-3
alkyl)heterocycle, --(C.sub.1-3alkyl)phenyl, --O(C.sub.1-3
alkyl)phenyl and --NR.sup.a(C.sub.1-3 alkyl)phenyl all of which are
substituted by 0, 1, 2 or 3 substituents selected from
C.sub.1-4haloalkyl, OC.sub.1-4alkyl, Br, Cl, F, I and
C.sub.1-4alkyl; [0356] R.sup.3 is selected from H, halo,
C.sub.1-4haloalkyl, cyano, nitro, --C(.dbd.O)R.sup.a,
--C(.dbd.O)OR.sup.a,
--C(.dbd.O)NR.sup.aR.sup.a--C(.dbd.NR.sup.a)NR.sup.aR.sup.a,
--OR.sup.a, --OC(.dbd.O)R.sup.a, --OC(.dbd.O)NR.sup.aR.sup.a,
--OC(.dbd.O)N(R.sup.a)S(.dbd.O).sub.2R.sup.a,
--OC.sub.2-6alkylOR.sup.a, --SR.sup.a, --S(.dbd.O)R.sup.a,
--S(.dbd.O).sub.2R.sup.a, --S(.dbd.O).sub.2NR.sup.aR.sup.a,
--S(.dbd.O).sub.2N(R.sup.a)C(.dbd.O)R.sup.a,
--S(.dbd.O).sub.2N(R.sup.a)C(.dbd.O)OR.sup.a,
--S(.dbd.O).sub.2N(R.sup.a)C(.dbd.O)NR.sup.aR.sup.a,
--NR.sup.aR.sup.a, --N(R.sup.a)C(.dbd.O)R.sup.a,
--N(R.sup.a)C(.dbd.O)OR.sup.a,
--N(R.sup.a)C(.dbd.O)NR.sup.aR.sup.a,
--N(R.sup.a)C(.dbd.NR.sup.a)NR.sup.aR.sup.a,
--N(R.sup.a)S(.dbd.O).sub.2R.sup.a,
--N(R.sup.a)S(.dbd.O).sub.2NR.sup.aNR.sup.a, --NR.sup.a,
--NR.sup.aC.sub.2-6 alkylOR.sup.a, C.sub.1-6alkyl, phenyl, benzyl,
heteroaryl and heterocycle, wherein the C.sub.1-6alkyl, phenyl,
benzyl, heteroaryl and heterocycle are additionally substituted by
0, 1, 2 or 3 substituents selected from C.sub.1-6haloalkyl,
OC.sub.1-6alkyl, Br, Cl, F, I and C.sub.1-6alkyl; [0357] R.sup.5
is, independently, in each instance, H, halo, C.sub.1-6alkyl,
C.sub.1-4haloalkyl, or C.sub.1-6alkyl substituted by 1, 2 or 3
substituents selected from halo, cyano, OH, OC.sub.1-4alkyl,
C.sub.1-4alkyl, C.sub.1-3haloalkyl, OC.sub.1-4alkyl, NH.sub.2,
NHC.sub.1-4alkyl, N(C.sub.1-4 alkyl)C.sub.1-4 alkyl; or both
R.sup.5 groups together form a C.sub.3-6-spiroalkyl substituted by
0, 1, 2 or 3 substituents selected from halo, cyano, OH,
OC.sub.1-4alkyl, C.sub.1-4alkyl, C.sub.1-3haloalkyl,
OC.sub.1-4alkyl, NH.sub.2, NHC.sub.1-4alkyl, N(C.sub.1-4
alkyl)C.sub.1-4 alkyl; [0358] R.sup.6 is selected from H, halo,
C.sub.1-6alkyl, C.sub.1-4haloalkyl, cyano, nitro,
--C(.dbd.O)R.sup.a, --C(.dbd.O)OR.sup.a,
--C(.dbd.O)NR.sup.aR.sup.a, --C(.dbd.NR.sup.a)NR.sup.aR.sup.a,
--S(.dbd.O)R.sup.a, --S(.dbd.O).sub.2R.sup.a,
--S(.dbd.O).sub.2NR.sup.aR.sup.a,
--S(.dbd.O).sub.2N(R.sup.a)C(.dbd.O)R.sup.a,
--S(.dbd.O).sub.2N(R.sup.a)C(.dbd.O)OR.sup.a,
--S(.dbd.O).sub.2N(R.sup.a)C(.dbd.O)NR.sup.aR.sup.a; [0359] R.sup.7
is selected from H, halo, C.sub.1-6alkyl, C.sub.1-4haloalkyl,
cyano, nitro, --C(.dbd.O)R.sup.a, --C(.dbd.O)OR.sup.a,
--C(.dbd.O)NR.sup.aR.sup.a, --C(.dbd.NR.sup.a)NR.sup.aR.sup.a,
--S(.dbd.O)R.sup.a, --S(.dbd.O).sub.2R.sup.a,
--S(.dbd.O).sub.2NR.sup.aR.sup.a,
--S(.dbd.O).sub.2N(R.sup.a)C(.dbd.O)R.sup.a,
--S(.dbd.O).sub.2N(R.sup.a)C(.dbd.O)OR.sup.a,
--S(.dbd.O).sub.2N(R.sup.a)C(.dbd.O)NR.sup.aR.sup.a; [0360] R.sup.8
is selected from H, C.sub.1-6haloalkyl, Br, Cl, F, I, OR.sup.a,
NR.sup.aR.sup.a, C.sub.1-6alkyl, phenyl, benzyl, heteroaryl and
heterocycle, wherein the C.sub.1-6alkyl, phenyl, benzyl, heteroaryl
and heterocycle are additionally substituted by 0, 1, 2 or 3
substituents selected from C.sub.1-6haloalkyl, OC.sub.1-6 alkyl,
Br, Cl, F, I and C.sub.1-6alkyl; [0361] R.sup.9 is selected from H,
halo, C.sub.1-4haloalkyl, cyano, nitro, --C(.dbd.O)R.sup.a,
--C(.dbd.O)OR.sup.a, --C(.dbd.O)NR.sup.aR.sup.a,
--C(.dbd.NR.sup.a)NR.sup.aR.sup.a, --OR.sup.a, --OC(.dbd.O)R.sup.a,
--OC(.dbd.O)NR.sup.aR.sup.a,
--OC(.dbd.O)N(R.sup.a)S(.dbd.O).sub.2R.sup.a,
--OC.sub.2-6alkylNR.sup.aR.sup.a, --OC.sub.2-6alkylOR.sup.a,
--SR.sup.a, --S(.dbd.O)R.sup.a, --S(.dbd.O).sub.2R.sup.a,
--S(.dbd.O).sub.2NR.sup.aR.sup.a,
--S(.dbd.O).sub.2N(R.sup.a)C(.dbd.O)R.sup.a,
--S(.dbd.O).sub.2N(R.sup.a)C(.dbd.O)OR.sup.a,
--S(.dbd.O).sub.2N(R.sup.a)C(.dbd.O)NR.sup.aR.sup.a,
--NR.sup.aR.sup.a, --N(R.sup.a)C(.dbd.O)R.sup.a,
--N(R.sup.a)C(.dbd.O)OR.sup.a,
--N(R.sup.a)C(.dbd.O)NR.sup.aR.sup.a,
--N(R.sup.a)C(.dbd.NR.sup.a)NR.sup.aR.sup.a,
--N(R.sup.a)S(.dbd.O).sub.2R.sup.a,
--N(R.sup.a)S(.dbd.O).sub.2NR.sup.aR.sup.a, --NR.sup.aC.sub.2-6
alkylNR.sup.aR.sup.a, --NR.sup.aC.sub.2-6 alkylOR.sup.a,
C.sub.1-6alkyl, phenyl, benzyl, heteroaryl and heterocycle, wherein
the C.sub.1-6alkyl, phenyl, benzyl, heteroaryl and heterocycle are
additionally substituted by 0, 1, 2 or 3 substituents selected from
halo, C.sub.1-4haloalkyl, cyano, nitro, --C(.dbd.O)R.sup.a,
--C(.dbd.O)OR.sup.a, --C(.dbd.O)NR.sup.aR.sup.a,
--C(.dbd.NR.sup.a)NR.sup.aR.sup.a, --OR.sup.a, --OC(.dbd.O)R.sup.a,
--OC(.dbd.O)NR.sup.aR.sup.a,
--OC(.dbd.O)N(R.sup.a)S(.dbd.O).sub.2R.sup.a,
--OC.sub.2-6alkylOR.sup.a, --SR.sup.a, --S(.dbd.O)R.sup.a,
--S(.dbd.O).sub.2R.sup.a, --S(.dbd.O).sub.2NR.sup.aR.sup.a,
--S(.dbd.O).sub.2N(R.sup.a)C(.dbd.O)R.sup.a,
--S(.dbd.O).sub.2N(R.sup.a)C(.dbd.O)OR.sup.a,
--S(.dbd.O).sub.2N(R.sup.a)C(.dbd.O)NR.sup.aR.sup.a,
--NR.sup.aR.sup.a, --N(R.sup.a)C(.dbd.O)R.sup.a,
--N(R.sup.a)C(.dbd.O)OR.sup.a,
--N(R.sup.a)C(.dbd.O)NR.sup.aR.sup.a,
--N(R.sup.a)C(.dbd.NR.sup.a)NR.sup.aR.sup.a,
--N(R.sup.a)S(.dbd.O).sub.2R.sup.a,
--N(R.sup.a)S(.dbd.O).sub.2NR.sup.aR.sup.a, --NR.sup.aC.sub.2-6
alkylNR.sup.aR.sup.a, --NR.sup.aC.sub.2-6 alkylOR.sup.a; or R.sup.9
is a saturated, partially-saturated or unsaturated 5-, 6- or
7-membered monocyclic ring containing 0, 1, 2, 3 or 4 atoms
selected from N, O and S, but containing no more than one O or S,
wherein the available carbon atoms of the ring are substituted by
0, 1 or 2 oxo or thioxo groups, wherein the ring is substituted by
0, 1, 2, 3 or 4 substituents selected from halo,
C.sub.1-4haloalkyl, cyano, nitro, --C(O)R.sup.a,
--C(.dbd.O)OR.sup.a, --C(.dbd.O)NR.sup.aR.sup.a,
--C(.dbd.NR.sup.a)NR.sup.a, --OR.sup.a, --OC(.dbd.O)R.sup.a,
--OC(.dbd.O)NR.sup.aR.sup.a,
--OC(.dbd.O)N(R.sup.a)S(.dbd.O).sub.2R.sup.a,
--OC.sub.2-6alkylNR.sup.aR.sup.a, --OC.sub.2-6alkylOR.sup.a,
--SR.sup.a, --S(.dbd.O)R.sup.a, --S(.dbd.O).sub.2R.sup.a,
--S(.dbd.O).sub.2NR.sup.aR.sup.a,
--S(.dbd.O).sub.2N(R.sup.a)C(.dbd.O)R.sup.a,
--S(.dbd.O).sub.2N(R.sup.a)C(.dbd.O)OR.sup.a,
--S(.dbd.O).sub.2N(R.sup.a)C(.dbd.O)NR.sup.aR.sup.a,
--NR.sup.aR.sup.a, --N(R.sup.a)C(.dbd.0)R.sup.a,
--N(R.sup.a)C(.dbd.O)OR.sup.a,
--N(R.sup.a)C(.dbd.O)NR.sup.aR.sup.a,
--N(R.sup.a)C(.dbd.NR.sup.a)NR.sup.a,
--N(R.sup.a)S(.dbd.O).sub.2R.sup.a,
--N(R.sup.a)S(.dbd.O).sub.2NR.sup.aR.sup.a, --NR.sup.aC.sub.2-6
alkylNR.sup.aR.sup.a and --NR.sup.aC.sub.2-6 alkylOR.sup.a; [0362]
R.sup.10 is H, C.sub.1-3alkyl, C.sub.1-3haloalkyl, cyano, nitro,
CO.sub.2R.sup.a, C(.dbd.O)NR.sup.aR.sup.a,
--C(.dbd.NR.sup.a)NR.sup.aR.sup.a,
--S(.dbd.O).sub.2N(R.sup.a)C(.dbd.O)R.sup.a,
--S(.dbd.O).sub.2N(R.sup.a)C(.dbd.O)OR.sup.a,
--S(.dbd.O).sub.2N(R.sup.a)C(.dbd.O)NR.sup.aR.sup.a,
--S(.dbd.O)R.sup.b, --S(.dbd.O).sub.2R.sup.b or
S(.dbd.O).sub.2NR.sup.aR.sup.a; [0363] R.sup.11 is H or
C.sub.1-4alkyl; [0364] R.sup.a is independently, at each instance,
H or R.sup.b; and [0365] R.sup.b is independently, at each
instance, phenyl, benzyl or C.sub.1-6alkyl, the phenyl, benzyl and
C.sub.1-6 alkyl being substituted by 0, 1, 2 or 3 substituents
selected from halo, C.sub.1-4alkyl, C.sub.1-3 haloalkyl,
--OC.sub.1-4alkyl, --NH.sub.2, --NHC.sub.1-4alkyl, --N(C.sub.1-4
alkyl)C.sub.1-4 alkyl.
[0366] In a preferred embodiment, X.sup.1 is C(R.sup.9). In a
further preferred embodiment, X.sup.1 is C(R.sup.9) and X.sup.2 is
N. In a further embodiment, X.sup.1 is C(R.sup.9) and X.sup.2 is
C(R.sup.10).
[0367] In a preferred embodiment, R.sup.1 is phenyl substituted by
0 or 1 R.sup.2 substituents, and the phenyl is additionally
substituted by 0, 1, 2 or 3 substituents independently selected
from halo, nitro, cyano, C.sub.1-4alkyl, OC.sub.1-4alkyl,
OC.sub.1-4haloalkyl, NHC.sub.1-4alkyl, N(C.sub.1-4 alkyl)C.sub.1-4
alkyl and C.sub.1-4haloalkyl. In one specific embodiment, R.sup.1
is unsubstituted phenyl. In a further specific embodiment, R.sup.1
is phenyl substituted by 1, 2 or 3 substituents independently
selected from halo, nitro, cyano, C.sub.1-4alkyl, OC.sub.1-4alkyl,
OC.sub.1-4haloalkyl, NHC.sub.1-4alkyl, N(C.sub.1-4 alkyl)C.sub.1-4
alkyl and C.sub.1-4haloalkyl.
[0368] In one specific embodiment, R.sup.1 is selected from
2-methylphenyl, 2-chlorophenyl, 2-trifluoromethylphenyl,
2-fluorophenyl and 2-methoxyphenyl.
[0369] In a further preferred embodiment, R.sup.1 is phenoxy.
[0370] In a further preferred embodiment, R.sup.1 is a
direct-bonded or oxygen-linked saturated, partially-saturated or
unsaturated 5-, 6- or 7-membered monocyclic ring containing 1, 2, 3
or 4 atoms selected from N, O and S, but containing no more than
one O or S, wherein the available carbon atoms of the ring are
substituted by 0, 1 or 2 oxo or thioxo groups, wherein the ring is
substituted by 0 or 1 R.sup.2 substituents, and the ring is
additionally substituted by 0, 1, 2 or 3 substituents independently
selected from halo, nitro, cyano, C.sub.1-4alkyl, OC.sub.1-4alkyl,
OC.sub.1-4haloalkyl, NHC.sub.1-4alkyl, N(C.sub.1-4 alkyl)C.sub.1-4
alkyl and C.sub.1-4haloalkyl.
[0371] In one specific embodiment, R.sup.1 is an unsaturated 5- or
6-membered monocyclic ring containing 1, 2, 3 or 4 atoms selected
from N, O and S, but containing no more than one O or S, wherein
the ring is substituted by 0 or 1 R.sup.2 substituents, and the
ring is additionally substituted by 0, 1, 2 or 3 substituents
independently selected from halo, nitro, cyano, C.sub.1-4alkyl,
OC.sub.1-4alkyl, OC.sub.1-4haloalkyl, NHC.sub.1-4alkyl, N(C.sub.1-4
alkyl)C.sub.1-4 alkyl and C.sub.1-4haloalkyl.
[0372] In a further specific embodiment, R.sup.1 is an unsaturated
5- or 6-membered monocyclic ring containing 1, 2, 3 or 4 atoms
selected from N, O and S, but containing no more than one O or S,
wherein the ring is substituted by 1, 2 or 3 substituents
independently selected from halo, nitro, cyano, C.sub.1-4alkyl,
OC.sub.1-4alkyl, OC.sub.1-4haloalkyl, NHC.sub.1-4alkyl, N(C.sub.1-4
alkyl)C.sub.1-4 alkyl and C.sub.1-4haloalkyl.
[0373] In one specific embodiment, R.sup.1 is an unsubstituted
unsaturated 5- or 6-membered monocyclic ring containing 1, 2, 3 or
4 atoms selected from N, O and S.
[0374] In a further specific embodiment, R.sup.1 is selected from
pyridyl and pyrimidinyl.
[0375] In one embodiment, R.sup.3 is selected from halo,
C.sub.1-4haloalkyl, cyano, nitro, --C(O)R.sup.a,
--C(.dbd.O)OR.sup.a, --C(.dbd.O)NR.sup.aR.sup.a,
--C(NR.sup.a)NR.sup.aR.sup.a, --OR.sup.a, --OC(.dbd.O)R.sup.a,
--OC(.dbd.O)NR.sup.aR.sup.a,
--OC(.dbd.O)N(R.sup.a)S(.dbd.O).sub.2R.sup.a,
--OC.sub.2-6alkylNR.sup.aR.sup.a, --OC.sub.2-6alkylOR.sup.a,
--SR.sup.a, --S(.dbd.O)R.sup.a, --S(.dbd.O).sub.2R.sup.a,
--S(.dbd.O)NR.sup.aR.sup.a,
--S(.dbd.O).sub.2N(R.sup.a)C(.dbd.O)R.sup.a,
--S(.dbd.O).sub.2N(R.sup.a)C(O)OR.sup.a,
--S(.dbd.O).sub.2N(R.sup.a)C(.dbd.O)NR.sup.aR.sup.a,
--NR.sup.aR.sup.a, --N(R.sup.a)C(.dbd.O)R.sup.a,
--N(R.sup.a)C(.dbd.O)OR.sup.a,
--N(R.sup.a)C(.dbd.O)NR.sup.aR.sup.a,
--N(R.sup.a)C(.dbd.NR.sup.a)NR.sup.aR.sup.a,
--N(R.sup.a)S(.dbd.O).sub.2R.sup.a,
--N(R.sup.a)S(.dbd.O).sub.2NR.sup.aR.sup.a, --NR.sup.aC.sub.2-6
alkylNR.sup.aR.sup.a, --NR.sup.a, C.sub.1-6alkyl, phenyl, benzyl,
heteroaryl and heterocycle, wherein the C.sub.1-6alkyl, phenyl,
benzyl, heteroaryl and heterocycle are additionally substituted by
0, 1, 2 or 3 substituents selected from C.sub.1-6haloalkyl,
OC.sub.1-6alkyl, Br, Cl, F, I and C.sub.1-6alkyl.
[0376] In one preferred embodiment, R.sup.3 is H.
[0377] In another preferred embodiment, R.sup.3 is selected from F,
Cl, C.sub.1-6alkyl, phenyl, benzyl, heteroaryl and heterocycle,
wherein the C.sub.1-6alkyl, phenyl, benzyl, heteroaryl and
heterocycle are additionally substituted by 0, 1, 2 or 3
substituents selected from C.sub.1-6haloalkyl, OC.sub.1-6alkyl, Br,
Cl, F, I and C.sub.1-6alkyl.
[0378] In one embodiment, R.sup.5 is, independently, in each
instance, H, halo, C.sub.1-6alkyl, C.sub.1-4 haloalkyl, or
C.sub.1-6alkyl substituted by 1, 2 or 3 substituents selected from
halo, cyano, OH, OC.sub.1-4 alkyl, C.sub.1-4alkyl,
C.sub.1-3haloalkyl, OC.sub.1-4alkyl, NH.sub.2, NHC.sub.1-4alkyl,
N(C.sub.1-4 alkyl)C.sub.1-4 alkyl; or both R.sup.5 groups together
form a C.sub.3-6spiroalkyl substituted by 0, 1, 2 or 3 substituents
selected from halo, cyano, OH, OC.sub.1-4alkyl, C.sub.1-4alkyl,
C.sub.1-3haloalkyl, OC.sub.1-4alkyl, NH.sub.2, NHC.sub.1-4alkyl,
N(C.sub.1-4 alkyl)C.sub.1-4alkyl.
[0379] In one preferred embodiment, R.sup.5 is H.
[0380] In another preferred embodiment, one R.sup.5 is S-methyl,
the other is H.
[0381] In another preferred embodiment, at least one R.sup.5 is
halo, C.sub.1-6alkyl, C.sub.1-4haloalkyl, or C.sub.1-6alkyl
substituted by 1, 2 or 3 substituents selected from halo, cyano,
OH, OC.sub.1-4alkyl, C.sub.1-4alkyl, C.sub.1-3haloalkyl,
OC.sub.1-4alkyl, NH.sub.2, NHC.sub.1-4alkyl, N(C.sub.1-4
alkyl)C.sub.1-4 alkyl.
[0382] In a preferred embodiment, R.sup.6 is H.
[0383] In another preferred embodiment, R.sup.6 is F, Cl, cyano or
nitro.
[0384] In a preferred embodiment, R.sup.7 is H.
[0385] In another preferred embodiment, R.sup.7 is F, Cl, cyano or
nitro.
[0386] In a preferred embodiment, R.sup.8 is selected from H,
CF.sub.3, C.sub.1-3alkyl, Br, Cl and F.
[0387] In one specific embodiment, R.sup.8 is H.
[0388] In another specific embodiment, R.sup.8 is selected from
CF.sub.3, C.sub.1-3alkyl, Br, Cl and F.
[0389] In a preferred embodiment, R.sup.9 is H.
[0390] In another embodiment, R.sup.9 is selected from halo,
C.sub.1-4haloalkyl, cyano, nitro, --C(.dbd.O)R.sup.a,
--C(.dbd.O)OR.sup.a, --C(.dbd.O)NR.sup.aR.sup.a,
--C(.dbd.NR.sup.a)NR.sup.aR.sup.a, --OR.sup.a, --OC(.dbd.O)R.sup.a,
--OC(.dbd.O)NR.sup.aR.sup.a,
--OC(.dbd.O)N(R.sup.a)S(.dbd.O).sub.2R.sup.a,
--OC.sub.2-6alkylNR.sup.aR.sup.a, --OC.sub.2-6alkylOR.sup.a,
--SR.sup.a, --S(.dbd.O)R.sup.a, --S(.dbd.O).sub.2R.sup.a,
--S(.dbd.O).sub.2NR.sup.aR.sup.a,
--S(.dbd.O).sub.2N(R.sup.a)C(.dbd.O)R.sup.a,
--S(.dbd.O).sub.2N(R.sup.a)C(.dbd.O)OR.sup.a,
--S(.dbd.O).sub.2N(R.sup.a)C(.dbd.O)NR.sup.aR.sup.a,
--NR.sup.aR.sup.a, --N(R.sup.a)C(.dbd.O)R.sup.a,
--N(R.sup.a)C(.dbd.O)OR.sup.a,
--N(R.sup.a)C(.dbd.O)NR.sup.aR.sup.a,
--N(R.sup.a)C(.dbd.NR.sup.a)NR.sup.aR.sup.a,
--N(R.sup.a)S(.dbd.O).sub.2R.sup.a,
--N(R.sup.a)S(.dbd.O).sub.2NR.sup.aR.sup.a, --NR.sup.aC.sub.2-6
alkylNR.sup.aR.sup.a, --NR.sup.aC.sub.2-6 alkylOR.sup.a,
C.sub.1-6alkyl, phenyl, benzyl, heteroaryl and heterocycle, wherein
the C.sub.1-6alkyl, phenyl, benzyl, heteroaryl and heterocycle are
additionally substituted by 0, 1, 2 or 3 substituents selected from
halo, C.sub.1-4haloalkyl, cyano, nitro, --C(.dbd.O)R.sup.a,
--C(.dbd.O)OR.sup.a, --C(.dbd.O)NR.sup.aR.sup.a,
--C(.dbd.NR.sup.a)NR.sup.aR.sup.a, --OR.sup.a, --OC(.dbd.O)R.sup.a,
--OC(.dbd.O)NR.sup.aR.sup.a,
--OC(.dbd.O)N(R.sup.a)S(.dbd.O).sub.2R.sup.a,
--OC.sub.2-6alkylOR.sup.a, --SR.sup.a, --S(.dbd.O)R.sup.a,
--S(.dbd.O).sub.2R.sup.a, --S(.dbd.O).sub.2NR.sup.aR.sup.a,
--S(.dbd.O).sub.2N(R.sup.a)C(.dbd.O)R.sup.a,
--S(.dbd.O).sub.2N(R.sup.a)C(.dbd.O)OR.sup.a,
--S(.dbd.O).sub.2N(R.sup.a)C(.dbd.O)NR.sup.aR.sup.a,
--NR.sup.aR.sup.a, --N(R.sup.a)C(.dbd.O)R.sup.a,
--N(R.sup.a)C(.dbd.O)OR.sup.a,
--N(R.sup.a)C(.dbd.O)NR.sup.aR.sup.a,
--N(R.sup.a)C(.dbd.NR.sup.a)NR.sup.aR.sup.a,
--N(R.sup.a)S(.dbd.O).sub.2R.sup.a,
--N(R.sup.a)S(.dbd.O).sub.2NR.sup.aR.sup.a, --NR.sup.aC.sub.2-6
alkylNR.sup.aR.sup.a, --NR.sup.aC.sub.2-6 alkylOR.sup.a.
[0391] In one embodiment, R.sup.9 is a saturated,
partially-saturated or unsaturated 5-, 6- or 7-membered monocyclic
ring containing 0, 1, 2, 3 or 4 atoms selected from N, O and S, but
containing no more than one O or S, wherein the available carbon
atoms of the ring are substituted by 0, 1 or 2 oxo or thioxo
groups, wherein the ring is substituted by 0, 1, 2, 3 or 4
substituents selected from halo, C.sub.1-4haloalkyl, cyano, nitro,
--C(.dbd.O)R.sup.a, --C(.dbd.O)OR.sup.a,
--C(.dbd.O)NR.sup.aR.sup.a, --C(.dbd.NR.sup.a)NR.sup.aR.sup.a,
--OR.sup.a, --OC(.dbd.O)R.sup.a, --OC(.dbd.O)NR.sup.aR.sup.a,
--OC(.dbd.O)N(R.sup.a)S(.dbd.O).sub.2R.sup.a,
--OC.sub.2-6alkylNR.sup.aR.sup.a, --OC.sub.2-6alkylOR.sup.a,
--SR.sup.a, --S(.dbd.O)R.sup.a, --S(.dbd.O).sub.2R.sup.a,
--S(.dbd.O).sub.2NR.sup.aR.sup.a,
--S(.dbd.O).sub.2N(R.sup.a)C(.dbd.O)R.sup.a,
--S(.dbd.O).sub.2N(R.sup.a)C(.dbd.O) OR.sup.a,
--S(.dbd.O).sub.2N(R.sup.a)C(.dbd.O)NR.sup.aR.sup.a,
--NR.sup.aR.sup.a, --N(R.sup.a)C(.dbd.O)R.sup.a,
--N(R.sup.a)C(.dbd.O)OR.sup.a,
--N(R.sup.a)C(.dbd.O)NR.sup.aR.sup.a,
--N(R.sup.a)C(.dbd.NR.sup.a)NR.sup.aR.sup.a,
--N(R.sup.a)S(.dbd.O).sub.2R.sup.a,
--N(R.sup.a)S(.dbd.O).sub.2NR.sup.aR.sup.a,
--NR.sup.aC.sub.2-6alkylNR.sup.aR.sup.a and
--NR.sup.aC.sub.2-6alkylOR.sup.a.
[0392] In one preferred embodiment, R.sup.10 is H.
[0393] In another preferred embodiment, R.sup.10 is cyano, nitro,
CO.sub.2R.sup.a, C(.dbd.O)NR.sup.aR.sup.a,
--C(.dbd.NR.sup.a)NR.sup.aR.sup.a,
--S(.dbd.O).sub.2N(R.sup.a)C(.dbd.O)R.sup.a,
--S(.dbd.O).sub.2N(R.sup.a)C(.dbd.O)OR.sup.a,
--S(.dbd.O).sub.2N(R.sup.a)C(.dbd.O)NR.sup.aR.sup.a,
S(.dbd.O)R.sup.b, S(.dbd.O).sub.2R.sup.b or
S(.dbd.O).sub.2NR.sup.aR.sup.a.
[0394] In one preferred embodiment, R.sup.11 is H.
[0395] In an exemplary preferred embodiment, the PI3K inhibitor is
a compound of Formula (IX):
##STR00012##
which is
(S)--N-(1-(7-fluoro-2-(pyridin-2-yl)quinolin-3-yl)ethyl)-9H-puri-
n-6-amine, or a pharmaceutically-acceptable salt thereof. In an
exemplary embodiment, the PI3K-.delta. inhibitor or PI3K-.delta.
inhibitor is
(S)--N-(1-(7-fluoro-2-(pyridin-2-yl)quinolin-3-yl)ethyl)-9H-purin-6-amine
or a pharmaceutically-acceptable salt thereof.
[0396] In an exemplary embodiment, the PI3K inhibitor is a
PI3K-.delta. inhibitor which is a compound of Formula (X):
##STR00013##
which is
(S)--N-(1-(6-fluoro-3-(pyridin-2-yl)quinoxalin-2-yl)ethyl)-9H-pu-
rin-6-amine, or a pharmaceutically-acceptable salt thereof.
[0397] In an exemplary embodiment, the PI3K inhibitor is a
PI3K-.delta. inhibitor, which is a compound of Formula (XI):
##STR00014##
which is
(S)--N-(1-(2-(3,5-difluorophenyl)-8-fluoroquinolin-3-yl)ethyl)-9-
H-purin-6-amine, or a pharmaceutically-acceptable salt thereof.
[0398] In an exemplary embodiment, the PI3K inhibitor or
PI3K-.delta. inhibitor is
(S)--N-(1-(2-(3,5-difluorophenyl)-8-fluoroquinolin-3-yl)ethyl)-9H-purin-6-
-amine or a pharmaceutically-acceptable salt thereof.
[0399] In an exemplary embodiment, the PI3K inhibitor is a
PI3K-.delta. inhibitor which is a compound of Formula (XII):
##STR00015##
which is
(S)-3-(1-((9H-purin-6-yl)amino)ethyl)-2-(pyridin-2-yl)quinoline--
8-carbonitrile, or a pharmaceutically-acceptable salt thereof.
[0400] In an exemplary embodiment, the PI3K inhibitor or
PI3K-.delta. inhibitor is
(S)-3-(1-((9H-purin-6-yl)amino)ethyl)-2-(pyridin-2-yl)quinoline-8-carboni-
trile or a pharmaceutically-acceptable salt thereof.
[0401] In an exemplary embodiment, the PI3K inhibitor is a
PI3K-.delta. inhibitor which is a compound of Formula (XIII):
##STR00016##
which is
(S)--N-(1-(5,7-difluoro-2-(pyridin-2-yl)quinolin-3-yl)ethyl)-9H--
purin-6-amine, or a pharmaceutically-acceptable salt thereof.
[0402] In an exemplary embodiment, the PI3K inhibitor or
PI3K-.delta. inhibitor is
(S)--N-(1-(5,7-difluoro-2-(pyridin-2-yl)quinolin-3-yl)ethyl)-9H-purin-6-a-
mine or a pharmaceutically-acceptable salt thereof.
[0403] In an exemplary embodiment, the PI3K inhibitor is a compound
selected from the structures disclosed in U.S. Pat. Nos. 7,932,260
and 8,207,153. In an exemplary embodiment, the PI3K inhibitor is a
compound of Formula (XIV):
##STR00017##
wherein [0404] X and Y, independently, are N or CH; [0405] Z is
N--R.sup.7 or O; [0406] R.sup.1 are the same and are hydrogen,
halo, or C.sub.1-3alkyl; [0407] R.sup.2 and R.sup.3, independently,
are hydrogen, halo, or C.sub.1-3alkyl; [0408] R.sup.4 is hydrogen,
halo, OR.sup.a, CN, C.sub.2-6alkynyl, C(.dbd.O)R.sup.a,
C(.dbd.O)NR.sup.aR.sup.b, C.sub.3-6heterocycloalkyl,
alkyleneC.sub.3-6heterocycloalkyl, OC.sub.1-3alkyleneOR.sup.a,
OC.sub.1-3alkyleneNR.sup.aR.sup.b, OC.sub.1-3alkyleneC.sub.3-6
cycloalkyl, OC.sub.3-6heterocycloalkyl,
OC.sub.1-3alkyleneC.ident.CH, or
OC.sub.1-3alkyleneC(.dbd.O)NR.sup.aR.sup.b; [0409] R.sup.5 is
CH.sub.2CF.sub.3, phenyl, CH.sub.2C.ident.CH,
C.sub.1-3alkyleneOR.sup.c, C.sub.1-4alkyleneNR.sup.aR.sup.b, or
C.sub.1-4 alkyleneNHC(.dbd.O)OR.sup.a, [0410] R.sup.6 is hydrogen,
halo, or NR.sup.aR.sup.b; [0411] R.sup.7 is hydrogen or R.sup.5 and
R.sup.7 are taken together with the atoms to which they are
attached to form a five- or six-membered saturated ring; [0412]
R.sup.8 is C.sub.1-3alkyl, halo, CF.sub.3, or
CH.sub.2C.sub.3-6heterocycloalkyl; [0413] n is 0, 1, or 2; [0414]
R.sup.a is hydrogen, C.sub.1-4alkyl, or CH.sub.2C.sub.6H.sub.5;
[0415] R.sup.b is hydrogen or C.sub.1-3alkyl; and [0416] R.sup.c is
hydrogen, C.sub.1-3alkyl, or halo, [0417] wherein when the R.sup.1
groups are different from hydrogen, R.sup.2 and R.sup.4 are the
same; or a pharmaceutically acceptable salt, or prodrug, or solvate
(e.g., hydrate) thereof.
[0418] In a preferred embodiment, the PI3K inhibitor is an
enantiomer of Formula (XIV), as shown in Formula (XV):
##STR00018##
wherein X, Y, Z, R.sup.1 through R.sup.8, R.sup.a, R.sup.b,
R.sup.c, and n are as defined above for Formula (XIV).
[0419] In various embodiments exhibiting increased potency relative
to other compounds, R.sup.8 is C.sub.1-3alkyl, F, Cl, or CF.sub.3.
Alternatively, in such embodiments, n is 0 (such that there is no
R.sup.8 substituent).
[0420] In further embodiments exhibiting increased potency, X is N
and Y is CH. Alternatively, X and Y may also both be CH.
[0421] In preferred embodiments, Z is NR.sup.7, and the bicyclic
ring system containing X and Y is:
##STR00019##
[0422] In further embodiments exhibiting increased potency, R.sup.6
is hydrogen, halo, or NH.sub.2. Preferably, R.sup.6 is
hydrogen.
[0423] In preferred embodiments exhibiting such increased potency,
n is 0 or 1; R.sup.8 (if n is 1) is C.sub.1-3alkyl, F, Cl, or
CF.sub.3; R.sup.6 is hydrogen; X is N and Y is CH or X and Y are
both CH; Z is NH; R.sup.1 are the same and are hydrogen, halo, or
C.sub.1-3alkyl; and R.sup.2 and R.sup.3, independently, are
hydrogen, halo, or C.sub.1-3alkyl. Preferably, R.sup.1, R.sup.2,
and R.sup.3 are hydrogen.
[0424] Unexpectedly, potency against PI3K-.delta. is conserved when
R.sup.1 is the same. In structural formulae (XIV) and (XV), R.sup.2
and R.sup.4 may differ provided that R.sup.1 is H. When R.sup.1 is
H, free rotation is unexpectedly permitted about the bond
connecting the phenyl ring substituent to the quinazoline ring, and
the compounds advantageously do not exhibit atropisomerism (i.e.,
multiple diastereomer formation is avoided). Alternatively, R.sup.2
and R.sup.4 can be the same such that the compounds advantageously
do not exhibit atropisomerism.
[0425] As used with respect to Formula (XIV) and Formula (XV), the
term "alkyl" is defined as straight chained and branched
hydrocarbon groups containing the indicated number of carbon atoms,
e.g., methyl, ethyl, and straight chain and branched propyl and
butyl groups. The terms "C.sub.1-3alkylene" and "C.sub.1-4alkylene"
are defined as hydrocarbon groups containing the indicated number
of carbon atoms and one less hydrogen than the corresponding alkyl
group. The term "C.sub.2-6 alkynyl" is defined as a hydrocarbon
group containing the indicated number of carbon atoms and a
carbon-carbon triple bond. The term "C.sub.3-6 cycloalkyl" is
defined as a cyclic hydrocarbon group containing the indicated
number of carbon atoms. The term "C.sub.2-6 heterocycloalkyl" is
defined similarly as cycloalkyl except the ring contains one or two
heteroatoms selected from the group consisting of O, NR.sup.a, and
S. The term "halo" is defined as fluoro, bromo, chloro, and
iodo.
[0426] In other preferred embodiments, R.sup.1 is hydrogen, fluoro,
chloro, methyl, or
##STR00020##
and R.sup.2 is hydrogen, methyl, chloro, or fluoro; R.sup.3 is
hydrogen or fluoro; R.sup.6 is NH.sub.2, hydrogen, or fluoro;
R.sup.7 is hydrogen or R.sup.5 and R.sup.7 are taken together to
form
##STR00021##
R.sup.8 is methyl, trifluoromethyl, chloro, or fluoro; R.sup.4 is
hydrogen, fluoro, chloro, OH, OCH.sub.3, OCH.sub.2C.ident.CH,
O(CH.sub.2).sub.2N(CH.sub.3).sub.2, C(.dbd.O)CH.sub.3, C.ident.CH,
CN, C(.dbd.O)NH.sub.2, OCH.sub.2C(.dbd.O)NH.sub.2,
O(CH.sub.2).sub.2OCH.sub.3, O(CH.sub.2).sub.2N(CH.sub.3).sub.2,
##STR00022##
and R.sup.5 is methyl, ethyl, propyl, phenyl, CH.sub.2OH,
CH.sub.2OCH.sub.2C.sub.6H.sub.5, CH.sub.2CF.sub.3,
CH.sub.2OC(CH.sub.3).sub.3, CH.sub.2C.ident.CH,
(CH.sub.2).sub.3N(C.sub.2H.sub.5).sub.2, (CH.sub.2).sub.3NH.sub.2,
(CH.sub.2).sub.4NH.sub.2,
(CH.sub.2).sub.3NHC(.dbd.O)OCH.sub.2C.sub.6H.sub.5, or
(CH.sub.2).sub.4NHC(.dbd.O)OCH.sub.2C.sub.6H.sub.5; R.sup.c is
hydrogen, methyl, fluoro, or bromo; and n is 0 or 1.
[0427] In a preferred embodiment, the PI3K inhibitor is a
PI3K-.delta. inhibitor of Formula (XVI):
##STR00023##
which is
(S)-2-(1-((9H-purin-6-yl)amino)propyl)-5-fluoro-3-phenylquinazol-
in-4(3H)-one (other names: 4(3H)-quinazolinone,
5-fluoro-3-phenyl-2-[(1S)-1-(9H-purin-6-ylamino)propyl], and
5-fluoro-3-phenyl-2-{(1S)-1-[(7H-purin-6-yl)amino]propyl}quinazolin-4(3H)-
-one) or a pharmaceutically-acceptable salt thereof.
[0428] In a preferred embodiment, the PI3K inhibitor or
PI3K-.delta. inhibitor is
(S)-2-(1-((9H-purin-6-yl)amino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)--
one or a pharmaceutically-acceptable salt thereof.
[0429] In an embodiment, the PI3K inhibitor or PI3K-.delta.
inhibitor is 4(3H)-quinazolinone,
5-fluoro-3-phenyl-2-[(1S)-1-(9H-purin-6-ylamino)propyl]-5-fluoro-3-phenyl-
-2-{(1S)-1-[(7H-purin-6-yl)amino]propyl}quinazolin-4(3H)-one or or
a pharmaceutically-acceptable salt thereof
[0430] Other PI3K inhibitors suitable for use in the described
combination with a BTK inhibitor also include, but are not limited
to, those described in, for example, U.S. Pat. No. 8,193,182 and
U.S. Published Application Nos. 2013/0267521; 2013/0053362;
2013/0029984; 2013/0029982; 2012/0184568; and 2012/0059000.
BTK Inhibitors
[0431] The BTK inhibitor may be any BTK inhibitor known in the art.
In particular, it is one of the BTK inhibitors described in more
detail in the following paragraphs. Preferably, it is a compound of
Formula XVII or a pharmaceutically acceptable salt thereof. In one
specific embodiment, it is a compound of Formula XVIII or a
pharmaceutically acceptable salt thereof.
[0432] In an exemplary embodiment, the BTK inhibitor is a compound
of Formula (XVII):
##STR00024##
or a pharmaceutically acceptable salt thereof, wherein: [0433] X is
CH, N, O or S; [0434] Y is C(R.sub.6), N, O or S; [0435] Z is CH, N
or bond; [0436] A is CH or N; [0437] B.sub.1 is N or C(R.sub.7);
[0438] B.sub.2 is N or C(R.sub.8); [0439] B.sub.3 is N or
C(R.sub.9); [0440] B.sub.4 is N or C(R.sub.10); [0441] R.sub.1 is
R.sub.11C(.dbd.O), R.sub.12S(.dbd.O), R.sub.13S(.dbd.O).sub.2 or
(1-6C)alkyl optionally substituted with R.sub.14; [0442] R.sub.2 is
H, (C.sub.1-3)alkyl or (C.sub.3-7)cycloalkyl; [0443] R.sub.3 is H,
(C.sub.1-6)alkyl or (C.sub.3-7)cycloalkyl); or [0444] R.sub.2 and
R.sub.3 form, together with the N and C atom they are attached to,
a (3-7C)heterocycloalkyl optionally substituted with one or more
fluorine, hydroxyl, (1-3C)alkyl, (1-3C)alkoxy or oxo; [0445]
R.sub.4 is H or (C.sub.1-3)alkyl; [0446] R.sub.5 is H, halogen,
cyano, (C.sub.1-4)alkyl, (C.sub.1-3)alkoxy, (C.sub.3-6)cycloalkyl,
any alkyl group of which is optionally substituted with one or more
halogen; or R.sub.5 is (C.sub.6-10)aryl or
(C.sub.2-6)heterocycloalkyl; [0447] R.sub.6 is H or
(C.sub.1-3)alkyl; or [0448] R.sub.5 and R.sub.6 together may form a
(C.sub.3-7)cycloalkenyl or (C.sub.2-6)heterocycloalkenyl, each
optionally substituted with (C.sub.1-3)alkyl or one or more
halogens; [0449] R.sub.7 is H, halogen, CF.sub.3, (C.sub.1-3)alkyl
or (C.sub.1-3)alkoxy; [0450] R.sub.8 is H, halogen, CF.sub.3,
(C.sub.1-3)alkyl or (C.sub.1-3)alkoxy; or [0451] R.sub.7 and
R.sub.8 together with the carbon atoms they are attached to, form
(C.sub.6-10)aryl or (C.sub.1-9)heteroaryl; [0452] R.sub.9 is H,
halogen, (C.sub.1-3)alkyl or (C.sub.1-3)alkoxy; [0453] R.sub.10 is
H, halogen, (C.sub.1-3)alkyl or (C.sub.1-3)alkoxy; [0454] R.sub.11
is independently selected from the group consisting of
(C.sub.1-6)alkyl, (C.sub.2-6)alkenyl and (C.sub.2-6)alkynyl, where
each alkyl, alkenyl or alkynyl is optionally substituted with one
or more substituents selected from the group consisting of
hydroxyl, (C.sub.1-4)alkyl, (C.sub.3-7)cycloalkyl,
[(C.sub.1-4)alkyl]amino, di[(C.sub.1-4)alkyl]amino,
(C.sub.1-3)alkoxy, (C.sub.3-7)cycloalkoxy, (C.sub.6-10)aryl and
(C.sub.3-7)heterocycloalkyl; or R.sub.11 is
(C.sub.1-3)alkyl-C(O)--S--(C.sub.1-3)alkyl; or [0455] R.sub.11 is
(C.sub.1-5)heteroaryl optionally substituted with one or more
substituents selected from the group consisting of halogen or
cyano; [0456] R.sub.12 and R.sub.13 are independently selected from
the group consisting of (C.sub.2-6)alkenyl or (C.sub.2-6)alkynyl,
both optionally substituted with one or more substituents selected
from the group consisting of hydroxyl, (C.sub.1-4)alkyl,
(C.sub.3-7)cycloalkyl, [(C.sub.1-4)alkyl]amino,
di[(C.sub.1-4)alkyl]amino, (C.sub.1-3)alkoxy,
(C.sub.3-7)cycloalkoxy, (C.sub.6-10)aryl and
(C.sub.3-7)heterocycloalkyl; or a (C.sub.1-5)heteroaryl optionally
substituted with one or more substituents selected from the group
consisting of halogen and cyano; and [0457] R.sub.14 is
independently selected from the group consisting of halogen, cyano,
(C.sub.2-6)alkenyl and (C.sub.2-6)alkynyl, both optionally
substituted with one or more substituents selected from the group
consisting of hydroxyl, (C.sub.1-4)alkyl, (C.sub.3-7)cycloalkyl,
(C.sub.1-4)alkylamino, di[(C.sub.1-4)alkyl]amino,
(C.sub.1-3)alkoxy, (C.sub.3-7)cycloalkoxy, (C.sub.6-10)aryl,
(C.sub.1-5)heteroaryl and (C.sub.3-7)heterocycloalkyl; [0458] with
the proviso that: [0459] 0 to 2 atoms of X, Y, Z can simultaneously
be a heteroatom; [0460] when one atom selected from X, Y is O or S,
then Z is a bond and the other atom selected from X, Y can not be O
or S; [0461] when Z is C or N then Y is C(R.sub.6) or N and X is C
or N; [0462] 0 to 2 atoms of B.sub.1, B.sub.2, B.sub.3 and B.sub.4
are N; [0463] with the terms used having the following meanings:
[0464] (C.sub.1-2)alkyl means an alkyl group having 1 to 2 carbon
atoms, being methyl or ethyl, [0465] (C.sub.1-3)alkyl means a
branched or unbranched alkyl group having 1-3 carbon atoms, being
methyl, ethyl, propyl or isopropyl; [0466] (C.sub.1-4)alkyl means a
branched or unbranched alkyl group having 1-4 carbon atoms, being
methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl and
tert-butyl, (C.sub.1-3)alkyl groups being preferred; [0467]
(C.sub.1-5)alkyl means a branched or unbranched alkyl group having
1-5 carbon atoms, for example methyl, ethyl, propyl, isopropyl,
butyl, isobutyl, sec-butyl, tert-butyl, pentyl and isopentyl,
(C.sub.1-4)alkyl groups being preferred. (C.sub.1-6)alkyl means a
branched or unbranched alkyl group having 1-6 carbon atoms, for
example methyl, ethyl, propyl, isopropyl, butyl, tert-butyl,
n-pentyl and n-hexyl. (C.sub.1-5)alkyl groups are preferred,
(C.sub.1-4)alkyl being most preferred; [0468] (C.sub.1-2)alkoxy
means an alkoxy group having 1-2 carbon atoms, the alkyl moiety
having the same meaning as previously defined; [0469]
(C.sub.1-3)alkoxy means an alkoxy group having 1-3 carbon atoms,
the alkyl moiety having the same meaning as previously defined.
(C.sub.1-2)alkoxy groups are preferred; [0470] (C.sub.1-4)alkoxy
means an alkoxy group having 1-4 carbon atoms, the alkyl moiety
having the same meaning as previously defined. (C.sub.1-3)alkoxy
groups are preferred, (C.sub.1-2)alkoxy groups being most
preferred; [0471] (C.sub.2-4)alkenyl means a branched or unbranched
alkenyl group having 2-4 carbon atoms, such as ethenyl, 2-propenyl,
isobutenyl or 2-butenyl; [0472] (C.sub.2-6)alkenyl means a branched
or unbranched alkenyl group having 2-6 carbon atoms, such as
ethenyl, 2-butenyl, and n-pentenyl, (C.sub.2-4)alkenyl groups being
most preferred; [0473] (C.sub.2-4)alkynyl means a branched or
unbranched alkynyl group having 2-4 carbon atoms, such as ethynyl,
2-propynyl or 2-butynyl; [0474] (C.sub.2-6)alkynyl means a branched
or unbranched alkynyl group having 2-6 carbon atoms, such as
ethynyl, propynyl, n-butynyl, n-pentynyl, isopentynyl, isohexynyl
or n-hexynyl. (C.sub.2-4)alkynyl groups are preferred;
(C.sub.3-6)cycloalkyl means a cycloalkyl group having 3-6 carbon
atoms, being cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl;
[0475] (C.sub.3-7)cycloalkyl means a cycloalkyl group having 3-7
carbon atoms, being cyclopropyl, cyclobutyl, cyclopentyl,
cyclohexyl or cycloheptyl; [0476] (C.sub.2-6)heterocycloalkyl means
a heterocycloalkyl group having 2-6 carbon atoms, preferably 3-5
carbon atoms, and one or two heteroatoms selected from N, O and/or
S, which may be attached via a heteroatom if feasible, or a carbon
atom; preferred heteroatoms are N or O; also preferred are
piperidine, morpholine, pyrrolidine and piperazine; with the most
preferred (C.sub.2-6)heterocycloalkyl being pyrrolidine; the
heterocycloalkyl group may be attached via a heteroatom if
feasible; [0477] (C.sub.3-7)heterocycloalkyl means a
heterocycloalkyl group having 3-7 carbon atoms, preferably 3-5
carbon atoms, and one or two heteroatoms selected from N, O and/or
S. Preferred heteroatoms are N or O; preferred (C.sub.3-7)
heterocycloalkyl groups are azetidinyl, pyrrolidinyl, piperidinyl,
homopiperidinyl or morpholinyl; more preferred
(C.sub.3-7)heterocycloalkyl groups are piperidine, morpholine and
pyrrolidine; and the heterocycloalkyl group may be attached via a
heteroatom if feasible; [0478] (C.sub.3-7)cycloalkoxy means a
cycloalkyl group having 3-7 carbon atoms, with the same meaning as
previously defined, attached via a ring carbon atom to an exocyclic
oxygen atom; [0479] (C.sub.6-10)aryl means an aromatic hydrocarbon
group having 6-10 carbon atoms, such as phenyl, naphthyl,
tetrahydronaphthyl or indenyl; the preferred (C.sub.6-10)aryl group
is phenyl; [0480] (C.sub.1-5)heteroaryl means a substituted or
unsubstituted aromatic group having 1-5 carbon atoms and 1-4
heteroatoms selected from N, O and/or S; the (C.sub.1-5)heteroaryl
may optionally be substituted; preferred (C.sub.1-5)heteroaryl
groups are tetrazolyl, imidazolyl, thiadiazolyl, pyridyl,
pyrimidyl, triazinyl, thienyl or furyl, a more preferred
(C.sub.1-5)heteroaryl is pyrimidyl; [0481] (C.sub.1-9)heteroaryl
means a substituted or unsubstituted aromatic group having 1-9
carbon atoms and 1-4 heteroatoms selected from N, O and/or S; the
(C.sub.1-9)heteroaryl may optionally be substituted; preferred
(C.sub.1-9)heteroaryl groups are quinoline, isoquinoline and
indole; [0482] [(C.sub.1-4)alkyl]amino means an amino group,
monosubstituted with an alkyl group containing 1-4 carbon atoms
having the same meaning as previously defined; preferred
[(C.sub.1-4)alkyl]amino group is methylamino; [0483]
di[(C.sub.1-4)alkyl]amino means an amino group, disubstituted with
alkyl group(s), each containing 1-4 carbon atoms and having the
same meaning as previously defined; preferred
di[(C.sub.1-4)alkyl]amino group is dimethylamino; [0484] halogen
means fluorine, chlorine, bromine or iodine; [0485]
(C.sub.1-3)alkyl-C(O)--S--(C.sub.1-3)alkyl means an
alkyl-carbonyl-thio-alkyl group, each of the alkyl groups having 1
to 3 carbon atoms with the same meaning as previously defined;
[0486] (C.sub.3-7)cycloalkenyl means a cycloalkenyl group having
3-7 carbon atoms, preferably 5-7 carbon atoms; preferred
(C.sub.3-7)cycloalkenyl groups are cyclopentenyl or cyclohexenyl;
cyclohexenyl groups are most preferred; [0487]
(C.sub.2-6)heterocycloalkenyl means a heterocycloalkenyl group
having 2-6 carbon atoms, preferably 3-5 carbon atoms; and 1
heteroatom selected from N, O and/or S; preferred
(C.sub.2-6)heterocycloalkenyl groups are oxycyclohexenyl and
azacyclohexenyl group. In the above definitions with
multifunctional groups, the attachment point is at the last group.
[0488] When, in the definition of a substituent, is indicated that
"all of the alkyl groups" of said substituent are optionally
substituted, this also includes the alkyl moiety of an alkoxy
group. A circle in a ring of Formula (XVII) indicates that the ring
is aromatic. Depending on the ring formed, the nitrogen, if present
in X or Y, may carry a hydrogen.
[0489] In an exemplary embodiment of Formula (XVII), B.sub.1 is
C(R.sub.7); B.sub.2 is C(R.sub.8); B.sub.3 is C(R.sub.9); B.sub.4
is C(R.sub.10); R.sub.7, R.sub.9, and R.sub.10 are each H; and
R.sub.8 is hydrogen or methyl.
[0490] In an exemplary embodiment of Formula (XVII), the ring
containing X, Y and Z is selected from the group consisting of
pyridyl, pyrimidyl, pyridazyl, triazinyl, thiazolyl, oxazolyl and
isoxazolyl.
[0491] In an exemplary embodiment of Formula (XVII), the ring
containing X, Y and Z is selected from the group consisting of
pyridyl, pyrimidyl and pyridazyl.
[0492] In an exemplary embodiment of Formula (XVII), the ring
containing X, Y and Z is selected from the group consisting of
pyridyl and pyrimidyl.
[0493] In an exemplary embodiment of Formula (XVII), the ring
containing X, Y and Z is pyridyl.
[0494] In an exemplary embodiment of Formula (XVII), R.sub.5 is
selected from the group consisting of hydrogen, fluorine, methyl,
methoxy and trifluoromethyl.
[0495] In an exemplary embodiment of Formula (XVII), R.sub.5 is
hydrogen.
[0496] In an exemplary embodiment of Formula (XVII), R.sub.2 and
R.sub.3 together form a heterocycloalkyl ring selected from the
group consisting of azetidinyl, pyrrolidinyl, piperidinyl,
homopiperidinyl and morpholinyl, optionally substituted with one or
more of fluoro, hydroxyl, (C.sub.1-3)alkyl and
(C.sub.1-3)alkoxy.
[0497] In an exemplary embodiment of Formula (XVII), R.sub.2 and
R.sub.3 together form a heterocycloalkyl ring selected from the
group consisting of azetidinyl, pyrrolidinyl and piperidinyl.
[0498] In an exemplary embodiment of Formula (XVII), R.sub.2 and
R.sub.3 together form a pyrrolidinyl ring.
[0499] In an exemplary embodiment of Formula (XVII), R.sub.1 is
independently selected from the group consisting of
(C.sub.1-6)alkyl, (C.sub.2-6)alkenyl or (C.sub.2-6)alkynyl, each
optionally substituted with one or more substituents selected from
the group consisting of hydroxyl, (C.sub.1-4)alkyl,
(C.sub.3-7)cycloalkyl, [(C.sub.1-4)alkyl]amino,
di[(C.sub.1-4)alkyl]amino, (C.sub.1-3)alkoxy,
(C.sub.3-7)cycloalkoxy, (C.sub.6-10)aryl and
(C.sub.3-7)heterocycloalkyl.
[0500] In an exemplary embodiment of Formula (XVII), B.sub.1,
B.sub.2, B.sub.3 and B.sub.4 are CH; X is N; Y and Z are CH;
R.sub.5 is CH.sub.3; A is N; R.sub.2, R.sub.3 and R.sub.4 are H;
and R.sub.1 is CO--CH.sub.3.
[0501] In an exemplary embodiment of Formula (XVII), B.sub.1,
B.sub.2, B.sub.3 and B.sub.4 are CH; X and Y are N; Z is CH;
R.sub.5 is CH.sub.3; A is N; R.sub.2, R.sub.3 and R.sub.4 are H;
and R.sub.1 is CO--CH.sub.3.
[0502] In an exemplary embodiment of Formula (XVII), B.sub.1,
B.sub.2, B.sub.3 and B.sub.4 are CH; X and Y are N; Z is CH;
R.sub.5 is CH.sub.3; A is CH; R.sub.2 and R.sub.3 together form a
piperidinyl ring; R.sub.4 is H; and R.sub.1 is CO-ethenyl.
[0503] In an exemplary embodiment of Formula (XVII), B.sub.1,
B.sub.2, B.sub.3 and B.sub.4 are CH; X, Y and Z are CH; R.sub.5 is
H; A is CH; R.sub.2 and R.sub.3 together form a pyrrolidinyl ring;
R.sub.4 is H; and R.sub.1 is CO-propynyl.
[0504] In an exemplary embodiment of Formula (XVII), B.sub.1,
B.sub.2, B.sub.3 and B.sub.4 are CH; X, Y and Z are CH; R.sub.5 is
CH.sub.3; A is CH; R.sub.2 and R.sub.3 together form a piperidinyl
ring; R.sub.4 is H; and R.sub.1 is CO-propynyl.
[0505] In an exemplary embodiment of Formula (XVII), B.sub.1,
B.sub.2, B.sub.3 and B.sub.4 are CH; X and Y are N; Z is CH;
R.sub.5 is H; A is CH; R.sub.2 and R.sub.3 together form a
morpholinyl ring; R.sub.4 is H; and R.sub.1 is CO-ethenyl.
[0506] In an exemplary embodiment of Formula (XVII), B.sub.1,
B.sub.2, B.sub.3 and B.sub.4 are CH; X and Y are N; Z is CH;
R.sub.5 is CH.sub.3; A is CH; R.sub.2 and R.sub.3 together form a
morpholinyl ring; R.sub.4 is H; and R.sub.1 is CO-propynyl.
[0507] In an exemplary preferred embodiment, the BTK inhibitor is a
compound of Formula (XVIII):
##STR00025##
which is
(S)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]p-
yrazin-1-yl)-N-(pyridin-2-yl)benzamide, or a
pharmaceutically-acceptable salt thereof. The preparation of this
compound is described at Example 6 of International Patent
Application Publication No. WO 2013/010868. The preparation of this
compound and related structures are described in the Examples of
International Patent Application Publication No. WO
2013/010868.
[0508] In an exemplary embodiment, the BTK inhibitor is
(S)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1--
yl)-N-(pyridin-2-yl)benzamide or pharmaceutically-acceptable salt
thereof.
[0509] In an exemplary embodiment, the BTK inhibitor is a compound
of Formula (XIX) or a pharmaceutically-acceptable salt of a
compound of Formula (XIX):
##STR00026##
In Formula (XIX) the substituents are defined as: [0510] X is CH,
N, O or S; [0511] Y is C(R.sub.6), N, O or S; [0512] Z is CH, N or
bond; [0513] A is CH or N; [0514] B.sub.1 is N or C(R.sub.7);
[0515] B.sub.2 is N or C(R.sub.8); [0516] B.sub.3 is N or
C(R.sub.9); [0517] B.sub.4 is N or C(R.sub.10); [0518] R.sub.1 is
R.sub.11C(O), R.sub.12S(O), R.sub.13SO.sub.2 or (C.sub.1-6)alkyl
optionally substituted with R.sub.14; [0519] R.sub.2 is H,
(C.sub.1-3)alkyl or (C.sub.3-7)cycloalkyl; [0520] R.sub.3 is H,
(C.sub.1-6)alkyl or (C.sub.3-7)cycloalkyl); or [0521] R.sub.2 and
R.sub.3 form, together with the N and C atom they are attached to,
a (C.sub.3-7)heterocycloalkyl optionally substituted with one or
more fluorine, hydroxyl, (C.sub.1-3)alkyl, (C.sub.1-3)alkoxy or
oxo; [0522] R.sub.4 is H or (C.sub.1-3)alkyl; [0523] R.sub.5 is H,
halogen, cyano, (C.sub.1-4)alkyl, (C.sub.1-3)alkoxy,
(C.sub.3-6)cycloalkyl; all alkyl groups of R.sub.5 are optionally
substituted with one or more halogen; or R.sub.5 is
(C.sub.6-10)aryl or (C.sub.2-6)heterocycloalkyl; [0524] R.sub.6 is
H or (C.sub.1-3)alkyl; or R.sub.5 and R.sub.6 together may form a
(C.sub.3-7)cycloalkenyl, or (C.sub.2-6)heterocycloalkenyl; each
optionally substituted with (C.sub.1-3)alkyl, or one or more
halogen; [0525] R.sub.7 is H, halogen, CF.sub.3, (C.sub.1-3)alkyl
or (C.sub.1-3)alkoxy; [0526] R.sub.8 is H, halogen, CF.sub.3,
(C.sub.1-3)alkyl or (C.sub.1-3)alkoxy; or [0527] R.sub.7 and
R.sub.8 together with the carbon atoms they are attached to, form
(6-10C)aryl or (1-5C)heteroaryl; [0528] R.sub.9 is H, halogen,
(C.sub.1-3)alkyl or (C.sub.1-3)alkoxy; [0529] R.sub.10 is H,
halogen, (C.sub.1-3)alkyl or (C.sub.1-3)alkoxy; [0530] R.sub.11 is
independently selected from a group consisting of (C.sub.1-6)alkyl,
(C.sub.2-6)alkenyl and (C.sub.2-6) alkynyl each alkyl, alkenyl or
alkynyl optionally substituted with one or more groups selected
from hydroxyl, (C.sub.1-4)alkyl, (C.sub.3-7)cycloalkyl,
[(C.sub.1-4)alkyl]amino, di[(C.sub.1-4) alkyl]amino,
(C.sub.1-3)alkoxy, (C.sub.3-7)cycloalkoxy, (C.sub.6-10)aryl or
(C.sub.3-7)heterocycloalkyl, or R.sub.11 is
(C.sub.1-3)alkyl-C(O)--S--(C.sub.1-3)alkyl; or [0531] R.sub.11 is
(C.sub.1-5)heteroaryl optionally substituted with one or more
groups selected from halogen or cyano. [0532] R.sub.12 and R.sub.13
are independently selected from a group consisting of
(C.sub.2-6)alkenyl or (C.sub.2-6)alkynyl both optionally
substituted with one or more groups selected from hydroxyl,
(C.sub.1-4)alkyl, (C.sub.3-7)cycloalkyl, [(C.sub.1-4)alkyl]amino,
di[(C.sub.1-4)alkyl]amino, (C.sub.1-3)alkoxy,
(C.sub.3-7)cycloalkoxy, (C.sub.6-10) aryl, or
(C.sub.3-7)heterocycloalkyl; or [0533] (C.sub.1-5)heteroaryl
optionally substituted with one or more groups selected from
halogen or cyano; [0534] R.sub.14 is independently selected from a
group consisting of halogen, cyano or (C.sub.2-6)alkenyl or
(C.sub.2-6) alkynyl both optionally substituted with one or more
groups selected from hydroxyl, (C.sub.1-4) alkyl,
(C.sub.3-7)cycloalkyl, [(C.sub.1-4)alkyl]amino,
di[(C.sub.1-4)alkyl]amino, (C.sub.1-3)alkoxy, (C.sub.3-7)
cycloalkoxy, (C.sub.6-10)aryl, (C.sub.1-5)heteroaryl or
(C.sub.3-7)heterocycloalkyl; [0535] with the proviso that [0536] 0
to 2 atoms of X, Y, Z can simultaneously be a heteroatom; [0537]
when one atom selected from X, Y is O or S, then Z is a bond and
the other atom selected from X, Y can not be O or S; [0538] when Z
is C or N then Y is C(R.sub.6) or N and X is C or N; [0539] 0 to 2
atoms of B.sub.1, B.sub.2, B.sub.3 and B.sub.4 are N; with the
terms used having the following meanings: [0540] (C.sub.1-3)alkyl
means a branched or unbranched alkyl group having 1-3 carbon atoms,
being methyl, ethyl, propyl or isopropyl; [0541] (C.sub.1-4)alkyl
means a branched or unbranched alkyl group having 1-4 carbon atoms,
being methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl
and tert-butyl, (C.sub.1-3)alkyl groups being preferred; [0542]
(C.sub.1-6)alkyl means a branched or unbranched alkyl group having
1-6 carbon atoms, for example methyl, ethyl, propyl, isopropyl,
butyl, tert-butyl, n-pentyl and n-hexyl, (C.sub.1-5)alkyl groups
are preferred, (C.sub.1-4)alkyl being most preferred; [0543]
(C.sub.1-2)alkoxy means an alkoxy group having 1-2 carbon atoms,
the alkyl moiety having the same meaning as previously defined;
[0544] (C.sub.1-3)alkoxy means an alkoxy group having 1-3 carbon
atoms, the alkyl moiety having the same meaning as previously
defined, with (C.sub.1-2)alkoxy groups preferred; [0545]
(C.sub.2-3)alkenyl means an alkenyl group having 2-3 carbon atoms,
such as ethenyl or 2-propenyl; [0546] (C.sub.2-4)alkenyl means a
branched or unbranched alkenyl group having 2-4 carbon atoms, such
as ethenyl, 2-propenyl, isobutenyl or 2-butenyl; [0547]
(C.sub.2-6)alkenyl means a branched or unbranched alkenyl group
having 2-6 carbon atoms, such as ethenyl, 2-butenyl, and
n-pentenyl, with (C.sub.2-4)alkenyl groups preferred, and
(C.sub.2-3)alkenyl groups even more preferred; [0548]
(C.sub.2-4)alkynyl means a branched or unbranched alkynyl group
having 2-4 carbon atoms, such as ethynyl, 2-propynyl or 2-butynyl;
[0549] (C.sub.2-3)alkynyl means an alkynyl group having 2-3 carbon
atoms, such as ethynyl or 2-propynyl; [0550] (C.sub.2-6)alkynyl
means a branched or unbranched alkynyl group having 2-6 carbon
atoms, such as ethynyl, propynyl, n-butynyl, n-pentynyl,
isopentynyl, isohexynyl or n-hexynyl, with (C.sub.2-4) alkynyl
groups preferred, and (2-3C)alkynyl groups more preferred; [0551]
(C.sub.3-6)cycloalkyl means a cycloalkyl group having 3-6 carbon
atoms, being cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl;
[0552] (C.sub.3-7)cycloalkyl means a cycloalkyl group having 3-7
carbon atoms, being cyclopropyl, cyclobutyl, cyclopentyl,
cyclohexyl or cycloheptyl; [0553] (C.sub.2-6)heterocycloalkyl means
a heterocycloalkyl group having 2-6 carbon atoms, preferably 3-5
carbon atoms, and one or two heteroatoms selected from N, O and/or
S, which may be attached via a heteroatom if feasible, or a carbon
atom; preferred heteroatoms are N or O; preferred groups are
piperidine, morpholine, pyrrolidine and piperazine; a most
preferred (C.sub.2-6)heterocycloalkyl is pyrrolidine; and the
heterocycloalkyl group may be attached via a heteroatom if
feasible; [0554] (C.sub.3-7)heterocycloalkyl means a
heterocycloalkyl group having 3-7 carbon atoms, preferably 3-5
carbon atoms, and one or two heteroatoms selected from N, O and/or
S; preferred heteroatoms are N or O; preferred (C.sub.3-7)
heterocycloalkyl groups are azetidinyl, pyrrolidinyl, piperidinyl,
homopiperidinyl or morpholinyl; more preferred
(C.sub.3-7)heterocycloalkyl groups are piperidine, morpholine and
pyrrolidine; even more preferred are piperidine and pyrrolidine;
and the heterocycloalkyl group may be attached via a heteroatom if
feasible; [0555] (C.sub.3-7)cycloalkoxy means a cycloalkyl group
having 3-7 carbon atoms, with the same meaning as previously
defined, attached via a ring carbon atom to an exocyclic oxygen
atom; [0556] (C.sub.6-10)aryl means an aromatic hydrocarbon group
having 6-10 carbon atoms, such as phenyl, naphthyl,
tetrahydronaphthyl or indenyl; the preferred (C.sub.6-10)aryl group
is phenyl; [0557] (C.sub.1-5)heteroaryl means a substituted or
unsubstituted aromatic group having 1-5 carbon atoms and 1-4
heteroatoms selected from N, O and/or S, wherein the
(C.sub.1-5)heteroaryl may optionally be substituted; preferred
(C.sub.1-5)heteroaryl groups are tetrazolyl, imidazolyl,
thiadiazolyl, pyridyl, pyrimidyl, triazinyl, thienyl or furyl, and
the more preferred (C.sub.1-5) heteroaryl is pyrimidyl; [0558]
[(C.sub.1-4)alkyl]amino means an amino group, monosubstituted with
an alkyl group containing 1-4 carbon atoms having the same meaning
as previously defined; the preferred [(C.sub.1-4) alkyl]amino group
is methylamino; [0559] di[(C.sub.1-4)alkyl]amino means an amino
group, disubstituted with alkyl group(s), each containing 1-4
carbon atoms and having the same meaning as previously defined; the
preferred di[(C.sub.1-4) alkyl]amino group is dimethylamino; [0560]
halogen means fluorine, chlorine, bromine or iodine; [0561]
(C.sub.1-3)alkyl-C(O)--S--(C.sub.1-3)alkyl means an
alkyl-carbonyl-thio-alkyl group, each of the alkyl groups having 1
to 3 carbon atoms with the same meaning as previously defined;
[0562] (C.sub.3-7)cycloalkenyl means a cycloalkenyl group having
3-7 carbon atoms, preferably 5-7 carbon atoms; preferred
(C.sub.3-7)cycloalkenyl groups are cyclopentenyl or cyclohexenyl;
and cyclohexenyl groups are most preferred; [0563]
(C.sub.2-6)heterocycloalkenyl means a heterocycloalkenyl group
having 2-6 carbon atoms, preferably 3-5 carbon atoms; and 1
heteroatom selected from N, O and/or S; the preferred (C.sub.2-6)
heterocycloalkenyl groups are oxycyclohexenyl and azacyclohexenyl
groups. In the above definitions with multifunctional groups, the
attachment point is at the last group. [0564] When, in the
definition of a substituent, is indicated that "all of the alkyl
groups" of said substituent are optionally substituted, this also
includes the alkyl moiety of an alkoxy group. A circle in a ring of
Formula (XIX) indicates that the ring is aromatic. Depending on the
ring formed, the nitrogen, if present in X or Y, may carry a
hydrogen.
[0565] In one embodiment the invention provides a compound
according to Formula XIX, wherein B.sub.1 is C(R.sub.7); B.sub.2 is
C(R.sub.8); B.sub.3 is C(R.sub.9) and B.sub.4 is C(R.sub.10).
[0566] In an exemplary embodiment, the BTK inhibitor is a compound
of Formula (XX):
##STR00027##
or a pharmaceutically acceptable salt thereof, wherein: [0567]
L.sub.a is CH.sub.2, 0, NH or S; [0568] Ar is a substituted or
unsubstituted aryl, or a substituted or unsubstituted heteroaryl;
[0569] Y is an optionally substituted group selected from the group
consisting of alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl,
aryl and heteroaryl; [0570] Z is C(.dbd.O), OC(.dbd.O),
NRC(.dbd.O), C(.dbd.S), S(.dbd.O).sub.x, OS(.dbd.O) or
NRS(.dbd.O).sub.x, where x is 1 or 2; [0571] R.sup.7 and R.sup.8
are each independently H; or R.sup.7 and R.sup.8 taken together
form a bond; [0572] R.sup.6 is H; and [0573] R is H or
C.sub.1-C.sub.6alkyl.
[0574] In an exemplary embodiment, the BTK inhibitor is ibrutinib
or a pharmaceutically-acceptable salt thereof. In an exemplary
embodiment, the BTK inhibitor is
(R)-1-(3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)pi-
peridin-1-yl)prop-2-en-1-one. In an exemplary embodiment, the BTK
inhibitor is
1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]p-
iperidin-1-yl]prop-2-en-1-one. In an exemplary embodiment, the BTK
inhibitor is
(S)-1-(3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)pi-
peridin-1-yl)prop-2-en-1-one. In an exemplary embodiment, the BTK
inhibitor has the structure of Formula (XX-A), or an enantiomer
thereof, or a pharmaceutically acceptable salt, solvate, hydrate,
cocrystal, or prodrug thereof.
##STR00028##
[0575] In an exemplary embodiment, the BTK inhibitor is a compound
of Formula (XXI):
##STR00029##
or a pharmaceutically acceptable salt thereof, wherein: [0576]
L.sub.a is CH.sub.2, O, NH or S; [0577] Ar is a substituted or
unsubstituted aryl, or a substituted or unsubstituted heteroaryl;
[0578] Y is an optionally substituted group selected from the group
consisting of alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl,
aryl and heteroaryl; [0579] Z is C(.dbd.O), OC(.dbd.O),
NRC(.dbd.O), C(.dbd.S), S(.dbd.O), OS(.dbd.O).sub.x or
NRS(.dbd.O).sub.x, where x is 1 or 2; [0580] R.sup.7 and R.sup.8
are each H; or R.sup.7 and R.sup.8 taken together form a bond;
[0581] R.sup.6 is H; and [0582] R is H or C.sub.1-C.sub.6alkyl.
[0583] In an exemplary embodiment, the BTK inhibitor is a compound
of Formula (XXII):
##STR00030##
or a pharmaceutically acceptable salt thereof, wherein: [0584]
L.sub.a is CH.sub.2, O, NH or S; [0585] Ar is a substituted or
unsubstituted aryl, or a substituted or unsubstituted heteroaryl;
[0586] Y is an optionally substituted group selected from the group
consisting of alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl,
aryl and heteroaryl; [0587] Z is C(.dbd.O), OC(.dbd.O),
NRC(.dbd.O), C(.dbd.S), S(.dbd.O), OS(.dbd.O) or NRS(.dbd.O), where
x is 1 or 2; [0588] R.sup.7 and R.sup.8 are each H; or R.sup.7 and
R.sup.8 taken together form a bond; [0589] R.sup.6 is H; and [0590]
R is H or C.sub.1-C.sub.6alkyl.
[0591] In an exemplary embodiment, the BTK inhibitor is a compound
of Formula (XXIII):
##STR00031##
or a pharmaceutically acceptable salt thereof, wherein: [0592]
L.sub.a is CH.sub.2, O, NH or S; [0593] Ar is a substituted or
unsubstituted aryl, or a substituted or unsubstituted heteroaryl;
[0594] Y is an optionally substituted group selected from the group
consisting of alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl,
aryl and heteroaryl; [0595] Z is C(.dbd.O), OC(.dbd.O),
NRC(.dbd.O), C(.dbd.S), S(.dbd.O).sub.x, OS(.dbd.O).sub.x or
NRS(.dbd.O).sub.x, where x is 1 or 2; [0596] R.sup.7 and R.sup.8
are each H; or R.sup.7 and R.sup.8 taken together form a bond;
[0597] R.sup.6 is H; and [0598] R is H or C.sub.1-C.sub.6alkyl.
[0599] In an exemplary embodiment, the BTK inhibitor is a compound
of Formula (XXIV):
##STR00032##
or a pharmaceutically acceptable salt thereof, wherein: [0600]
Q.sup.1 is aryl.sup.1, heteroaryl.sup.1, cycloalkyl, heterocyclyl,
cycloalkenyl, or heterocycloalkenyl, any of which is optionally
substituted by one to five independent G.sup.1 substituents; [0601]
R.sup.1 is alkyl, cycloalkyl, bicycloalkyl, aryl, heteroaryl,
aralkyl, heteroaralkyl, heterocyclyl, or heterobicycloalkyl, any of
which is optionally substituted by one or more independent G.sup.11
substituents; [0602] G.sup.1 and G.sup.41 are each independently
halo, oxo, --CF.sub.3, --OCF.sub.3, --OR.sup.2,
--NR.sup.2R.sup.3(R.sup.3a).sub.j1, --C(O)R.sup.2,
--CO.sub.2R.sup.2, --CONR.sup.2R.sup.3, --NO.sub.2, --CN,
--S(O).sub.j1R.sup.2, --SO.sub.2NR.sup.2R.sup.3,
NR.sup.2(C.dbd.O)R.sup.3, NR.sup.2(C.dbd.O)OR.sup.3,
NR.sup.2(C.dbd.O)NR.sup.2R.sup.3, NR.sup.2S(O).sub.j1R.sup.3,
--(C.dbd.S)OR.sup.2, --(C.dbd.O)SR.sup.2,
--NR.sup.2(C.dbd.NR.sup.3)NR.sup.2aR.sup.3a,
--NR.sup.2(C.dbd.NR.sup.3)OR.sup.2a,
--NR.sup.2(C.dbd.NR.sup.3)SR.sup.3a, --O(C.dbd.O)OR.sup.2,
--O(C.dbd.O)NR.sup.2R.sup.3, --O(C.dbd.O)SR.sup.2,
--S(C.dbd.O)OR.sup.2, --S(C.dbd.O)NR.sup.2R.sup.3, C.sub.0-10alkyl,
C.sub.2-10alkenyl, C.sub.2-10alkynyl,
C.sub.1-10alkoxyC.sub.2-10alkenyl,
C.sub.1-10alkoxyC.sub.2-10alkynyl,
C.sub.1-10alkylthioC.sub.1-10alkyl,
C.sub.1-10alkylthioC.sub.2-10alkenyl,
C.sub.1-10alkylthioC.sub.2-10alkynyl, cycloC.sub.3-8alkyl,
cycloC.sub.3-8alkenyl, cycloC.sub.3-8alkylC.sub.1-10alkyl,
cycloC.sub.3-8alkenylC.sub.1-10alkyl,
cycloC.sub.3-8alkylC.sub.2-10alkenyl,
cycloC.sub.3-8alkenylC.sub.2-10alkenyl,
cycloC.sub.3-8alkylC.sub.2-10alkynyl,
cycloC.sub.3-8alkenylC.sub.2-10alkynyl,
heterocyclyl-C.sub.0-10alkyl, heterocyclyl-C.sub.2-10alkenyl, or
heterocyclyl-C.sub.2-10alkynyl, any of which is optionally
substituted with one or more independent halo, oxo, --CF.sub.3,
--OCF.sub.3, --OR.sup.222,
--NR.sup.222R.sup.333(R.sup.333a).sub.j1a, --C(O)R.sup.222,
--CO.sub.2R.sup.222, --CONR.sup.222R.sup.333, --NO.sub.2, --CN,
--S(O).sub.j1aR.sup.222, --SO.sub.2NR.sup.222R.sup.333,
NR.sup.222(C.dbd.O)R.sup.333, NR.sup.222(C.dbd.O)OR.sup.333,
NR.sup.222(C.dbd.O)NR.sup.222R.sup.333,
NR.sup.222S(O).sub.j1aR.sup.333, --(C.dbd.S)OR.sup.222,
--(C.dbd.O)SR.sup.222,
--NR.sup.222(C.dbd.NR.sup.333)NR.sup.222aR.sup.333a,
--NR.sup.222(C.dbd.NR.sup.333)OR.sup.222a,
--NR.sup.222(C.dbd.NR.sup.333)SR.sup.333a, --O(C.dbd.O)OR.sup.222,
--O(C.dbd.O)NR.sup.222R.sup.333, --O(C.dbd.O)SR.sup.222,
--S(C.dbd.O)OR.sup.222, or --S(C.dbd.O)NR.sup.222R.sup.333
substituents; or --(X.sup.1).sub.n--(Y.sup.1).sub.m--R.sup.4; or
aryl-C.sub.0-10alkyl, aryl-C.sub.2-10alkenyl, or
aryl-C.sub.2-10alkynyl, any of which is optionally substituted with
one or more independent halo, --CF.sub.3, --OCF.sub.3,
--OR.sup.222, --NR.sup.222R.sup.333(R.sup.333a).sub.j2a,
--C(O)R.sup.222, --CO.sub.2R.sup.222, --CONR.sup.222R.sup.333,
--NO.sub.2, --CN, --S(O).sub.j2aR.sup.222,
--SO.sub.2NR.sup.222R.sup.333, NR.sup.222(C.dbd.O)R.sup.333,
NR.sup.222(C.dbd.O)OR.sup.333,
NR.sup.222(C.dbd.O)NR.sup.222R.sup.333,
NR.sup.222S(O).sub.j2aR.sup.333, --(C.dbd.S)OR.sup.222,
--(C.dbd.O)SR.sup.222,
NR.sup.222(C.dbd.NR.sup.333)NR.sup.222aR.sup.333a,
--NR.sup.222(C.dbd.NR.sup.333)OR.sup.222a,
--NR.sup.222(C.dbd.NR.sup.333)SR.sup.333a, --O(C.dbd.O)OR.sup.222,
--O(C.dbd.O)NR.sup.222R.sup.333, --O(C.dbd.O)SR.sup.222,
--S(C.dbd.O)OR.sup.222, or --S(C.dbd.O)NR.sup.222R.sup.333
substituents; or hetaryl-C.sub.0-10alkyl,
hetaryl-C.sub.2-10alkenyl, or hetaryl-C.sub.2-10alkynyl, any of
which is optionally substituted with one or more independent halo,
--CF.sub.3, --OCF.sub.3, --OR.sup.222, --NR.sup.222,
R.sup.333(R.sup.333a).sub.j3a, --C(O)R.sup.222,
--CO.sub.2R.sup.222, --CONR.sup.222R.sup.333, --NO.sub.2, --CN,
--S(O).sub.j3aR.sup.222, --SO.sub.2NR.sup.222R.sup.333,
NR.sup.222(C.dbd.O)R.sup.333, NR.sup.222(C.dbd.O)OR.sup.333,
NR.sup.222(C.dbd.O)NR.sup.222R.sup.333,
NR.sup.222S(O).sub.j3aR.sup.333, --(C.dbd.S)OR.sup.222,
--(C.dbd.O)SR.sup.222,
--NR.sup.222(C.dbd.NR.sup.333)NR.sup.222aR.sup.333a,
--NR.sup.222(C.dbd.NR.sup.333)OR.sup.222a,
--NR.sup.222(C.dbd.NR.sup.333)SR.sup.333a, --O(C.dbd.O)OR.sup.222,
--O(C.dbd.O)NR.sup.222R.sup.333, --O(C.dbd.O)SR.sup.222,
--S(C.dbd.O)OR.sup.222, or --S(C.dbd.O)NR.sup.222R.sup.333
substituents; [0603] G.sup.11 is halo, oxo, --CF.sub.3,
--OCF.sub.3, --OR.sup.21, --NR.sup.21R.sup.31(R.sup.3a1).sub.j4,
--C(O)R.sup.21, --CO.sub.2R.sup.21, --CONR.sup.21R.sup.31,
--NO.sub.2, --CN, --S(O).sub.j4R.sup.21,
--SO.sub.2NR.sup.21R.sup.31, NR.sup.21(C.dbd.O)OR.sup.31,
NR.sup.21(C.dbd.O)OR.sup.31, NR.sup.21(C.dbd.O)NR.sup.21R.sup.31,
NR.sup.21S(O).sub.j4R.sup.31, --(C.dbd.S)OR.sup.21,
--(C.dbd.O)SR.sup.21,
--NR.sup.21(C.dbd.NR.sup.31)NR.sup.2a1R.sup.3a1,
--NR.sup.21(C.dbd.NR.sup.31)OR.sup.2a1,
--NR.sup.21(C.dbd.NR.sup.31)SR.sup.3a1, --O(C.dbd.O)OR.sup.21,
--O(C.dbd.O)NR.sup.21R.sup.31, --O(C.dbd.O)SR.sup.21,
--S(C.dbd.O)OR.sup.21, --S(C.dbd.O)NR.sup.21R.sup.31,
--P(O)OR.sup.21OR.sup.31, C.sub.0-10alkyl, C.sub.2-10alkenyl,
C.sub.2-10alkynyl, C.sub.1-10alkoxyC.sub.1-10alkyl,
C.sub.1-10alkoxyC.sub.2-10alkenyl,
C.sub.1-10alkoxyC.sub.2-10alkynyl,
C.sub.1-10alkylthioC.sub.1-10alkyl,
C.sub.1-10alkylthioC.sub.2-10alkenyl,
C.sub.1-10alkylthioC.sub.2-10alkynyl, cycloC.sub.3-8alkyl,
cycloC.sub.3-8alkenyl, cycloC.sub.3-8alkylC.sub.1-10alkyl,
cycloC.sub.3-8alkenylC.sub.1-10alkyl,
cycloC.sub.3-8alkylC.sub.2-10alkenyl,
cycloC.sub.3-8alkenylC.sub.2-10alkenyl,
cycloC.sub.3-8alkylC.sub.2-10alkynyl,
cycloC.sub.3-8alkenylC.sub.2-10alkynyl,
heterocyclyl-C.sub.0-10alkyl, heterocyclyl-C.sub.2-10alkenyl, or
heterocyclyl-C.sub.2-10alkynyl, any of which is optionally
substituted with one or more independent halo, oxo, --CF.sub.3,
--OCF.sub.3, --OR.sup.2221,
--NR.sup.2221R.sup.3331(R.sup.333a1).sub.j4a, --COR.sup.2221,
--CO.sub.2R.sup.2221, --CONR.sup.2221R.sup.3331, --NO.sub.2, --CN,
--S(O).sub.j4aR.sup.2221, --SO.sub.2NR.sup.2221R.sup.3331,
NR.sup.2221(C.dbd.O)R.sup.3331, NR.sup.2221(C.dbd.O)OR.sup.3331,
NR.sup.2221(C.dbd.O)NR.sup.2221R.sup.3331,
NR.sup.2221S(O).sub.j4aR.sup.3331, --(C.dbd.S)OR.sup.2221,
--(C.dbd.O)SR.sup.2221,
--NR.sup.2221(C.dbd.NR.sup.3331)NR.sup.222a1R.sup.333a1,
--NR.sup.2221(C.dbd.NR.sup.3331)OR.sup.222a1,
--NR.sup.2221(C.dbd.NR.sup.3331)SR.sup.333a1,
--O(C.dbd.O)OR.sup.2221, --O(C.dbd.O)NR.sup.2221R.sup.3331,
--O(C.dbd.O)SR.sup.2221, --S(C.dbd.O)OR.sup.2221,
--P(O)OR.sup.2221OR.sup.3331, or --S(C.dbd.O)NR.sup.2221R.sup.3331
substituents; or aryl-C.sub.0-10alkyl, aryl-C.sub.2-10alkenyl, or
aryl-C.sub.2-10alkynyl, any of which is optionally substituted with
one or more independent halo, --CF.sub.3, --OCF.sub.3,
--OR.sup.2221, --NR.sup.2221R.sup.3331(R.sup.333a1).sub.j5a,
--C(O)R.sup.2221, --CO.sub.2R.sup.2221, --CONR.sup.2221R.sup.3331,
--NO.sub.2, --CN, --S(O).sub.j5aR.sup.2221,
--SO.sub.2NR.sup.2221R.sup.3331, NR.sup.2221(C.dbd.O)R.sup.3331,
NR.sup.2221(C.dbd.O)OR.sup.3331,
NR.sup.2221(C.dbd.O)NR.sup.2221R.sup.3331,
NR.sup.2221S(O).sub.j5aR.sup.3331, --(C.dbd.S)OR.sup.2221,
--(C.dbd.O)SR.sup.2221,
--NR.sup.2221(C.dbd.NR.sup.3331)NR.sup.222a1R.sup.333a1,
--NR.sup.2221(C.dbd.NR.sup.3331)OR.sup.222a1,
--NR.sup.2221(C.dbd.NR.sup.3331)SR.sup.333a1,
--O(C.dbd.O)OR.sup.2221, --O(C.dbd.O)NR.sup.2221R.sup.3331,
--O(C.dbd.O)SR.sup.2221, --S(C.dbd.O)OR.sup.2221,
--P(O)OR.sup.2221R.sup.3331, or --S(C.dbd.O)NR.sup.2221R.sup.3331
substituents; or hetaryl-C.sub.0-10alkyl,
hetaryl-C.sub.2-10alkenyl, or hetaryl-C.sub.2-10alkynyl, any of
which is optionally substituted with one or more independent halo,
--CF.sub.3, --OCF.sub.3, --OR.sup.2221,
--NR.sup.2221R.sup.3331(R.sup.333a1).sub.j6a, --C(O)R.sup.2221,
--CO.sub.2R.sup.2221, --CONR.sup.2221R.sup.3331, --NO.sub.2, --CN,
--S(O).sub.j6aR.sup.2221, --SO.sub.2NR.sup.2221R.sup.3331,
NR.sup.2221(C.dbd.O)R.sup.3331, NR.sup.2221(C.dbd.O)OR.sup.3331,
NR.sup.2221(C.dbd.O)NR.sup.2221R.sup.3331,
NR.sup.2221S(O).sub.j6aR.sup.3331, --(C.dbd.S)OR.sup.2221,
--(C.dbd.O)SR.sup.2221,
--NR.sup.2221(C.dbd.NR.sup.3331)NR.sup.222a1R.sup.333a1,
--NR.sup.2221(C.dbd.NR.sup.3331)OR.sup.222a1,
--NR.sup.2221(C.dbd.NR.sup.3331)SR.sup.333a1,
--O(C.dbd.O)OR.sup.2221, --O(C.dbd.O)NR.sup.2221R.sup.3331,
--O(C.dbd.O)SR.sup.2221, --S(C.dbd.O)OR.sup.2221,
--P(O)OR.sup.2221OR.sup.3331, or --S(C.dbd.O)NR.sup.2221R.sup.3331
substituents; or G.sup.11 is taken together with the carbon to
which it is attached to form a double bond which is substituted
with R.sup.5 and G.sup.111; [0604] R.sup.2, R.sup.2a, R.sup.3,
R.sup.3a, R.sup.222, R.sup.222a, R.sup.333, R.sup.333a, R.sup.21,
R.sup.2a1, R.sup.31, R.sup.3a1, R.sup.2221, R.sup.222a1,
R.sup.3331, and R.sup.333a1 are each independently equal to
C.sub.0-10alkyl, C.sub.2-10alkenyl, C.sub.2-10alkynyl,
C.sub.1-10alkoxyC.sub.1-10alkyl, C.sub.1-10alkoxyC.sub.2-10alkenyl,
C.sub.1-10alkoxyC.sub.2-10alkynyl,
C.sub.1-10alkylthioC.sub.2-10alkenyl,
C.sub.1-10alkylthioC.sub.2-10alkynyl, cycloC.sub.3-8alkyl,
cycloC.sub.3-8alkenyl, cycloC.sub.3-8alkylC.sub.1-10alkyl,
cycloC.sub.3-8alkenylC.sub.1-10alkyl,
cycloC.sub.3-8alkylC.sub.2-10alkenyl,
cycloC.sub.3-8alkenylC.sub.2-10alkenyl,
cycloC.sub.3-8alkylC.sub.2-10alkynyl,
cycloC.sub.3-8alkenylC.sub.2-10alkynyl,
heterocyclyl-C.sub.0-10alkyl, heterocyclyl-C.sub.2-10alkenyl, or
heterocyclyl-C.sub.2-10alkynyl, any of which is optionally
substituted by one or more G.sup.111 substituents; or
aryl-C.sub.0-10alkyl, aryl-C.sub.2-10alkenyl, or
aryl-C.sub.2-10alkynyl, hetaryl-C.sub.0-10alkyl,
hetaryl-C.sub.2-10alkenyl, or hetaryl-C.sub.2-10alkynyl, any of
which is optionally substituted by one or more G.sup.111
substituents; or in the case of --NR.sup.2R.sup.3(R.sup.3a).sub.j1
or --NR.sup.222R.sup.333(R.sup.333a).sub.j1a or
--NR.sup.222R.sup.333(R.sup.333a).sub.j2a or
--NR.sup.2221R.sup.3331 (R.sup.333a1).sub.j3a or
--NR.sup.2221R.sup.3331(R.sup.333a1).sub.j4a or
--NR.sup.2221R.sup.3331(R.sup.333a1).sub.j5a or
--NR.sup.2221R.sup.3331(R.sup.333a1).sub.j6a, R.sup.2 and R.sup.3
or R.sup.222 and R.sup.3333 or R.sup.2221 and R.sup.3331 taken
together with the nitrogen atom to which they are attached form a
3-10 membered saturated ring, unsaturated ring, heterocyclic
saturated ring, or heterocyclic unsaturated ring, wherein said ring
is optionally substituted by one or more G.sup.111 substituents;
[0605] X.sup.1 and Y.sup.1 are each independently --O--,
--NR.sup.7--, --S(O).sub.j7--, --CR.sup.5R.sup.6--,
--N(C(O)OR.sup.7)--, --N(C(O)R.sup.7)--, --N(SO.sub.2R.sup.7)--,
--CH.sub.2O--, --CH.sub.2S--, --CH.sub.2N(R.sup.7)--,
--CH(NR.sup.7)--, --CH.sub.2N(C(O)R.sup.7)--,
--CH.sub.2N(C(O)OR.sup.7)--, --CH.sub.2N(SO.sub.2R.sup.7)--,
--CH(NHR.sup.7)--, --CH(NHC(O)R.sup.7)--,
--CH(NHSO.sub.2R.sup.7)--, --CH(NHC(O)OR.sup.7)--,
--CH(OC(O)R.sup.7)--, --CH(OC(O)NHR.sup.7)--, --CH.dbd.CH--,
--C.ident.C--, --C(.dbd.NOR.sup.7)--, --C(O)--, --CH(OR.sup.7)--,
--C(O)N(R.sup.7)--, --N(R.sup.7)C(O)--, --N(R.sup.7)S(O)--,
--N(R.sup.7)S(O).sub.2-- --OC(O)N(R.sup.7)--,
--N(R.sup.7)C(O)N(R.sup.7)--, --NR.sup.7C(O)O--,
--S(O)N(R.sup.7)--, --S(O).sub.2N(R.sup.7)--,
--N(C(O)R.sup.7)S(O)--, --N(C(O)R.sup.7)S(O).sub.2--,
--N(R.sup.7)S(O)N(R.sup.7)--, --N(R.sup.7)S(O).sub.2N(R.sup.7)--,
--C(O)N(R.sup.7)C(O)--, --S(O)N(R.sup.7)C(O)--,
--S(O).sub.2N(R.sup.7)C(O)--, --OS(O)N(R.sup.7)--,
--OS(O).sub.2N(R.sup.7)--, --N(R.sup.7)S(O)O--,
--N(R.sup.7)S(O).sub.2O--, --N(R.sup.7)S(O)C(O)--,
--N(R.sup.7)S(O).sub.2C(O)--, --SON(C(O)R.sup.7)--,
--SO.sub.2N(C(O)R.sup.7)--, --N(R.sup.7)SON(R.sup.7)--,
--N(R.sup.7)SO.sub.2N(R.sup.7)--, --C(O)O--,
--N(R.sup.7)P(OR.sup.8)O--, --N(R.sup.7)P(OR.sup.8)--,
--N(R.sup.7)P(O)(OR.sup.8)O--, --N(R.sup.7)P(O)(OR.sup.8)--,
--N(C(O)R.sup.7)P(OR.sup.8)O--, --N(C(O)R.sup.7)P(OR.sup.8)--,
--N(C(O)R.sup.7)P(O)(OR.sup.8)O--, --N(C(O)R.sup.7)P(OR.sup.8)--,
--CH(R.sup.7)S(O)--, --CH(R.sup.7)S(O).sub.2--,
--CH(R.sup.7)N(C(O)OR.sup.7)--, --CH(R.sup.7)N(C(O)R.sup.7)--,
--CH(R.sup.7)N(SO.sub.2R.sup.7)--, --CH(R.sup.7)O--,
--CH(R.sup.7)S--, --CH(R.sup.7)N(R.sup.7)--,
--CH(R.sup.7)N(C(O)R.sup.7)--, --CH(R.sup.7)N(C(O)OR.sup.7)--,
--CH(R.sup.7)N(SO.sub.2R.sup.7)--,
--CH(R.sup.7)C(.dbd.NOR.sup.7)--, --CH(R.sup.7)C(O)--,
--CH(R.sup.7)CH(OR.sup.7)--, --CH(R.sup.7)C(O)N(R.sup.7)--,
--CH(R.sup.7)N(R.sup.7)C(O)--, --CH(R.sup.7)N(R.sup.7)S(O)--,
--CH(R.sup.7)N(R.sup.7)S(O).sub.2--,
--CH(R.sup.7)OC(O)N(R.sup.7)--,
--CH(R.sup.7)N(R.sup.7)C(O)N(R.sup.7)--,
--CH(R.sup.7)NR.sup.7C(O)O--, --CH(R.sup.7)S(O)N(R.sup.7)--,
--CH(R.sup.7)S(O).sub.2N(R.sup.7)--,
--CH(R.sup.7)N(C(O)R.sup.7)S(O)--,
--CH(R.sup.7)N(C(O)R.sup.7)S(O)--,
--CH(R.sup.7)N(R.sup.7)S(O)N(R.sup.7)--,
--CH(R.sup.7)N(R.sup.7)S(O).sub.2N(R.sup.7)--,
--CH(R.sup.7)C(O)N(R.sup.7)C(O)--,
--CH(R.sup.7)S(O)N(R.sup.7)C(O)--,
--CH(R.sup.7)S(O).sub.2N(R.sup.7)C(O)--,
--CH(R.sup.7)OS(O)N(R.sup.7)--,
--CH(R.sup.7)OS(O).sub.2N(R.sup.7)--,
--CH(R.sup.7)N(R.sup.7)S(O)O--,
--CH(R.sup.7)N(R.sup.7)S(O).sub.2O--,
--CH(R.sup.7)N(R.sup.7)S(O)C(O)--,
--CH(R.sup.7)N(R.sup.7)S(O).sub.2C(O)--,
--CH(R.sup.7)SON(C(O)R.sup.7)--,
--CH(R.sup.7)SO.sub.2N(C(O)R.sup.7)--,
--CH(R.sup.7)N(R.sup.7)SON(R.sup.7)--,
--CH(R.sup.7)N(R.sup.7)SO.sub.2N(R.sup.7)--, --CH(R.sup.7)C(O)O--,
--CH(R.sup.7)N(R.sup.7)P(OR.sup.8)O--,
--CH(R.sup.7)N(R.sup.7)P(OR.sup.8)--,
--CH(R.sup.7)N(R.sup.7)P(O)(OR.sup.8)O--,
--CH(R.sup.7)N(R.sup.7)P(O)(OR.sup.8)--,
--CH(R.sup.7)N(C(O)R.sup.7)P(OR.sup.8)O--,
--CH(R.sup.7)N(C(O)R.sup.7)P(OR.sup.8)--,
--CH(R.sup.7)N(C(O)R.sup.7)P(O)(OR.sup.8)O--, or
--CH(R.sup.7)N(C(O)R.sup.7)P(OR.sup.8)--; [0606] or X.sup.1 and
Y.sup.1 are each independently represented by one of the following
structural formulas:
[0606] ##STR00033## [0607] R.sup.10, taken together with the
phosphinamide or phosphonamide, is a 5-, 6-, or 7-membered aryl,
heteroaryl or heterocyclyl ring system; [0608] R.sup.5, R.sup.6,
and G.sup.111 are each independently a C.sub.0-10alkyl,
C.sub.2-10alkenyl, C.sub.2-10alkynyl,
C.sub.1-10alkoxyC.sub.1-10alkyl, C.sub.1-10alkoxyC.sub.2-10alkenyl,
C.sub.1-10alkoxyC.sub.2-10alkynyl,
C.sub.1-10alkylthioC.sub.1-10alkyl,
C.sub.1-10alkylthioC.sub.2-10alkenyl,
C.sub.1-10alkylthioC.sub.2-10alkynyl, cycloC.sub.3-8alkyl,
cycloC.sub.3-8alkenyl, cycloC.sub.3-8alkylC.sub.1-10alkyl,
cycloC.sub.3-8alkenylC.sub.1-10alkyl,
cycloC.sub.3-8alkylC.sub.2-10alkenyl,
cycloC.sub.3-8alkenylC.sub.2-10alkenyl,
cycloC.sub.3-8alkylC.sub.2-10alkynyl,
cycloC.sub.3-8alkenylC.sub.2-10alkynyl,
heterocyclyl-C.sub.0-10alkyl, heterocyclyl-C.sub.2-10alkenyl, or
heterocyclyl-C.sub.2-10alkynyl, any of which is optionally
substituted with one or more independent halo, --CF.sub.3,
--OCF.sub.3, --OR.sup.77, --NR.sup.77R.sup.87, --C(O)R.sup.77,
--CO.sub.2R.sup.77, --CONR.sup.77R.sup.87, --NO.sub.2, --CN,
--S(O).sub.j5aR.sup.77, --SO.sub.2NR.sup.77R.sup.87,
NR.sup.77(C.dbd.O)R.sup.87, NR.sup.77(C.dbd.O)OR.sup.87,
NR.sup.77(C.dbd.O)NR.sup.78R.sup.87, NR.sup.77S(O).sub.j5aR.sup.87,
--(C.dbd.S)OR.sup.77, --(C.dbd.O)SR.sup.77,
--NR.sup.77(C.dbd.NR.sup.87)NR.sup.78R.sup.88,
--NR.sup.77(C.dbd.NR.sup.87)OR.sup.78,
--NR.sup.77(C.dbd.NR.sup.87)SR.sup.78, --O(C.dbd.O)OR.sup.77,
--O(C.dbd.O)NR.sup.77R.sup.87, --O(C.dbd.O)SR.sup.77,
--S(C.dbd.O)OR.sup.77, --P(O)OR.sup.77OR.sup.87, or
--S(C.dbd.O)NR.sup.77R.sup.87 substituents; or
aryl-C.sub.0-10alkyl, aryl-C.sub.2-10alkenyl, or
aryl-C.sub.2-10alkynyl, any of which is optionally substituted with
one or more independent halo, --CF.sub.3, --OCF.sub.3, --OR.sup.77,
--NR.sup.77R.sup.87, --C(O)R.sup.77, --CO.sub.2R.sup.77,
--CONR.sup.77R.sup.87, --NO.sub.2, --CN, --S(O).sub.j5aR.sup.77,
--SO.sub.2NR.sup.77R.sup.87, NR.sup.77(C.dbd.O)R.sup.87,
NR.sup.77(C.dbd.O)OR.sup.87, NR.sup.77(C.dbd.O)NR.sup.78R.sup.87,
NR.sup.77S(O).sub.j5aR.sup.87, --(C.dbd.S)OR.sup.77,
--(C.dbd.O)SR.sup.77,
--NR.sup.77(C.dbd.NR.sup.87)NR.sup.78R.sup.88,
--NR.sup.77(C.dbd.NR.sup.87)OR.sup.78,
--NR.sup.77(C.dbd.NR.sup.87)SR.sup.78, --O(C.dbd.O)OR.sup.77,
--O(C.dbd.O)NR.sup.77R.sup.87, --O(C.dbd.O)SR.sup.77,
--S(C.dbd.O)OR.sup.77, --P(O)OR.sup.77R.sup.87, or
--S(C.dbd.O)NR.sup.77R.sup.87 substituents; or
hetaryl-C.sub.0-10alkyl, hetaryl-C.sub.2-10alkenyl, or
hetaryl-C.sub.2-10alkynyl, any of which is optionally substituted
with one or more independent halo, --CF.sub.3, --OCF.sub.3,
--OR.sup.77, --NR.sup.77R.sup.87, --C(O)R.sup.77,
--CO.sub.2R.sup.77, --CONR.sup.77R.sup.87, --NO.sub.2, --CN,
--S(O).sub.j5aR.sup.77, --SO.sub.2NR.sup.77R.sup.87,
NR.sup.77(C.dbd.O)R.sup.87, NR.sup.77(C.dbd.O)OR.sup.87,
NR.sup.77(C.dbd.O)NR.sup.78R.sup.87, NR.sup.77S(O).sub.j5aR.sup.87,
--(C.dbd.S)OR.sup.77, --(C.dbd.O)SR.sup.77,
--NR.sup.77(C.dbd.NR.sup.87)NR.sup.78R.sup.88,
--NR.sup.77(C.dbd.NR.sup.87)OR.sup.78,
--NR.sup.77(C.dbd.NR.sup.87)SR.sup.78, --O(C.dbd.O)OR.sup.77,
--O(C.dbd.O)NR.sup.77R.sup.87, --O(C.dbd.O)SR.sup.77,
--S(C.dbd.O)OR.sup.77, --P(O)OR.sup.77OR.sup.87, or
--S(C.dbd.O)NR.sup.77R.sup.87 substituents; or R.sup.5 with R.sup.6
taken together with the respective carbon atom to which they are
attached, form a 3-10 membered saturated or unsaturated ring,
wherein said ring is optionally substituted with R.sup.69; or
R.sup.5 with R.sup.6 taken together with the respective carbon atom
to which they are attached, form a 3-10 membered saturated or
unsaturated heterocyclic ring, wherein said ring is optionally
substituted with R.sup.69; [0609] R.sup.7 and R.sup.8 are each
independently H, acyl, alkyl, alkenyl, aryl, heteroaryl,
heterocyclyl or cycloalkyl, any of which is optionally substituted
by one or more substituents; [0610] R.sup.4 is H, alkyl, alkenyl,
alkynyl, aryl, heteroaryl, cycloalkyl, heterocyclyl, cycloalkenyl,
or heterocycloalkenyl, any of which is optionally substituted by
one or more G.sup.41 substituents; [0611] R.sup.69 is equal to
halo, --OR.sup.a, --SH, --NR.sup.78R.sup.88, --CO.sub.2R.sup.78,
--CONR.sup.78R.sup.88, --NO.sub.2, --CN, --S(O).sub.j8R.sup.78,
--SO.sub.2NR.sup.78R.sup.88, C.sub.2-10alkenyl, C.sub.2-10alkynyl,
C.sub.1-10alkoxyC.sub.1-10alkyl, C.sub.1-10alkoxyC.sub.2-10alkenyl,
C.sub.1-10alkoxyC.sub.2-10alkynyl,
C.sub.1-10alkylthioC.sub.2-10alkenyl,
C.sub.1-10alkylthioC.sub.2-10alkynyl, cycloC.sub.3-8alkyl,
cycloC.sub.3-8alkenyl, cycloC.sub.3-8alkylC.sub.rioalkyl,
cycloC.sub.3-8alkenylC.sub.1-10alkyl,
cycloC.sub.3-8alkylC.sub.2-10alkenyl,
cycloC.sub.3-8alkenylC.sub.2-10alkenyl,
cycloC.sub.3-8alkylC.sub.2-10alkynyl,
cycloC.sub.3-8alkenylC.sub.2-10alkynyl,
heterocyclyl-C.sub.0-10alkyl, heterocyclyl-C.sub.2-10alkenyl, or
heterocyclyl-C.sub.2-10alkynyl, any of which is optionally
substituted with one or more independent halo, cyano, nitro,
--OR.sup.778, --SO.sub.2NR.sup.778R.sup.888, or
--NR.sup.778R.sup.888 substituents; or aryl-C.sub.0-10alkyl,
aryl-C.sub.2-10alkenyl, or aryl-C.sub.2-10alkynyl, any of which is
optionally substituted with one or more independent halo, cyano,
nitro, --OR.sup.778, C.sub.1-10alkyl, C.sub.2-10alkenyl,
C.sub.2-10alkynyl, haloC.sub.1-10alkyl, haloC.sub.2-10alkenyl,
haloC.sub.2-10alkynyl, --COOH, C.sub.1-4alkoxycarbonyl,
--CONR.sup.778R.sup.888, --SO.sub.2NR.sup.778R.sup.888, or
--NR.sup.778R.sup.888 substituents; or hetaryl-C.sub.0-10alkyl,
hetaryl-C.sub.2-10alkenyl, or hetaryl-C.sub.2-10alkynyl, any of
which is optionally substituted with one or more independent halo,
cyano, nitro, --OR.sup.778, C.sub.1-10alkyl, C.sub.2-10alkenyl,
C.sub.2-10alkynyl, haloC.sub.1-10alkyl, haloC.sub.2-10alkenyl,
haloC.sub.2-10alkynyl, --COOH, C.sub.1-4alkoxycarbonyl,
--CONR.sup.778R.sup.888, --SO.sub.2NR.sup.778R.sup.888, or
--NR.sup.778R.sup.888 substituents; or
mono(C.sub.1-6alkyl)aminoC.sub.1-6alkyl,
di(C.sub.1-6alkyl)aminoC.sub.1-6alkyl,
mono(aryl)aminoC.sub.1-6alkyl, di(aryl)aminoC.sub.1-6alkyl, or
--N(C.sub.1-6alkyl)-C.sub.1-6alkyl-aryl, any of which is optionally
substituted with one or more independent halo, cyano, nitro,
--OR.sup.778, C.sub.2-10alkenyl, C.sub.2-10alkynyl,
haloC.sub.1-10alkyl, haloC.sub.2-10alkenyl, haloC.sub.2-10alkynyl,
--COOH, C.sub.1-4alkoxycarbonyl, --CONR.sup.778R.sup.888
SO.sub.2NR.sup.778R.sup.888, or --NR.sup.778R.sup.888 substituents;
or in the case of --NR.sup.78R.sup.88, R.sup.78 and R.sup.88 taken
together with the nitrogen atom to which they are attached form a
3-10 membered saturated ring, unsaturated ring, heterocyclic
saturated ring, or heterocyclic unsaturated ring, wherein said ring
is optionally substituted with one or more independent halo, cyano,
hydroxy, nitro, C.sub.1-10alkoxy, --SO.sub.2NR.sup.778R.sup.888, or
--NR.sup.778R.sup.888 substituents; [0612] R.sup.77, R.sup.78,
R.sup.87, R.sup.88, R.sup.778, and R.sup.888 are each independently
C.sub.0-10alkyl, C.sub.2-10alkenyl, C.sub.2-10alkynyl,
C.sub.1-10alkoxyC.sub.1-10alkyl, C.sub.1-10alkoxyC.sub.2-10alkenyl,
C.sub.1-10alkoxyC.sub.2-10alkynyl,
C.sub.1-10alkylthioC.sub.1-10alkyl,
C.sub.1-10alkylthioC.sub.2-10alkenyl,
C.sub.1-10alkylthioC.sub.2-10alkynyl, cycloC.sub.3-8alkyl,
cycloC.sub.3-8alkenyl, cycloC.sub.3-8alkylC.sub.1-10alkyl,
cycloC.sub.3-8alkenylC.sub.1-10alkyl,
cycloC.sub.3-8alkylC.sub.2-10alkenyl,
cycloC.sub.3-8alkenylC.sub.2-10alkenyl,
cycloC.sub.3-8alkylC.sub.2-10alkynyl,
cycloC.sub.3-8alkenylC.sub.2-10alkynyl,
heterocyclyl-C.sub.0-10alkyl, heterocyclyl-C.sub.2-10alkenyl,
heterocyclyl-C.sub.2-10alkynyl, C.sub.1-10alkylcarbonyl,
C.sub.2-10alkenylcarbonyl, C.sub.2-10alkynylcarbonyl,
C.sub.1-10alkoxycarbonyl, C.sub.1-10alkoxycarbonylC.sub.1-10alkyl,
monoC.sub.1-6alkylaminocarbonyl, diC.sub.1-6alkylaminocarbonyl,
mono(aryl)aminocarbonyl, di(aryl)aminocarbonyl, or
C.sub.1-10alkyl(aryl)aminocarbonyl, any of which is optionally
substituted with one or more independent halo, cyano, hydroxy,
nitro, C.sub.1-10alkoxy,
--SO.sub.2N(C.sub.0-4alkyl)(C.sub.0-4alkyl), or
--N(C.sub.0-4alkyl)(C.sub.0-4alkyl) substituents; or
aryl-C.sub.0-10alkyl, aryl-C.sub.2-10alkenyl, or
aryl-C.sub.2-10alkynyl, any of which is optionally substituted with
one or more independent halo, cyano, nitro, --O(C.sub.0-4alkyl),
C.sub.2-10alkenyl, C.sub.2-10alkynyl haloC.sub.2-10alkenyl,
haloC.sub.2-10alkynyl, --COOH, C.sub.1-4alkoxycarbonyl,
--CON(C.sub.0-4alkyl)(C.sub.0-10alkyl),
--SO.sub.2N(C.sub.0-4alkyl)(C.sub.0-4alkyl), or
--N(C.sub.0-4alkyl)(C.sub.0-4alkyl) substituents; or
hetaryl-C.sub.0-10alkyl, hetaryl-C.sub.2-10alkenyl, or
hetaryl-C.sub.2-10alkynyl, any of which is optionally substituted
with one or more independent halo, cyano, nitro,
--O(C.sub.0-4alkyl), C.sub.2-10alkenyl, C.sub.2-10alkynyl,
haloC.sub.2-10alkenyl, haloC.sub.2-10alkynyl, --COOH,
C.sub.1-4alkoxycarbonyl, --CON(C.sub.0-4alkyl)(C.sub.0-4alkyl),
--SO.sub.2N(C.sub.0-4alkyl)(C.sub.0-4alkyl), or
--N(C.sub.0-4alkyl)(C.sub.0-4alkyl) substituents; or
mono(C.sub.1-6alkyl)aminoC.sub.1-6alkyl,
di(C.sub.1-6alkyl)aminoC.sub.1-6alkyl,
mono(aryl)aminoC.sub.1-6alkyl, di(aryl)aminoC.sub.1-6alkyl, or
--N(C.sub.1-6alkyl)-C.sub.1-6alkyl-aryl, any of which is optionally
substituted with one or more independent halo, cyano, nitro,
--O(C.sub.0-4alkyl), C.sub.1-10alkyl, C.sub.2-10alkenyl,
C.sub.2-10alkynyl, haloC.sub.2-10alkenyl, haloC.sub.2-10alkynyl,
--COOH, C.sub.1-4alkoxycarbonyl,
--CON(C.sub.0-4alkyl)(C.sub.0-4alkyl),
--SO.sub.2N(C.sub.0-4alkyl)(C.sub.0-4alkyl), or
--N(C.sub.0-4alkyl)(C.sub.0-4alkyl) substituents; and [0613] n, m,
j1, j1a, j2a, j3a, j4, j4a, j5a, j6a, j7, and j8 are each
independently equal to 0, 1, or 2.
[0614] In an exemplary embodiment, the BTK inhibitor is a compound
selected from the structures disclosed in U.S. Pat. Nos. 8,450,335
and 8,609,679, and U.S. Patent Application Publication Nos.
2010/0029610 A1, 2012/0077832 A1, 2013/0065879 A1, 2013/0072469 A1,
and 2013/0165462 A1. In an exemplary embodiment, the BTK inhibitor
is a compound of Formula (XXV) or Formula (XXVI):
##STR00034##
or a pharmaceutically acceptable salt thereof, wherein: [0615] Ring
A is an optionally substituted group selected from phenyl, a 3-7
membered saturated or partially unsaturated carbocyclic ring, an
8-10 membered bicyclic saturated, partially unsaturated or aryl
ring, a 5-6 membered monocyclic heteroaryl ring having 1-4
heteroatoms independently selected from nitrogen, oxygen, or
sulfur, a 4-7 membered saturated or partially unsaturated
heterocyclic ring having 1-3 heteroatoms independently selected
from nitrogen, oxygen, or sulfur, a 7-10 membered bicyclic
saturated or partially unsaturated heterocyclic ring having 1-5
heteroatoms independently selected from nitrogen, oxygen, or
sulfur, or an 8-10 membered bicyclic heteroaryl ring having 1-5
heteroatoms independently selected from nitrogen, oxygen, or
sulfur; [0616] Ring B is an optionally substituted group selected
from phenyl, a 3-7 membered saturated or partially unsaturated
carbocyclic ring, an 8-10 membered bicyclic saturated, partially
unsaturated or aryl ring, a 5-6 membered monocyclic heteroaryl ring
having 1-4 heteroatoms independently selected from nitrogen,
oxygen, or sulfur, a 4-7 membered saturated or partially
unsaturated heterocyclic ring having 1-3 heteroatoms independently
selected from nitrogen, oxygen, or sulfur, a 7-10 membered bicyclic
saturated or partially unsaturated heterocyclic ring having 1-5
heteroatoms independently selected from nitrogen, oxygen, or
sulfur, or an 8-10 membered bicyclic heteroaryl ring having 1-5
heteroatoms independently selected from nitrogen, oxygen, or
sulfur; [0617] R.sup.1 is a warhead group; [0618] R.sup.y is
hydrogen, halogen, --CN, --CF.sub.3, C.sub.1-4 aliphatic,
C.sub.1-4haloaliphatic, --OR, --C(O)R, or --C(O)N(R).sub.2, [0619]
each R group is independently hydrogen or an optionally substituted
group selected from C.sub.1-6 aliphatic, phenyl, a 4-7 membered
heterocyclic ring having 1-2 heteroatoms independently selected
from nitrogen, oxygen, or sulfur, or a 5-6 membered monocyclic
heteroaryl ring having 1-4 heteroatoms independently selected from
nitrogen, oxygen, or sulfur; [0620] W.sup.1 and W.sup.2 are each
independently a covalent bond or a bivalent C.sub.1-3 alkylene
chain wherein one methylene unit of W.sup.1 or W.sup.2 is
optionally replaced by --NR.sup.2--, --N(R.sup.2)C(O)--,
--C(O)N(R.sup.2)--, --N(R.sup.2)SO.sub.2--, --SO.sub.2N(R.sup.2)--,
--O--, --C(O)--, --OC(O)--, --C(O)O--, --S--, --SO-- or
--SO.sub.2--, [0621] R.sup.2 is hydrogen, optionally substituted
C.sub.1-6 aliphatic, or --C(O)R, or: [0622] R.sup.2 and a
substituent on Ring A are taken together with their intervening
atoms to form a 4-6 membered saturated, partially unsaturated, or
aromatic fused ring, or: [0623] R.sup.2 and R.sup.y are taken
together with their intervening atoms to form a 4-7 membered
partially unsaturated or aromatic fused ring; [0624] m and p are
independently 0-4; and [0625] R.sup.x and R.sup.v are independently
selected from --R, halogen, --OR, --O(CH.sub.2).sub.qOR, --CN,
--NO.sub.2, --SO.sub.2R, --SO.sub.2N(R).sub.2, --SOR, --C(O)R,
--CO.sub.2R, --C(O)N(R).sub.2, --NRC(O)R, --NRC(O)NR.sub.2,
--NRSO.sub.2R, or --N(R).sub.2, wherein q is 1-4; or: [0626]
R.sup.x and R.sup.1 when concurrently present on Ring B are taken
together with their intervening atoms to form a 5-7 membered
saturated, partially unsaturated, or aryl ring having 0-3
heteroatoms independently selected from nitrogen, oxygen, or
sulfur, wherein said ring is substituted with a warhead group and
0-3 groups independently selected from oxo, halogen, --CN, or
C.sub.1-6 aliphatic; or [0627] R.sup.v and R.sup.1 when
concurrently present on Ring A are taken together with their
intervening atoms to form a 5-7 membered saturated, partially
unsaturated, or aryl ring having 0-3 heteroatoms independently
selected from nitrogen, oxygen, or sulfur, wherein said ring is
substituted with a warhead group and 0-3 groups independently
selected from oxo, halogen, --CN, or C.sub.1-6 aliphatic.
[0628] In an exemplary embodiment, the BTK inhibitor is a compound
of Formula (XXV) or Formula (XXVI), wherein:
Ring A is an optionally substituted group selected from phenyl, a
3-7 membered saturated or partially unsaturated carbocyclic ring,
an 8-10 membered bicyclic saturated, partially unsaturated or aryl
ring, a 5-6 membered monocyclic heteroaryl ring having 1-4
heteroatoms independently selected from nitrogen, oxygen, or
sulfur, a 4-7 membered saturated or partially unsaturated
heterocyclic ring having 1-3 heteroatoms independently selected
from nitrogen, oxygen, or sulfur, a 7-10 membered bicyclic
saturated or partially unsaturated heterocyclic ring having 1-5
heteroatoms independently selected from nitrogen, oxygen, or
sulfur, or an 8-10 membered bicyclic heteroaryl ring having 1-5
heteroatoms independently selected from nitrogen, oxygen, or
sulfur; Ring B is an optionally substituted group selected from
phenyl, a 3-7 membered saturated or partially unsaturated
carbocyclic ring, an 8-10 membered bicyclic saturated, partially
unsaturated or aryl ring, a 5-6 membered monocyclic heteroaryl ring
having 1-4 heteroatoms independently selected from nitrogen,
oxygen, or sulfur, a 4-7 membered saturated or partially
unsaturated heterocyclic ring having 1-3 heteroatoms independently
selected from nitrogen, oxygen, or sulfur, a 7-10 membered bicyclic
saturated or partially unsaturated heterocyclic ring having 1-5
heteroatoms independently selected from nitrogen, oxygen, or
sulfur, or an 8-10 membered bicyclic heteroaryl ring having 1-5
heteroatoms independently selected from nitrogen, oxygen, or
sulfur; R.sup.1 is -L-Y, wherein: L is a covalent bond or a
bivalent C.sub.1-8 saturated or unsaturated, straight or branched,
hydrocarbon chain, wherein one, two, or three methylene units of L
are optionally and independently replaced by cyclopropylene,
--NR--, --N(R)C(O)--, --C(O)N(R)--, --N(R)SO.sub.2--,
--SO.sub.2N(R)--, --O--, --C(O)--, --OC(O)--, --C(O)O--, --S--,
--SO--, --SO.sub.2--, --C(.dbd.S)--, --C(.dbd.NR)--, --N.dbd.N--,
or --C(.dbd.N.sub.2)--; Y is hydrogen, C.sub.1-6 aliphatic
optionally substituted with oxo, halogen, or CN, or a 3-10 membered
monocyclic or bicyclic, saturated, partially unsaturated, or aryl
ring having 0-3 heteroatoms independently selected from nitrogen,
oxygen, or sulfur, and wherein said ring is substituted with at 1-4
groups independently selected from -Q-Z, oxo, NO.sub.2, halogen,
CN, or C.sub.1-6 aliphatic, wherein: Q is a covalent bond or a
bivalent C.sub.1-6 saturated or unsaturated, straight or branched,
hydrocarbon chain, wherein one or two methylene units of Q are
optionally and independently replaced by --NR--, --S--, --O--,
--C(O)--, --SO--, or --SO.sub.2--; and Z is hydrogen or C.sub.1-6
aliphatic optionally substituted with oxo, halogen, or CN; R.sup.y
is hydrogen, halogen, --CN, --CF.sub.3, C.sub.1-4 aliphatic,
C.sub.1-4 haloaliphatic, --OR, --C(O)R, or --C(O)N(R).sub.2; each R
group is independently hydrogen or an optionally substituted group
selected from C.sub.1-6 aliphatic, phenyl, a 4-7 membered
heterocyclic ring having 1-2 heteroatoms independently selected
from nitrogen, oxygen, or sulfur, or a 5-6 membered monocyclic
heteroaryl ring having 1-4 heteroatoms independently selected from
nitrogen, oxygen, or sulfur; W.sup.1 and W.sup.2 are each
independently a covalent bond or a bivalent C.sub.1-3 alkylene
chain wherein one methylene unit of W.sup.1 or W.sup.2 is
optionally replaced by --NR.sup.2--, --N(R.sup.2)C(O)--,
--C(O)N(R.sup.2)--, --N(R.sup.2)SO.sub.2--, --SO.sub.2N(R.sup.2)--,
--O--, --C(O)--, --OC(O)--, --C(O)O--, --S--, --SO-- or
--SO.sub.2--; R.sup.2 is hydrogen, optionally substituted C.sub.1-6
aliphatic, or --C(O)R, or: R.sup.2 and a substituent on Ring A are
taken together with their intervening atoms to form a 4-6 membered
partially unsaturated or aromatic fused ring; or R.sup.2 and
R.sup.y are taken together with their intervening atoms to form a
4-6 membered saturated, partially unsaturated, or aromatic fused
ring; m and p are independently 0-4; and R.sup.x and R.sup.v are
independently selected from --R, halogen, --OR,
--O(CH.sub.2).sub.qOR, --CN, --NO.sub.2, --SO.sub.2R,
--SO.sub.2N(R).sub.2, --SOR, --C(O)R, --CO.sub.2R,
--C(O)N(R).sub.2, --NRC(O)R, --NRC(O)NR.sub.2, --NRSO.sub.2R, or
--N(R).sub.2, or: R.sup.x and R.sup.1 when concurrently present on
Ring B are taken together with their intervening atoms to form a
5-7 membered saturated, partially unsaturated, or aryl ring having
0-3 heteroatoms independently selected from nitrogen, oxygen, or
sulfur, wherein said ring is substituted with a warhead group and
0-3 groups independently selected from oxo, halogen, --CN, or
C.sub.1-6 aliphatic; or R.sup.v and R.sup.1 when concurrently
present on Ring A are taken together with their intervening atoms
to form a 5-7 membered saturated, partially unsaturated, or aryl
ring having 0-3 heteroatoms independently selected from nitrogen,
oxygen, or sulfur, wherein said ring is substituted with a warhead
group and 0-3 groups independently selected from oxo, halogen,
--CN, or C.sub.1-6 aliphatic. As defined generally above, Ring A is
an optionally substituted group selected from phenyl, a 3-7
membered saturated or partially unsaturated carbocyclic ring, an
8-10 membered bicyclic saturated, partially unsaturated or aryl
ring, a 5-6 membered monocyclic heteroaryl ring having 1-4
heteroatoms independently selected from nitrogen, oxygen, or
sulfur, a 4-7 membered saturated or partially unsaturated
heterocyclic ring having 1-3 heteroatoms independently selected
from nitrogen, oxygen, or sulfur, a 7-10 membered bicyclic
saturated or partially unsaturated heterocyclic ring having 1-5
heteroatoms independently selected from nitrogen, oxygen, or
sulfur, or an 8-10 membered bicyclic heteroaryl ring having 1-5
heteroatoms independently selected from nitrogen, oxygen, or
sulfur. In certain embodiments, Ring A is an optionally substituted
phenyl group. In some embodiments, Ring A is an optionally
substituted naphthyl ring or an optionally substituted bicyclic
8-10 membered heteroaryl ring having 1-4 heteroatoms independently
selected from nitrogen, oxygen, or sulfur. In certain other
embodiments, Ring A is an optionally substituted 3-7 membered
carbocyclic ring. In yet other embodiments, Ring A is an optionally
substituted 4-7 membered heterocyclic ring having 1-3 heteroatoms
independently selected from nitrogen, oxygen, or sulfur. In certain
embodiments, Ring A is substituted as defined herein. In some
embodiments, Ring A is substituted with one, two, or three groups
independently selected from halogen, R.sup.o, or
--(CH.sub.2).sub.0-4OR.sup.o, or --O(CH.sub.2).sub.0-4R.sup.o,
wherein each R.sup.o is an alkyl or aryl group. Exemplary
substituents on Ring A include Br, I, Cl, methyl, --CF.sub.3,
--C.ident.CH, --OCH.sub.2phenyl, --OCH.sub.2(fluorophenyl), or
--OCH.sub.2pyridyl.
[0629] In an exemplary embodiment, the BTK inhibitor is CC-292. In
an exemplary embodiment, the BTK inhibitor is a compound of Formula
(XXVII):
##STR00035##
which is
N-(3-((5-fluoro-2-((4-(2-methoxyethoxy)phenyl)amino)pyrimidin-4--
yl)amino)phenyl)acrylamide, or a pharmaceutically acceptable salt
thereof, in an exemplary embodiment a hydrochloride salt or
besylate salt thereof. The preparation of this compound is
described in U.S. Patent Application Publication No. 2010/0029610
A1 at Example 20. The preparation of the hydrochloride salt or
besylate salt of this compound is described in U.S. Patent
Application Publication No. 2012/0077832 A1.
[0630] In an exemplary embodiment, the BTK inhibitor is
N-(3-((5-fluoro-2-((4-(2-methoxyethoxy)phenyl)amino)pyrimidin-4-yl)amino)-
phenyl)acrylamide or a pharmaceutically acceptable salt thereof, or
a hydrochloride salt thereof. The preparation of this compound is
described in U.S. Patent Application Publication No. 2012/0077832
A1.
[0631] In an exemplary embodiment, the BTK inhibitor is
(N-(3-(5-fluoro-2-(4-(2-methoxyethoxy)phenylamino)pyrimidin-4-ylamino)phe-
nyl)acrylamide), or a pharmaceutically acceptable salt thereof, or
a besylate salt thereof. The preparation of this compound is
described in U.S. Patent Application Publication No. 2010/0029610
A1 at Example 20. The preparation of its besylate salt is described
in U.S. Patent Application Publication No. 2012/0077832 A1.
[0632] In an exemplary embodiment, the BTK inhibitor is a compound
of Formula (XXVIII):
##STR00036##
or a pharmaceutically acceptable salt thereof. In an exemplary
embodiment, the BTK inhibitor is the hydrochloride salt of a
compound of Formula (XXVIII). The preparation of this compound is
described in International Patent Application Publication No. WO
2013/081016 A1. In an exemplary embodiment, the BTK inhibitor is
6-amino-9-(1-(but-2-ynoyl)pyrrolidin-3-yl)-7-(4-phenoxyphenyl)-7,9-dihydr-
o-8H-purin-8-one or a pharmaceutically acceptable salt thereof, or
a hydrochloride salt thereof.
[0633] In an exemplary embodiment, the BTK inhibitor is
6-amino-9-[(3R)-1-(2-butynoyl)-3-pyrrolidinyl]-7-(4-phenoxyphenyl)-7,9-di-
hydro-8H-purin-8-one or a pharmaceutically acceptable salt thereof,
or a hydrochloride salt thereof. The preparation of this compound
is described in International Patent Application Publication No. WO
2013/081016 A1.
[0634] In an exemplary embodiment, the BTK inhibitor is
6-amino-9-[(3S)-1-(2-butynoyl)-3-pyrrolidinyl]-7-(4-phenoxyphenyl)-7,9-di-
hydro-8H-purin-8-one or a pharmaceutically acceptable salt thereof,
or a hydrochloride salt thereof. The preparation of this compound
is described in International Patent Application Publication No. WO
2013/081016 A1.
[0635] BTK inhibitors suitable for use in the described combination
with a PI3K inhibitor, the PI3K inhibitor in selected embodiments
being selected from the group consisting of a PI3K-.gamma.
inhibitor, a PI3K-.delta. inhibitor, and a PI3K-.gamma.,8 inhibitor
also include, but are not limited to, those described in, for
example, International Patent Application Publication Nos. WO
2013/010868; WO 2012/158843; WO 2012/135944; WO 2012/135937; U.S.
Patent Application Publication No. 2011/0177011; and U.S. Pat. Nos.
8,501,751; 8,476,284; 8,008,309; 7,960,396; 7,825,118; 7,732,454;
7,514,444; 7,459,554; 7,405,295; and 7,393,848.
Pharmaceutical Compositions
[0636] In one embodiment, the invention provides a pharmaceutical
composition comprising a combination of a PI3K inhibitor and a BTK
inhibitor. In selected embodiments, the PI3K inhibitor is selected
from the group consisting of a PI3K-.gamma. inhibitor, a
PI3K-.delta. inhibitor, and a PI3K-.gamma.,.delta. inhibitor. Said
pharmaceutical composition typically also comprises at least one
pharmaceutically acceptable excipient.
[0637] Said pharmaceutical composition is in one embodiment for use
in the treatment of the diseases and conditions described below. In
particular, it is for use in the treatment of hyperproliferative
disorders.
[0638] In selected embodiments, the invention provides a
pharmaceutical composition comprising a combination of a PI3K
inhibitor and a BTK inhibitor for treating solid tumor cancers,
lymphomas and leukemia. In selected embodiments, the PI3K inhibitor
is selected from the group consisting of a PI3K-.gamma. inhibitor,
a PI3K-.delta. inhibitor, and a PI3K-.gamma.,.delta. inhibitor.
[0639] In selected embodiments, the invention provides a
pharmaceutical composition comprising a combination of a PI3K
inhibitor, including a PI3K inhibitor selected from the group
consisting of a PI3K-.gamma., a PI3K-.delta. inhibitor, and a
PI3K-.gamma.,.delta. inhibitor, and a BTK inhibitor for the
treatment of disorders such as hyperproliferative disorder
including but not limited to cancer such as acute myeloid leukemia,
thymus, brain, lung, squamous cell, skin, eye, retinoblastoma,
intraocular melanoma, oral cavity and oropharyngeal, bladder,
gastric, stomach, pancreatic, bladder, breast, cervical, head,
neck, renal, kidney, liver, ovarian, prostate, colorectal,
esophageal, testicular, gynecological, thyroid, CNS, PNS,
AIDS-related (e.g., lymphoma and Kaposi's sarcoma) or viral-induced
cancer. In some embodiments, said pharmaceutical composition is for
the treatment of a non-cancerous hyperproliferative disorder such
as benign hyperplasia of the skin (e.g., psoriasis), restenosis, or
prostate (e.g., benign prostatic hypertrophy (BPH)).
[0640] The invention further provides a pharmaceutical composition
comprising a combination of a PI3K inhibitor and a BTK inhibitor
for the prevention of blastocyte implantation in a mammal.
[0641] The invention also provides a pharmaceutical composition
comprising a combination of a PI3K inhibitor and a BTK inhibitor
for treating a disease related to vasculogenesis or angiogenesis in
a mammal which can manifest as tumor angiogenesis, chronic
inflammatory disease such as rheumatoid arthritis, inflammatory
bowel disease, atherosclerosis, skin diseases such as psoriasis,
eczema, and scleroderma, diabetes, diabetic retinopathy,
retinopathy of prematurity, age-related macular degeneration,
hemangioma, glioma, melanoma, Kaposi's sarcoma and ovarian, breast,
lung, pancreatic, prostate, colon and epidermoid cancer.
[0642] The pharmaceutical compositions are typically formulated to
provide a therapeutically effective amount of a combination of a
PI3K inhibitor, including a PI3K inhibitor selected from the group
consisting of a PI3K-.gamma. inhibitor, a PI3K-.delta. inhibitor,
and a PI3K-.gamma.,.delta. inhibitor, and BTK inhibitor as the
active ingredients, or a pharmaceutically acceptable salt, ester,
prodrug, solvate, or hydrate thereof. Where desired, the
pharmaceutical compositions contain a pharmaceutically acceptable
salt and/or coordination complex thereof, and one or more
pharmaceutically acceptable excipients, carriers, including inert
solid diluents and fillers, diluents, including sterile aqueous
solution and various organic solvents, permeation enhancers,
solubilizers and adjuvants.
[0643] The pharmaceutical compositions are administered as a
combination of a PI3K inhibitor, including a PI3K inhibitor
selected from the group consisting of a PI3K-.gamma. inhibitor, a
PI3K-.delta. inhibitor, and a PI3K-.gamma.,.delta. inhibitor, and a
BTK inhibitor. Where desired, other agent(s) may be mixed into a
preparation or both components may be formulated into separate
preparations for use in combination separately or at the same time.
A kit containing both components formulated into separate
preparations for said use in also provided by the invention.
[0644] The weight ratio of the PI3K inhibitor to the BTK inhibitor
in the combination is typically with the range from 0.01 to 100,
preferably from 2.5:1 to 1:2.5, and more preferably about 1:1.
[0645] In selected embodiments, the concentration of each of the
PI3K and BTK inhibitors provided in the pharmaceutical compositions
of the invention is independently less than, for example, 100%,
90%, 80%, 70%, 60%, 50%, 40%, 30%, 20%, 19%, 18%, 17%, 16%, 15%,
14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.5%,
0.4%, 0.3%, 0.2%, 0.1%, 0.09%, 0.08%, 0.07%, 0.06%, 0.05%, 0.04%,
0.03%, 0.02%, 0.01%, 0.009%, 0.008%, 0.007%, 0.006%, 0.005%,
0.004%, 0.003%, 0.002%, 0.001%, 0.0009%, 0.0008%, 0.0007%, 0.0006%,
0.0005%, 0.0004%, 0.0003%, 0.0002% or 0.0001% w/w, w/v or v/v of
each of the BTK or PI3K inhibitors.
[0646] In selected embodiments, the concentration of each of the
PI3K and BTK inhibitors provided in the pharmaceutical compositions
of the invention is independently greater than 90%, 80%, 70%, 60%,
50%, 40%, 30%, 20%, 19.75%, 19.50%, 19.25% 19%, 18.75%, 18.50%,
18.25% 18%, 17.75%, 17.50%, 17.25% 17%, 16.75%, 16.50%, 16.25% 16%,
15.75%, 15.50%, 15.25% 15%, 14.75%, 14.50%, 14.25% 14%, 13.75%,
13.50%, 13.25% 13%, 12.75%, 12.50%, 12.25% 12%, 11.75%, 11.50%,
11.25% 11%, 10.75%, 10.50%, 10.25% 10%, 9.75%, 9.50%, 9.25% 9%,
8.75%, 8.50%, 8.25% 8%, 7.75%, 7.50%, 7.25% 7%, 6.75%, 6.50%, 6.25%
6%, 5.75%, 5.50%, 5.25% 5%, 4.75%, 4.50%, 4.25%, 4%, 3.75%, 3.50%,
3.25%, 3%, 2.75%, 2.50%, 2.25%, 2%, 1.75%, 1.50%, 125%, 1%, 0.5%,
0.4%, 0.3%, 0.2%, 0.1%, 0.09%, 0.08%, 0.07%, 0.06%, 0.05%, 0.04%,
0.03%, 0.02%, 0.01%, 0.009%, 0.008%, 0.007%, 0.006%, 0.005%,
0.004%, 0.003%, 0.002%, 0.001%, 0.0009%, 0.0008%, 0.0007%, 0.0006%,
0.0005%, 0.0004%, 0.0003%, 0.0002% or 0.0001% w/w, w/v, or v/v of
each of the BTK or PI3K inhibitors.
[0647] In selected embodiments, the concentration of each of the
PI3K and BTK inhibitors of the invention is independently in the
range from about 0.0001% to about 50%, about 0.001% to about 40%,
about 0.01% to about 30%, about 0.02% to about 29%, about 0.03% to
about 28%, about 0.04% to about 27%, about 0.05% to about 26%,
about 0.06% to about 25%, about 0.07% to about 24%, about 0.08% to
about 23%, about 0.09% to about 22%, about 0.1% to about 21%, about
0.2% to about 20%, about 0.3% to about 19%, about 0.4% to about
18%, about 0.5% to about 17%, about 0.6% to about 16%, about 0.7%
to about 15%, about 0.8% to about 14%, about 0.9% to about 12% or
about 1% to about 10% w/w, w/v or v/v. v/v of each of the BTK or
PI3K inhibitors.
[0648] In selected embodiments, the concentration of each of the
PI3K and BTK inhibitors of the invention is independently in the
range from about 0.001% to about 10%, about 0.01% to about 5%,
about 0.02% to about 4.5%, about 0.03% to about 4%, about 0.04% to
about 3.5%, about 0.05% to about 3%, about 0.06% to about 2.5%,
about 0.07% to about 2%, about 0.08% to about 1.5%, about 0.09% to
about 1%, about 0.1% to about 0.9% w/w, w/v or v/v of each of the
BTK or PI3K inhibitors.
[0649] In selected embodiments, the amount of each of the PI3K and
BTK inhibitors of the invention is independently equal to or less
than 10 g, 9.5 g, 9.0 g, 8.5 g, 8.0 g, 7.5 g, 7.0 g, 6.5 g, 6.0 g,
5.5 g, 5.0 g, 4.5 g, 4.0 g, 3.5 g, 3.0 g, 2.5 g, 2.0 g, 1.5 g, 1.0
g, 0.95 g, 0.9 g, 0.85 g, 0.8 g, 0.75 g, 0.7 g, 0.65 g, 0.6 g, 0.55
g, 0.5 g, 0.45 g, 0.4 g, 0.35 g, 0.3 g, 0.25 g, 0.2 g, 0.15 g, 0.1
g, 0.09 g, 0.08 g, 0.07 g, 0.06 g, 0.05 g, 0.04 g, 0.03 g, 0.02 g,
0.01 g, 0.009 g, 0.008 g, 0.007 g, 0.006 g, 0.005 g, 0.004 g, 0.003
g, 0.002 g, 0.001 g, 0.0009 g, 0.0008 g, 0.0007 g, 0.0006 g, 0.0005
g, 0.0004 g, 0.0003 g, 0.0002 g or 0.0001 g.
[0650] In selected embodiments, the amount of each of the PI3K and
BTK inhibitors of the invention is independently more than 0.0001
g, 0.0002 g, 0.0003 g, 0.0004 g, 0.0005 g, 0.0006 g, 0.0007 g,
0.0008 g, 0.0009 g, 0.001 g, 0.0015 g, 0.002 g, 0.0025 g, 0.003 g,
0.0035 g, 0.004 g, 0.0045 g, 0.005 g, 0.0055 g, 0.006 g, 0.0065 g,
0.007 g, 0.0075 g, 0.008 g, 0.0085 g, 0.009 g, 0.0095 g, 0.01 g,
0.015 g, 0.02 g, 0.025 g, 0.03 g, 0.035 g, 0.04 g, 0.045 g, 0.05 g,
0.055 g, 0.06 g, 0.065 g, 0.07 g, 0.075 g, 0.08 g, 0.085 g, 0.09 g,
0.095 g, 0.1 g, 0.15 g, 0.2 g, 0.25 g, 0.3 g, 0.35 g, 0.4 g, 0.45
g, 0.5 g, 0.55 g, 0.6 g, 0.65 g, 0.7 g, 0.75 g, 0.8 g, 0.85 g, 0.9
g, 0.95 g, 1 g, 1.5 g, 2 g, 2.5, 3 g, 3.5, 4 g, 4.5 g, 5 g, 5.5 g,
6 g, 6.5 g, 7 g, 7.5 g, 8 g, 8.5 g, 9 g, 9.5 g or 10 g.
[0651] Each of the PI3K and BTK inhibitors according to the
invention is effective over a wide dosage range. For example, in
the treatment of adult humans, dosages independently range from
0.01 to 1000 mg, from 0.5 to 100 mg, from 1 to 50 mg per day, and
from 5 to 40 mg per day are examples of dosages that may be used.
The exact dosage will depend upon the route of administration, the
form in which the compound is administered, the gender and age of
the subject to be treated, the body weight of the subject to be
treated, and the preference and experience of the attending
physician.
[0652] Efficacy of the compounds and combinations of compounds
described herein in treating, preventing and/or managing the
indicated diseases or disorders can be tested using various animal
models known in the art. Efficacy in treating, preventing and/or
managing asthma can be assessed using the ova induced asthma model
described, for example, in Lee et al., J. Allergy Clin. Immunol.
118(2):403-9 (2006). Efficacy in treating, preventing and/or
managing arthritis (e.g., rheumatoid or psoriatic arthritis) can be
assessed using the autoimmune animal models described in, for
example, Williams et al., Chem Biol, 17(2):123-34 (2010), WO
2009/088986, WO 2009/088880, and WO 2011/008302. Efficacy in
treating, preventing and/or managing psoriasis can be assessed
using transgenic or knockout mouse model with targeted mutations in
epidermis, vasculature or immune cells, mouse model resulting from
spontaneous mutations, and immuno-deficient mouse model with
xenotransplantation of human skin or immune cells, all of which are
described, for example, in Boehncke et al., Clinics in Dermatology,
25: 596-605 (2007). Efficacy in treating, preventing and/or
managing fibrosis or fibrotic conditions can be assessed using the
unilateral ureteral obstruction model of renal fibrosis, which is
described, for example, in Chevalier et al., Kidney International
75:1145-1152 (2009); the bleomycin induced model of pulmonary
fibrosis described in, for example, Moore et al., Am. J. Physiol.
Lung. Cell. Mol. Physiol. 294:L152-L160 (2008); a variety of
liver/biliary fibrosis models described in, for example, Chuang et
al., Clin. Liver Dis.12:333-347 (2008) and Omenetti et al.,
Laboratory Investigation 87:499-514 (2007) (biliary duct-ligated
model); or any of a number of myelofibrosis mouse models such as
described in Varicchio et al., Expert Rev. Hematol. 2(3):315-334
(2009). Efficacy in treating, preventing and/or managing
scleroderma can be assessed using a mouse model induced by repeated
local injections of bleomycin described, for example, in Yamamoto
et al., J. Invest. Dermatol. 112: 456-462 (1999). Efficacy in
treating, preventing and/or managing dermatomyositis can be
assessed using a myositis mouse model induced by immunization with
rabbit myosin as described, for example, in Phyanagi et al.,
Arthritis & Rheumatism, 60(10): 3118-3127 (2009). Efficacy in
treating, preventing and/or managing lupus can be assessed using
various animal models described, for example, in Ghoreishi et al.,
Lupus, 19: 1029-1035 (2009); Ohl et al., Journal of Biomedicine and
Biotechnology, Article ID 432595 (2011); Xia et al., Rheumatology,
50:2187-2196 (2011); Pau et al., PLoS ONE, 7(5):e36761 (2012);
Mustafa et al., Toxicology, 290:156-168 (2011); Ichikawa et al.,
Arthritis and Rheumatism, 62(2): 493-503 (2012); Ouyang et al., J.
Mol. Med. (2012); Rankin et al., Journal of Immunology,
188:1656-1667 (2012). Efficacy in treating, preventing and/or
managing Sjogren's syndrome can be assessed using various mouse
models described, for example, in Chiorini et al., J. Autoimmunity,
33: 190-196 (2009).
[0653] To explore the role of PI3K signaling in diffuse large
B-cell lymphoma ("DLBCL"), several DLBCL cell lines of varying
molecular profiles may be utilized. In an exemplary embodiment, a
cellular growth inhibition assay used five cell lines, including
four GCB (SU-DHL-4, SU-DHL-6, OCI-LY-8 and WSU-DLCL-2) and one ABC
(Ri-1) subtype. In an exemplary embodiment, a cellular growth
inhibition assay used five cell lines that were OCI-LY-3, OCI-LY-7,
Pfeiffer, Toledo and U2932. In an exemplary embodiment, evidence of
PI3K pathway inhibition is measured by reduction in phospho
(p)-AKT. In an exemplary embodiment, the kinetics of pathway
modulation was characterized by examination of phosphorylation of
AKT, PRAS40 and S6 following a time-course of treatment by a
PI3K-inhibitor in selected cell lines. In one embodiment, upon
B-cell receptor stimulation via antibody-induced crosslinking, some
cell lines exhibited enhanced AKT phosphorylation.
[0654] In an exemplary embodiment, the combination effect of a PI3K
inhibitor with a BTK inhibitor was observed in a cellular growth
inhibition assay in the SU-DHL-4 cell line and in the OCI-LY-8 cell
line with BCR crosslinking.
[0655] In one embodiment, provided herein is a method of treating,
preventing and/or managing asthma. As used herein, "asthma"
encompasses airway constriction regardless of the cause. Common
triggers of asthma include, but are not limited to, exposure to an
environmental stimulants (e.g., allergens), cold air, warm air,
perfume, moist air, exercise or exertion, and emotional stress.
Also provided herein is a method of treating, preventing and/or
managing one or more symptoms associated with asthma. Examples of
the symptoms include, but are not limited to, severe coughing,
airway constriction and mucus production.
[0656] Described below are non-limiting exemplary pharmaceutical
compositions and methods for preparing the same.
Pharmaceutical Compositions for Oral Administration
[0657] In selected embodiments, the invention provides a
pharmaceutical composition for oral administration containing the
combination of a PI3K and BTK inhibitor, and a pharmaceutical
excipient suitable for oral administration.
[0658] In selected embodiments, the invention provides a solid
pharmaceutical composition for oral administration containing: (i)
an effective amount of each of a PI3K and BTK inhibitor in
combination and (ii) a pharmaceutical excipient suitable for oral
administration. In selected embodiments, the composition further
contains (iii) an effective amount of a fourth compound.
[0659] In selected embodiments, the pharmaceutical composition may
be a liquid pharmaceutical composition suitable for oral
consumption. Pharmaceutical compositions of the invention suitable
for oral administration can be presented as discrete dosage forms,
such as capsules, cachets, or tablets, or liquids or aerosol sprays
each containing a predetermined amount of an active ingredient as a
powder or in granules, a solution, or a suspension in an aqueous or
non-aqueous liquid, an oil-in-water emulsion, or a water-in-oil
liquid emulsion. Such dosage forms can be prepared by any of the
methods of pharmacy, but all methods include the step of bringing
the active ingredient(s) into association with the carrier, which
constitutes one or more necessary ingredients. In general, the
compositions are prepared by uniformly and intimately admixing the
active ingredient(s) with liquid carriers or finely divided solid
carriers or both, and then, if necessary, shaping the product into
the desired presentation. For example, a tablet can be prepared by
compression or molding, optionally with one or more accessory
ingredients. Compressed tablets can be prepared by compressing in a
suitable machine the active ingredient in a free-flowing form such
as powder or granules, optionally mixed with an excipient such as,
but not limited to, a binder, a lubricant, an inert diluent, and/or
a surface active or dispersing agent. Molded tablets can be made by
molding in a suitable machine a mixture of the powdered compound
moistened with an inert liquid diluent.
[0660] The invention further encompasses anhydrous pharmaceutical
compositions and dosage forms since water can facilitate the
degradation of some compounds. For example, water may be added
(e.g., 5%) in the pharmaceutical arts as a means of simulating
long-term storage in order to determine characteristics such as
shelf-life or the stability of formulations over time. Anhydrous
pharmaceutical compositions and dosage forms of the invention can
be prepared using anhydrous or low moisture containing ingredients
and low moisture or low humidity conditions. Pharmaceutical
compositions and dosage forms of the invention which contain
lactose can be made anhydrous if substantial contact with moisture
and/or humidity during manufacturing, packaging, and/or storage is
expected. An anhydrous pharmaceutical composition may be prepared
and stored such that its anhydrous nature is maintained.
Accordingly, anhydrous compositions may be packaged using materials
known to prevent exposure to water such that they can be included
in suitable formulary kits. Examples of suitable packaging include,
but are not limited to, hermetically sealed foils, plastic or the
like, unit dose containers, blister packs, and strip packs.
[0661] Each of the PI3K and BTK inhibitors active ingredients can
be combined in an intimate admixture with a pharmaceutical carrier
according to conventional pharmaceutical compounding techniques.
The carrier can take a wide variety of forms depending on the form
of preparation desired for administration. In preparing the
compositions for an oral dosage form, any of the usual
pharmaceutical media can be employed as carriers, such as, for
example, water, glycols, oils, alcohols, flavoring agents,
preservatives, coloring agents, and the like in the case of oral
liquid preparations (such as suspensions, solutions, and elixirs)
or aerosols; or carriers such as starches, sugars,
micro-crystalline cellulose, diluents, granulating agents,
lubricants, binders, and disintegrating agents can be used in the
case of oral solid preparations, in some embodiments without
employing the use of lactose. For example, suitable carriers
include powders, capsules, and tablets, with the solid oral
preparations. If desired, tablets can be coated by standard aqueous
or nonaqueous techniques.
[0662] Binders suitable for use in pharmaceutical compositions and
dosage forms include, but are not limited to, corn starch, potato
starch, or other starches, gelatin, natural and synthetic gums such
as acacia, sodium alginate, alginic acid, other alginates, powdered
tragacanth, guar gum, cellulose and its derivatives (e.g., ethyl
cellulose, cellulose acetate, carboxymethyl cellulose calcium,
sodium carboxymethyl cellulose), polyvinyl pyrrolidone, methyl
cellulose, pre-gelatinized starch, hydroxypropyl methyl cellulose,
microcrystalline cellulose, and mixtures thereof.
[0663] Examples of suitable fillers for use in the pharmaceutical
compositions and dosage forms disclosed herein include, but are not
limited to, talc, calcium carbonate (e.g., granules or powder),
microcrystalline cellulose, powdered cellulose, dextrates, kaolin,
mannitol, silicic acid, sorbitol, starch, pre-gelatinized starch,
and mixtures thereof.
[0664] Disintegrants may be used in the compositions of the
invention to provide tablets that disintegrate when exposed to an
aqueous environment. Too much of a disintegrant may produce tablets
which disintegrate in the bottle. Too little may be insufficient
for disintegration to occur, thus altering the rate and extent of
release of the active ingredients from the dosage form. Thus, a
sufficient amount of disintegrant that is neither too little nor
too much to detrimentally alter the release of the active
ingredient(s) may be used to form the dosage forms of the compounds
disclosed herein. The amount of disintegrant used may vary based
upon the type of formulation and mode of administration, and may be
readily discernible to those of ordinary skill in the art. About
0.5 to about 15 weight percent of disintegrant, or about 1 to about
5 weight percent of disintegrant, may be used in the pharmaceutical
composition. Disintegrants that can be used to form pharmaceutical
compositions and dosage forms of the invention include, but are not
limited to, agar-agar, alginic acid, calcium carbonate,
microcrystalline cellulose, croscarmellose sodium, crospovidone,
polacrilin potassium, sodium starch glycolate, potato or tapioca
starch, other starches, pre-gelatinized starch, other starches,
clays, other algins, other celluloses, gums or mixtures
thereof.
[0665] Lubricants which can be used to form pharmaceutical
compositions and dosage forms of the invention include, but are not
limited to, calcium stearate, magnesium stearate, mineral oil,
light mineral oil, glycerin, sorbitol, mannitol, polyethylene
glycol, other glycols, stearic acid, sodium lauryl sulfate, talc,
hydrogenated vegetable oil (e.g., peanut oil, cottonseed oil,
sunflower oil, sesame oil, olive oil, corn oil, and soybean oil),
zinc stearate, ethyl oleate, ethyl laureate, agar, or mixtures
thereof. Additional lubricants include, for example, a silica gel,
a coagulated aerosol of synthetic silica, or mixtures thereof. A
lubricant can optionally be added, in an amount of less than about
1 weight percent of the pharmaceutical composition.
[0666] When aqueous suspensions and/or elixirs are desired for oral
administration, the essential active ingredient therein may be
combined with various sweetening or flavoring agents, coloring
matter or dyes and, if so desired, emulsifying and/or suspending
agents, together with such diluents as water, ethanol, propylene
glycol, glycerin and various combinations thereof.
[0667] The tablets can be uncoated or coated by known techniques to
delay disintegration and absorption in the gastrointestinal tract
and thereby provide a sustained action over a longer period. For
example, a time delay material such as glyceryl monostearate or
glyceryl distearate can be employed. Formulations for oral use can
also be presented as hard gelatin capsules wherein the active
ingredient is mixed with an inert solid diluent, for example,
calcium carbonate, calcium phosphate or kaolin, or as soft gelatin
capsules wherein the active ingredient is mixed with water or an
oil medium, for example, peanut oil, liquid paraffin or olive
oil.
[0668] Surfactants which can be used to form pharmaceutical
compositions and dosage forms of the invention include, but are not
limited to, hydrophilic surfactants, lipophilic surfactants, and
mixtures thereof. That is, a mixture of hydrophilic surfactants may
be employed, a mixture of lipophilic surfactants may be employed,
or a mixture of at least one hydrophilic surfactant and at least
one lipophilic surfactant may be employed.
[0669] A suitable hydrophilic surfactant may generally have an HLB
value of at least 10, while suitable lipophilic surfactants may
generally have an HLB value of or less than about 10. An empirical
parameter used to characterize the relative hydrophilicity and
hydrophobicity of non-ionic amphiphilic compounds is the
hydrophilic-lipophilic balance ("HLB" value). Surfactants with
lower HLB values are more lipophilic or hydrophobic, and have
greater solubility in oils, while surfactants with higher HLB
values are more hydrophilic, and have greater solubility in aqueous
solutions. Hydrophilic surfactants are generally considered to be
those compounds having an HLB value greater than about 10, as well
as anionic, cationic, or zwitterionic compounds for which the HLB
scale is not generally applicable. Similarly, lipophilic (i.e.,
hydrophobic) surfactants are compounds having an HLB value equal to
or less than about 10. However, HLB value of a surfactant is merely
a rough guide generally used to enable formulation of industrial,
pharmaceutical and cosmetic emulsions.
[0670] Hydrophilic surfactants may be either ionic or non-ionic.
Suitable ionic surfactants include, but are not limited to,
alkylammonium salts; fusidic acid salts; fatty acid derivatives of
amino acids, oligopeptides, and polypeptides; glyceride derivatives
of amino acids, oligopeptides, and polypeptides; lecithins and
hydrogenated lecithins; lysolecithins and hydrogenated
lysolecithins; phospholipids and derivatives thereof;
lysophospholipids and derivatives thereof; carnitine fatty acid
ester salts; salts of alkylsulfates; fatty acid salts; sodium
docusate; acylactylates; mono- and di-acetylated tartaric acid
esters of mono- and di-glycerides; succinylated mono- and
di-glycerides; citric acid esters of mono- and di-glycerides; and
mixtures thereof.
[0671] Within the aforementioned group, ionic surfactants include,
by way of example: lecithins, lysolecithin, phospholipids,
lysophospholipids and derivatives thereof; carnitine fatty acid
ester salts; salts of alkylsulfates; fatty acid salts; sodium
docusate; acylactylates; mono- and di-acetylated tartaric acid
esters of mono- and di-glycerides; succinylated mono- and
di-glycerides; citric acid esters of mono- and di-glycerides; and
mixtures thereof.
[0672] Ionic surfactants may be the ionized forms of lecithin,
lysolecithin, phosphatidylcholine, phosphatidylethanolamine,
phosphatidylglycerol, phosphatidic acid, phosphatidylserine,
lysophosphatidylcholine, lysophosphatidylethanolamine,
lysophosphatidylglycerol, lysophosphatidic acid,
lysophosphatidylserine, PEG-phosphatidylethanolamine,
PVP-phosphatidylethanolamine, lactylic esters of fatty acids,
stearoyl-2-lactylate, stearoyl lactylate, succinylated
monoglycerides, mono/diacetylated tartaric acid esters of
mono/diglycerides, citric acid esters of mono/diglycerides,
cholylsarcosine, caproate, caprylate, caprate, laurate, myristate,
palmitate, oleate, ricinoleate, linoleate, linolenate, stearate,
lauryl sulfate, teracecyl sulfate, docusate, lauroyl carnitines,
palmitoyl carnitines, myristoyl carnitines, and salts and mixtures
thereof.
[0673] Hydrophilic non-ionic surfactants may include, but not
limited to, alkylglucosides; alkylmaltosides; alkylthioglucosides;
lauryl macrogolglycerides; polyoxyalkylene alkyl ethers such as
polyethylene glycol alkyl ethers; polyoxyalkylene alkylphenols such
as polyethylene glycol alkyl phenols; polyoxyalkylene alkyl phenol
fatty acid esters such as polyethylene glycol fatty acids
monoesters and polyethylene glycol fatty acids diesters;
polyethylene glycol glycerol fatty acid esters; polyglycerol fatty
acid esters; polyoxyalkylene sorbitan fatty acid esters such as
polyethylene glycol sorbitan fatty acid esters; hydrophilic
transesterification products of a polyol with at least one member
of the group consisting of glycerides, vegetable oils, hydrogenated
vegetable oils, fatty acids, and sterols; polyoxyethylene sterols,
derivatives, and analogues thereof; polyoxyethylated vitamins and
derivatives thereof; polyoxyethylene-polyoxypropylene block
copolymers; and mixtures thereof; polyethylene glycol sorbitan
fatty acid esters and hydrophilic transesterification products of a
polyol with at least one member of the group consisting of
triglycerides, vegetable oils, and hydrogenated vegetable oils. The
polyol may be glycerol, ethylene glycol, polyethylene glycol,
sorbitol, propylene glycol, pentaerythritol, or a saccharide.
[0674] Other hydrophilic-non-ionic surfactants include, without
limitation, PEG-10 laurate, PEG-12 laurate, PEG-20 laurate, PEG-32
laurate, PEG-32 dilaurate, PEG-12 oleate, PEG-15 oleate, PEG-20
oleate, PEG-20 dioleate, PEG-32 oleate, PEG-200 oleate, PEG-400
oleate, PEG-15 stearate, PEG-32 distearate, PEG-40 stearate,
PEG-100 stearate, PEG-20 dilaurate, PEG-25 glyceryl trioleate,
PEG-32 dioleate, PEG-20 glyceryl laurate, PEG-30 glyceryl laurate,
PEG-20 glyceryl stearate, PEG-20 glyceryl oleate, PEG-30 glyceryl
oleate, PEG-30 glyceryl laurate, PEG-40 glyceryl laurate, PEG-40
palm kernel oil, PEG-50 hydrogenated castor oil, PEG-40 castor oil,
PEG-35 castor oil, PEG-60 castor oil, PEG-40 hydrogenated castor
oil, PEG-60 hydrogenated castor oil, PEG-60 corn oil, PEG-6
caprate/caprylate glycerides, PEG-8 caprate/caprylate glycerides,
polyglyceryl-10 laurate, PEG-30 cholesterol, PEG-25 phytosterol,
PEG-30 soya sterol, PEG-20 trioleate, PEG-40 sorbitan oleate,
PEG-80 sorbitan laurate, polysorbate 20, polysorbate 80, POE-9
lauryl ether, POE-23 lauryl ether, POE-10 oleyl ether, POE-20 oleyl
ether, POE-20 stearyl ether, tocopheryl PEG-100 succinate, PEG-24
cholesterol, polyglyceryl-10oleate, Tween 40, Tween 60, sucrose
monostearate, sucrose monolaurate, sucrose monopalmitate, PEG
10-100 nonyl phenol series, PEG 15-100 octyl phenol series, and
poloxamers.
[0675] Suitable lipophilic surfactants include, by way of example
only: fatty alcohols; glycerol fatty acid esters; acetylated
glycerol fatty acid esters; lower alcohol fatty acids esters;
propylene glycol fatty acid esters; sorbitan fatty acid esters;
polyethylene glycol sorbitan fatty acid esters; sterols and sterol
derivatives; polyoxyethylated sterols and sterol derivatives;
polyethylene glycol alkyl ethers; sugar esters; sugar ethers;
lactic acid derivatives of mono- and di-glycerides; hydrophobic
transesterification products of a polyol with at least one member
of the group consisting of glycerides, vegetable oils, hydrogenated
vegetable oils, fatty acids and sterols; oil-soluble
vitamins/vitamin derivatives; and mixtures thereof. Within this
group, preferred lipophilic surfactants include glycerol fatty acid
esters, propylene glycol fatty acid esters, and mixtures thereof,
or are hydrophobic transesterification products of a polyol with at
least one member of the group consisting of vegetable oils,
hydrogenated vegetable oils, and triglycerides.
[0676] In an exemplary embodiment, the composition may include a
solubilizer to ensure good solubilization and/or dissolution of the
compound of the present invention and to minimize precipitation of
the compound of the present invention. This can be especially
important for compositions for non-oral use--e.g., compositions for
injection. A solubilizer may also be added to increase the
solubility of the hydrophilic drug and/or other components, such as
surfactants, or to maintain the composition as a stable or
homogeneous solution or dispersion.
[0677] Examples of suitable solubilizers include, but are not
limited to, the following: alcohols and polyols, such as ethanol,
isopropanol, butanol, benzyl alcohol, ethylene glycol, propylene
glycol, butanediols and isomers thereof, glycerol, pentaerythritol,
sorbitol, mannitol, transcutol, dimethyl isosorbide, polyethylene
glycol, polypropylene glycol, polyvinylalcohol, hydroxypropyl
methylcellulose and other cellulose derivatives, cyclodextrins and
cyclodextrin derivatives; ethers of polyethylene glycols having an
average molecular weight of about 200 to about 6000, such as
tetrahydrofurfuryl alcohol PEG ether (glycofurol) or methoxy PEG;
amides and other nitrogen-containing compounds such as
2-pyrrolidone, 2-piperidone, .epsilon.-caprolactam,
N-alkylpyrrolidone, N-hydroxyalkylpyrrolidone, N-alkylpiperidone,
N-alkylcaprolactam, dimethylacetamide and polyvinylpyrrolidone;
esters such as ethyl propionate, tributylcitrate, acetyl
triethylcitrate, acetyl tributyl citrate, triethylcitrate, ethyl
oleate, ethyl caprylate, ethyl butyrate, triacetin, propylene
glycol monoacetate, propylene glycol diacetate,
.epsilon.-caprolactone and isomers thereof, 6-valerolactone and
isomers thereof, .beta.-butyrolactone and isomers thereof; and
other solubilizers known in the art, such as dimethyl acetamide,
dimethyl isosorbide, N-methyl pyrrolidones, monooctanoin,
diethylene glycol monoethyl ether, and water.
[0678] Mixtures of solubilizers may also be used. Examples include,
but not limited to, triacetin, triethylcitrate, ethyl oleate, ethyl
caprylate, dimethylacetamide, N-methylpyrrolidone,
N-hydroxyethylpyrrolidone, polyvinylpyrrolidone, hydroxypropyl
methylcellulose, hydroxypropyl cyclodextrins, ethanol, polyethylene
glycol 200-100, glycofurol, transcutol, propylene glycol, and
dimethyl isosorbide. Particularly preferred solubilizers include
sorbitol, glycerol, triacetin, ethyl alcohol, PEG-400, glycofurol
and propylene glycol.
[0679] The amount of solubilizer that can be included is not
particularly limited. The amount of a given solubilizer may be
limited to a bioacceptable amount, which may be readily determined
by one of skill in the art. In some circumstances, it may be
advantageous to include amounts of solubilizers far in excess of
bioacceptable amounts, for example to maximize the concentration of
the drug, with excess solubilizer removed prior to providing the
composition to a patient using conventional techniques, such as
distillation or evaporation. Thus, if present, the solubilizer can
be in a weight ratio of 10%, 25%, 50%, 100%, or up to about 200% by
weight, based on the combined weight of the drug, and other
excipients. If desired, very small amounts of solubilizer may also
be used, such as 5%, 2%, 1% or even less. Typically, the
solubilizer may be present in an amount of about 1% to about 100%,
more typically about 5% to about 25% by weight.
[0680] The composition can further include one or more
pharmaceutically acceptable additives and excipients. Such
additives and excipients include, without limitation, detackifiers,
anti-foaming agents, buffering agents, polymers, antioxidants,
preservatives, chelating agents, viscomodulators, tonicifiers,
flavorants, colorants, odorants, opacifiers, suspending agents,
binders, fillers, plasticizers, lubricants, and mixtures
thereof.
[0681] In addition, an acid or a base may be incorporated into the
composition to facilitate processing, to enhance stability, or for
other reasons. Examples of pharmaceutically acceptable bases
include amino acids, amino acid esters, ammonium hydroxide,
potassium hydroxide, sodium hydroxide, sodium hydrogen carbonate,
aluminum hydroxide, calcium carbonate, magnesium hydroxide,
magnesium aluminum silicate, synthetic aluminum silicate, synthetic
hydrocalcite, magnesium aluminum hydroxide, diisopropylethylamine,
ethanolamine, ethylenediamine, triethanolamine, triethylamine,
triisopropanolamine, trimethylamine,
tris(hydroxymethyl)aminomethane (TRIS) and the like. Also suitable
are bases that are salts of a pharmaceutically acceptable acid,
such as acetic acid, acrylic acid, adipic acid, alginic acid,
alkanesulfonic acid, amino acids, ascorbic acid, benzoic acid,
boric acid, butyric acid, carbonic acid, citric acid, fatty acids,
formic acid, fumaric acid, gluconic acid, hydroquinosulfonic acid,
isoascorbic acid, lactic acid, maleic acid, oxalic acid,
para-bromophenylsulfonic acid, propionic acid, p-toluenesulfonic
acid, salicylic acid, stearic acid, succinic acid, tannic acid,
tartaric acid, thioglycolic acid, toluenesulfonic acid, uric acid,
and the like. Salts of polyprotic acids, such as sodium phosphate,
disodium hydrogen phosphate, and sodium dihydrogen phosphate can
also be used. When the base is a salt, the cation can be any
convenient and pharmaceutically acceptable cation, such as
ammonium, alkali metals and alkaline earth metals. Example may
include, but not limited to, sodium, potassium, lithium, magnesium,
calcium and ammonium.
[0682] Suitable acids are pharmaceutically acceptable organic or
inorganic acids. Examples of suitable inorganic acids include
hydrochloric acid, hydrobromic acid, hydriodic acid, sulfuric acid,
nitric acid, boric acid, phosphoric acid, and the like. Examples of
suitable organic acids include acetic acid, acrylic acid, adipic
acid, alginic acid, alkanesulfonic acids, amino acids, ascorbic
acid, benzoic acid, boric acid, butyric acid, carbonic acid, citric
acid, fatty acids, formic acid, fumaric acid, gluconic acid,
hydroquinosulfonic acid, isoascorbic acid, lactic acid, maleic
acid, methanesulfonic acid, oxalic acid, para-bromophenylsulfonic
acid, propionic acid, p-toluenesulfonic acid, salicylic acid,
stearic acid, succinic acid, tannic acid, tartaric acid,
thioglycolic acid, toluenesulfonic acid and uric acid.
Pharmaceutical Compositions for Injection
[0683] In selected embodiments, the invention provides a
pharmaceutical composition for injection containing the combination
of the PI3K and BTK inhibitors and a pharmaceutical excipient
suitable for injection. Components and amounts of agents in the
compositions are as described herein.
[0684] The forms in which the compositions of the present invention
may be incorporated for administration by injection include aqueous
or oil suspensions, or emulsions, with sesame oil, corn oil,
cottonseed oil, or peanut oil, as well as elixirs, mannitol,
dextrose, or a sterile aqueous solution, and similar pharmaceutical
vehicles.
[0685] Aqueous solutions in saline are also conventionally used for
injection. Ethanol, glycerol, propylene glycol and liquid
polyethylene glycol (and suitable mixtures thereof), cyclodextrin
derivatives, and vegetable oils may also be employed. The proper
fluidity can be maintained, for example, by the use of a coating,
such as lecithin, for the maintenance of the required particle size
in the case of dispersion and by the use of surfactants. The
prevention of the action of microorganisms can be brought about by
various antibacterial and antifungal agents, for example, parabens,
chlorobutanol, phenol, sorbic acid and thimerosal.
[0686] Sterile injectable solutions are prepared by incorporating
the combination of the PI3K and BTK inhibitors in the required
amounts in the appropriate solvent with various other ingredients
as enumerated above, as required, followed by filtered
sterilization. Generally, dispersions are prepared by incorporating
the various sterilized active ingredients into a sterile vehicle
which contains the basic dispersion medium and the required other
ingredients from those enumerated above. In the case of sterile
powders for the preparation of sterile injectable solutions,
certain desirable methods of preparation are vacuum-drying and
freeze-drying techniques which yield a powder of the active
ingredient plus any additional desired ingredient from a previously
sterile-filtered solution thereof.
Pharmaceutical Compositions for Topical Delivery
[0687] In some embodiments, the invention provides a pharmaceutical
composition for transdermal delivery containing the combination of
the PI3K and BTK inhibitors and a pharmaceutical excipient suitable
for transdermal delivery.
[0688] Compositions of the present invention can be formulated into
preparations in solid, semi-solid, or liquid forms suitable for
local or topical administration, such as gels, water soluble
jellies, creams, lotions, suspensions, foams, powders, slurries,
ointments, solutions, oils, pastes, suppositories, sprays,
emulsions, saline solutions, dimethylsulfoxide (DMSO)-based
solutions. In general, carriers with higher densities are capable
of providing an area with a prolonged exposure to the active
ingredients. In contrast, a solution formulation may provide more
immediate exposure of the active ingredient to the chosen area.
[0689] The pharmaceutical compositions also may comprise suitable
solid or gel phase carriers or excipients, which are compounds that
allow increased penetration of, or assist in the delivery of,
therapeutic molecules across the stratum corneum permeability
barrier of the skin. There are many of these penetration-enhancing
molecules known to those trained in the art of topical formulation.
Examples of such carriers and excipients include, but are not
limited to, humectants (e.g., urea), glycols (e.g., propylene
glycol), alcohols (e.g., ethanol), fatty acids (e.g., oleic acid),
surfactants (e.g., isopropyl myristate and sodium lauryl sulfate),
pyrrolidones, glycerol monolaurate, sulfoxides, terpenes (e.g.,
menthol), amines, amides, alkanes, alkanols, water, calcium
carbonate, calcium phosphate, various sugars, starches, cellulose
derivatives, gelatin, and polymers such as polyethylene
glycols.
[0690] Another exemplary formulation for use in the methods of the
present invention employs transdermal delivery devices ("patches").
Such transdermal patches may be used to provide continuous or
discontinuous infusion of the combination of the PI3K and BTK
inhibitors in controlled amounts, either with or without another
agent.
[0691] The construction and use of transdermal patches for the
delivery of pharmaceutical agents is well known in the art. See,
e.g., U.S. Pat. Nos. 5,023,252; 4,992,445 and 5,001,139. Such
patches may be constructed for continuous, pulsatile, or on demand
delivery of pharmaceutical agents.
Pharmaceutical Compositions for Inhalation
[0692] Compositions for inhalation or insufflation include
solutions and suspensions in pharmaceutically acceptable, aqueous
or organic solvents, or mixtures thereof, and powders. The liquid
or solid compositions may contain suitable pharmaceutically
acceptable excipients as described supra. Preferably the
compositions are administered by the oral or nasal respiratory
route for local or systemic effect. Compositions in preferably
pharmaceutically acceptable solvents may be nebulized by use of
inert gases. Nebulized solutions may be inhaled directly from the
nebulizing device or the nebulizing device may be attached to a
face mask tent, or intermittent positive pressure breathing
machine. Solution, suspension, or powder compositions may be
administered, preferably orally or nasally, from devices that
deliver the formulation in an appropriate manner.
Other Pharmaceutical Compositions
[0693] Pharmaceutical compositions may also be prepared from
compositions described herein and one or more pharmaceutically
acceptable excipients suitable for sublingual, buccal, rectal,
intraosseous, intraocular, intranasal, epidural, or intraspinal
administration. Preparations for such pharmaceutical compositions
are well-known in the art. See, e.g., Anderson, Philip O.; Knoben,
James E.; Troutman, William G, eds., Handbook of Clinical Drug
Data, Tenth Edition, McGraw-Hill, 2002; and Pratt and Taylor, eds.,
Principles of Drug Action, Third Edition, Churchill Livingston,
N.Y., 1990.
[0694] Administration of the combination of the PI3K and BTK
inhibitors or pharmaceutical composition of these compounds can be
effected by any method that enables delivery of the compounds to
the site of action. These methods include oral routes,
intraduodenal routes, parenteral injection (including intravenous,
intraarterial, subcutaneous, intramuscular, intravascular,
intraperitoneal or infusion), topical (e.g., transdermal
application), rectal administration, via local delivery by catheter
or stent or through inhalation. The combination of compounds can
also be administered intraadiposally or intrathecally.
[0695] The compositions of the invention may also be delivered via
an impregnated or coated device such as a stent, for example, or an
artery-inserted cylindrical polymer. Such a method of
administration may, for example, aid in the prevention or
amelioration of restenosis following procedures such as balloon
angioplasty. Without being bound by theory, compounds of the
invention may slow or inhibit the migration and proliferation of
smooth muscle cells in the arterial wall which contribute to
restenosis. A compound of the invention may be administered, for
example, by local delivery from the struts of a stent, from a stent
graft, from grafts, or from the cover or sheath of a stent. In some
embodiments, a compound of the invention is admixed with a matrix.
Such a matrix may be a polymeric matrix, and may serve to bond the
compound to the stent. Polymeric matrices suitable for such use,
include, for example, lactone-based polyesters or copolyesters such
as polylactide, polycaprolactonglycolide, polyorthoesters,
polyanhydrides, polyaminoacids, polysaccharides, polyphosphazenes,
poly(ether-ester) copolymers (e.g. PEO-PLLA); polydimethylsiloxane,
poly(ethylene-vinylacetate), acrylate-based polymers or copolymers
(e.g., polyhydroxyethyl methylmethacrylate, polyvinyl
pyrrolidinone), fluorinated polymers such as
polytetrafluoroethylene and cellulose esters. Suitable matrices may
be nondegrading or may degrade with time, releasing the compound or
compounds. The combination of the PI3K and BTK inhibitors may be
applied to the surface of the stent by various methods such as
dip/spin coating, spray coating, dip-coating, and/or brush-coating.
The compounds may be applied in a solvent and the solvent may be
allowed to evaporate, thus forming a layer of compound onto the
stent. Alternatively, the compound may be located in the body of
the stent or graft, for example in microchannels or micropores.
When implanted, the compound diffuses out of the body of the stent
to contact the arterial wall. Such stents may be prepared by
dipping a stent manufactured to contain such micropores or
microchannels into a solution of the compound of the invention in a
suitable solvent, followed by evaporation of the solvent. Excess
drug on the surface of the stent may be removed via an additional
brief solvent wash. In yet other embodiments, compounds of the
invention may be covalently linked to a stent or graft. A covalent
linker may be used which degrades in vivo, leading to the release
of the compound of the invention. Any bio-labile linkage may be
used for such a purpose, such as ester, amide or anhydride
linkages. The combination of the PI3K and BTK inhibitors may
additionally be administered intravascularly from a balloon used
during angioplasty. Extravascular administration of the combination
of the PI3K and BTK inhibitors via the pericard or via advential
application of formulations of the invention may also be performed
to decrease restenosis.
[0696] Exemplary parenteral administration forms include solutions
or suspensions of active compound in sterile aqueous solutions, for
example, aqueous propylene glycol or dextrose solutions. Such
dosage forms can be suitably buffered, if desired.
[0697] The invention also provides kits. The kits include each of
the PI3K and BTK inhibitors, either alone or in combination in
suitable packaging, and written material that can include
instructions for use, discussion of clinical studies and listing of
side effects. Such kits may also include information, such as
scientific literature references, package insert materials,
clinical trial results, and/or summaries of these and the like,
which indicate or establish the activities and/or advantages of the
composition, and/or which describe dosing, administration, side
effects, drug interactions, or other information useful to the
health care provider. Such information may be based on the results
of various studies, for example, studies using experimental animals
involving in vivo models and studies based on human clinical
trials. The kit may further contain another agent. In selected
embodiments, the PI3K and BTK inhibitors and the agent are provided
as separate compositions in separate containers within the kit. In
selected embodiments, the PI3K and BTK inhibitors and the agent are
provided as a single composition within a container in the kit.
Suitable packaging and additional articles for use (e.g., measuring
cup for liquid preparations, foil wrapping to minimize exposure to
air, and the like) are known in the art and may be included in the
kit. Kits described herein can be provided, marketed and/or
promoted to health providers, including physicians, nurses,
pharmacists, formulary officials, and the like. Kits may also, in
selected embodiments, be marketed directly to the consumer.
Dosages and Dosing Regimens
[0698] The amounts of the combination of the PI3K and BTK
inhibitors administered will be dependent on the mammal being
treated, the severity of the disorder or condition, the rate of
administration, the disposition of the compounds and the discretion
of the prescribing physician. However, an effective dosage of a
PI3K or a BTK inhibitor is in the range of about 0.001 to about 100
mg per kg body weight per day, such as about 1 to about 35
mg/kg/day, in single or divided doses. For a 70 kg human, this
would amount to about 0.05 to 7 g/day, such as about 0.05 to about
2.5 g/day. In some embodiments, an effective dosage of a BTK
inhibitor disclosed herein, either alone or administered in
combination with a PI3K inhibitor, is in the range of about 1 mg to
about 300 mg, about 10 mg to about 250 mg, about 20 mg to about 225
mg, about 25 mg to about 200 mg, about 10 mg to about 200 mg, about
20 mg to about 150 mg, about 30 mg to about 120 mg, about 10 mg to
about 90 mg, about 20 mg to about 80 mg, about 30 mg to about 70
mg, about 40 mg to about 60 mg, about 45 mg to about 55 mg, about
48 mg to about 52 mg, about 50 mg to about 150 mg, about 60 mg to
about 140 mg, about 70 mg to about 130 mg, about 80 mg to about 120
mg, about 90 mg to about 110 mg, about 95 mg to about 105 mg, about
150 mg to about 250 mg, about 160 mg to about 240 mg, about 170 mg
to about 230 mg, about 180 mg to about 220 mg, about 190 mg to
about 210 mg, about 195 mg to about 205 mg, or about 198 to about
202 mg. In some embodiments, an effective dosage of a BTK inhibitor
disclosed herein, either alone or in combination with a PI3K
inhibitor, is about 25 mg, about 50 mg, about 75 mg, about 100 mg,
about 125 mg, about 150 mg, about 175 mg, about 200 mg, about 225
mg, or about 250 mg. In some embodiments a BTK inhibitor disclosed
herein, is administered either alone or administered in combination
with a PI3K inhibitor, in a single dose, while in other embodiments
a BTK inhibitor disclosed herein, is administered either alone or
in combination with a PI3K inhibitor, b.i.d. (twice a day).
[0699] In some embodiments, an effective dosage of a BTK inhibitor
disclosed herein, either alone or administered in combination with
a PI3K inhibitor, is in the range of about 0.01 mg/kg to about 4.3
mg/kg, about 0.15 mg/kg to about 3.6 mg/kg, about 0.3 mg/kg to
about 3.2 mg/kg, about 0.35 mg/kg to about 2.85 mg/kg, about 0.15
mg/kg to about 2.85 mg/kg, about 0.3 mg to about 2.15 mg/kg, about
0.45 mg/kg to about 1.7 mg/kg, about 0.15 mg/kg to about 1.3 mg/kg,
about 0.3 mg/kg to about 1.15 mg/kg, about 0.45 mg/kg to about 1
mg/kg, about 0.55 mg/kg to about 0.85 mg/kg, about 0.65 mg/kg to
about 0.8 mg/kg, about 0.7 mg/kg to about 0.75 mg/kg, about 0.7
mg/kg to about 2.15 mg/kg, about 0.85 mg/kg to about 2 mg/kg, about
1 mg/kg to about 1.85 mg/kg, about 1.15 mg/kg to about 1.7 mg/kg,
about 1.3 mg/kg mg to about 1.6 mg/kg, about 1.35 mg/kg to about
1.5 mg/kg, about 2.15 mg/kg to about 3.6 mg/kg, about 2.3 mg/kg to
about 3.4 mg/kg, about 2.4 mg/kg to about 3.3 mg/kg, about 2.6
mg/kg to about 3.15 mg/kg, about 2.7 mg/kg to about 3 mg/kg, about
2.8 mg/kg to about 3 mg/kg, or about 2.85 mg/kg to about 2.95
mg/kg. In some embodiments, an effective dosage of a BTK inhibitor
disclosed herein, either alone or administered in combination with
a PI3K inhibitor, is about 0.35 mg/kg, about 0.7 mg/kg, about 1
mg/kg, about 1.4 mg/kg, about 1.8 mg/kg, about 2.1 mg/kg, about 2.5
mg/kg, about 2.85 mg/kg, about 3.2 mg/kg, or about 3.6 mg/kg. In
some embodiments a BTK inhibitor disclosed herein, is administered
either alone or in combination with a PI3K inhibitor, in a single
dose, while in other embodiments a BTK inhibitor disclosed herein,
is administered either alone or in combination with a PI3K
inhibitor, b.i.d. (twice a day).
[0700] In some embodiments, an effective dosage of a PI3K inhibitor
disclosed herein, either alone or administered in combination with
a BTK inhibitor, is in the range of about 1 mg to about 300 mg,
about 10 mg to about 250 mg, about 20 mg to about 225 mg, about 25
mg to about 200 mg, about 1 mg to about 50 mg, about 5 mg to about
45 mg, about 10 mg to about 40 mg, about 15 mg to about 35 mg,
about 20 mg to about 30 mg, about 23 mg to about 28 mg, about 50 mg
to about 150 mg, about 60 mg to about 140 mg, about 70 mg to about
130 mg, about 80 mg to about 120 mg, about 90 mg to about 110 mg,
or about 95 mg to about 105 mg, about 98 mg to about 102 mg, about
150 mg to about 250 mg, about 160 mg to about 240 mg, about 170 mg
to about 230 mg, about 180 mg to about 220 mg, about 190 mg to
about 210 mg, about 195 mg to about 205 mg, or about 198 to about
207 mg. In some embodiments, an effective dosage of a PI3K
inhibitor disclosed herein, either alone or administered in
combination with a BTK inhibitor, is about 25 mg, about 50 mg,
about 75 mg, about 100 mg, about 125 mg, about 150 mg, about 175
mg, about 200 mg, about 225 mg, or about 250 mg. In some
embodiments the PI3K inhibitor disclosed herein, is administered
either alone or in combination with a BTK inhibitor, in a single
dose, while in other embodiments a PI3K inhibitor disclosed herein,
is administered either alone or in combination with a BTK
inhibitor, b.i.d. (twice a day).
[0701] In some embodiments, an effective dosage of a PI3K inhibitor
disclosed herein, either alone or administered in combination with
a BTK inhibitor, is in the range of about 0.01 mg/kg to about 4.3
mg/kg, about 0.15 mg/kg to about 3.6 mg/kg, about 0.3 mg/kg to
about 3.2 mg/kg, about 0.35 mg/kg to about 2.85 mg/kg, about 0.01
mg/kg to about 0.7 mg/kg, about 0.07 mg/kg to about 0.65 mg/kg,
about 0.15 mg/kg to about 0.6 mg/kg, about 0.2 mg/kg to about 0.5
mg/kg, about 0.3 mg/kg to about 0.45 mg/kg, about 0.3 mg/kg to
about 0.4 mg/kg, about 0.7 mg/kg to about 2.15 mg/kg, about 0.85
mg/kg to about 2 mg/kg, about 1 mg/kg to about 1.85 mg/kg, about
1.15 mg/kg to about 1.7 mg/kg, about 1.3 mg/kg to about 1.6 mg/kg,
about 1.35 mg/kg to about 1.5 mg/kg, about 1.4 mg/kg to about 1.45
mg/kg, about 2.15 mg/kg to about 3.6 mg/kg, about 2.3 mg/kg to
about 3.4 mg/kg, about 2.4 mg/kg to about 3.3 mg/kg, about 2.6
mg/kg to about 3.15 mg/kg, about 2.7 mg/kg to about 3 mg/kg, about
2.8 mg/kg to about 3 mg/kg, or about 2.85 mg/kg to about 2.95
mg/kg. In some embodiments, an effective dosage of a PI3K inhibitor
disclosed herein, either alone or administered in combination with
a BTK inhibitor, is about 0.4 mg/kg, about 0.7 mg/kg, about 1
mg/kg, about 1.4 mg/kg, about 1.8 mg/kg, about 2.1 mg/kg, about 2.5
mg/kg, about 2.85 mg/kg, about 3.2 mg/kg, or about 3.6 mg/kg. In
some embodiments a PI3K inhibitor disclosed herein, is administered
either alone or in combination with a BTK inhibitor, in a single
dose, while in other embodiments a PI3K inhibitor disclosed herein,
is administered either alone or in combination with a BTK
inhibitor, b.i.d. (twice a day).
[0702] In some embodiments, 10 to 200 mg BID including 50, 60, 70,
80, 90, 100 or 150 mg BID, for the BTK inhibitor, and 10 to 300 mg
BID including 25, 50, 75, 100, 150 or 200 mg BID for the PI3K
inhibitor. In some instances, dosage levels below the lower limit
of the aforesaid range may be more than adequate, while in other
cases still larger doses may be employed without causing any
harmful side effect--e.g., by dividing such larger doses into
several small doses for administration throughout the day.
[0703] In selected embodiments, the combination of the PI3K and BTK
inhibitors is administered in a single dose. In selected
embodiments, such administration will be by injection--e.g.,
intravenous injection, in order to introduce the agents quickly.
However, other routes may be used as appropriate. A single dose of
the combination of the PI3K and BTK inhibitors may also be used for
treatment of an acute condition.
[0704] In selected embodiments, the combination of the PI3K and BTK
inhibitors is administered in multiple doses. Dosing may be about
once, twice, three times, four times, five times, six times, or
more than six times per day. Dosing may be about once a month, once
every two weeks, once a week, or once every other day. In other
embodiments, the combination of the PI3K and BTK inhibitors is
administered about once per day to about 6 times per day. In
another embodiment the administration of the combination of the
PI3K and BTK inhibitors continues for less than about 7 days. In
yet another embodiment the administration continues for more than
about 6, 10, 14, 28 days, two months, six months, or one year. In
some cases, continuous dosing is achieved and maintained as long as
necessary.
[0705] Administration of the agents of the invention may continue
as long as necessary. In selected embodiments, the combination of
the PI3K and BTK inhibitors is administered for more than 1, 2, 3,
4, 5, 6, 7, 14, or 28 days. In some embodiments, the combination of
the PI3K and BTK inhibitors is administered for less than 28, 14,
7, 6, 5, 4, 3, 2, or 1 day. In selected embodiments, the
combination of the PI3K and BTK inhibitors is administered
chronically on an ongoing basis--e.g., for the treatment of chronic
effects.
[0706] An effective amount of the combination of the PI3K and BTK
inhibitors may be administered in either single or multiple doses
by any of the accepted modes of administration of agents having
similar utilities, including rectal, buccal, intranasal and
transdermal routes, by intra-arterial injection, intravenously,
intraperitoneally, parenterally, intramuscularly, subcutaneously,
orally, topically, or as an inhalant.
Methods of Treatment
[0707] In selected embodiments, the invention provides a method of
treating a hyperproliferative disorder in a mammal that comprises
administering to said mammal a therapeutically effective amount of
a PI3K inhibitor (or a PI3K-.gamma. inhibitor, PI3K-.delta.
inhibitor, or PI3K-.gamma.,.delta. inhibitor) and BTK inhibitor, or
a pharmaceutically acceptable salt or ester, prodrug, solvate or
hydrate of either or both the PI3K inhibitor (or a PI3K-.gamma.
inhibitor, PI3K-.delta. inhibitor, or PI3K-.gamma.,.delta.
inhibitor) or the BTK inhibitor. In selected embodiments, the
method relates to the treatment of cancer such as non-Hodgkin's
lymphomas (such as diffuse large B-cell lymphoma), acute myeloid
leukemia, thymus, brain, lung, squamous cell, skin, eye,
retinoblastoma, intraocular melanoma, oral cavity and
oropharyngeal, bladder, gastric, stomach, pancreatic, bladder,
breast, cervical, head, neck, renal, kidney, liver, ovarian,
prostate, colorectal, bone (e.g., metastatic bone), esophageal,
testicular, gynecological, thyroid, CNS, PNS, AIDS-related (e.g.
lymphoma and Kaposi's sarcoma), viral-induced cancers such as
cervical carcinoma (human papillomavirus), B-cell
lymphoproliferative disease and nasopharyngeal carcinoma
(Epstein-Barr virus), Kaposi's Sarcoma and primary effusion
lymphomas (Kaposi's sarcoma herpesvirus), hepatocellular carcinoma
(hepatitis B and hepatitis C viruses), and T-cell leukemias (Human
T-cell leukemia virus-1), and T-cell leukemias (Human T-cell
leukemia virus-1), B cell acute lymphoblastic leukemia, Burkitt's
leukemia, juvenile myelomonocytic leukemia, hairy cell leukemia,
Hodgkin's disease, multiple myeloma, mast cell leukemia, or
mastocytosis. In selected embodiments, the method relates to the
treatment of a non-cancerous hyperproliferative disorder such as
benign hyperplasia of the skin (e.g., psoriasis), restenosis, or
prostate conditions (e.g., benign prostatic hypertrophy (BPH)).
[0708] In selected embodiments, the invention provides a method of
treating an inflammatory, immune, or autoimmune disorder in a
mammal that comprises administering to said mammal a
therapeutically effective amount of a PI3K inhibitor (or a
PI3K-.gamma. inhibitor, PI3K-.delta. inhibitor, or
PI3K-.gamma.,.delta. inhibitor) and BTK inhibitor, or a
pharmaceutically acceptable salt or ester, prodrug, solvate or
hydrate of either or both the PI3K inhibitor (or a PI3K-.gamma.
inhibitor, PI3K-.delta. inhibitor, or PI3K-.gamma.,.delta.
inhibitor) or the BTK inhibitor. In selected embodiments, the
invention also provides a method of treating a disease selected
from the group consisting of tumor angiogenesis, chronic
inflammatory disease, rheumatoid arthritis, atherosclerosis,
inflammatory bowel disease, skin diseases such as psoriasis,
eczema, and scleroderma, diabetes, diabetic retinopathy,
retinopathy of prematurity, age-related macular degeneration,
hemangioma, glioma and melanoma, ulcerative colitis, atopic
dermatitis, pouchitis, spondylarthritis, uveitis, Behcets disease,
polymyalgia rheumatica, giant-cell arteritis, sarcoidosis, Kawasaki
disease, juvenile idiopathic arthritis, hidratenitis suppurativa,
Sjogren's syndrome, psoriatic arthritis, juvenile rheumatoid
arthritis, ankylosing spondylitis, Crohn's Disease, lupus, and
lupus nephritis.
[0709] In selected embodiments, the invention provides a method of
treating a solid tumor cancer with a composition including a
combination of a PI3K inhibitor, including a PI3K-.gamma. or
PI3K-.delta. inhibitor, and a BTK inhibitor, wherein the dose is
effective to inhibit signaling between the solid tumor cells and at
least one microenvironment selected from the group consisting of
macrophages, monocytes, mast cells, helper T cells, cytotoxic T
cells, regulatory T cells, natural killer cells, myeloid-derived
suppressor cells, regulatory B cells, neutrophils, dendritic cells,
and fibroblasts. In selected embodiments, the invention provides a
method of treating pancreatic cancer, breast cancer, ovarian
cancer, melanoma, lung cancer, head and neck cancer, and colorectal
cancer using a combination of a BTK inhibitor and a PI3K inhibitor,
wherein the dose is effective to inhibit signaling between the
solid tumor cells and at least one microenvironment selected from
the group consisting of macrophages, monocytes, mast cells, helper
T cells, cytotoxic T cells, regulatory T cells, natural killer
cells, myeloid-derived suppressor cells, regulatory B cells,
neutrophils, dendritic cells, and fibroblasts. Efficacy of the
compounds and combinations of compounds described herein in
treating, preventing and/or managing the indicated diseases or
disorders can be tested using various models known in the art. For
example, models for determining efficacy of treatments for
pancreatic cancer are described in Herreros-Villanueva, et al.
World J. Gastroenterol. 2012, 18, 1286-1294. Models for determining
efficacy of treatments for breast cancer are described e.g. in A.
Fantozzi, Breast Cancer Res. 2006, 8, 212. Models for determining
efficacy of treatments for ovarian cancer are described e.g. in
Mullany et al., Endocrinology 2012, 153, 1585-92; and Fong et al.,
J. Ovarian Res. 2009, 2, 12. Models for determining efficacy of
treatments for melanoma are described e.g. in Damsky et al.,
Pigment Cell & Melanoma Res. 2010, 23, 853-859. Models for
determining efficacy of treatments for lung cancer are described
e.g. in Meuwissen et al., Genes & Development, 2005, 19,
643-664. Models for determining efficacy of treatments for lung
cancer are described e.g. in Kim, Clin. Exp. Otorhinolaryngol.
2009, 2, 55-60; and Sano, Head Neck Oncol. 2009, 1, 32. Models for
determining efficacy of treatments for colorectal cancer, including
the CT26 model, are described below in the examples.
[0710] Efficacy of the compounds and combinations of compounds
described herein in treating, preventing and/or managing other
indicated diseases or disorders described here can also be tested
using various models known in the art. Efficacy in treating,
preventing and/or managing asthma can be assessed using the ova
induced asthma model described, for example, in Lee et al., J.
Allergy Clin. Immunol. 2006, 118, 403-9. Efficacy in treating,
preventing and/or managing arthritis (e.g., rheumatoid or psoriatic
arthritis) can be assessed using the autoimmune animal models
described in, for example, Williams et al., Chem. Biol. 2010, 17,
123-34, WO 2009/088986, WO 2009/088880, and WO 2011/008302.
Efficacy in treating, preventing and/or managing psoriasis can be
assessed using transgenic or knockout mouse model with targeted
mutations in epidermis, vasculature or immune cells, mouse model
resulting from spontaneous mutations, and immuno-deficient mouse
model with xenotransplantation of human skin or immune cells, all
of which are described, for example, in Boehncke et al., Clinics in
Dermatology, 2007, 25, 596-605. Efficacy in treating, preventing
and/or managing fibrosis or fibrotic conditions can be assessed
using the unilateral ureteral obstruction model of renal fibrosis,
which is described, for example, in Chevalier et al., Kidney
International 2009, 75, 1145-1152; the bleomycin induced model of
pulmonary fibrosis described in, for example, Moore et al., Am. J.
Physiol. Lung. Cell. Mol. Physiol. 2008, 294, L152-L160; a variety
of liver/biliary fibrosis models described in, for example, Chuang
et al., Clin. Liver Dis. 2008, 12, 333-347 and Omenetti et al.,
Laboratory Investigation, 2007, 87, 499-514 (biliary duct-ligated
model); or any of a number of myelofibrosis mouse models such as
described in Varicchio et al., Expert Rev. Hematol. 2009, 2,
315-334. Efficacy in treating, preventing and/or managing
scleroderma can be assessed using a mouse model induced by repeated
local injections of bleomycin described, for example, in Yamamoto
et al., J. Invest. Dermatol. 1999, 112, 456-462. Efficacy in
treating, preventing and/or managing dermatomyositis can be
assessed using a myositis mouse model induced by immunization with
rabbit myosin as described, for example, in Phyanagi et al.,
Arthritis & Rheumatism, 2009, 60(10), 3118-3127. Efficacy in
treating, preventing and/or managing lupus can be assessed using
various animal models described, for example, in Ghoreishi et al.,
Lupus, 2009, 19, 1029-1035; Ohl et al., J. Biomed. &
Biotechnol., Article ID 432595 (2011); Xia et al., Rheumatology,
2011, 50, 2187-2196; Pau et al., PLoS ONE, 2012, 7(5), e36761;
Mustafa et al., Toxicology, 2011, 90, 156-168; Ichikawa et al.,
Arthritis & Rheumatism, 2012, 62(2), 493-503; Rankin et al., J.
Immunology, 2012, 188, 1656-1667. Efficacy in treating, preventing
and/or managing Sjogren's syndrome can be assessed using various
mouse models described, for example, in Chiorini et al., J.
Autoimmunity, 2009, 33, 190-196.
[0711] In selected embodiments, the invention provides a method of
treating a cancer in a human sensitive to platelet-mediated
thrombosis, comprising the step of administering a therapeutically
effective dose of a BTK inhibitor, or a pharmaceutically-acceptable
salt, cocrystal, hydrate, solvate, or prodrug thereof. In a
preferred embodiment, the invention provides a method of treating a
cancer in a human sensitive to platelet-mediated thrombosis,
comprising the step of administering a therapeutically effective
dose of a BTK inhibitor, wherein the BTK inhibitor is Formula
(XVIII), or a pharmaceutically-acceptable salt, cocrystal, hydrate,
solvate, or prodrug thereof. In a preferred embodiment, the
invention provides a method of treating a cancer in a human
sensitive to platelet-mediated thrombosis, comprising the step of
administering a therapeutically effective dose of a BTK inhibitor,
wherein the BTK inhibitor is Formula (XVIII), or a
pharmaceutically-acceptable salt, cocrystal, hydrate, solvate, or
prodrug thereof, further comprising the step of administering a
therapeutically effective dose of an anticoagulent or antiplatelet
agent.
[0712] In a preferred embodiment, the invention provides a method
of treating a cancer in a human sensitive to platelet-mediated
thrombosis, comprising the step of administering a therapeutically
effective dose of a BTK inhibitor, wherein the BTK inhibitor is
Formula (XVIII), or a pharmaceutically-acceptable salt, cocrystal,
hydrate, solvate, or prodrug thereof, further comprising the step
of administering a therapeutically effective dose of an
anticoagulent or antiplatelet agent, wherein the anticoagulent or
antiplatelet agent is selected from the group consisting of
clopidogrel, prasugrel, ticagrelor, ticlopidine, warfarin,
acenocoumarol, dicumarol, phenprocoumon, heparain, low molecular
weight heparin, fondaparinux, and idraparinux.
[0713] In selected embodiments, the invention provides a method of
treating a cancer in a human sensitive to platelet-mediated
thrombosis, comprising the step of administering a therapeutically
effective dose of a BTK inhibitor, wherein the BTK inhibitor is
Formula (XVIII), and wherein the cancer is selected from the group
consisting of bladder cancer, squamous cell carcinoma including
head and neck cancer, pancreatic ductal adenocarcinoma (PDA),
pancreatic cancer, colon carcinoma, mammary carcinoma, breast
cancer, fibrosarcoma, mesothelioma, renal cell carcinoma, lung
carcinoma, thyoma, prostate cancer, colorectal cancer, ovarian
cancer, acute myeloid leukemia, thymus cancer, brain cancer,
squamous cell cancer, skin cancer, eye cancer, retinoblastoma,
melanoma, intraocular melanoma, oral cavity and oropharyngeal
cancers, gastric cancer, stomach cancer, cervical cancer, head,
neck, renal cancer, kidney cancer, liver cancer, ovarian cancer,
prostate cancer, colorectal cancer, esophageal cancer, testicular
cancer, gynecological cancer, thyroid cancer, aquired immune
deficiency syndrome (AIDS)-related cancers (e.g., lymphoma and
Kaposi's sarcoma), viral-induced cancer, glioblastoma, esophogeal
tumors, hematological neoplasms, non-small-cell lung cancer,
chronic myelocytic leukemia, diffuse large B-cell lymphoma,
esophagus tumor, follicle center lymphoma, head and neck tumor,
hepatitis C virus infection, hepatocellular carcinoma, Hodgkin's
disease, metastatic colon cancer, multiple myeloma, non-Hodgkin's
lymphoma, indolent non-Hogkin's lymphoma, ovary tumor, pancreas
tumor, renal cell carcinoma, small-cell lung cancer, stage IV
melanoma, chronic lymphocytic leukemia, B-cell acute lymphoblastic
leukemia (ALL), mature B-cell ALL, follicular lymphoma, mantle cell
lymphoma, and Burkitt's lymphoma.
[0714] In selected embodiments, the invention provides a method of
treating a cancer in a human with a history of thrombosis,
comprising the step of administering a therapeutically effective
dose of a BTK inhibitor, or a pharmaceutically-acceptable salt,
cocrystal, hydrate, solvate, or prodrug thereof. In selected
embodiments, the invention provides a method of treating a cancer
in a human sensitive to platelet-mediated thrombosis, method of
treating a cancer in a human with a history of thrombosis,
comprising the step of administering a therapeutically effective
dose of a BTK inhibitor, wherein the BTK inhibitor is a compound of
Formula (XVIII) or a pharmaceutically-acceptable salt, cocrystal,
hydrate, solvate, or prodrug thereof.
[0715] In selected embodiments, the BTK inhibitor and the
anticoagulent or the antiplatelet agent are administered
sequentially. In selected embodiments, the BTK inhibitor and the
anticoagulent or the antiplatelet agent are administered
concomittently. In selected embodiments, the BTK inhibitor is
administered before the anticoagulent or the antiplatelet agent. In
selected embodiments, the BTK inhibitor is administered after the
anticoagulent or the antiplatelet agent.
[0716] Preferred anti-platelet and anticoagulent agents for use in
the methods of the present invention include, but are not limited
to, cyclooxygenase inhibitors (e.g., aspirin), adenosine
diphosphate (ADP) receptor inhibitors (e.g., clopidogrel and
ticlopidine), phosphodiesterase inhibitors (e.g., cilostazol),
glycoprotein IIb/IIIa inhibitors (e.g., abciximab, eptifibatide,
and tirofiban), adenosine reuptake inhibitors (e.g., dipyridamole),
and acetylsalicylic acid (aspirin). In other embodiments, examples
of anti-platelet agents for use in the methods of the present
invention include anagrelide, aspirin/extended-release
dipyridamole, cilostazol, clopidogrel, dipyridamole, prasugrel,
ticagrelor, ticlopidine, vorapaxar, tirofiban HCl, eptifibatide,
abciximab, argatroban, bivalirudin, dalteparin, desirudin,
enoxaparin, fondaparinux, heparin, lepirudin, apixaban, dabigatran
etexilate mesylate, rivaroxaban, and warfarin.
Combinations of PI3K and BTK Inhibitors
[0717] Non-limiting, exemplary embodiments of combinations of the
PI3K inhibitors and BTK inhibitors described above are given in the
following numbered paragraphs 1 to 50. The disclosure encompassed
herein should in no way be construed as being limited to these
examples, but rather should be construed to encompass any and all
variations which become evident as a result of the teachings
provided herein.
[0718] In an embodiment, the PI3K inhibitor and BTK inhibitor are
provided in a PI3K inhibitor to BTK inhibitor ratio (by mass)
selected from the group consisting of 0.01 to 1, 0.05 to 1, 0.1 to
1, 0.5 to 1, 1 to 1, 2 to 1, 5 to 1, 10 to 1, 20 to 1, and 100 to
1.
[0719] While preferred embodiments of the invention are shown and
described herein, including the above embodiments, such embodiments
are provided by way of example only and are not intended to
otherwise limit the scope of the invention. Various alternatives to
the described embodiments of the invention may be employed in
practicing the invention.
EXAMPLES
[0720] The embodiments encompassed herein are now described with
reference to the following examples. These examples are provided
for the purpose of illustration only and the disclosure encompassed
herein should in no way be construed as being limited to these
examples, but rather should be construed to encompass any and all
variations which become evident as a result of the teachings
provided herein.
Example 1 Synergistic Combination of a BTK Inhibitor and a
PI3K-.delta. Inhibitor
[0721] Ficoll purified mantle cell lymphoma (MCL) cells
(2.times.10.sup.5) isolated from bone marrow or peripheral blood
were treated with each drug alone and with six equimolar
concentrations of a BTK inhibitor (Formula XVIII) and a
PI3K-.delta. inhibitor (Formula IX) ranging from 0.01 nM to 10
.mu.M on 96-well plates in triplicate. Plated cells were then
cultured in HS-5 conditioned media at 37.degree. C. with 5%
CO.sub.2. After 72 hours of culture, cell viability was determined
using an
(3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl-
)-2H-tetrazolium) (MTS) assay (Cell Titer 96, Promega). Viability
data were used to generate cell viability curves for each drug
alone and in combination for each sample. The potential synergy of
the combination of the BTK inhibitor of Formula XVIII and the
PI3K-.delta. inhibitor of Formula IX at a given equimolar
concentration was determined using the median effect model as
described in Chou and Talalay, Adv Enzyme Regul. 1984, 22, 27-55.
The statistical modeling was run in R using a script that utilizes
the median effect model as described in Lee et al., J. Biopharm.
Stat. 2007, 17, 461-80. A value of 1, less than 1, and greater than
1 using R defines an additive interaction, synergistic and
antagonistic, respectively. The Lee et al. method calculates a 95%
confidence interval for each data point. For each viability curve,
to be considered synergistic, a data point must have an interaction
index below 1 and the upper confidence interval must also be below
1. In order to summarize and demonstrate collective synergy
results, an interaction dot blot was generated for the primary
patient samples.
[0722] A similar approach was utilized to study diffuse large B
cell lymphoma (DLBCL) (TMD8) and MCL (MINO) cell lines. Cells were
treated with each drug alone and with six equimolar concentrations
of the BTK inhibitor of Formula XVIII and the PI3K-.delta.
inhibitor of Formula IX ranging from 0.003 nM to 1.0 .mu.M (for
TMD8) or 0.03 nM to 10 .mu.M (for MINO) on 96-well plates in
triplicate. Plated cells were then cultured in standard conditioned
media plus FBS at 37.degree. C. with 5% CO.sub.2. After 72 hours of
culture, viability was determined using an MTS assay (Cell Titer
96, Promega). Viability data were used to generate cell viability
curves for each drug alone and in combination for each sample. The
results of the experiments described in this example are shown in
FIG. 1, FIG. 2, FIG. 3, and FIG. 4.
Example 2 Synergistic Combination of a BTK Inhibitor and a
PI3K-.delta. Inhibitor
[0723] Combination experiments were performed to determine the
synergistic, additive, or antagonistic behavior of drug
combinations using the Chou/Talalay method/algorithm by defining
combination indexes for drug combinations. Information about
experimental design for evaluation of synergy is described in e.g.
Chou and Talalay, Adv. Enzyme Regul. 1984, 22, 27-55 and more
generally in e.g. Greco et al., Pharmacol. Rev. 1995, 47, 331-385.
The study was performed using the BTK inhibitor of Formula (XVIII)
and the PI3K-.delta. inhibitor of Formula (IX). Single agent
activities were first determined in the various cell lines and
subsequently, the combination indexes were established using
equimolar ratios taking the single agent drug EC50s into
consideration. For individual agents that displayed no single agent
activity, equimolar ratios were used at fixed concentrations to
establish combination indexes. The readout from 72 hour
proliferation assays using Cell TiterGlo (ATP content of remaining
cells) determined the fraction of cells that were effected as
compared to untreated cells (Fa=fraction
affected=(1-((cells+inhibitor)background signal)/((cells+DMSO)
background signal)).
[0724] The combination index obtained was ranked according to Table
1.
TABLE-US-00001 TABLE 1 Combination Index (CI) Ranking Scheme Range
of CI Description <0.1 Very strong synergism 0.1-0.3 Strong
synergism 0.3-0.7 Synergism 0.7-0.85 Moderate synergism 0.85-0.9
Slight synergism 0.9-1.1 Nearly additive 1.1-1.2 Slight antagonism
1.2-1.45 Moderate antagonism 1.45-3.3 Antagonism 3.3-10 Strong
antagonism >10 Very strong antagonism
[0725] The detailed results of the cell line studies for the BTK
inhibitor of Formula (XVIII) and the PI3K-.delta. inhibitor of
Formula (IX) are given in FIG. 5 to FIG. 37. The results of the
cell line studies are summarized in Table 2.
TABLE-US-00002 TABLE 2 Summary of results of the combination of a
BTK inhibitor with a PI3K-.delta. inhibitor (S = synergistic, A =
additive, X = no effect). Cell Line Indication ED25 ED50 ED75 ED90
Raji Burkitt's S S S S Ramos Burkitt's X X X X Daudi Burkitt's S S
S S Mino MCL S S S S Pfeiffer iNHL S S S S DOHH iNHL S S S S REC-1
iNHL S S A A U937 Myeloid S S S S K562 CML X X X X SU-DHL-1 ABC S A
X X SU-DHL-2 ABC S S S S HBL-1 ABC S S S S TMD8 ABC S S S S LY19
GCB X X X X LY7 GCB S S S S LY1 GCB X X X X SU-DHL-6 GCB S S S S
SupB15 B-ALL S S S S CCRF B-ALL S A/S X X
Example 3 BTK Inhibitory Effects on Solid Tumor Microenvironment in
an Orthotopic Pancreatic Cancer Model
[0726] An orthotopic pancreatic cancer model was used to
investigate the therapeutic efficacy of the combination of the BTK
inhibitor of Formula (XVIII) and the PI3K-.delta. inhibitor of
Formula (IX) through treatment of the solid tumor microenvironment.
Mice were dosed orally with 15 mg/kg of Formula (XVIII), 15 mg/kg
of Formula (IX), or a combination of 15 mg/kg of both drugs.
[0727] Cell line derived from KrasG12D; Trp53R172H; Pdx1-Cre (KPC)
mice were orthotopically implanted into the head of the pancreas
after 35 passages. Based on the mice background from where the cell
lines were generated, 1.times.10.sup.6 cells were injected in
C57BL/6 mice. Throughout the experiment, animals were provided with
food and water ad libitum and subjected to a 12-h dark/light cycle.
Animal studies were performed in accordance with the U.S. Public
Health Service "Guidelines for the Care and Use of Laboratory
Animals" (IACUC). After euthanization, pancreatic tumors were
dissected out, weighed and single cell suspensions were prepared
for flow cytometry analysis.
[0728] Results of the experiments are shown in FIG. 38, which
illustrates tumor growth suppression in the orthotopic pancreatic
cancer model. The statistical p-value (presumption against null
hypothesis) is shown for each tested single agent and for the
combination against the vehicle. The results show that all three
treatments provide statistically significant reductions in tumor
volume in the pancreatic cancer model.
[0729] Additional results of the experiments relating to treatment
of the tumor microenvironment are shown in FIG. 39 to FIG. 41. FIG.
39 shows the effects of oral dosing with 15 mg/kg of the BTK
inhibitor of Formula (XVIII), 15 mg/kg of the PI3K inhibitor of
Formula (IX), or a combination of both drugs on myeloid
tumor-associated macrophages (TAMs) in pancreatic tumor-bearing
mice. FIG. 40 illustrates the effects of oral dosing with 15 mg/kg
of the BTK inhibitor of Formula (XVIII), 15 mg/kg of the PI3K
inhibitor of Formula (IX), or a combination of both inhibitors on
myeloid-derived suppressor cells (MDSCs) in pancreatic
tumor-bearing mice. FIG. 41 illustrates the effects of oral dosing
with 15 mg/kg of the BTK inhibitor of Formula (XVIII), 15 mg/kg of
the PI3K inhibitor of Formula (IX), or a combination of both
inhibitors on regulatory T cells (Tregs) in pancreatic
tumor-bearing mice. The results shown in FIG. 39 to FIG. 41
demonstrate that administration of the BTK inhibitor of Formula
(XVIII) and the combination of the BTK inhibitor of Formula (XVIII)
and the PI3K inhibitor of Formula (IX) reduce immunosuppressive
tumor associated myeloid cells and Tregs in pancreatic
tumor-bearing mice. Overall, BTK inhibition with Formula (XVIII) or
a combination of Formula (XVIII) and Formula (IX) significantly
reduced tumor burden in an aggressive orthotopic PDA model,
decreased immature myeloid infiltrate, reduced the number of tumor
associated macrophages, and reduced the number of immunosuppressive
Tregs, demonstrating a strong effect on the tumor
microenvironment.
Example 4 BTK Inhibitory Effects on Solid Tumor Microenvironment in
an Ovarian Cancer Model
[0730] The ID8 syngeneic orthotropic ovarian cancer murine model
was used to investigate the therapeutic efficacy of the BTK
inhibitor of Formula (XVIII) through treatment of the solid tumor
microenvironment. Human ovarian cancer models, including the ID8
syngeneic orthotropic ovarian cancer model and other animal models,
are described in Fong and Kakar, J. Ovarian Res. 2009, 2, 12;
Greenaway et al., Gynecol. Oncol. 2008, 108, 385-94; Urzua et al.,
Tumour Biol. 2005, 26, 236-44; Janat-Amsbury et al., Anticancer
Res. 2006, 26, 3223-28; Janat-Amsbury et al., Anticancer Res. 2006,
26, 2785-89. Animals were treated with vehicle or Formula (XVIII),
15 mg/kg/BID given orally. The results of the study are shown in
FIG. 42, FIG. 43, FIG. 44, FIG. 45, FIG. 46, FIG. 47, FIG. 48, and
FIG. 49.
[0731] FIG. 42 and FIG. 43 demonstrate that the BTK inhibitor of
Formula (XVIII) impairs ID8 ovarian cancer growth in the ID8
syngeneic murine model. FIG. 44 shows that tumor response to
treatment with the BTK inhibitor of Formula (XVIII) correlates with
a significant reduction in immunosuppressive tumor-associated
lymphocytes in tumor-bearing mice. FIG. 45 shows treatment with the
BTK inhibitor of Formula (XVIII) impairs ID8 ovarian cancer growth
(through reduction in tumor volume) in the syngeneic murine model.
FIG. 46 and FIG. 47 show that the tumor response induced by
treatment with the BTK inhibitor of Formula (XVIII) correlates with
a significant reduction in immunosuppressive B cells in
tumor-bearing mice. FIG. 48 and FIG. 49 show that the tumor
response induced by treatment with the BTK inhibitor of Formula
(XVIII) correlates with a significant reduction in
immunosuppressive tumor associated Tregs and an increase in
CD8.sup.+ T cells.
[0732] The results shown in FIG. 42 to FIG. 49 illustrate the
surprising efficacy of the BTK inhibitor of Formula (XVIII) in
modulating tumor microenvironment in a model predictive of efficacy
as a treatment for ovarian cancer in humans.
Example 5 BTK Inhibitory Effects on Solid Tumor Microenvironment
Through Modulation of Tumor-Infiltrating MDSCs and TAMs
[0733] A study was performed to observe potential reduction in
tumor burden through modulation of tumor infiltrating MDSCs and
TAMs using the BTK inhibitor of Formula (XVIII) and/or gemcitabine
("Gem"). In this study, KPC derived mouse pancreatic cancer cells
(KrasG12D; Trp53R172H; Pdx1-Cre) were injected into the pancreases.
Animals were treated with (1) vehicle; (2) Formula (XVIII), 15
mg/kg/BID given orally; (3) gemcitabine 15 mg/kg intravenous (IV)
administered every 4 days for 3 injections; or (4) Formula (XVIII),
15 mg/kg/BID given orally with together with gemcitabine, 15 mg/kg
IV administered every 4 days for 3 injections.
[0734] Single cell suspensions from tumor samples. Mouse tumor
tissue was collected and stored in PBS/0.1% soybean trypsin
inhibitor prior to enzymatic dissociation. Samples were finely
minced with a scissors and mouse tissue was transferred into DMEM
containing 1.0 mg/ml collagenase IV (Gibco), 0.1% soybean trypsin
inhibitor, and 50 U/ml DNase (Roche) and incubated at 37 C for 30
min. with constant stirring while human tissue was digested in 2.0
mg/ml collagenase IV, 1.0 mg/ml hyluronidase, 0.1% soybean trypsin
inhibitor, and 50 U/ml DNase for 45 minutes. Suspensions were
filtered through a 100 micron filter and washed with FACS buffer
(PBS/0.5% BSA/2.0 mM EDTA) prior to staining. Two million total
cells were stained with antibodies as indicated. Intracellular
detection of FoxP3 was achieved following permeabilization with BD
Perm Buffer III (BD Biosciences) and eBioscience Fix/Perm
respectively. Following surface staining, samples were acquired on
a BD Fortessa and analyzed using FlowJo (Treestar) software.
[0735] In FIG. 50, the reduction in tumor size upon treatment is
shown. The effects on particular cell subsets are shown in the flow
cytometry data presented in FIG. 51, FIG. 52, FIG. 53, and FIG.
54.
[0736] The results shown in FIG. 50 to FIG. 54 illustrate reduction
in tumor burden by modulating the tumor infiltrating MDSCs and
TAMs, which affects Treg and CD8.sup.+ T cell levels, through
inhibition of BTK using Formula (XVIII).
Example 6 Effects of BTK Inhibitors on Thrombosis
[0737] Clinical studies have shown that targeting the BCR signaling
pathway by inhibiting BTK produces significant clinical benefit
(Byrd, et al., N. Engl. J. Med. 2013, 369(1), 32-42, Wang, et al.,
N. Engl. J. Med. 2013, 369(6), 507-16). However, in these studies,
bleeding has been reported in up to 50% of ibrutinib-treated
patients. Most bleeding events were of grade 1-2 (spontaneous
bruising or petechiae) but, in 5% of patients, they were of grade 3
or higher after trauma. These results are reflected in the
prescribing information for ibrutinib, where bleeding events of any
grade, including bruising and petechiae, were reported in
approximately half of patients treated with ibrutinib (IMBRUVICA
package insert and prescribing information, revised July 2014, U.S.
Food and Drug Administration).
[0738] Constitutive or aberrant activation of the BCR signaling
cascade has been implicated in the propagation and maintenance of a
variety of B cell malignancies. Small molecule inhibitors of BTK, a
protein early in this cascade and specifically expressed in B
cells, have emerged as a new class of targeted agents. There are
several BTK inhibitors, including Formula XXVII (CC-292), and
Formula XX-A (PCI-32765, ibrutinib), in clinical development.
Importantly, early stage clinical trials have found ibrutinib to be
particularly active in chronic lymphocytic leukemia (CLL) and
mantle cell lymphoma (MCL), suggesting that this class of
inhibitors may play a significant role in various types of cancers
(Aalipour and Advani, Br. J. Haematol. 2013, 163, 436-43). However,
their effects are not limited to leukemia or lymphomas as platelets
also rely on the Tec kinases family members BTK and Tec for signal
transduction in response to various thrombogenic stimuli (Oda, et
al., Blood 2000, 95(5), 1663-70; Atkinson, et al. Blood 2003,
102(10), 3592-99). In fact, both Tec and BTK play an important role
in the regulation of phospholipase C.gamma.2 (PLC.gamma.2)
downstream of the collagen receptor glycoprotein VI (GPVI) in human
platelets. In addition, BTK is activated and undergoes tyrosine
phosphorylation upon challenge of the platelet thrombin receptor,
which requires the engagement of OW integrin and PI3K activity
(Laffargue, et al., FEBS Lett. 1999, 443(1), 66-70). It has also
been implicated in GPIb.alpha.-dependent thrombus stability at
sites of vascular injury (Liu, et al., Blood 2006, 108(8),
2596-603). Thus, BTK and Tec are involved in several processes
important in supporting the formation of a stable hemostatic plug,
which is critical for preventing significant blood loss in response
to vascular injury. Hence, the effects of the BTK inhibitor of
Formula (XVIII) and ibrutinib were evaluated on human
platelet-mediated thrombosis by utilizing the in vivo human
thrombus formation in the VWF HAI mice model described in Chen et
al. Nat. Biotechnol. 2008, 26(1), 114-19.
[0739] Administration of anesthesia, insertion of venous and
arterial catheters, fluorescent labeling and administration of
human platelets (5.times.10.sup.8/ml), and surgical preparation of
the cremaster muscle in mice have been previously described (Chen
et al. Nat Biotechnol. 2008, 26(1), 114-19). Injury to the vessel
wall of arterioles (.about.40-65 mm diameter) was performed using a
pulsed nitrogen dye laser (440 nm, Photonic Instruments) applied
through a 20.times. water-immersion Olympus objective (LUMPlanFl,
0.5 numerical aperature (NA)) of a Zeiss Axiotech vario microscope.
Human platelet and wall interactions were visualized by
fluorescence microscopy using a system equipped with a Yokogawa
CSU-22 spinning disk confocal scanner, iXON EM camera, and 488 nm
and 561 nm laser lines to detect BCECF-labeled and
rhodamine-labeled platelets, respectively (Revolution XD, Andor
Technology). The extent of thrombus formation was assessed for 2
min after injury and the area (.mu.m.sup.2) of coverage determined
(Image IQ, Andor Technology). For the Formula (XVIII), Formula
(XXVII) (CC-292), and Formula (XX-A) (ibrutinib) inhibition
studies, the BTK inhibitors were were added to purified human
platelets for 30 min before administration.
[0740] The in vivo throbus effects of the BTK inhibitors, Formula
(XVIII), Formula (XXVII) (CC-292), and Formula (XX-A) (ibrutinib),
were evaluated on human platelet-mediated thrombosis by utilizing
the in vivo human thrombus formation in the VWF HAI mice model,
which has been previously described (Chen et al. Nat Biotechnol.
2008, 26(1), 114-19). Purified human platelets were preincubated
with various concentrations of the BTK inhibitors (0.1 .mu.M, 0.5
.mu.M, or 1 .mu.M) or DMSO and then administered to VWF HAI mice,
followed by laser-induced thrombus formation. The BTK
inhibitor-treated human platelets were fluorescently labeled and
infused continuously through a catheter inserted into the femoral
artery. Their behavior in response to laser-induced vascular injury
was monitored in real time using two-channel confocal intravital
microscopy (Furie and Furie, J. Clin. Invest. 2005, 115(12),
2255-62). Upon induction of arteriole injury untreated platelets
rapidly formed thrombi with an average thrombus size of
6,450.+-.292 mm.sup.2 (mean.+-.s.e.m.), as shown in FIG. 55 and
FIG. 56. Similarly, Formula (XVIII) (1 .mu.M) treated platelets
formed a slightly smaller but not significantly different thrombi
with an average thrombus size of 5733.+-.393 mm.sup.2
(mean.+-.s.e.m.). In contrast, a dramatic reduction in thrombus
size occurred in platelets pretreated with 1 .mu.M of Formula XX-A
(ibrutinib), 2600.+-.246 mm.sup.2 (mean.+-.s.e.m.), resulting in a
reduction in maximal thrombus size by approximately 61% compared
with control (P>0.001) (FIGS. 55 and 57). Similar results were
obtained with platelets pretreated with 500 nM of Formula (XVIII)
or ibrutinib: thrombus size of 5946.+-.283 mm.sup.2, and
2710.+-.325 mm.sup.2 respectively. These initial results may
provide some mechanic background and explanation on the reported
44% bleeding related adverse event rates in the Phase III
RESONATE.TM. study comparing ibrutinib with ofatumumab. The results
obtained for Formula XXVII (CC-292) were similar to that for
Formula XX-A (ibrutinib), as shown in FIGS. 55, 56, and 57. The
effect of the BTK inhibitor concentration is shown in FIG. 58.
These results demonstrate the surprising advantage of the BTK
inhibitor of Formula (XVIII), which does not interfere with
thrombus formation, while the BTK inhibitors of Formula XXVII
(CC-292) and Formula XX-A (ibrutinib) interfere with thrombus
formation.
[0741] The objective of this study was to evaluate in vivo thrombus
formation in the presence of BTK inhibitors. In vivo testing of
novel antiplatelet agents requires informative biomarkers. By
utilizing a genetic modified mouse von Willebrand factor
(VWFR1326H) model that supports human but not mouse
platelet-mediated thrombosis, we evaluated the effects of Formula
(XVIII), Formula XXVII (CC-292), and Formula XX-A (ibrutinib) on
thrombus formation. These results show that Formula (XVIII) had no
significant effect on human platelet-mediated thrombus formation
while Formula XX-A (ibrutinib) was able to limit this process,
resulting in a reduction in maximal thrombus size by 61% compared
with control. Formula XXVII (CC-292) showed an effect similar to
Formula XX-A (ibrutinib). These results, which show reduced
thrombus formation for ibrutinib at physiologically relevant
concentrations, may provide some mechanistic background for the
Grade .gtoreq.3 bleeding events (eg, subdural hematoma,
gastrointestinal bleeding, hematuria and postprocedural hemorrhage)
that have been reported in .ltoreq.6% of patients treated with
Formula XX-A (ibrutinib).
[0742] GPVI platelet aggregation was measured for Formula (XVIII)
and Formula XX-A (ibrutinib). Blood was obtained from untreated
humans, and platelets were purified from plasma-rich protein by
centrifugation. Cells were resuspended to a final concentration of
350,000/.mu.L in buffer containing 145 mmol/L NaCl, 10 mmol/L
HEPES, 0.5 mmol/L Na.sub.2HPO.sub.4, 5 mmol/L KCl, 2 mmol/L
MgCl.sub.2, 1 mmol/L CaCl.sub.2, and 0.1% glucose, at pH 7.4. Stock
solutions of Convulxin (CVX) GPVI were prepared on the day of
experimentation and added to platelet suspensions 5 minutes
(37.degree. C., 1200 rpm) before the induction of aggregation.
Aggregation was assessed with a Chronolog Lumi-Aggregometer (model
540 VS; Chronolog, Havertown, PA) and permitted to proceed for 6
minutes after the addition of agonist. The results are reported as
maximum percent change in light transmittance from baseline with
platelet buffer used as a reference. The results are shown in FIG.
59.
[0743] In FIG. 60, the results of CVX-induced (250 ng/mL) human
platelet aggregation results before and 15 min after administration
of the BTK inhibitors to 6 healthy individuals are shown.
[0744] The results depicted in FIG. 59 and FIG. 60 indicate that
the BTK inhibitor of Formula XX-A (ibrutinib) significantly
inhibits GPVI platelet aggregation, while the BTK inhibitor of
Formula (XVIII) does not, further illustrating the surprising
benefits of the latter compound.
Example 7 Study of a BTK Inhibitor and a Combination of a BTK
Inhibitor and a PI3K Inhibitor in Canine Lymphoma
[0745] Canine B cell lymphoma exists as a pathological entity that
is characterized by large anaplastic, centroblastic or
immunoblastic lymphocytes with high proliferative grade,
significant peripheral lymphadenopathy and an aggressive clinical
course. While some dogs respond initially to prednisone, most
canine lymphomas progress quickly and must be treated with
combination therapies, including cyclophosphamide, vincristine,
doxorubicin, and prednisone (CHOP), or other cytotoxic agents. In
their histopathologic features, clinical course, and high relapse
rate after initial treatment, canine B cell lymphomas resemble
diffuse large B cell lymphoma (DLBCL) in humans. Thus, responses of
canine B cell lymphomas to experimental treatments are considered
to provide proof of concept for therapeutic candidates in
DLBCL.
[0746] In this example, companion dogs with newly diagnosed or
relapsed/refractory LSA were enrolled on a veterinary clinical
trial of the BTK inhibitor of Formula (XVIII) ("Arm 1") or the BTK
inhibitor of Formula (XVIII) and the PI3K-.delta. inhibitor of
Formula (IX) ("Arm 2"). Enrollment has completed for Arm 1 and is
ongoing for Arm 2. With approximately 1/3 of Arm 2 subjects
treated, the preliminary results show that combined treatment with
the BTK inhibitor of Formula (XVIII) and the PI3K-.delta. inhibitor
of Formula (IX) may have greater efficacy than treatment with the
BTK inhibitor of Formula (XVIII) alone in aggressive lymphoma.
[0747] Twenty-one dogs were treated in Arm 1 with the BTK inhibitor
of Formula (XVIII) at dosages of 2.5 mg/kg once daily to 20 mg/kg
twice daily. Intra-subject dose escalation was allowed. Six of the
11 dogs that initiated at 2.5 or 5 mg/kg once daily were escalated
and completed the study with dosages of 10 mg/kg twice daily. Among
all the dose cohorts, 8 dogs had shrinkage of target lesions
>20%; the best tumor responses were between 45-49% reduction in
the sum of target lesions in two dogs. Complete responses ("CR",
disappearance of all evidence of disease per evaluator judgment;
and absence of new lesions) were not observed in Arm 1.
[0748] In the combination phase of the study (Arm 2), 7 dogs have
been treated with 10 mg/kg the BTK inhibitor of Formula (XVIII) and
the PI3K-.delta. inhibitor of Formula (IX) at 2.5 or 3.5 mg/kg, on
a twice daily schedule. To date, 4 dogs had shrinkage of target
lesions >20%; and the best tumor responses were between 58-65%
reduction in the sum of target lesions, with one sustained CR
observed. Initial reductions in the sum of target lesions were
observed to deepen during the course of therapy in 4 of the 7 dogs.
A summary of the results is presented in Table 5.
TABLE-US-00003 TABLE 5 Summary of the results of the canine
lymphoma study. Formula Formula (XVIII) and (XVIII) Response Metric
Formula (IX).sup.a monotherapy Sum LD.sup.b decreased by
.gtoreq.20% 4/7 (57.1%) 8/21 (38.1%) Sum LD.sup.b decreased by
.gtoreq.30% 2/7 (28.6%) 6/21 (28.6%) (PR) CR by investigator
evaluation 1/7 (14.3%) 0/21 Median time on study (all subjects) 25
days 24 days Median time to best response 21 days 7 days .sup.aArm
2 is still recruiting subjects .sup.bLD, longest diameter of up to
5 target lesion
[0749] These preliminary data suggest that in companion dogs with
naturally occurring B cell lymphomas, treatment with the
combination of the BTK inhibitor of Formula (XVIII) and the
PI3K-.delta. inhibitor of Formula (IX) may provide increased
biological activity (tumor shrinkage and stable disease) and may
possibly lead to deeper responses than treatment with the BTK
inhibitor of Formula (XVIII) alone. Although the available data
represent only 1/3 of the planned Arm 2 population, the extended
response time (median time to best response) and observation of a
CR among the few dogs treated to date may be evidence of synergy
between Formula (XVIII) and Formula (IX) in this highly aggressive
disease.
* * * * *